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Abstract 
Links between health behaviours are potentially of great importance for cost-
effectiveness estimates in economic evaluations of behaviour change strategies.  
This thesis investigates bias in economic evaluations due to the omission of links 
between health behaviours.  A framework to evaluate the health costs and 
consequences of behaviour change strategies while accounting for links to other 
health-related behaviours is proposed, and tested using a case study of the link 
between tobacco and alcohol use.   
There is strong evidence of correlation between alcohol use and tobacco use.  
Nevertheless, while many economic evaluations of interventions for alcohol and 
tobacco behaviour change have been conducted and used to inform resource 
allocation decisions, none have considered implications of links between the two 
behaviours.  Assumptions about behaviour beyond typical trial endpoints in 
historical economic evaluations have in general been based on limited follow-up 
data.  Analysis of the joint dynamics of tobacco and alcohol use employing large-
scale longitudinal survey data is used in this thesis as an alternative to inform 
assumptions about long-run smoking behaviour and its link to alcohol use, in a de 
novo individual-level simulation to appraise the cost-effectiveness of smoking 
cessation interventions.   
Smoking behaviour is found to be persistent and dynamically linked to alcohol use, 
but also influenced by numerous other factors, including unobserved time-
invariant person-specific characteristics which determine the propensity to smoke.  
The ability of smoking cessation interventions to permanently reduce the 
propensity to smoke is important for their long-run cost-effectiveness.  In the 
absence of data on this effect, historical economic evaluations may have 
misinformed decision makers.  There is a need for robust and tested assumptions 
about long-term behaviour and case by case consideration of the importance of 
inter-behavioural links in future economic evaluations of behaviour change 
strategies, and for further investigation into the dynamics and interrelation of 
health-related behaviours.             
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1. Chapter 1: Introduction 
Links between health behaviours are potentially of great importance for cost-
effectiveness estimates in economic evaluations of competing behaviour change 
strategies.  The aim of this thesis is to investigate bias in health economic 
evaluations of behaviour change strategies caused by omission of links between 
different behaviours.  A framework proposed to evaluate the health costs and 
consequences of behaviour change strategies while accounting for links to other 
health-related behaviours is set out, and tested using a case study of the link 
between alcohol use and smoking.   
In this chapter, the concept of health-related behaviour is introduced, the use of 
economic evaluation methods to justify healthcare resource allocation decisions 
described, and a framework to conduct economic evaluations of health-related 
behaviours proposed. 
1.1. Health-related Behaviour 
Health-related behaviours are defined as the behaviours or habits of individuals 
that directly impact health (be it own-health or the health of others), as supported 
by evidence.  For brevity, the term ‘health-related behaviour’ is used 
interchangeably with ‘health behaviour’ throughout this thesis. Examples of health 
behaviours include smoking tobacco, drinking excessive amounts of alcohol, 
exercising, diet choices and taking care of sexual and mental wellbeing [1, 2].  
Factors that influence health but cannot be attributed to behaviour, such as age 
and gender, are not health behaviours, nor are behaviours for which there is no 
evidence that they are linked to health, for which there is evidence that the link to 
health is negligible, nor for which there is substantiated evidence that there is no 
link to health.  
If people in the UK didn’t smoke, drink alcohol to excess, ate more healthily, and 
improved other health-related behaviours, the financial burden of health-related 
diseases upon the National Health Service (NHS) would be significantly reduced [1, 
3].  In recognition of this, public resources are committed to improving health 
behaviours through a variety of measures.  To cite two examples, public funds have 
been dedicated to policies inside and outside of schools to improve the diet choices 
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of UK children in recent years [4], while the NHS Stop Smoking service has been in 
operation since the turn of the century [5].  When there is a choice between funding 
competing alternatives to improve health behaviours in the context of a finite 
public budget, the choice between alternatives is of consequence to the public 
purse and public health. This raises the question of how healthcare financing 
decisions are made in the UK. 
1.2. Economic Evaluation to Justify Healthcare Resource Allocation 
Decisions 
1.2.1. Health Economic Methods for Health Technology Appraisal 
Since 1999, the National Institute for Health and Care Excellence (NICE) has been 
mandated by the Department of Health to appraise the health benefits and costs of 
new and established health technologies in England and Wales [6].    Economic 
evaluation involves the examination of both costs and consequences of two or 
more alternatives [7] and is the preferred means of appraisal in England and Wales 
[6].   
The value of each alternative    considered in an economic evaluation can be 
expressed as its net benefit (NB) [8]: 
  (  )                                                                                                    (1) 
where    denotes the benefits and    the total costs of alternative  . In the NICE 
reference case [9], health benefits are measured in Quality Adjusted Life Years 
(QALYs), the perspective on costs in health technology appraisal is of the NHS and 
personal social services (PSS) and the perspective on benefits is of all direct health 
effects on patients or, where relevant, carers.  The symbol   describes the societal 
willingness to pay threshold for health benefits, enabling monetary quantification 
of the NB of each alternative [6].  In the UK, this is around £20,000 to £30,000 per 
QALY [6]. 
The relative benefit of one competing alternative i over another j can then be 
expressed as incremental net benefit (INB): 
   (   )  (     )  (     )               (2) 
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In this way, the gains or losses of selecting alternative i over alternative j can be 
quantified in monetary terms.  If    (   ) is positive, i is preferable to j. 
Alternatively, where the willingness to pay threshold is not fixed, not known, or 
where decision makers wish to use discretion, the relative merits of alternative i 
over j can be assessed using an incremental cost-effectiveness ratio (ICER), which 
can be compared to different thresholds: 
    (   )  
(     ) 
(     )
⁄               (3) 
A robust economic evaluation will compare alternatives with the full range of 
available alternatives, incorporating all appropriate evidence and reflecting 
uncertainty in the evidence in the conclusion of the analysis [10].  Health economic 
models are used to combine data from different sources and often to extrapolate to 
long-term costs and consequences [10].  Uncertainty in the evidence can be 
characterised using probabilistic sensitivity analysis (PSA).  PSA is conducted by 
first assigning probability distributions to uncertain input parameters, then 
sampling from these probability distributions, incorporating correlation where 
appropriate, to generate an INB estimate multiple times.  The distribution of INB 
estimates describes uncertainty around the INB of one competing alternative 
versus another, providing the decision maker with information about the 
probability that treatment i has a positive INB, as well as the point estimate of INB.  
More recently, health economic models have been used to quantify the value of 
collecting further information to reduce uncertainty around the INB estimate [11]. 
1.2.2. Economic evaluation for health behaviour interventions    
The relative benefits and costs of health technologies have not been appraised 
equally across all types of healthcare interventions.  Public health has been broadly 
defined as the art and science of preventing disease, prolonging life and promoting 
health through community efforts [12]  and public health measures range from 
disease vaccination to motor vehicle safety.  In contrast, ‘clinical’ interventions 
have been more narrowly defined as comprising drugs, devices and medical 
procedures [13].  These two definitions are clearly not mutually exclusive.  In the 
case of behaviour change interventions, ‘clinical’ strategies can be used to improve 
public health, as is the case with Nicotine Replacement Therapy (NRT) for smoking 
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cessation.  Some public health strategies are non-clinical though: a tobacco tax 
increase could be viewed as a public health strategy if the aim is to reduce smoking.  
The reason for drawing a distinction between ‘public health’ interventions and 
‘clinical’ interventions is to highlight that the majority of health technology 
evaluations have focussed on clinical interventions [12].  Key methodological 
challenges for economic appraisal of public health interventions have been 
highlighted, including the attribution of effects, measuring and valuing of outcomes 
and identification of inter-sector costs and consequences, explaining this trend [13].   
Given the different challenges for economic appraisals of clinical and public health 
interventions, it is as expected that more ‘clinical’ than ‘public health’ behaviour 
change strategies have had supporting economic evidence in England and Wales.   
However, NICE guidance on smoking cessation and prevention, prevention of 
harmful drinking, treatment for drug abuse, promotion of physical activity and 
prevention of obesity and social and emotional wellbeing have all been supported 
by bespoke economic analyses [9].   NICE is clearly keen to use the same criteria to 
support decisions between competing alternatives for behaviour change strategies 
as is used for competing alternatives for clinical disease treatment.  These bespoke 
economic analyses supporting NICE guidance have however not considered links 
between health behaviours. 
1.2.3. Summary 
Economic evaluation is a widely used means of deciding between competing 
strategies to improve health behaviours in England and Wales, and much of the 
guidance for behaviour change strategies is supported by economic evidence.  
Guidance for strategies to improve various health behaviours has been supported 
by bespoke economic analyses, but none of these analyses have considered links to 
other health behaviours, and the possible consequences [9].  With this in mind, the 
next section sets out a framework for economic evaluation of health behaviour 
interventions with the implicit inclusion of inter-behavioural links and their 
consequences, which this thesis will test. 
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1.3. A Framework for Economic Evaluation of an Intervention to 
Improve Health Behaviour 
The proposed framework is an extension of the usual steps of an economic 
modelling study, for the case of competing health behaviour change strategies.  The 
framework is described by the flow diagram, Figure 1. 
The assumed starting point for the framework is an answerable research question, 
such as ‘What is the cost-effectiveness of Treatment X in comparison to Treatment 
Y for smoking cessation in population Z?’ It is first important to identify the 
existing economic evaluations in the area.  The type and structure of any economic 
model used should be determined by the natural pathway of the diseases and 
clinical and care process at hand [14, 15], and past economic evaluations can inform 
appropriate model structure and type.  In the context of evaluating strategies to 
change behaviour, a review of existing economic studies would also reveal 
whether behavioural links have been considered in any analyses to date.   
Once the model type and structure had been determined, it would be necessary to 
source the outcome, cost and probability data for the model.  The model should be 
based on the highest quality data available [16, 17], consistent with the perspective of 
the analysis and population of interest.  Randomised controlled trial (RCT) data are 
established as the gold standard source of data for decision modelling, though 
there are limitations to RCT data such as typically short follow-up, and thus 
retrospective data, observational trials and expert opinion are often needed to 
answer the research question and are valid data sources [15, 16].  
It would then be necessary to understand the effectiveness of the strategy in 
improving the targeted behaviour, and the impact of behaviour change upon 
disease outcomes.  Past economic analyses would likely yield data fit for this 
purpose, but it may be necessary to conduct separate searches of effectiveness 
studies.  Past economic evaluations could provide appropriate cost data for the 
model, inflated where appropriate, but again it may be necessary to conduct a 
separate search to identify the best available cost data.   
Next are the issues specific to interventions to change behaviour.  It would be 
necessary to investigate links between the targeted health behaviour and other 
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health behaviours, and also what consequences these would have for costs and 
outcomes.   
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Figure 1: Flow Diagram Depicting Stages Involved in an Economic Evaluation of Behaviour Change Strategies  
N
Y
Identify existing economic 
evaluations of strategy and 
comparators
•Determine model type and structure
• Identify / generate data on effectiveness of 
intervention in causing intended behavioural 
improvement
• Identify / generate data on impact of intended 
behaviour change upon disease and HRQoL
outcomes
• Identify /generate data on cost of strategy and 
long run cost consequences of disease 
outcomes
Complete, populate and execute probabilistic 
model that incorporates all relevant behavioural 
interactions and consequences
The ICER will reflect the 
consequences of cross-behavioural 
effects
Have links with other health behaviours been 
incorporated into existing economic 
evaluations? 
Analyse how other health behaviours have been incorporated
NY
Is this method relevant to the strategy at hand and is the 
quantification robust?
Search for evidence of link between targeted 
behaviour and other health behaviours in existing 
behavioural science literature
YN
Any evidence of relevant behavioural links found?
Identify / generate data 
quantifying relevant behavioural 
links
•Determine model type and structure for impact of related change on disease outcomes and costs
• Identify / generate data on impact of related behaviour change upon cost and HRQoL outcomes 
• Identify long run cost consequences of disease outcomes resulting from related behaviour change
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If past economic evaluations have incorporated inter-behavioural links into their 
analyses, it would be necessary to understand how they have quantified such links 
and the uncertainty surrounding them.  Regardless, an explorative search of the 
behavioural science literature would be beneficial to learn about the potential links 
the targeted health behaviour has with other health behaviours.  Once behavioural 
links have been identified, quantification of these links would be needed in an 
appropriate form for incorporation into the economic model.  It may be that trial 
data can be informative here, but retrospective observational data or even expert 
opinion data may be the best source available. 
Next, the cost and disease outcomes of changes in related behaviours would need 
to be modelled.  This would essentially involve developing an adjoining economic 
model for each related behaviour.  Searches for past economic models of behaviour 
change interventions for the related behaviour(s) would be necessary, and once 
model type and structure are determined, cost, outcome and probability data 
would need to be sourced for the model.  The remaining tasks would include 
building and populating the economic model, modelling input uncertainty 
appropriately to enable PSA and value of further information analysis.  The 
decision maker would then be able to perform their role with the capability that 
contemporary health economic models offer, with the implicit knowledge of cross-
behavioural implications.   
The benefits to the decision maker of the additional information of course come at 
a cost.  The resource expense of (i) identifying or potentially generating estimates 
of links between health behaviours to inform health economic models and (ii) 
building adjoining economic models for behaviours linked to the targeted health 
behaviours will be significant.  The case study presented in this thesis will provide 
perspective on the merit of this approach in practice. 
 
1.4. Summary and Thesis Outline 
Improving health-related behaviour in any population reduces the incidence of 
behaviour-related diseases and associated healthcare costs.  Health economic 
models are used to inform and support decisions between competing strategies for 
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behaviour change in the UK, but the implications of links between health 
behaviours have not been considered.  If such links are ignored, health economic 
model outputs could misinform decision makers and lead to sub-optimal resource 
allocation decisions.  The framework described in this introduction can be used to 
guide development of health economic models of behaviour change strategies 
which account for cross-behavioural links. 
A key aim of this thesis is to investigate bias in health economic evaluations of 
behaviour change strategies caused by omission of links between different 
behaviours.  This thesis will test the proposed framework with a case study of the 
importance of the link between alcohol use and smoking for health economic 
models of smoking cessation interventions.   
In doing so, this work contributes to the existing knowledge base in several ways.  
First, the thesis presents a narrative synthesis of current evidence on the link 
between alcohol and tobacco use.  Second, the novel analysis of the dynamics of 
this link presented represents a clear and important contribution to this evidence 
base.  Third, the individual-level simulation model to appraise competing 
strategies for smoking cessation presented represents an improvement on the 
prevailing mode of economic evaluation models in the field, in its capacity to 
incorporate complex patterns of long-term behaviour.  Fourth, an economic 
appraisal of a pharmaceutical smoking cessation aid yet to be approved for use 
within the UK NHS using this model represents new evidence on the merit of a 
potentially important alternative for smoking cessation treatment.  Fifth, the 
analysis explores the consequences of omission of the dynamics of smoking 
behaviour, including its link to alcohol use.  Sixth, and crucially, the work allows 
better understanding of the merits and feasibility of using the proposed 
framework for economic evaluation in appraisals of strategies for further types of 
health-related behaviour. 
The remainder of this thesis is structured as follows.  Chapter 2 sets out the case 
study focusing on the link between alcohol and tobacco use and assesses the 
current knowledge base in the field.   Chapters 3 and 4 present systematic reviews 
of economic appraisals of interventions to (i) aid smoking cessation and (ii) reduce 
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alcohol use.  Chapter 5 contains an econometric analysis of the joint dynamics of 
smoking and alcohol use.  Chapter 6 reports a health economic model of competing 
interventions for smoking cessation which ignores links to other health behaviours, 
based on an economic model used historically to support several intervention 
adoption decisions.  Chapter 7 presents the methods and data for the Behavioural 
Interactions in Tobacco use (BIT) model, a de novo health economic model linking 
smoking and alcohol use changes to related diseases, health-related quality of life 
(HRQoL) and healthcare costs.  Chapter 8 presents and analyses key results from 
this model.  Chapter 9 contains discussion on key findings and the merit of the 
framework and concluding remarks. 
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2. Chapter 2: A Case Study of the Link between Alcohol 
Use and Smoking 
In this thesis, the framework for economic appraisal of competing behaviour 
change strategies proposed in Chapter 1 is tested with a case study of the 
implications of the link between two specific health behaviours: alcohol use and 
smoking.  NICE guidance for treatment and prevention of many different health 
behaviours is supported by evidence and there may be important links between 
health behaviours which are currently ignored by this evidence.  Chapter 2 has two 
key objectives: (i) to highlight the reasons behind the choice of case study; and (ii) 
to present a broad picture of knowledge and research on links between alcohol 
and tobacco use, in order to identify where this work can contribute to the 
knowledge base.   
The choice of case study was driven by four points. First, the financial burden of 
treating diseases linked to tobacco and alcohol use upon the NHS.  Much public 
money is spent on policies to reduce alcohol and tobacco use, even more on 
treating alcohol and tobacco related disease.  There is a great opportunity cost of 
these policies to other branches of the NHS and importance in making correct 
allocation decisions.  Second, there is a link between alcohol and tobacco use, 
supported by theory and evidence.  Third, the evidence of this link is as yet 
incomplete and further research could contribute to knowledge in this area.  
Evidence suggests a complex and dynamic link, but this is generally from data 
collected over a year or less and relatively little appears to be known about the link 
in the long-run.  Fourth, data exist that can be used to better quantify the link 
between alcohol use and tobacco use.  The following sections expand on these 
points, giving a sense of the current knowledge on the link between alcohol and 
tobacco use, and where evidence gaps lie. 
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2.1. The financial burden of tobacco and alcohol related disease to 
the NHS 
Tobacco is the greatest single cause of illness and premature death in the UK and 
around half of tobacco smokers can expect to die from smoking-related diseases 
[18].  Approximately a fifth of UK adults smoke [19, 20].  The last Labour government 
announced new targets to reduce smoking prevalence in England to 10% of the 
adult population, through long-term policies concerning tobacco advertising, the 
protection of children from tobacco products, product regulation and labelling, 
tobacco tax, prevention of cigarette smuggling and NHS Stop Smoking services [19].  
The current Conservative and Liberal Democrat coalition Government is 
committed to sustaining current funding on tobacco control in real terms and 
increasing duty on cigarettes above inflation, year on year [5]. 
Gross annual spending on tobacco policy is nearly £300 million, with the majority 
of resources funding NHS Stop Smoking services, anti-smuggling efforts and mass 
media campaigns [5].  The greatest cost of smoking to the UK purse is the burden of 
treating smoking-related disease.  Estimates of the annual cost to the NHS range 
from £3.3 billion [21] to as high as £5.1 billion [22], and are rising as links to different 
diseases are discovered [21].  However, with smoking-related diseases putting a 
significant strain on healthcare resources, it is important to consider the financial 
benefits that the Government accrues from effective anti-smoking policies.  The 
Government receives just under £10 billion in tobacco duties revenue every year 
[23], and this figure does not include additional revenue from effective anti-
smuggling policy increasing the market share of legal trade. 
Alcohol-related morbidity and mortality are significant concerns in the UK.  Up to 
70% of all peak-time admissions to accident and emergency departments are 
related to alcohol consumption [24] and the number of alcohol-related deaths more 
than doubled over the period 1991 to 2008 [25].  The estimated annual NHS cost of 
treating alcohol-related disease is also £3.3 billion [21].  Improving alcohol use is 
arguably as great a priority for public health practitioners as eradicating smoking. 
However, annual spending on alcohol information and educational campaigns is 
around £17 million [26], less than 6% of the annual sum estimated to be spent on 
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tobacco policy.  In addition, Government revenues from alcohol duties are even 
greater than those from tobacco duties: over £10 billion [23].  
The health implications of alcohol use are of course different to those linked to 
tobacco use, in that low alcohol consumption is not thought to be harmful.  
Nevertheless, in contrast to tobacco policy, few substantial steps were taken by 
Labour Governments between 1997 and 2005 to reduce alcohol consumption in 
the general population [24, 27].  Duty on alcohol increased only in line with inflation 
up to 2006 [28], while the 2003 Licensing Act notably removed fixed closing hours 
[29].  The same Act included provisions to increase police powers over disorderly 
drinking offences and clamp down on the sale of alcohol to minors, but the 
overriding narrative of alcohol policy in this period was one of enabling people to 
make informed choices rather than actively influencing behaviour [24, 27, 30].  After 
forming in May 2010, the coalition Government was quick to promise to tackle 
disorderly drinking and the sale of alcohol to children [31]. After investment in 
research on the potential health effect of minimum pricing for alcohol, the coalition 
Government recently scrapped plans to introduce a minimum price of at least 40p 
per unit of alcohol [32].  Prime Minister David Cameron justified this retraction on 
the basis that the resulting health effects were unproven [32],  though the 
commissioned research concluded that a significant reduction in alcohol use and 
improvement in health would result from a move to minimum pricing [33].   
The picture painted is that while modest sums are spent on tackling misuse of 
tobacco and alcohol, and large costs are imposed upon the NHS in treating illnesses 
attributable to drinking and smoking, even larger sums are accrued by the state 
every year in alcohol and tobacco duties.  This may suggest a financial disincentive 
to reduce demand for alcohol and tobacco from the perspective of the state, but 
from an NHS viewpoint there is great incentive.  The NHS budget is drawn from the 
revenue raised by UK taxes, but this does not mean the former increases 
proportionally with the latter.  In the 2013 April Budget, spending on healthcare 
was unchanged from 2012 [34], while duties on alcohol and cigarettes increased [23].  
Within the constraints of the NHS and Personal Social Services budget, reducing 
the cost of treating alcohol and tobacco disease allows reallocation of resources to 
other areas; strategies to improve alcohol and tobacco use in the population are 
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therefore highly valuable [21].  Aside from financial considerations, since 1948 and 
still relevant in the 2011 NHS constitution, the NHS has sought to improve health 
and well-being of patients as a core principle.  NHS-funded strategies to improve 
alcohol and tobacco use are justified on the basis of resource allocation and 
principle, but do have an opportunity cost.     
2.2. Theory and evidence of a link between alcohol and tobacco use 
The opportunity cost of funding strategies to improve alcohol and tobacco use is 
significant, and the cost-effectiveness of such strategies could be mis-estimated if 
links to related lifestyle choices are ignored, but what evidence of a link between 
alcohol and tobacco use exists? This subsection presents evidence of links in 
consumption between the goods in the context of economic theory and further 
justifies state intervention to prevent misuse of alcohol and tobacco.  The 
characteristics of alcohol and tobacco suggest that there is a relationship between 
use of each, and this is supported by evidence. 
Microeconomic theory makes some assumptions about the way consumers’ 
preferences behave.  Specifically, three basic axioms about consumer preferences 
can be stated [35]: 
1. Completeness.  Any two goods or bundles of goods can be compared, so that 
an individual will either prefer one good or bundle to the other, or be 
indifferent between the two. 
2. Reflexivity.  Any good or bundle of goods is at least as good as itself. 
3. Transitivity.  If a consumer prefers good (or bundle of goods) X to good (or 
bundle of goods) Y and also prefers Y to good (or bundle of goods) Z, then 
the consumer by definition prefers X to Z.                                                                                          
 In addition to these axioms, it is logical that preferences for some goods will be 
dependent on consumption of another good or goods.  Specifically, complements 
are goods that are consumed together, in that in some sense the goods 
complement each other.  An example of very strong complements is left and right 
shoes: people with two feet are likely only to buy a right shoe when they buy a left 
shoe to go with it [35].   Another example is that of toothpaste and toothbrushes.  
When goods such as these are consumed together in fixed proportions, they are 
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said to be perfect complements.  In contrast, substitutes are goods that are 
consumed in place of each other.  An individual might have a preference for classic 
cars, yet be indifferent towards car colour.  In this simple hypothetical case, red 
classic cars and blue classic cars would be perfect substitutes. 
Alcohol and nicotine have both been defined as addictive substances [36], and 
addiction can cause consumers to violate the basic axioms of preferences stated 
above.  Addiction leads to consumers engaging in compulsive, repeated and 
unwanted use despite clearly harmful consequences, and often despite a strong 
desire to quit [37].  It follows that use of alcohol and tobacco products among 
addicts is frequently a mistake, and this could be judged to contravene the first 
axiom of consumer preferences.  An individual may arguably incur negative utility 
from smoking a cigarette, by exacerbating a cough or incurring the wrath of their 
spouse, but smoke a cigarette despite this due to their addiction.  In this way, it is 
plausible that addiction leads to actions contravening preferences. 
Nehring has described the effect that this phenomenon might have on consumer 
behaviour by introducing the concept of second-order preferences [38].  While first-
order preferences are those that are revealed by our behaviour in the marketplace, 
and those from which economists have derived the three basic axioms above, 
second-order preferences are preferences that we have about our own preferences 
[39].  Nehring describes an individual with a mild problem of excessive alcohol 
consumption, in that when faced with certain situations he will consume excessive 
amounts of alcohol (this is his first-order preference) [38].  However, this individual 
is aware of his problem and deep down wants to avoid drinking alcohol to excess 
(this is his second-order preference) [38].  Here, Nehring discusses the use of 
cognitive control by the individual to ensure his second-order preferences win out 
and the decremental effect this process of self-control has on utility [38].  But it is 
clear that the state could also intervene to ensure our second-order preferences 
are satisfied.  Thus, when addicted cigarette smokers and alcohol drinkers have a 
deep-set desire to quit, government interventions to override first-order individual 
preferences can be justified.   
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If the state has a responsibility to help individuals limit their addictive behaviours, 
then understanding the interdependency of different addictive behaviours is 
necessary in order to provide an effective strategy, particularly in the context of 
limited financial resources.  Attention now turns to the factors motivating 
similarities between alcohol and tobacco consumption, in order to better 
understand this interdependency. 
Firstly there are ‘external’ factors which may influence the consumption of both 
tobacco and alcohol products.  Such factors are termed ‘external’ because they are 
not specific to the individual, but characteristics of the environment in which 
consumers exist and make decisions.  Tobacco and alcohol products are typically 
available for consumption from the same premises (supermarkets, convenience 
stores, public houses and bars) and in some cases (high level spirits and tobacco 
products in some supermarkets and convenience stores) grouped together in 
displays.   
This in itself is perhaps unremarkable; many goods are sold concurrently in 
supermarkets and other premises.  In addition though, the external effect of peer-
group pressure on tobacco and alcohol consumption, particularly in terms of 
initiation of each at a young age, has been widely noted as important [40, 41].  Youths 
are more likely to smoke tobacco and drink alcohol when their friends exhibit 
similar behaviours [40, 41].  This finding is particular to youths in that purchasing, 
and in many contexts, consuming alcohol is illegal in the UK for those under 
eighteen years old, with similar laws in place in most other western countries.  For 
adults, increased stress levels have been documented as leading to greater use of 
both alcohol and tobacco [42, 43], and to relapse in successful quitters of both [44, 45]. 
Secondly, there are ‘internal’ factors which might influence the consumption of 
both tobacco and alcohol.  ‘Internal’ factors are defined as specific to the individual, 
and separate from context.  Tobacco and alcohol are both products which are 
arguably consumed because of the acute pharmacological effects which each 
induces [46].  These pharmacological effects relate to changes in mood, behavioural 
performance and physiological responses [47]. 
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Tobacco and alcohol products are also both addictive, through the respective 
chemical compounds nicotine and ethanol [48, 49].  This means that an individual’s 
consumption of alcohol is positively influenced by their past consumption of 
alcohol, and the same relationship is true for an individual’s consumption of 
tobacco. 
Given these internal and external similarities, questions over the relationship 
between alcohol and tobacco behaviours arise.  Specifically, whether alcohol and 
tobacco are complements, or substitutes, or whether there is no apparent 
relationship, is of interest.   
The availability of both for sale together in supermarkets, convenience stores, bars 
and other premises cannot tell us much about whether the goods are substitutes or 
complements.  Many substitutes are sold together, such as baguettes and bread 
loaves at a bakery; similarly, complements are often sold together, for example 
tyres and hub-caps at a mechanic’s garage.  Goods with no interdependencies are 
also regularly available from the same sales premises: fabric softener and celery 
are both available from most supermarkets, but it would be difficult to argue that 
there is a link in consumption of the two.  Perhaps what is more suggestive here is 
that tobacco and alcohol products are in some cases two of only a very limited 
choice of products available to consume.  This is the case in many public houses 
and bars.  But while this reinforces the notion that tobacco and alcohol products 
might be linked in consumption, it cannot tell us whether the goods are 
complements or substitutes: snacks, contraceptives, alcohol products, tobacco 
products and soft drinks are all sold in most public houses, and some are 
complements of each other, some are substitutes for each other, and in some cases 
the relationship in consumption is not clear. 
The implication of a peer effect on the relationship between consumption of 
alcohol and tobacco products is similarly unclear.  Individuals who habitually 
smoke cigarettes and drink alcohol often initiate these habits in adolescence [50], 
when individuals within a peer group typically behave similarly.  This has been 
widely argued to be a result of individuals conforming to rapidly established group 
norms [41, 51].  However, Urberg et al [41] have highlighted the importance of 
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friendship selection, which is often ignored: individuals will seek friendships with 
like-minded people. 
Taking this into account, there are personality traits which can typify both alcohol 
drinkers and cigarette smokers: strong positive time preferences [52, 53] and 
arguably attraction to morally illicit activities.  Both alcohol and tobacco offer 
immediate and short-term benefits in the form of positive sensations along with 
the prospect of future negative health consequences, attracting those who place 
much greater emphasis on the present than the future.  Similarly, though 
consuming tobacco and alcohol is legal, if sometimes frowned upon, in the adult 
population, both are morally and legally illicit activities for adolescent children, the 
age group in which both behaviours are often initiated.  This highlights that the 
distinction between ‘external’ and ‘internal’ factors discussed above can become 
blurred, but still leaves us unwise as to whether tobacco and alcohol are 
complements or substitutes.  On the one hand, similar personality traits and peer 
group effects could lead individuals to adopt both drinking and smoking 
behaviours as complements; on the other hand, being a smoker could fulfil the 
peer group and individual personality needs of rebellion that alcohol would 
provide, and vice versa, meaning the two are substitutes. 
Tobacco and alcohol are often consumed at the same sitting, or shortly after one 
another [47], and this certainly indicates that the products may be complements 
rather than substitutes.  Perkins highlighted many ways in which nicotine and 
ethanol interact pharmacologically [47].  In terms of mood, nicotine attenuates the 
increase in intoxication due to alcohol and eliminates ethanol’s sedative effects 
when blood alcohol concentration is falling [47], but nicotine can have an additive 
stimulant effect when blood alcohol concentration is rising.  Individuals might use 
cigarettes to smooth the transition from sober to intoxicated and back to sober 
when drinking alcohol.  In terms of performance, nicotine acts to attenuate the 
slowing of reaction times attributable to ethanol [47], which hints that tobacco is a 
complement to alcohol during activities requiring quick reactions in an ethanol-
induced state.  Results from physiological studies reinforce these findings [47].  The 
findings of Perkins indicate that tobacco and alcohol may often be consumed as 
complementary goods. 
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Johnson has since reviewed the neurochemical evidence for interactions between 
alcohol and nicotine [54].  Alcohol and nicotine appear to combine such that their 
ability on reinforcement mechanisms is additive.  There is chemical evidence of a 
complementary relationship between drinking and smoking.  
Stolerman and Jarvis [49] and Heidbreder et al [48] separately reviewed evidence 
that nicotine and ethanol, respectively, are both addictive substances.  While 
Stolerman and Jarvis’ review analysed patterns of use by smokers and the efficacy 
of nicotine replacement therapy (NRT) during attempts to withdraw from nicotine 
to assess the addictiveness of the drug and conclude strongly that the drug is 
addictive [49], the later review of the addictive properties of ethanol by Heidbreder 
et al [48] took a different approach. Here, the authors focused on the 
neurotransmitter dopamine, and specifically the effect that ethanol has on the 
dopamine   receptors [48].  It was reported that evidence suggests intoxicating 
doses of ethanol can affect dopaminergic mechanisms and that the status of 
dopamine   receptors may partially account for vulnerability to alcohol 
dependence [48].  But significantly, Heidbreder et al further reported that adaptive 
changes in the dopamine   receptors can also result from repeated exposure to 
nicotine [48].  This hints that similar mechanisms in the brain are responsible for 
addiction to both nicotine and ethanol.  However, a study by Larsson and Engel has 
reviewed neurochemical studies on ethanol and nicotine interactions and found no 
clear evidence that the two drugs act on the same sites in the brain [55].  Though 
there appears to be some evidence for a link between the addictiveness of ethanol 
and nicotine, it is not certain whether such a link exists and implications for the 
market relationship between tobacco and alcohol are unclear. 
In summary, there is a theoretical argument for government intervention to 
influence both tobacco and alcohol behaviours, and there are several ‘external’ and 
‘internal’ factors which suggest a relationship between alcohol consumption and 
tobacco consumption.  The typical availability of alcohol and tobacco products 
from the same sales premises, the evidence for peer influence on the consumption 
of both, particularly in adolescence, the similar addictive mechanisms at work for 
both nicotine and ethanol, all suggest that the consumption decisions for alcohol 
and tobacco products are interdependent and it seems likely that the two types of 
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products are complements rather than substitutes.  Evidence that tobacco and 
alcohol are often consumed together and on pharmacological interactions between 
nicotine and ethanol further suggests a complementary relationship. There 
remains much to be learnt about the relationship, though. A more detailed 
examination of research analysing the link between alcohol and tobacco use and in 
particular consideration of causality in this context helps establish what is 
currently known. 
2.3. Further evidence: contemporaneous and inter-temporal links 
and causality 
The previous section analysed evidence of a link between alcohol and tobacco use, 
with little reference to causation.  Further studies on the relationship between 
alcohol and tobacco use were sought, with an interest in how use, or a change in 
use, of one substance, affects use of the other and whether studies can be used to 
infer causality between behaviours.  An exploratory search in Google Scholar using 
combinations of the search terms ‘drinking’, ‘alcohol’, ‘smoking’, ‘tobacco’ and 
‘cigarettes’ with terms such as ‘secondary effect’, ‘knock-on’ and ‘related’ was the 
starting point to identify studies.  Further evidence was found by scanning 
reference lists, and performing citations searches in Web of Knowledge, for key 
studies.  The aims, data, analysis method and findings of the forty eight studies 
identified are summarised in Table 32 of Appendix A. 
The studies identified were varied in the types of data used.  In many cases, trials 
have been used to investigate links between alcohol and tobacco use [56-75]. 
Elsewhere, survey data have been used to investigate correlation and where 
possible to attempt to establish causal links between alcohol use and tobacco use, 
and these data have been either cross-sectional [76-85] or longitudinal [86-95]. Cross-
sectional data observe a set of individuals at the same point in time;  longitudinal 
data track a sample of individuals over time, and are alternatively termed panel 
data [96]. 
Cross-sectional studies can be useful in identifying correlations between 
behaviours, but such links cannot to be said to be causal if they could be caused by 
another factor(s).  For example, contemporaneous smoking and drinking could be 
explained by stress, and not necessarily imply a causal relationship between the 
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two behaviours.  In order to understand causal relationships between tobacco and 
alcohol use, longitudinal data may be more useful.  However, one event preceding 
another does not imply causality; careful analysis of longitudinal data is needed in 
order to infer causality. 
The most widely used survey dataset in this area is the National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC), used in five different studies 
in Table 32 [79, 81, 89, 97, 98].  The first wave of NESARC, comprising data from over 
43,000 individuals from the US general population, was conducted in 2001/2; a 
subsequent wave of data was collected in 2004/5 [99].   The vast majority of 
research in this area comes from the US; very little from the UK.  The International 
Tobacco Control Four Country Survey (ITC-4), a cohort study of over 2,000 
smokers in each of Australia, Canada, the UK and the US, is the only longitudinal 
dataset with UK person-specific data on both alcohol and tobacco use in Table 32 
[63].  Another prospective study conducted in Finland collected information every 
four months for five to eight years, with a sample of ageing male smokers [86].  The 
remainder of survey data employed in Table 32 studies were either cross-sectional 
or recorded less frequently than annually.  No identified study other than the 
Finnish study used more than three consecutive waves of annual longitudinal data. 
Therefore few identified studies analysed data with the potential to infer causal 
links between alcohol, and tobacco use over a number of years. 
It appears from Table 32 that alcohol and tobacco use are positively correlated.  
Tobacco use and alcohol misuse co-occur in people, consistently across different 
populations [76, 78-82, 85, 98].  Further, tobacco use increases with alcohol 
consumption among those who smoke and drink [79].  Several studies have 
examined the immediate effect of alcohol upon smoking behaviour in individuals 
who drink and smoke using placebo-alcohol drinks to verify the effect [65, 69-71].  
Alcohol increases smoking urge and enjoyment gained from smoking [65, 69-71].  
There is strong evidence for, and explanation of, the positive correlation between 
alcohol use and smoking. 
Interestingly, some UK general population data suggest that while smokers drink 
more than non-smokers, this may be predominantly due to lower drinking in 
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never-smokers: ex-smokers drank nearly as much as smokers [85].  This highlights 
two possible mechanisms at work: (i) the act of drinking induces smoking, as 
supported by studies of the immediate effect of alcohol upon smoking behaviour [65, 
69-71] and the pharmacological properties of ethanol and nicotine [47]; (ii) other 
unobserved factor(s) influence both the propensity to drink and the propensity to 
smoke, driving correlation between the two.  Several studies in Table 32 
considered other observable factors which are predictors of tobacco and alcohol 
use, including age and gender [76, 79, 82, 91].  Factors which are difficult to observe 
might also be important, such as having an ‘addictive’ nature [100, 101].     
Some research has addressed more specific questions about the relationship 
between tobacco and alcohol use, such as ‘Does alcohol use predict smoking 
cessation?’.  Here, there is evidence that those who drink to hazardous levels are 
less likely to quit smoking, and less likely to succeed in attempts to quit [56, 86, 88, 91, 
93, 95, 102].  This tallies with evidence of alcohol inducing an urge to smoke [65, 70].   
This effect may be true for hazardous drinkers, but not all drinkers, as drinking a 
moderate amount (less than 100g of alcohol per week) has been found to predict 
smoking cessation, relative to alcohol abstention [77].  Further, some studies found 
no significant correlation between alcohol use and smoking persistence [92, 103].  
Two reviews considered evidence on the link between smoking cessation and past 
alcohol use problems [104, 105]; history of alcohol problems was judged as not 
important in predicting smoking cessation. 
Research into tobacco use as a predictor of changes in alcohol use is divided into (i) 
studies of individuals meeting some published criteria for alcohol dependence and 
(ii) studies of non-dependent drinkers.  The latter were fewer in number and 
generally found no effect upon alcohol use of changes in tobacco use [63, 90, 94], 
though one recent study found lifetime smoking cessation to predict lifetime 
alcohol cessation [97]. 
Studies of the role of tobacco in alcohol dependence treatment generally found a 
mild positive association between smoking and relapse to alcohol [57, 75, 89], but this 
was possibly offset by the beneficial effects of nicotine on alcohol withdrawal 
symptoms [74, 106].  Clinicians and researchers are interested in concurrent 
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treatment of smoking and alcohol problems in alcohol dependence patients [58].  
Smoking cessation interventions for alcohol dependence patients have been shown 
to be beneficial for alcohol abstinence [107], possibly because smoking cessation 
drugs such as NRT, bupropion and varenicline attenuate alcohol withdrawal 
symptoms [108].  These drugs have been found to reduce alcohol consumption in 
non-dependent drinkers [67, 68].  Overall, concurrent interventions for smoking 
cessation and alcohol withdrawal are supported [58, 62, 64, 73]. 
This brief review has substantiated the tentative evidence from the previous 
section that tobacco use and alcohol use are positively correlated; they co-occur in 
individuals and complement each other in consumption.  However, the range of 
research questions among studies reviewed here highlights the complexities of the 
link between alcohol use and tobacco use, while the datasets used perhaps 
highlight limited data in order to estimate causal long-term relationships between 
alcohol and tobacco use.  Many studies used trial data to infer knock on effects 
from a change in tobacco (alcohol) use to changes in alcohol (tobacco) use, but trial 
follow-up is typically short, whereas the relationship between alcohol use and 
tobacco use may be long-term.  Other studies have used survey data, but aside 
from one Finnish study the longitudinal datasets used have contained no more 
than three consecutive waves of annual data [86].   
Hazardous drinkers are less likely to quit smoking; alcohol dependence patients 
who smoke are less likely to quit drinking; smoking cessation drugs may reduce 
alcohol use in dependent and non-dependent drinkers.  All these factors may be 
important when considering the implications of the link between alcohol use and 
tobacco use for economic evaluations of behaviour change interventions. 
There is a link between alcohol use and tobacco use; in ignorance of this, NICE 
guidance may be based on biased estimates of NB of competing strategies to 
improve alcohol and tobacco behaviours.  This section suggests that the link is both 
complex and not fully understood.  Little appears to be known about how alcohol 
and tobacco use causally interact in the long-term.  Such information is pertinent 
to understanding long-term consequences of behaviour change strategies.  With a 
view to adding to the existing literature and facilitating completion of this case 
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study through estimation of interactions between alcohol and tobacco use over 
time, the next section summarises the availability of surveys with data on both 
alcohol and tobacco use. 
2.4. Available survey data on alcohol and tobacco use 
The brief review above highlighted some datasets that could be used to analyse the 
interaction between alcohol and tobacco use, but these were limited in that alcohol 
and tobacco use data was collected infrequently, and over few time periods.  The 
best data for understanding the inter-relation of alcohol and tobacco use over time 
will have regular data points over a long period with information on confounding 
factors  that influence both alcohol and tobacco use, though the specific 
requirements will depend upon the information needed to inform cost-
effectiveness models.  This research is interested in the mis-estimation of cost-
effectiveness in the UK context specifically, so UK data were prioritised. However, 
with consideration that more appropriate data may be available elsewhere, and 
considering that reasonable assumptions about transferability may be possible, 
non-UK datasets were also considered.  A search for further survey datasets 
containing both alcohol and tobacco use data began with a search of the UK Data 
archive (http://www.data-archive.ac.uk) and continued with Google searches. 
 
In the UK, the British Household Panel Survey (BHPS) collected individual-level 
data annually on a range of topics from an expanding panel of households from 
1991 to 2009 [109], and has recently been replaced and incorporated by the 
Understanding Society longitudinal dataset project [110].  While the BHPS 
questionnaire did include questions on smoking behaviour, questions on alcohol 
consumption and frequency were absent from the survey.  The survey included 
only one question relating to alcohol in each wave, enquiring if respondents have 
any health problems related to alcohol or drugs [109].  As a result, the BHPS is not 
adequate for the purpose of estimating the relationship between alcohol and 
tobacco behaviours. 
Other British datasets are limited in their applicability to a study on long-term 
interactions between alcohol and tobacco use. Some datasets with information on 
  25  
 
both alcohol and tobacco behaviour have been repeated cross-sectional surveys 
(Health Survey for England (HSE), Welsh Health Survey, Scottish Health Survey, 
Living Cost and Food Survey (LCS) (formerly the Expenditure and Food Survey), 
Smoking, Drinking and Drugs Use among Young People (SDD)).  Again, cross-
sectional data are only useful in identifying correlations between behaviour and so 
are of limited use for this thesis.  The General Lifestyle Survey (GLS) (formerly the 
General Household Survey) switched from cross-sectional to quasi-longitudinal 
design in 2005, so that respondents now remain in the sample for four annual 
survey waves, but again this is of limited use. Others have been longitudinal in 
format, but collected data irregularly (1970 British Cohort Study, National Survey 
of Health and Development), or for specific sub-populations (English Longitudinal 
Study of Ageing (ELSA), Families and Children Study (FACS), Longitudinal study of 
Young People in England, Avon Longitudinal Study of Parents and Children 
(ALSPAC)).   
The available British dataset with the most potential for use in this research is the 
Whitehall II study (also known as the Stress & Health Study). Whitehall II 
comprises a longitudinal cohort study that has followed an initial 10,308 men and 
women working as civil servants in London in 1985 aged 35 to 55.  Detailed 
smoking and alcohol use data has been collected. However, there are several 
drawbacks for the purposes of this research.  Firstly, the format of the 
questionnaire has been through many transformations (the study is currently in 
‘phase 10’) in which details of smoking and drinking questions have been altered.  
In three phases, smoking and drinking questions have been absent. Secondly, data 
has been collected irregularly, and less frequently than annually: data collection 
has taken place once in each ‘phase’ of the study.  Thirdly, Whitehall II contains a 
wealth of health data, but survey information on socio-economic variables that are 
known to co-vary with smoking and drinking behaviours is limited.  Lastly, the 
Whitehall II sample is unrepresentative of the contemporary general population. 
The sample of middle-aged London-based civil servants in this study is 
significantly wealthier, better educated, more male and older than contemporary 
Britain.   
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With appropriate survey data lacking in England and Wales or the UK generally, 
data from overseas requires consideration.  Similar publicly available national 
longitudinal surveys to the BHPS have been running in Australia, America and 
Germany, respectively.  The Household, Income and Labour Dynamics in Australia 
(HILDA) survey has collected annual data on a range of topics from an initial 
sample of nearly 8,000 households since 2001 [111].  In each year, respondents have 
provided information about their smoking status and weekly smoking 
consumption, but weekly alcohol consumption cannot be derived from the first 
wave of data.  In each year since 2002, data on (i) the frequency of drinking and (ii) 
the usual number of alcoholic drinks on a drinking day have also been collected. 
The Panel Study of Income Dynamics (PSID) has been running in America since 
1968 and is the longest running longitudinal household survey in the world [112].  
The original focus was on the dynamics of poverty and so the PSID sample was 
disproportionately representative of low income households until 1999 whereby 
additional families had been recruited to make the sample representative of the 
general population [113].  In 1999, the PSID sample numbered nearly 7,000 
households [113].  In 1997 the study switched from annual to biennial surveying, 
and in the same year respondents were first asked about their alcohol behaviour; 
questions on smoking status and cigarette consumption have been asked in every 
survey since conception.  As a result, there are currently eight waves of available 
PSID data in which respondents have recorded alcohol and tobacco behaviours, 
spanning fourteen years.  Questions on smoking have remained constant 
throughout the survey, demanding a ‘Yes/No’ response for smoking status and a 
qualitative response concerning daily cigarette consumption.  Questions on alcohol 
behaviour changed in 2005. In the four surveys from 1997 to 2003 respondents 
were asked ‘Do you ever drink alcoholic beverages?’, and then asked to quantify 
their average daily consumption.  In subsequent surveys the first alcohol question 
remains the same, but instead of average daily consumption, respondents have 
been asked to categorise their drinking frequency and report average alcoholic 
drink consumption on drinking days. 
The German Socio-Economic Panel Study (SOEP) has collected data from an initial 
sample of nearly 11,000 households annually since 1984 [114].  SOEP respondents 
  27  
 
have not been asked to describe their smoking behaviour in every questionnaire: 
smoking status and consumption questions were asked only in the 1999, 2001, 
2002, 2004, 2006 and 2008 surveys.  Questions on alcohol behaviour have been 
asked even less frequently: only in 2006 and 2008, waves 23 and 25 of the survey, 
have SOEP respondents described their alcoholic beverage consumption, for four 
categories of drink: spirits; beer; wine and champagne; mixed drinks.  For each 
category of alcoholic beverage, respondents were asked to characterise their 
consumption using one of four options: ‘never’; ‘seldom’; ‘once in a while’; ‘regularly’. 
The HILDA dataset is preferable to both PSID and SOEP in terms of regular 
longitudinal data on alcohol and tobacco use.  Whereas HILDA contains repeated 
unchanging questions on both alcohol and tobacco behaviour every year at nine 
time points to the latest released results, PSID only tracks behaviour at two year 
intervals.  An interval of twelve months between observations from an individual 
may be too lengthy to accurately record the impact of changes in behaviour, but it 
is certainly preferable compared with intervals of twenty four months.  PSID also 
has fewer available waves of data with information on both alcohol and tobacco 
behaviour than HILDA.   Though the SOEP sample size is larger than that of both 
HILDA and PSID, only two waves of data contain information on both alcohol and 
tobacco behaviours.  In addition, translating the qualitative categories ‘seldom’, 
‘once in a while’ and ‘regularly’ into alcohol consumption levels would require 
unproven assumptions. 
HILDA data also compare favourably with those available from datasets in Table 
32 for the purpose of estimating causal links between alcohol and tobacco use.  
Nevertheless, no identified studies have used HILDA to investigate links between 
tobacco and alcohol use.   There is certainly scope to contribute to the existing 
knowledge base in this area using analysis of HILDA data. 
2.5. Chapter Summary 
A key aim of this chapter was to provide an overview of existing evidence of the 
link between alcohol and tobacco use.  There are many factors suggestive of a 
relationship between alcohol and tobacco use.  The two goods are often consumed 
together, affect the same sites of the brain in complementary ways, share addictive 
properties and are typically available for sale together.  Survey and trial data have 
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been analysed by a multitude of researchers in an effort to understand different 
aspects of the relationship.  Smoking and alcohol misuse co-occur in individuals; 
hazardous drinkers are less likely to quit smoking; alcohol dependence patients 
who smoke are less likely to quit drinking.   
Despite the high number of publications in this area, relatively little is apparently 
known about long-term causal interactions between alcohol use and tobacco use.  
This could be a result of the scarcity of appropriate data, but HILDA contains 
recent, detailed, annual, longitudinal data on alcohol and tobacco use from a large 
sample of individuals.  There is scope to undertake new analysis of these data and 
contribute to the existing evidence base in addition to taking steps towards 
answering the primary research question. 
Another aim of this chapter was to explain the choice of case study. Smoking and 
excessive alcohol use place considerable burden upon NHS resources, and there is 
clear financial incentive from the perspective of the NHS to choose an optimal 
bundle of strategies to reduce this burden.  There is also an argument for the state 
to intervene to help individuals to tackle their unhealthy behaviours, and satisfy 
their second order preferences, in the case of addictive goods. 
It is believed that the case study is a justified choice because of the evidence base 
of a relationship between alcohol and tobacco use, as well as the burden of treating 
related diseases upon the NHS, in addition to the opportunity to add to existing 
evidence and better understand causal inter-temporal links between alcohol and 
tobacco use, for the purposes of economic appraisal of behaviour change strategies.     
Chapter 5 will analyse the inter-related dynamics of alcohol use and smoking 
status using HILDA data, generating evidence that can be directly used in economic 
appraisal models.  Before this though, Chapters 3 and 4 systematically identify and 
review existing economic appraisals of interventions to improve tobacco and 
alcohol behaviours, respectively.  These two chapters help inform the modelling 
required to appraise strategies for smoking cessation while incorporating links to 
alcohol use and its consequences, and establish whether any such links have been 
considered in economic appraisals to date. 
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3. Chapter 3: Systematic review of economic 
evaluations of pharmaceutical interventions to aid 
smoking cessation 
3.1. Introduction 
In general, strategies to improve smoking behaviour can be first divided into (i) 
those targeted at individuals (e.g. counselling) and (ii) those targeted at 
populations (e.g. excise tax increases).  Individual-level strategies can then be sub-
divided into (i) those targeting smoking cessation and (ii) those targeting smoking 
reduction.  The former are far more prevalent; as there is no healthy level of 
smoking, health bodies such as the NHS target smoking cessation in individuals.  
Smoking cessation strategies can be further sub-divided into (i) those designed to 
prompt quit attempts and (ii) those designed to assist quit attempts.  This case 
study focuses on strategies to assist quit attempts.  
The key aims of Chapter 3 are to (i) identify and (ii) evaluate published economic 
evaluations of interventions to assist smoking cessation aimed at individuals, in 
order to understand the methods and data employed.  Of key interest was whether 
existing studies have considered a link to alcohol use.  Evaluation of studies in the 
review included quality appraisal.  The search strategy was tailored to identify 
studies with interventions that represent current standard practice in the UK. 
It is well documented that quit attempts are substantially more successful when 
pharmacotherapy is employed [115] and experts have advised that pharmaceuticals 
should be used for smoking cessation unless there are specific contraindications 
for doing so [116].  The advice of an experienced General Practitioner (GP)1 was 
sought and further reaffirmed that it is current standard practice in the UK to use 
pharmacology as an adjunctive therapy for patients willing to stop smoking.  As a 
result, the tobacco search strategy included terms to identify relevant 
pharmacological interventions but the review did not include studies which 
evaluated the cost-effectiveness of interventions without pharmacological adjuncts.  
                                                        
1 Dr Sally Hope; The Surgery, Park Lane. OX20 1UD Woodstock, Oxfordshire  
  30 
 
The drugs varenicline, bupropion and various NRT products are licensed for 
prescription use and recommended for use as an adjunct to smoking cessation 
along with motivational support [117, 118] (NRT products are available on general 
sale [118]).   
 
3.2. Methods 
An initial scoping exercise revealed a Health Technology Assessment (HTA) of 
bupropion and NRT for smoking cessation by Woolacott et al, including a 
comprehensive systematic review of existing economic evaluations, undertaken as 
part of the NHS Research and Development HTA Programme [118].  The systematic 
review identified 17 relevant full economic evaluations [119-135].  Searches were 
performed up to May 2001, so the review is now outdated and was performed 
before the drug varenicline was available.  However, the search strategy used by 
the authors was considered to be of good quality and was pivotal in developing a 
contemporary search strategy. 
The contemporary search comprised two stages.  Firstly, the resources Econlit (via 
Ovid), NHS Economic Evaluation Database (NHS EED) (via york.ac.uk), Health 
Technology Assessment (via york.ac.uk) and the Health Management Information 
Consortium (HMIC) databases (via Ovid) were searched using search terms similar 
to those used by Woolacott et al [118].  These resources were selected to imitate as 
closely as possible the economic evaluation databases searched in 2001.  As some 
databases searched by Woolacott et al were no longer in operation (EconBase) or 
not available at this author’s institution (Office of Health Economics Economic 
Evaluation Database), the medical database MEDLINE was searched using a 
combination of search terms from Woolacott et al and the Centre for Reviews and 
Dissemination (CRD) search filter for economic evaluation studies 
(http://www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html) in order to 
capture any relevant studies that might otherwise have been missed.  The search 
strategy is replicated in detail in Figure 22 of Appendix B. 
The second stage of the contemporary search involved citation searches of the 17 
studies included in Woolacott et al’s final review using the ‘Times Cited’ function 
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available within the Web of Knowledge database.  It was reasoned that if the first 
stage of the search strategy was not comprehensive then any studies missed 
should be picked up by this second stage, as it is usual practice to cite preceding 
economic evaluation studies when reporting a cost-effectiveness analysis, even if a 
systematic search has not been used to identify informative data.   
It was anticipated that the contemporary search strategy might identify additional 
comprehensive systematic review studies in the area, published after Woolacott et 
al.  If such systematic reviews were found, it was reasoned that the sensitivity of 
the contemporary search strategy could be assessed by comparing the results of 
this systematic search with the results of other recent systematic reviews.   
The search strategy was performed in February 2011.  To identify additional 
studies published after this date, Ovid’s Auto Alert service was utilised, whereby 
newly identified studies from the searches in Medline and EconLit were delivered 
monthly in citation and abstract form to this author’s email address, up to the 1st of 
March 2014.  These citations and abstracts were scanned to identify studies which 
improved on those identified by the original search in terms of methodology.  
However, those studies excluded at this stage and the reasons for exclusion were 
not recorded. 
3.2.1. Inclusion and Exclusion Criteria 
Selection criteria were specified in terms of study type, study population, types of 
intervention and other reasons.  Identified studies were excluded if they failed to 
satisfy all inclusion criteria or met any of the exclusion criteria, specified below.  
Titles and abstract of all identified studies were screened for inclusion by one 
reviewer and full texts of potential inclusions were retrieved for further inspection. 
Study Type.  As described in Chapter 1, the NICE reference case states a preference 
for economic evaluations where effects are measured in QALYs [6].  Such cost-utility 
analyses (CUAs) are one type of economic evaluation. Different types of economic 
evaluations are defined by the nature of the consequences being assessed.  Cost-
effectiveness analyses (CEAs) quantify consequences in terms of a single, common 
effect that may differ in magnitude across comparators, such as life years [7].  CUAs 
are a sub-group of CEAs in which consequences are measured by utility.  Cost-
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benefit analyses (CBAs) measure both costs and consequences in monetary terms, 
allowing the absolute benefit of competing technologies to be assessed. It is worth 
noting that CEAs and CUAs can achieve this, if a monetary value is placed upon the 
measure of effect or utility.  Cost-minimisation analyses (CMAs) assume equivalent 
consequences across comparators and base the analysis upon costs only and are 
rarely used in health technology evaluation studies [7].  This review included CUAs, 
CEAs, CBAs and CMAs. Partial economic evaluations, cost-of-illness studies, 
commentary type studies and unpublished work were excluded.   
Study population.  Smokers from the general population of any country worldwide 
were included.  Sub-populations comprising military servicemen, pregnant women 
or patients with co-morbidities were excluded, as long-term health outcomes from 
these groups will differ, appropriate treatment may vary from that for the general 
smoking population, and it was difficult to incorporate this level of detail into the 
analysis of HILDA data detailed in Chapter 5.   
Intervention Type.  Studies assessing one or more alternative involving 
pharmacological treatment were included.  Studies assessing alternatives involving 
counselling only and studies in which the alternatives were otherwise clearly not 
relevant to UK practice were excluded.  Studies solely assessing interventions at 
the population level e.g. new legislature were excluded. 
Other.  Studies were excluded if an English language version was not available, or if 
a full text version could not be obtained. 
3.2.2. Data Extraction and Analysis 
The author extracted data from full economic evaluation studies included in the 
final review.  Data extraction tables were developed using a published checklist for 
quality appraisal of economic evaluation studies [136].  The results of the systematic 
review were analysed in a narrative review but not synthesised.  Systematic 
review studies included in the final review were discussed in the narrative review 
but did not have data formally extracted. 
For the purpose of this review, and elsewhere in this thesis, economic evaluations 
alongside a trial are categorised as ‘primary studies’.  Economic evaluations that 
use modelling techniques to estimate costs and outcomes from multiple sources 
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are categorised as ‘modelling studies’.  Quality of modelling studies in the review 
was appraised using fifteen questions taken from peer reviewed quality appraisal 
recommendation documents [15, 136]. 
3.3. Results 
Figure 2, Figure 3 and Figure 4 comprise the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [137], describing 
information about the number of potentially relevant publications identified, 
included and excluded and aggregate reasons for exclusions.  Reasons for 
exclusions at the final stage, after full publication retrievals, are reported 
separately in Table 35 of Appendix B. 
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Figure 2: Screening Abstracts Identified by the Search Strategy for Potential Inclusion 
Potentially relevant citations identified by the search 
strategy (n=354)
Citations excluded as duplicates identified electronically or by 
hand (n=43)
Potentially relevant citation titles and abstracts 
screened for inclusion/exclusion according to stated 
criteria (n=311)
Citations excluded because failed to meet inclusion criteria or 
met exclusion criteria (n=248) 
Comprising:                                                                 
Commentary-type discussion papers, surveys, policy statements, 
conference proceedings reports (n=49);                                             
Effectiveness studies (n=74);                                                                                                
Non-systematic literature reviews or systematic reviews not 
relevant to the research question (n=42);                                                                        
Non-English language papers (n=13);                                              
Other analyses not meeting criteria for an economic evaluation 
relevant to standard smoking cessation care (n=70)  
Potential publications (n=63)
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5 
Figure 3: Screening Abstracts Identified by the Citation Search of Woolacott et al’s Inclusions for Potential Inclusion 
Potentially relevant citations identified by the citation 
search (n=1045)
Citations excluded as duplicates identified electronically or by 
hand (n=333)
Potentially relevant citation titles and abstracts 
screened for inclusion/exclusion according to stated 
criteria (n=712)
Citations excluded because failed to meet inclusion criteria or 
met exclusion criteria (n=640) 
Comprising:                                                                 
Commentary-type discussion papers, surveys, policy statements, 
conference proceedings reports (n=279);                                             
Effectiveness studies (n=79);                                                                                                
Non-systematic literature reviews or systematic reviews not 
relevant to the research question (n=35);                                             
Other analyses not meeting criteria for an economic evaluation 
relevant to standard smoking cessation care (n=247)  
Potential publications (n=72)
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6 
Figure 4: Screening Potential Inclusions for Final Inclusion 
Citations identified for retrieval from database and 
citation searches (n=135) [n=63 + n=72]
Citations excluded as duplicates identified electronically or by 
hand (n=16)
Full publications retrieved (n=128)
Publications excluded because failed to meet inclusion criteria or 
met exclusion criteria (n=67) 
Reasons for exclusion reported in the Appendix, Table 2A
Full economic evaluations included in the final 
review (n=59)
Additional publications found {through hand-searching 
retrieved publications [(n=5) (3 from Woolacott et al 
inclusions + 2 from Tran et al inclusions)] or via Pubget 
(n=4)}: (n=9)
Systematic Reviews included in the final review (n=2) 
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3.3.1. Study Characteristics 
Fifty nine full economic evaluations were included in the final review, as shown in 
Figure 4.  Table 33, which is displayed in Appendix B due to its size, presents key 
methods and results from each of these studies.  None considered the effect of 
changing smoking behaviour upon alcohol behaviour, and the associated health 
and economic consequences.  
For the purpose of this thesis an HTA is defined as a full economic evaluation of 
one or more health technology where the purpose of the assessment is to directly 
inform policy. By this definition five full HTA reports were identified by the search 
strategy.  One of these studies was the report from Woolacott et al identified in the 
initial scoping exercise [118]; another was a more recent NICE-sponsored HTA 
report focusing on ‘cut down to quit’ interventions [138]; a third was a Canadian 
Agency for Drugs and Technologies in Health (CADTH) report on the cost-
effectiveness of pharmacological interventions for smoking cessation [139].  Two 
further NICE-sponsored HTAs were identified: a Single Technology Appraisal (STA) 
of varenicline [117] (manufacturer’s submission and Evidence Review Group report 
were classified as a single study) and a Rapid Review and report from a group at 
the University of York [140].   
Table 1 and Figure 5 show the distribution of country settings and plot the pattern 
of publication dates for the fifty nine economic evaluations in the review.  As Table 
1 highlights, two fifths of included studies used an American study population and 
setting; nearly two thirds of all economic evaluations of interventions for smoking 
cessation are set in either America or the UK.  The majority of the remainder of 
studies have used a European study population. However, the review does include 
studies set in Canada, Australia, Africa and East Asia. Figure 5 shows how the 
number of studies in this area published has increased markedly over time.  The 
first full economic evaluation estimating the cost-effectiveness of a smoking 
cessation intervention involving pharmacology was published in 1986 [132].  No 
further studies satisfying the inclusion criteria were published until 1994, which 
saw the publication of two further relevant economic evaluations [119, 120].  From 
this point on there has been a general upward trend in the publication rate, with 
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sixteen relevant studies being published between January 2008 and December 
2009. 
Table 1: Country of Setting for Included Economic Evaluation Studies 
Setting Percentage of Total 
Inclusions 
References 
USA 39.0% [124, 127, 128, 130, 132, 135, 141-157] 
UK 23.7% [117-120, 131, 133, 134, 138, 140, 158-162] 
Holland 5.1% [163-165] 
Australia 5.1% [166-168] 
Sweden 5.1% [169-171] 
Switzerland 1.7% [172] 
Spain 1.7% [173] 
Canada 1.7% [139] 
Belgium 1.7% [174] 
Germany 1.7% [175] 
Finland 1.7% [176] 
Seychelles 1.7% [177] 
Japan 1.7% [178] 
South Korea 1.7% [179] 
Thailand 1.7% [180] 
Cross-border 
comparison 
5.1% [181-183] 
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Figure 5: Number of Included Economic Evaluations Published by Year 
 
Eight of the fifty nine economic evaluation studies in the final review were primary 
studies [141, 142, 144, 146, 148, 154, 159, 175]; the remainder were modelling studies.  Seven 
of the 8 primary studies in the review were CEAs [141, 142, 144, 146, 154, 159, 175] and all 
bar one of these used cost per additional quitter or average cost per quit as the 
main outcome measure; one study described costs and effects separately [144].  The 
remaining primary study was a CBA and reported net monetary benefit as the 
main outcome measure [148].  Eighteen of the 51 modelling studies in the review 
were CEAs: 5 of these 18 studies used a similar main outcome measure to the 
majority of primary studies in the review [143, 153, 157, 167, 168], but the remaining 13 
studies measured outcomes in terms of cost per life year (LY) gained [119, 120, 131-135, 
145, 160, 172, 177, 180, 182].  Two of these 18 studies undertook both a CEA and a CBA [143, 
157].  Twenty seven of the 51 modelling studies in the review were CUAs [117, 118, 124, 
127, 134, 138-140, 147, 151, 156, 158, 161-166, 169-171, 174, 176, 178, 179, 181, 183] and all bar one of these 
27 studies used cost per QALY gained as their main outcome measure: the 
exception reported cost per Disability-Adjusted Life Year (DALY) gained [166].  The 
remaining 5 modelling studies in the review were CBAs: 2 of these 5 studies used a 
benefit-to-cost ratio as the main outcome measure [128, 152], while 3 reported 
outcomes as net monetary benefit from the perspective of an employer [130, 149, 155].   
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It was possible to sub-divide the 51 modelling studies by model structure type.  All 
bar one of the 51 modelling studies used cohort state-transition models; the 
remaining study used an individual-level simulation model [145].  Cohort models 
follow a group of identical individuals through a process, typically comprising 
health states in health technology appraisal applications.  Thus, cohort models can 
be used to characterise the ‘average’ experience of an individual [10].  If differences 
between individuals are important, cohort models can account for attributes such 
as age or gender by subdividing health states [14], but the number of dimensions 
will rise exponentially with subdivisions, and modelling multiple differences 
within cohorts can soon become complex.  Individual-level models simulate the 
movement of each individual with different attributes through a process [14], 
meaning the attribution of individual characteristics is less cumbersome.  There 
are calls for individual-level analyses to supersede cohort analyses as the 
preferred technique for health economic evaluations [184]. 
The study which used an individual-level simulation approach evaluated the use of 
a genetic test to tailor smoking cessation treatment [145].  This approach was 
perhaps selected over a cohort model for ease of incorporating the complexity of 
genetic differences between individuals, a complexity which other models did not 
have.  However, a cohort state-transition modelling approach is limiting even when 
genetic complexities are not considered, for example in flexible projection of 
smoking status beyond trial end points.   
Many of the recent modelling studies identified  [117, 151, 164, 170, 171, 174, 176, 179, 181, 183] 
used the Benefits of Smoking Cessation on Outcomes (BENESCO) model, developed 
for use by Howard et al in 2008 [147].  This model is an extension of the Health and 
Economic Consequences of Smoking (HECOS) model, developed and implemented 
by Orme et al in 2001 [131] and later used by Godfrey et al [160] . The BENESCO 
model is a state transition cohort model with a lifetime perspective, which has 
gained international use, but is subject to key limitations.  The model does not 
allow for the possibility that a patient may have two smoking-related diseases at 
the same time and does not allow for the possibility of more than a single quit 
attempt.  These limitations are perhaps explained by the practical constraints of 
modelling within a cohort framework.   
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Other cohort modelling studies in the review have incorporated a constant 
underlying quit rate, but have not incorporated a relapse rate which decreases 
with time since quit [118, 140, 160], a real life complexity that the BENESCO model does 
boast.  Relapse rates assumed post trial follow up varied in general across 
modelling studies in Table 33, and were typically based on dated information from 
external samples with limited follow up.  Perhaps the best example of relapse data 
was from an eight year follow-up study of 1686 patients in an RCT of NRT 
treatment (840 were successfully contacted in 1999) [185], used to inform one study 
in the review [160].  None of the studies included the costs or consequences of 
adverse events from smoking cessation interventions in analyses. 
As shown in Table 33, interventions under comparison varied across the 59 
economic evaluation studies.  The vast majority of included studies evaluated one 
or more alternatives involving some form of NRT [117-120, 124, 127, 128, 130-135, 138-141, 143-
169, 172-175, 177, 179-183].  Bupropion was licensed for smoking cessation in the UK in 
2000 [186] and the majority of studies in the review published since the turn of the 
century include bupropion in one or more study alternative [117, 118, 128, 130, 131, 139, 140, 
142-145, 147-153, 158-170, 172, 174, 175, 177, 179, 182, 183].  Varenicline was licensed as an aid to 
smoking cessation in 2006 [187] and similarly the overwhelming majority of 
included studies published since 2006 include varenicline in one or more study 
alternatives [117, 139, 143, 145, 147, 151, 158, 159, 164, 170, 171, 174, 176, 178, 179, 181, 183].  The majority 
of studies aimed to compare the optimality of different pharmaceutical 
interventions [117-120, 124, 127, 130, 132, 134, 135, 139-143, 145-148, 151, 153, 155, 156, 161-172, 174-179, 181-
183].  In these studies it was typical to offer some form of support from a health 
professional in conjunction with pharmaceuticals, and some studies also tested the 
relative optimality of different levels of support.  For a significant minority of 
studies though, the aim was to assess the optimality of some service configuration 
including pharmaceuticals, where the optimality of the pharmaceuticals 
themselves was arguably of secondary importance [128, 131, 133, 138, 152, 154, 157-159, 180].  
Three studies specifically analysed different counselling intensities in alternatives 
involving pharmacological treatment [144, 149, 150].   
Forty three of the 59 studies in the review used 12 month cessation rates as the 
primary measure of intervention effectiveness.  Eighteen of these 43 studies 
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reported that continuous cessation was measured [117, 118, 138, 139, 148, 151, 158, 161, 163, 
169-171, 176-178, 180, 181, 183]; 6 of these 43 studies used point prevalence estimates [130, 
146, 149, 150, 165, 182].  The remaining 19 of these 43 studies did not elaborate on their 
definition of 12 month smoking cessation [119, 127, 128, 132, 134, 135, 140, 142, 143, 147, 153, 162, 
164, 166, 167, 172-175].  Twelve studies reported using biochemically confirmed smoking 
cessation estimates [127, 130, 134, 139, 142, 147, 148, 158, 165, 175, 176, 178].  Aside from these 
forty three studies, eleven studies in the review used cessation rates at less than 12 
months from intervention as the primary effectiveness measure [124, 133, 141, 144, 145, 
154-156, 159, 160, 168].  3 of these eleven studies reported measuring continuous 
cessation [145, 156, 168] while 2 of these eleven studies used self-reported point 
prevalence estimates [144, 154].  Two of these eleven studies used biochemically 
confirmed effectiveness data [159, 160]; the time from intervention to measurement 
of effectiveness ranged from 4 weeks [159, 160] to 8 months [144] across the 11 studies.  
The remaining 5 studies in the review did not clearly define the period over which 
cessation was measured.   
Nineteen of the fifty nine studies in the review stated that their study population 
was motivated to quit smoking [117, 134, 139, 141, 142, 146, 149-151, 154, 158-160, 162, 166, 170, 171, 
176, 179].  Seventeen further studies accounted for willingness to quit by assuming a 
stated percentage of the study population were motivated to stop smoking [118, 124, 
128, 133, 140, 145, 147, 153, 156, 159, 164, 169, 172, 174, 177, 182, 183].  Twenty one studies did not 
make any explicit assumptions about motivation to quit [119, 120, 127, 130-132, 135, 143, 144, 
148, 152, 155, 157, 159, 161, 163, 167, 168, 173, 175, 178, 180].  Of the 2 remaining studies in the 
review, one explicitly stated that the study population did not need to be motivated 
to stop smoking [165], while one explicitly excluded smokers willing and able to 
make an abrupt quit attempt in order to answer their research question [138]. 
The main difference in the costing approach taken in the 59 economic evaluation 
studies in the review was between studies that included future medical costs for 
smoking-related diseases alongside intervention costs.  The 8 primary studies all 
had a time horizon of 1 year or less and so did not include future smoking-related 
disease medical costs (SRDMC).  Five of fifty one modelling studies had similarly 
short time horizons and so did not include SRDMC [130, 153, 155, 167, 168].  Of the 
remaining 46 modelling studies, 21 included SRDMC [117, 120, 128, 131, 139, 140, 147, 151, 160, 
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164, 166, 169-171, 173, 174, 176, 179-181, 183] and 3 studies (performed from the perspective of 
an employer or insurer) included all future medical expenses [143, 152, 157].  There 
was variation in which diseases qualified as smoking-related diseases between 
studies, but these were defined as chronic obstructive pulmonary disease (COPD), 
coronary heart disease (CHD), lung cancer, stroke and asthma exacerbations in the 
BENESCO model.   One modelling study included SRMDC for CHD only[173] . 
3.3.2. Study Findings 
Table 33 shows that when an alternative including varenicline was compared to an 
alternative including bupropion and/or an alternative including NRT in any of the 
included economic evaluation studies, the alternative including varenicline was 
consistently the most effective.  In every study where an alternative including 
bupropion was compared to one or more alternatives involving NRT, the 
alternative involving bupropion was more effective.  Similarly, alternatives 
involving NRT were consistently more effective than alternatives where 
pharmaceutical treatment was absent.  In addition, increased support alongside 
drug treatment led to higher effectiveness when this was tested and alternatives 
were generally more effective when the treatment period was extended. 
Where costs were fully reported, intervention costs for alternatives involving NRT, 
bupropion and varenicline were similar, with intervention costs for alternatives 
involving NRT often the most expensive because of the higher drug cost.  When 
SRDMC were included, the most effective alternatives generally became the least 
costly, as long-term cost savings are incurred from the prevention of smoking-
related diseases.  In the three studies where future general medical expenses were 
estimated, cost savings from the prevention of smoking related diseases were 
generally cancelled out by medical costs incurred in an extended life span [143, 152, 
157]. 
In Table 33, where a full incremental analysis was performed by the authors the 
optimal alternative is displayed in bold font.  It can be seen that in all but one study 
[168], the most effective alternative was also the optimal alternative, and even this 
anomaly might be explained by the short time horizon used by Shearer and 
Shanahan [168].  Interventions involving varenicline were therefore consistently the 
optimal alternative in recent studies. 
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3.3.3. Study Quality 
The results of the quality appraisal of modelling studies are presented in Table 34 
of Appendix B.  Overall, the quality of reporting, data identification and analysis 
was varied but reasonable across the 51 modelling studies.  All studies posed a 
well-defined and answerable research question and reported valid conclusions 
given the data presented. 
The three included HTA reports, the STA of varenicline and the NICE Rapid Review, 
along with a handful of other studies, used a systematic search and review of the 
literature to inform model parameter evidence [117-119, 132, 133, 138-140, 161, 166, 168], 
though two of these used findings from previously published systematic reviews 
[133, 166].  The remainder reported sources of model parameter data but it was not 
clear in these studies if the best available data was used. 
Philips et al identified types of uncertainty in health economic models: parameter, 
structural, methodological and population heterogeneity [15].  All bar 3 of 51 
studies assessed [120, 128, 167]  made some attempt to analyse uncertainty in their 
model results and 19 studies [117, 127, 139, 147, 151, 156, 162, 164-166, 169-171, 174, 176, 178-181]  
used probabilistic methods to analyse parameter uncertainty.  Only 4 studies [117, 
169-171] made some attempt to analyse all four types of uncertainty. 
Generally, more recent studies, such as those using the BENESCO model, were of 
higher quality, but this trend was not pronounced. Notably, the quality appraisal 
checklist does not highlight the structural limitations of the BENESCO model and 
other cohort models, noted above.  HTA studies generally satisfied more of the 
fifteen quality criteria than peer-reviewed journal studies.  Only one study satisfied 
all elements of the quality appraisal [117]. 
3.3.4. Search Sensitivity  
It was anticipated that the search strategy would identify any relevant and recently 
published comprehensive systematic review studies.  As reported above, one of the 
economic evaluation studies identified was a CADTH health technology assessment 
by Tran et al published in 2010 [139].  A key aim of the study was to compare the 
cost-effectiveness of pharmacological agents, with or without behavioural support 
programs, for smoking cessation and an extensive search of 10 databases 
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(MEDLINE, Embase, BIOSIS Previews, PsycINFO, the Cochrane library, CINAHL, 
HEED, DARE, NHS EED, HTA) was undertaken in February 2009 with search 
updates running to March 2010 [139].   
Tran et al included 25 full economic evaluation studies in their final review [118, 119, 
130, 133, 140, 142, 143, 145, 147, 148, 155, 163-170, 173, 177, 178, 182, 188, 189]; all of these were identified 
by the search performed here, though one was excluded from the final review 
because the full text for the study was unobtainable [189].  This suggests that the 
search performed here was comprehensive, but Tran et al also reported a list of 
101 excluded studies [139], which enables further analysis of the relative sensitivity 
of the current search strategy.  Several studies were included in the final review of 
the current study that were not identified by Tran et al [117, 151, 154, 158, 159, 164, 165, 171, 
174, 176, 179, 181, 183], but all of these bar two [154, 165] were published after the date of 
Tran et al’s initial search.  It is possible that one of these studies was excluded by 
Tran et al at an early stage as the authors estimated the cost-effectiveness of 
reimbursing smokers for pharmacological treatment rather than the treatment 
itself [165], but it is difficult to explain why Tran et al failed to identify the other [154].  
Several studies were identified and excluded by Tran et al but included by this 
study [120, 124, 127, 131, 132, 134, 135, 138, 149, 150, 156, 161, 172, 175, 180].  Further, there were 23 
studies that were identified and excluded by Tran et al that were not identified by 
this search strategy [190-212]; none, however, met the inclusion criteria for the 
current review.   Overall the results from Tran et al suggest that the search strategy 
used here was highly sensitive.  This suggests that scanning references and 
performing citation searches in Web of Knowledge using a selection of studies in 
the area of interest was in this instance a comprehensive and significantly less time 
consuming search method than employing highly sensitive and comprehensive 
search strategies within a selection of databases. 
In addition to the economic evaluation studies which used systematic reviews to 
inform model parameters, the search also yielded 2 stand alone systematic review 
studies in the area [115, 213]. 
Zimovetz et al aimed to identify and review economic evaluations of varenicline for 
smoking cessation by searching three key databases (MEDLINE, the Cochrane 
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Library and NHS EED) and additional sources for unpublished studies up to 
October 2009 [213].  Ten relevant published economic evaluation studies were 
identified [143, 145, 147, 148, 164, 170, 174, 176, 178, 181], all of which were identified by this 
author’s search strategy.  Ten further unpublished studies including conference 
abstracts and presentations were identified, of which one was identified as a full 
published economic evaluation by our search [179].   
Faulkner [115] also reviewed economic evaluations of varenicline for smoking 
cessation in a 2009 publication, but did not report a search strategy to identify 
studies.  Six relevant studies were included in Faulkner’s review [143, 145, 147, 148, 164, 
170], comprising the studies included by Zimovetz et al that were published in 2008 
or earlier.   
3.3.5. Recently Identified Studies 
Since this systematic search was conducted, there have been signs that the mode of 
modelling approach in the area is moving from the cohort analyses that have been 
prevalent in the review, to individual-level analyses.  The Smoking Cessation 
Treatment and Outcomes Patterns (STOP) Simulation is a recently published 
lifetime individual-level simulation model for appraisal of smoking cessation 
strategies [214, 215].  Through a patient-level approach, the STOP model is able to 
overcome the key structural constraints of cohort models identified and 
incorporate multiple changes in smoking status over the life course.   
Briefly, the model works by simulating individuals from trial data characteristics 
and predicting smoking cessation success through ‘driving’ equations for 
abstinence at 12 weeks and relapse up to 52 weeks, estimated using trial outcome 
data and sample characteristics.  Times to relapse and next quit attempt are then 
based on an analysis of a cross-sectional web-based survey of 1078 current and 
former smokers in the US [216] and a four year study of smoking behaviour among 
548 US college students [217], respectively [214].  If relapsers are predicted to 
attempt to quit again after 52 weeks, their one year quit attempt outcome is again 
predicted from the driving equations, with characteristics such as age updated and 
controlled for.  
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The STOP model considers similar smoking-related diseases to the BENESCO 
model, and has been used to compare a situation where only one quit attempt at 
the start of the model is allowed with a situation where multiple quit attempts over 
the life course are allowed [214].  Unsurprisingly, the latter predicts fewer smoking 
related disease incidences and more life years [214].  Comparison of competing 
strategies to aid smoking cessation using the model is as yet untested.   
Strengths of the STOP model are the ability to predict cessation attempt outcomes 
using patient characteristics and the ability to model multiple quit attempts over 
the life course, but the data to predict times to quit attempt and relapse after trial 
data end points are again a key limitation.  From the brief review in Chapter 2 and 
the studies identified here it is apparent that long-run patterns of smoking 
behaviour are not well evidenced or understood. 
3.4. Discussion 
This chapter has reported the results of a systematic review of economic 
evaluations of smoking cessation interventions targeting individuals.  Crucially, 
while many economic evaluations have been performed in this area, with 
increasing volumes of publications in recent years, no study has considered the 
impact of changing an individual’s smoking behaviour upon their alcohol 
behaviour, and subsequent cost and health consequences. 
Modelling techniques have been widely and increasingly used to incorporate long-
run health and health-related cost outcomes of smoking cessation strategies, in 
line with NICE guidance [6].  The model types employed in identified studies is of 
great interest.  Cohort state-transition models have been widely used in the 
appraisal of health technologies [184], and this approach could be described as 
‘standard practice’ for economic appraisal of strategies to aid smoking cessation, 
having been employed in all bar one [145] of the 51 modelling studies originally 
identified.  The cohort modelling approach has imposed limitations on these 
studies though.  Due to the difficulty of modelling multiple lifetime changes in 
smoking status within a cohort, these studies have made simple and unrealistic 
assumptions about behavioural patterns over the life course.  The most widely 
used model structure, the BENESCO model, assumes no future smoking quits are 
possible after an initial quit attempt.  Patient-level modelling offers the flexibility 
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to accurately capture complex behavioural patterns over time, and should be the 
future platform for economic analyses in this area. 
The recently published STOP simulation model [214, 215] demonstrates the benefits 
of individual-level simulation to address appraisal decisions in this area.  The 
model improves on others in the field in allowing multiple quit attempts and 
relapses over the life course and estimating cessation attempt outcomes using trial 
patient characteristics.  However, the data to predict smoking behaviour patterns 
after trial follow-up endpoints are limited. Lack of knowledge about individual 
behavioural patterns over time has been a theme of the studies analysed in this 
chapter and the brief review of evidence in Chapter 2.  Analysis of the longitudinal 
individual-level data available in the HILDA dataset detailed in Chapter 5 will be a 
valuable contribution to the knowledge base in this area.  The long-term patterns 
of smoking behaviour are clearly an important factor of the value of strategies to 
aid smoking cessation attempts. 
The results from the many economic evaluations in the review strongly suggest 
that individual-level smoking cessation aids are a cost-effective use of healthcare 
resources.  Since the pharmaceutical varenicline was licensed for use as an aid to 
smoking cessation in 2006, an alternative involving a course of varenicline has 
been evaluated in the vast majority of studies meeting the inclusion criteria, and 
the overwhelming message from the results of these studies is that interventions 
involving varenicline are the most effective and most cost-effective strategies for 
smoking cessation.  To what extent this result is due to the flawed modelling 
assumptions of cohort studies identified is not clear from this review, but will 
become clearer when results from a ‘standard practice’ cohort model in Chapter 6 
are compared with those from a patient-level model in Chapter 8. 
An individual’s smoking status has a direct impact upon their health in the long-
term and associated long-term healthcare costs. A lesson from this chapter is that 
the way these costs are accounted for in analyses can have an impact upon results.  
When long-term smoking-related disease costs were included in studies, the most 
effective study alternatives were highly cost-effective, and in some cases cost-
saving, in comparison to other alternatives.  The NICE reference case dictates that 
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such costs should be included, but future medical costs unrelated to the condition 
or technology of interest should not [6].   
Which diseases qualify as smoking-related is a further area of contention.  The 
BENESCO model has emerged as the most widely implemented model structure for 
economic evaluations of interventions for smoking cessation in individuals, and 
includes COPD, CHD, lung cancer, strokes and asthma exacerbations as smoking-
related diseases.   Methods and data to link smoking status to health in the STA of 
varenicline in the review will be useful to inform both the ‘standard practice’ 
model analysis in Chapter 6 and the individual-level analysis in Chapter 8. 
3.5. Chapter Summary 
The review presented in this chapter has highlighted that while many economic 
evaluations of pharmaceutical aids to smoking cessation have been performed, 
none have considered the link to alcohol use and its health-related consequences.  
Modelling techniques have been widely used to extrapolate beyond trial endpoints 
and incorporate long-run consequences of smoking cessation.  The vast majority of 
modelling studies have used cohort model structures, and this has contributed to 
various unrealistic assumptions about long-run behaviour which may have 
influenced results.  Regardless, cohort modelling studies and the BENESCO model 
in particular have become standard practice in the field.  Individual-level models 
offer the flexibility to incorporate complex behavioural patterns over the life 
course, as demonstrated by the recent STOP model [214], and may well become the 
standard framework for economic evaluation of strategies for smoking cessation in 
the future.  Analysis in Chapter 8 allows further evaluation of the relative benefits 
of individual-level modelling in this area.  
This review has also served to further highlight the lack of evidence on long-term 
patterns of smoking behaviour.  This could be of great consequence for economic 
evaluation estimates: long-term patterns of smoking behaviour, and what 
determines these patterns are clearly important for cost-effectiveness estimates.  
This chapter has thus further motivated the analysis of HILDA data in Chapter 5.  
Before this though, Chapter 4 presents a systematic review of economic 
evaluations of strategies to improve alcohol use. 
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4. Chapter 4: Systematic Review of economic 
evaluations of individual-level interventions to 
change alcohol behaviour 
4.1. Introduction 
While the review of economic evaluations of treatments for smoking cessation in 
the previous chapter focussed on interventions involving pharmacotherapy, 
standard alcohol treatment does not routinely include pharmacological treatment 
and so no such restrictions were in place here.  Further, while individual-level 
treatment to change smoking behaviour aims for cessation, the goal in alcohol 
treatment is sometimes reducing consumption and/or changing consumption 
patterns, rather than abstinence.  As a result, the scope of interventions amenable 
to current standard practice for alcohol treatment for individuals in the UK was 
considered to be broad. 
The key aims of Chapter 4 are to (i) identify and (ii) evaluate published economic 
evaluations of alcohol reduction and cessation interventions aimed at individuals, 
in order to understand the methods and data employed, with the need to link 
alcohol use to health consequences in Chapter 7 in mind, but with keen interest 
also in whether links to smoking behaviour have been considered.  Evaluation of 
studies in the review included quality appraisal.  The search strategy was tailored 
to identify studies with interventions that represent current standard practice in 
the UK. 
4.2. Methods 
An initial scoping exercise identified a systematic review of economic evaluations 
of alcohol treatment, published in 2010  by Barbosa et al [218].  Further 
investigation revealed that this systematic review and a subsequent economic 
evaluation study formed part of a successful UK PhD thesis by the lead author [219].  
The inclusion and exclusion criteria for the review were similar to those needed 
for the current review and the search timeline ran to February 2009 [218].  The 
search was applied primarily to the database NHS EED, but the authors correctly 
observed that this database searches MEDLINE, EMBASE, PsychINFO and CINAHL 
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for potential economic evaluations [218].  In addition, Barbosa et al performed a 
separate search in MEDLINE covering the period January 2008 to February 2009 
for relevant records not yet reviewed and added to the NHS EED [218].  The search 
terms were appropriate and thorough; therefore an update to Barbosa et al’s 
search in NHS EED (via york.ac.uk, 1st January 2009 to 28th February 2011) and 
MEDLINE (via Ovid, 1st January 2009 to 28th February 2011) was deemed almost 
sufficient for the present review.  In addition, a similar search of the database 
Health Technology Assessment (via york.ac.uk) was run for all years up to 28th 
February 2011 as the previous strategy may have been insensitive to important 
health technology assessments only otherwise available directly from individual 
funding agencies around the world [220].  Reference lists from each included study 
were screened for potential inclusions and the search strategy is replicated in full 
in Figure 23 of Appendix C. 
Though Barbosa et al did not cite any previous systematic review studies in the 
area, it was anticipated that the contemporary search strategy might identify 
additional relevant systematic review studies [218].  It was hypothesised that the 
results from any such study, plus screening the references of included studies, 
would provide evidence for the degree of sensitivity of the search strategy.   
As stated, all searches were run in February 2011.  As for the review reported in 
the previous chapter, Ovid’s Auto Alert service was utilised to identify additional 
studies published after this date, whereby newly identified studies from the 
searches in Medline and EconLit were delivered monthly in citation and abstract 
form to this author’s email address, up to the 1st of March 2014.  These citations 
and abstracts were scanned to identify studies which improved on those identified 
by the original search in terms of methodology.  However, those studies excluded 
at this stage and the reasons for exclusion were not recorded. 
4.2.1. Inclusion and Exclusion Criteria 
Selection criteria were specified in terms of study type, study population, types of 
intervention and other reasons.  Identified studies were excluded if they failed to 
satisfy all inclusion criteria or met any of the exclusion criteria, specified below.  
Titles and abstract of all identified studies were screened for inclusion by one 
reviewer and full texts of potential inclusions were retrieved for further inspection. 
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Study Type.  Full economic evaluations (CEAs, CUAs, CBAs or CMAs) and systematic 
reviews of full economic evaluations were included.  Partial economic evaluations, 
cost-of-illness studies, methodological studies, commentary type studies and 
unpublished work were excluded.   
Study population.  Individuals from any country worldwide at which treatment to 
alter alcohol consumption was directed were included.  Sub-populations 
comprising military servicemen, pregnant women or patients with co-morbidities 
were excluded, as long-term health outcomes from these groups will differ, 
appropriate treatment may vary from that for the general population, and it was 
difficult to incorporate this level of detail into the analysis of HILDA data in 
Chapter 5.   
Intervention Type.  Studies assessing one or more strategy to counter excessive 
alcohol use, alcohol abuse, problem drinking or alcohol dependence were included.  
Studies solely assessing screening alternatives without follow-up treatment were 
excluded.  Studies solely assessing interventions at the population level e.g. new 
legislature were excluded.  
Other.  Studies were excluded if an English language version was not available, or if 
a full text version could not be obtained.  
4.2.2. Data Extraction and Analysis 
The author extracted data from the full economic evaluation studies included in 
the final review. Twenty seven full economic evaluations were identified and 
reviewed by Barbosa et al [221-247] and these studies were included in the final 
review alongside further studies identified by the search.  Data extraction tables 
were identical to those used in the previous chapter and populated using a 
published checklist for quality appraisal of economic evaluation studies [136].  The 
results of the systematic review were analysed in a narrative review but not 
synthesised.  Any systematic review studies included in the final review were to be 
discussed in the narrative review but without data formally extracted, and used to 
assess the sensitivity of the search strategy, as in Chapter 3.   
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Quality of economic evaluation studies in the review was appraised using fifteen 
questions taken from peer reviewed quality appraisal recommendation documents 
[15, 136]. 
4.3. Results 
Figure 6 comprises the PRISMA flow diagram, describing information about the 
number of potentially relevant publications identified, included and excluded and 
aggregate reasons for exclusions [137].  Reasons for exclusions at the final stage, 
after full publication retrievals, are reported separately in Appendix C, Table 38. 
  54 
 
Figure 6: Identification of Studies in the Review 
Potentially relevant citations identified by the search 
strategy (n=233) Citations excluded as duplicates identified electronically or by 
hand (n=14)
Potentially relevant citation titles and abstracts 
screened for inclusion/exclusion according to stated 
criteria (n=219)
Citations excluded because failed to meet inclusion criteria or 
met exclusion criteria (n=194) 
Comprising:                                                                 
Commentary-type discussion papers, surveys, policy statements, 
conference proceedings reports (n=29);                                             
Effectiveness studies (n=26);                                                                                                
Non-systematic literature reviews or systematic reviews not 
relevant to the research question (n=24);                                                                        
Non-English language papers (n=13);                                                            
Inaccessible studies (n=1);                                                                                                
Other analyses not meeting criteria for an economic evaluation of 
intervention(s) to reduce/cease alcohol consumption (n=101)  
Full publications retrieved and screened for 
inclusion/exclusion (n=25)
Publications excluded because failed to meet inclusion criteria or 
met exclusion criteria (n=11) 
Reasons for exclusion reported in Table X
Publications included by Barbosa et al (n=27)
Full economic evaluations included in the final review 
(n=40)
Systematic Reviews included in the final review (n=1)
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4.3.1. Study Characteristics 
Forty full economic evaluations were included in the final review, as shown in 
Figure 6, and details of key methods and results from these forty studies are 
reported in Table 36, which is displayed in Appendix C due to its size.  None of 
these studies considered the effect of changing alcohol behaviours upon smoking 
behaviour, and the associated health and economic consequences.  Two studies [248, 
249] used data from respective previous studies [228, 247] to perform economic 
evaluations from alternative viewpoints; these studies are treated as stand-alone 
studies in this review. 
Three of the economic evaluation studies identified by the search strategy were 
full HTA reports.  Two of these reports were recent NICE clinical guideline 
documents which included CUAs: one estimated the cost-utility of the diagnosis 
and clinical management of acute alcohol withdrawal patients [250]; the other 
estimated the cost-utility of adding pharmacological treatment to psychological 
therapy for individuals in recovery from alcohol dependence [251].  The third HTA 
identified was a report of the cost-effectiveness of strategies to prevent relapse in 
alcohol dependent patients from the Health Technology Board for Scotland [252]. 
Another study identified was a NICE funded investigation into screening and brief 
intervention for problems linked to excessive alcohol consumption using the 
Sheffield Alcohol Policy Model (SAPM) [253].  This model was developed by the 
Sheffield Alcohol Research Group (SARG) at the University of Sheffield to inform a 
range of alcohol policy questions.  The crux of the model links alcohol consumption 
in an English general population sample to alcohol-related health effects and costs.  
Using different data to inform the link between policy and alcohol consumption, 
the SAPM has been used by the SARG to analyse the potential consequences of 
pricing policies, availability laws and advertising policies, as well as brief 
interventions aimed at individuals [253].   
Table 2 and Figure 7 show the distribution of country settings and plot the pattern 
of publication dates for the forty economic evaluations in the review.  There have 
been fewer publications of economic evaluations of individual level interventions 
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to change alcohol behaviour than economic evaluations of individual-level 
interventions to assist smoking cessation, but the patterns of publications across 
jurisdictions and time hold similar traits. As Table 2 shows, 30% of all inclusions in 
this review were set in the USA; another 30% were set in the UK.  Apart from these, 
a significant number of studies have been set in Australia.  The remainder were 
conducted using a study population and setting elsewhere in Europe, in Canada or 
in Brazil.  No relevant study set in Africa or Asia was identified.  As can be seen in 
Figure 7, there has been a general rise in the number of economic evaluations 
published in the area each year over the past fifteen years, peaking in 2010, the 
last full year recorded.  The first economic evaluation of individual level treatment 
to change alcohol behaviour was published in 1996, a decade after the first 
economic evaluation of smoking cessation interventions.   
 
Table 2: Country of Setting for Included Economic Evaluation Studies 
Setting Percentage of Total 
Inclusions 
References 
USA 30.0% [222, 227-231, 237, 240, 247-249, 254] 
UK 30.0% [221, 223, 233, 234, 239, 241, 250-253, 255, 256] 
Australia 17.5% [225, 226, 235, 244, 246, 257, 258] 
Germany 10.0% [224, 238, 242, 243] 
France 2.5% [236] 
Holland 2.5% [259] 
Sweden 2.5% [232] 
Canada 2.5% [245] 
Brazil 2.5% [260] 
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Figure 7: Number of Included Economic Evaluations Published by Year 
 
Twenty three of the forty economic evaluations in the final review were primary 
studies [221-224, 227, 228, 230, 231, 233, 234, 236, 237, 239-242, 244, 245, 247, 248, 256, 258, 260].  As the data 
in Table 36 shows, the primary outcome measure in these studies varied greatly, 
including: (i) number of days abstinent; (ii) number of drinks per day; (iii) 
measures of binge drinking. Nineteen of these studies were CEAs [221-224, 227, 230, 231, 
233, 234, 236, 237, 240, 242, 244, 245, 247, 248, 258, 260];  the main outcome measure in these 
studies was in most cases some comparison of primary outcome relative to costs, 
though several primary CEA studies reported costs and outcomes separately [221, 
224, 230, 233, 234, 236, 245].  The three primary CUA studies measured outcome as 
cost/QALY gained using EQ-5D estimates [239, 241, 256], while the one primary CBA 
study measured outcome as net monetary benefit to (i) the healthcare payer and 
(ii) society [228]. 
 The remaining 17 economic evaluations in the final review were modelling studies 
[225, 226, 229, 232, 235, 238, 243, 246, 249-255, 257, 259].  There was not a single model structure 
that was used consistently across these studies, though the SAPM model has been 
used in various applications not separately reviewed here [33, 261-263].  Table 36 
shows that the primary measure of effectiveness again varied from study to study, 
and included: (i) number of days abstinent; (ii) mean alcohol consumption; (iii) 
measures of binge drinking; (iv) hospital admissions; and (v) drink driving rates.  
Six of these studies were CEAs and measured outcome as either cost per life year 
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gained [232, 238, 246] or some comparison of primary outcome relative to costs [226, 243, 
252].  The one modelling CBA study in the review used net monetary benefit as the 
main outcome measure [249].  The majority of modelling studies in the review 
however, were CUAs, and all bar two CUAs used cost per QALY gained as the main 
outcome measure; the two remaining CUA studies were set in Australia and used 
cost per DALY gained [257] and cost per years lived with disability averted [225] as 
main outcome measures, respectively. 
It was again possible to sub-divide the modelling studies by model structure type.  
No study in the review performed an individual-level analysis; all used cohort 
model structures.  Several studies with short time horizons used untimed decision 
tree type structures [225, 226, 243, 250-252]; the remainder were timed state-transition 
models. Unsurprisingly given this lack of model complexity, studies extrapolating 
to alcohol use in the long-run made simplistic assumptions about long-term 
alcohol use patterns [232, 235, 238, 246, 252, 253, 255, 257, 259], generally involving a 
percentage of sustained effect or an assumed relapse rate where drinking states 
were modelled, as reported in Table 36.  
The length of time over which effectiveness was measured also differed across 
economic evaluations in the review.  In all bar one of the twenty three primary 
studies reviewed effectiveness was measured from intervention until the end of 
the trial time horizon.  The remaining primary study measured effectiveness from 
12 months before intervention to the end of the trial time horizon [237].  For twelve 
of twenty three studies, the time horizon spanned 12 months , but across the 
remaining eleven primary studies, effectiveness was measured over periods 
ranging from 12 weeks [231, 258] to 3 years [230, 237].  In the seventeen modelling 
studies in the review the length of time over which primary effectiveness was 
measured was not always explicitly reported, as indicated by the absence of such 
details for respective studies in Table 36.  Otherwise, primary effectiveness was 
measured over 12 months [235, 251, 252, 255, 259], 96 weeks [243] or 3 years [229]. 
As the primary outcome measure was much varied across the forty economic 
evaluations in the review, so were the interventions under comparison, and study 
populations at which these interventions were aimed.  Ten studies included one or 
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more alternative involving pharmacology [238, 242, 243, 247, 248, 250-252, 257, 258] and the 
drugs administered included acamprosate, naltrexone and disulfiram. These 
interventions were always targeted at individuals with alcohol dependency, 
usually newly detoxified.  The NICE HTA of treatment regimes for acute alcohol 
withdrawal was unique within the review in comparing alternatives including 
oxazepam, chlordiazepoxide, clomethiazole and lorazepam.   Three studies 
compared in-patient detoxification of alcohol dependent patients with some form 
of alternative detoxification strategy [234, 239, 240], but the majority of studies in 
Table 36 have compared alternatives involving varying degrees of counselling and 
personal intervention techniques from health professionals for patients with 
ranging alcohol problems [222-233, 235, 237, 241, 244, 245, 249, 254-256, 259, 260].  Aside from 
these, one study has compared different levels of training for health professionals 
to implement brief interventions [246] and another has compared the impact of the 
same detoxification regime for alcohol dependent patients across 4 different 
centres [236]. 
One trend that is clear from Table 36 is that there is some distinction between the 
types of treatment aimed at hazardous or harmful drinkers, as defined by their 
alcohol consumption, and dependent drinkers, often defined by an instrument or 
tool such as Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria 
[264].  Thirteen of the forty studies defined their target population by their drinking 
habits rather than a measure of mental or use disorder [222-224, 226, 228, 232, 245, 246, 249, 
253, 255, 256, 259], and the interventions in these studies were typified by some form of 
motivational or psychological support, and not in-patient or pharmacological 
treatment.   
As in the review of economic evaluations of smoking cessation interventions in the 
previous chapter, a key difference in costing methods across the modelling studies 
in this review was whether or not studies included future medical costs alongside 
intervention costs.  Six of the 17 modelling studies in the review included future 
alcohol-related disease costs in their base case analysis [238, 243, 252, 253, 255, 257]; the 
alcohol-related diseases considered were wide ranging but not consistent across 
studies, and included heart disease, stroke, pancreatitis, liver cirrhosis, alcohol 
dependence syndrome and various cancers.  The SAPM considered 47 diseases and 
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health events linked to alcohol [253], based on extensive research of evidence on 
harm related to alcohol [265], by far the most extensive battery of diseases and 
health-related events considered by any study in this review.  Two further studies 
included general future medical costs alongside intervention costs in total cost 
estimates [232, 259].  Further differences in costing methodologies across studies in 
the review were consistent with the range of study perspectives employed, as 
described by the data in Table 36. 
4.3.2. Study Findings 
As the interventions assessed, measures of effectiveness, and to some extent the 
specific study populations varied greatly across the forty studies in the review, it 
was difficult to identify consistent findings.  As in Table 33, the optimal alternative 
in Table 36 is displayed in bold font, where an incremental analysis has been 
performed.  Effectiveness was not always summarised as a rate or odds ratio, and 
it was difficult to analyse the interaction between effectiveness and economic 
optimality across studies because of this, and because only fifteen of forty studies 
were considered to report an incremental analysis [223, 228, 229, 234, 237, 238, 243-245, 249, 
251, 253, 254, 258, 260].   
Of the thirteen studies that targeted individuals based on their alcohol 
consumption, only four studies identified economically optimal alternatives after 
performing incremental analyses [223, 228, 245, 249, 253].  Three of these studies found 
some form of brief intervention from a health professional preferable to a cheaper 
alternative such as an information leaflet [223, 228, 249] (though two studies used the 
same data [228, 249]). Another study found an intervention consisting of information 
on drinking guidelines to be preferable to motivational enhancement with 
personalised feedback, because there was no statistically significant difference in 
effectiveness of the two alternatives [245].   
In the studies that assessed one or more alternative involving pharmacology 
targeted at alcohol dependent patients, regimens of the drugs acamprosate and 
naltrexone have been found to be effective and cost-effective as respective 
adjuncts to some kind of psychological care, in maintaining abstinence in newly 
detoxified alcoholic patients [238, 243, 251, 258].  One study has compared an alternative 
including naltrexone to an alternative including acamprosate, but did not find 
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evidence that one drug is more effective than the other in maintaining abstinence 
[251].  In a study targeting patients seeking help for alcohol problems or categorised 
as alcohol dependent, outpatient and day programmes for detoxification were 
generally found to be economically preferable to residential treatment, due mostly 
to the high intervention costs of the latter [234].  Another study found that personal 
follow-up care in the form of home visits was an important driver of effectiveness 
in outpatient detoxification [260]. 
Of the six modelling studies that included future alcohol-related disease costs in 
their analyses, in the two studies where effectiveness rates were clearly reported 
and incremental analysis was performed, the most effective alternative compared 
favourably with its comparator(s) [243, 252].   However, there was evidence from one 
study that intervention costs for some alcohol cessation programmes, such as in-
patient programmes for alcohol dependents, might be so high that a reduction in 
long-term costs for more effective interventions  would not be enough to justify the 
initial outlay [257].   
4.3.3. Study Quality 
The results of the quality appraisal of modelling studies are presented in Table 37 
of Appendix C.  Overall, the quality of reporting, data identification and analysis 
was reasonable across the 17 modelling studies, and of a similar standard to the 
modelling studies reviewed in Chapter 3.  Of course, as in Chapter 3, the quality 
appraisal checklist used does not account for the limitation inherent in cohort 
state-transition modelling of long-run behavioural patterns.  Again, all studies 
posed a well-defined and answerable research question and reported valid 
conclusions given the data presented. 
The three HTA-type analyses [250-252], the NICE funded analysis using the SAPM [253] 
and an analysis forming part of a UK PhD thesis [255] were the only studies to use a 
systematic search and review of evidence to inform model parameters.  These 
studies also generally satisfied more of the fifteen quality criteria than peer-
reviewed journal studies.   
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4.3.4. Search Sensitivity 
It was anticipated that the sensitivity of the search strategy used by Barbosa et al, 
and relied upon here, could be assessed by comparing the results of the search to 
those of other similar searches performed over the same time period.  The most 
recent economic evaluation identified for inclusion in this review was the HTA 
study comprising part of a NICE guidance document on care for alcohol 
dependence and harmful alcohol use [251].  The review team searched the databases 
EMBASE, MEDLINE, HTA, PsycINFO, CINAHL, EconLit and NHS EED to identify 
economic studies and HTA reports on interventions relevant to care for alcohol use 
disorders [251].  These searches identified fifteen studies that met the review team’s 
inclusion criteria: two of these studies were published after Barbosa et al’s search 
but identified for inclusion in the updated search performed here [256, 258] .  Of the 
remaining thirteen studies identified by the NICE review team, ten were included 
in the Barbosa et al review and two were cost studies, thus not meeting the 
inclusion criteria set out by Barbosa et al, or stated here.  The outstanding study 
identified by the NICE review team did meet the inclusion criteria for this review, 
and was identified by this author’s search of the HTA database [252]. 
It should be recognised that as Barbosa et al identified and included seventeen 
economic evaluation studies that were not included in the NICE review [222-226, 228-
234, 236, 237, 244-246], it is highly plausible that relevant studies not identified here 
would not have been included by the NICE review team.  However, the results of 
the NICE review suggest that the search strategy used by Barbosa et al was 
sensitive in general, but insensitive specifically to Health Technology Assessments 
available directly from individual funding agencies and the HTA database.  As the 
updated search used here anticipated this shortcoming in the Barbosa et al search 
strategy and included an all-years search of the HTA database, the implication is 
that the search strategy used here was sensitive. 
Aside from the systematic review identified in the exploratory search and used to 
develop the search strategy [218], no further stand alone systematic review of 
economic evaluations of individual-level interventions to change alcohol behaviour 
was identified. 
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4.3.5. Recently Identified Studies 
Intermittent citation searches since February 2011 have revealed no significant 
methodological progress in models for economic appraisals of individual-level 
strategies for alcohol use behaviour change; no individual-level modelling studies 
have been identified.   
4.4. Discussion 
This chapter has reported the results of a systematic review of economic 
evaluations of alcohol behaviour change interventions aimed at individuals.  Only 
limited data could be found to test the sensitivity of the search, but there is 
indication that the search strategy was sensitive.   
Though not as numerous as economic appraisals of strategies to aid smoking 
cessation, many economic evaluations have been performed in this area, with a 
significant number of studies set in the UK, and some indication that the rate of 
publications in increasing. Still, no study has considered the impact of changing an 
individual’s alcohol behaviour upon their smoking behaviour, and subsequent cost 
and health consequences. 
A significant number of modelling studies were identified, and in many cases these 
studies extrapolated effects beyond effectiveness data end points.  All used cohort 
models and made simplistic assumptions about behavioural trends in the long-run.  
In studies assessing treatment options for alcohol dependence, this involved 
making assumptions about a relapse rate [238, 252, 257].  In studies where 
consumption among non-dependent drinkers was targeted, assumptions about 
duration of intervention effect were made [232, 235, 246, 253, 259].  As with long-run 
smoking patterns in the previous chapter, these assumptions were based on little 
evidence.  Indeed, long-run data on alcohol use patterns is lacking [235, 257].  While 
important health outcomes depend on behaviour years and decades into the 
futures, trial follow-up end points are typically much, much shorter.   Health 
economic models to assess strategies to improve drinking behaviour, much like 
models to appraise smoking cessation strategies, can be improved in the future in 
two key ways,  First, with better data to inform projections of long-term behaviour.  
Second, with individual-level model structures to allow complex individual-level 
behaviour to be captured. 
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Analysis of the longitudinal alcohol use data in HILDA in Chapter 5 will contribute 
to the existing knowledge about individual-level patterns of alcohol use.  What the 
dataset does not capture though, is information about alcohol use disorders.  It is 
possible to predict alcohol dependency using consumption data, but perhaps the 
best avenue to improved understanding of long-run behavioural outcomes in 
alcohol dependence patients is improved trial follow-up.  A recent study reported 
7-year follow up of 127 alcohol dependence patients [266].  In the future, larger 
trials with repeated follow-up over this length of time frame or longer should be 
encouraged to understand long-run behavioural patterns in alcohol dependent 
patients post treatment. 
The health consequences of sustained reductions in alcohol use in the general 
population are considerable, and the next chapter will help inform the possible 
long-term consequences of changes in alcohol use.  These findings will be primarily 
useful in informing long-run projections of alcohol use following smoking 
cessation treatment in the economic appraisal in Chapters 7 and 8, but will also 
provide evidence for use in future appraisals of individual- level strategies to 
reduce alcohol consumption.  Among reviewed studies targeting behaviour change 
in drinkers defined by their alcohol consumption, some form of motivational or 
psychological support was generally found to be effective and cost-effective 
compared to a less costly alternative, such as information pamphlets.   
A key aim of this chapter was to establish methods and data to link alcohol use to 
health in the de novo economic appraisal model described in Chapter 7. As 
discussed in Chapter 3, NICE methods guidance dictates that relevant long-term 
costs should be considered in health technology appraisals [6].  Only six of the 
seventeen modelling studies in the review considered alcohol-related disease costs 
[238, 243, 252, 253, 255, 257], and the diseases considered varied across these studies.  The 
analysis of the SAPM considered 47 diseases and health events linked to alcohol 
[253], based on extensive research of evidence on harm related to alcohol [265], by far 
the most extensive battery of diseases and health-related events considered by any 
study in this review.  The data and methods employed to link alcohol use to health 
effects in this study were the most thorough and appropriate for use in this project. 
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4.5. Chapter Summary 
The discussion points raised by the review presented in this chapter have 
mirrored those of Chapter 3.  Forty relevant economic appraisal studies were 
identified, yet none have considered the link between alcohol and tobacco use. 
Modelling techniques have been used to extrapolate beyond trial end points and 
incorporate long-run consequences of changes to alcohol behaviour.  Cohort model 
structures have been used consistently, and this along with data limitations has led 
to various unrealistic assumptions about long-run behaviour which may have 
influenced results.  Nevertheless, methods and data to link alcohol use to health in 
Chapters 7 and 8 have been identified in a recent application of the SAPM [253].  
Overall, Chapters 3 and 4 have shown that while the economics of strategies for 
smoking cessation and alcohol reduction are not under-researched areas, existing 
studies have generally used cohort analyses, when individual-level modelling is a 
far more suitable approach to capture the complexity of these behaviours.  
Chapters 2, 3 and 4 have together highlighted a narrative of limited knowledge 
about long-run patterns of smoking and drinking behaviour.  Next, Chapter 5 aims 
to contribute evidence in this area, for use in economic appraisal models and 
elsewhere, with analysis of HILDA data. 
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5. Chapter 5: The Dynamics and Interdependency of 
Smoking Status and Alcohol Use: Evidence from 
HILDA 
5.1. Introduction 
Chapter 2 presented existing evidence that smoking and alcohol use are related 
behaviours.  Chapters 3 and 4 underlined that economic appraisals of strategies to 
influence smoking or alcohol use in individuals have not considered the 
implications of such a link.  Together, Chapters 2, 3 and 4 have highlighted the lack 
of analyses on the long-run link between alcohol use and smoking, but also the 
probable lack of analyses of long-run patterns of behaviour for each separately.  
Longitudinal survey data offer an opportunity to estimate causal behavioural 
relationships and produce evidence on the interrelated and dynamic natures of 
alcohol use and smoking, in a form that is useful to better inform assumptions 
about long-run behaviour in future economic appraisals.  A key aim of Chapter 5 is 
to generate such evidence for use in economic models. 
The analysis uses nine waves of data from HILDA.  HILDA contains rich 
longitudinal individual-level data on alcohol and tobacco use, as well as a range of 
important socio-economic confounding factors, and represents the best available 
data source [111]. The core analysis jointly estimates the dynamics of tobacco and 
alcohol use.   
Chapter 5 is structured as follows.  Section 5.2 reviews existing studies which have 
aimed to estimate links between alcohol use and smoking.  Section 5.3 then 
describes the rational addiction theoretical framework underpinning the analysis.  
Section 5.4 sets out the econometric framework and estimation procedure.  Section 
5.5 briefly recounts the characteristics of HILDA and describes the variables 
employed in the analysis.  Section 5.6 presents model results.  Section 5.7 then sets 
out how these results can be used to project long-term behaviour in economic 
appraisal models. Finally, Section 5.8 then discusses and evaluates the results, with 
consideration of their usefulness and various limitations for the purpose of this 
thesis and elsewhere, before the chapter is summarised.   
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5.2. Literature Review 
An exploratory search for existing econometric analyses estimating links between 
smoking and drinking using individual-level data was performed using the 
database Econlit (via Ovid).  The initial search comprised the following: [(alcohol$) 
and [(tobac$ or cigaret$ or smok$)]].  Following this search, citation searches using 
key identified studies were intermittently performed.  The studies found varied in 
terms of questions addressed, data and methodology. 
Only one study used panel data with individual-level socioeconomic information to 
estimate the relationship between tobacco behaviour and alcohol behaviour.  
Picone et al took advantage of a natural experiment in the form of public smoking 
bans and price increases across American states to test the impact of tobacco 
policy upon alcohol consumption in their 2004 publication [267].  Data from the first 
six waves of the Health and Retirement Survey (HRS), a health and socio-
demographic panel survey beginning in 1992 with a sample of individuals aged 51 
to 61 years, with successive waves every two years, was supplemented with price 
data on alcohol and cigarettes [267].   
Picone et al based their econometric strategy upon a rational addiction theoretical 
framework, described further in Section 5.2, whereby individuals maximise their 
utility by consuming addictive goods (tobacco and alcohol) and non-addictive 
goods subject to a budget constraint [267].  Assuming a quadratic utility function, 
the authors derived reduced-form equations for tobacco and alcohol consumption: 
 
                                                                
           
(4)  
 
In equations (4) and (5),               are respective tobacco and alcohol 
consumption for individual i at time t,     is a vector of observable determinants of 
alcohol and tobacco consumption,    is the composite of non-addictive goods in 
                                                                
         
(5)  
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time t and                      are the prices of           that individual i faces at 
time t. Time-invariant unobservable individual factors that influence tobacco and 
alcohol consumption, such as personal taste, are modelled by     and    , 
respectively, while      and      are respective error terms for the two equations.   
Econometric models such as that estimated by Picone et al are useful if their 
parameter estimates have causal interpretation.  In simple terms, the causal effect 
of a change in an explanatory variable upon the outcome in an econometric 
equation is measured by some transformation of its parameter value, when all 
other explanatory variables in the model (observed and unobserved) are held 
constant [268].  Causal interpretation is not achievable when it is impossible to 
change an explanatory variable while holding all other explanatory factors 
constant.   This is the case when observed explanatory variables are correlated 
with unobserved explanatory variables, which in Picone et al’s specification 
comprise the time-invariant unobservable effects     and     and the time-variant 
errors      and     .   In econometric models, explanatory variables are described 
as exogenous when they are uncorrelated with the unobserved explanatory 
variable(s) (and endogenous when they are not) [268]. 
Picone et al recognised that unobserved preferences for tobacco (alcohol) are 
correlated with         and likely         in equation (4) (        and likely         in 
equation (5)), and used a first-differences transformation (removing all variation 
between observations at the same time-point to leave only ‘within’ variation) to 
eliminate     and    .   
Recognising that lagged first differences in tobacco and alcohol were potentially 
correlated with the transformed error terms, the strategy was then to find a set of 
instrumental variables for          and          (uncorrelated with       and      ) 
[267].  Instrumental variables can be useful when causality cannot be established.  
Essentially, observable variables correlated with endogenous variables, but 
uncorrelated with other variables in the model, act as ‘instruments’ for the 
endogenous variables.  The instruments used by Picone et al were taken from 
lagged levels of      and      and lagged differences in prices.  
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Picone et al estimated equations (4) and (5) separately, for male and female sub-
samples [267].  Results showed instrumented lagged smoking and drinking to have a 
modest and not always significant effect upon alcohol and tobacco consumption.  
The reinforcement effect of past cigarette consumption upon present cigarette 
consumption was more important than the cross-behaviour effect of past alcohol 
consumption, and similarly past alcohol use was more important than past 
smoking in explaining current alcohol consumption. Increasing the price of 
cigarettes was shown to increase alcohol consumption, while smoking bans 
appeared to lead to reduced consumption of alcohol among females.  Taken at face 
value, this implies that cigarettes and alcohol are both complements and 
substitutes in consumption: potentially contradictory results.  However, price 
increases and clean air laws are clearly different types of policies, and are difficult 
to compare. Picone et al argued that these results could reflect different consumer 
types responding to price increases and physical smoking restrictions in different 
ways:  for those who primarily drink alcohol socially, at pubs and bars, cigarettes 
are a complement to alcohol, whereas for those who drink primarily to relieve 
stress, cigarettes act as a substitute [267].  Though speculative, this argument 
correctly highlights that the relationship between alcohol behaviours and cigarette 
behaviours may be different for different sub-groups. 
Overall, the work of Picone et al has been most useful in underlining the 
importance of addiction and difficulty of addressing the problem of endogeneity in 
modelling the dynamic links between alcohol and tobacco use.  However, by 
eliminating unobserved time-invariant effects in their approach, and estimating 
equations separately, Picone and colleagues were then not able to quantify the 
correlation between preferences for alcohol and tobacco use; something that 
would be a useful addition to the literature.   
No further relevant analyses have employed panel data.  Goodman used data from 
the 2001-2002 NESARC, a familiar dataset from the brief review in Chapter 2, to 
estimate the determinants of alcohol, tobacco and unspecified illicit drug 
participation [269].  Goodman was interested in the endogenous nature of these 
decisions, and modelled the joint participation decisions using a multinomial logit 
model [269].   
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Briefly, a logit model could be described by equation (6): 
               
 
(6)  
               
 
             
 
 
Where    is a latent variable,   is a vector of exogenous explanatory variables and 
  has a mean value of zero and is assumed to follow a logistic distribution [96].  The 
logit model (and equally the probit model, which differs in that it imposes a 
normality assumption on the distribution of the error term) is thus useful in 
estimating the determinants of a binary variable, such as the decision of whether 
to participate in an activity or behaviour.   
The logit model extends to the unordered multinomial logit model when the 
dependent variable constitutes a single choice between J unordered alternatives.  
It is possible to describe such a multinomial logit model by the following equation 
[96]: 
    (    )  
 
     
∑       
 
   
      
(7)  
 
                  
 
In the context of Goodman’s model, the dependent variable comprised eight 
alternatives (J=7 in equation (7)) with corresponding probabilities, from not 
participating in alcohol, cigarettes or drug use, to participating in all three 
behaviours.   
Consistent estimation of the multinomial logit model parameters by maximum 
likelihood is reliant on the condition that the odds ratios are independent of 
alternatives in the model [96]; this condition is known as independence from 
irrelevant alternatives (IIA) [96].  IIA imposes that the probability of choosing 
between two alternatives should not be affected by the addition of a third 
alternative.  IIA is a helpful assumption for estimation, but is fallible in the context 
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of many real-world multiple-choice problems.  Goodman tested the assumption of 
IIA by testing whether the parameter estimates systematically change when 
supposedly irrelevant choices are omitted from the model.  In doing so, Goodman 
tested the impact of (i) adding the choice of recreational drugs participation to the 
tobacco and alcohol choices; (ii) adding the choice of alcohol to the tobacco and 
drugs choices; (iii) adding the choice of tobacco to the alcohol and drugs choices; 
using Chi-squared statistics [269].  The results of Goodman’s tests generally support 
the assumption of IIA, but the tests performed were not comprehensive.  Goodman 
did not test the assumption of IIA in the context of adding the option of tobacco 
and alcohol participation jointly to the choice between alcohol participation only 
and tobacco participation only, or adding the option of participating in drugs, 
alcohol and tobacco jointly to the options of participating in drugs and alcohol 
jointly or participating in alcohol and tobacco jointly.   
Higher cigarette taxes were found to be correlated with slightly higher 
probabilities of drinking, leading the author to conclude that a mild substitution 
effect was present [269], an unexpected result in the context of the wider literature 
encountered in earlier chapters.  Estimation of the multinomial logit model is fairly 
straightforward, and so the approach is appealing, but the assumption of IIA may 
not be realistic, and so the parameter estimates presented by Goodman may not be 
the most efficient.  
Zhao and Harris investigated a similar research question to Goodman [269], aiming 
to understand the determinants of alcohol, tobacco and marijuana participation 
(and consumption), but in the context of correlation between behavioural choices 
[270].  Pooled cross-sections of Australian National Drug Strategy Household Survey 
(NDSHS) data on alcohol, tobacco and drug use and various socio-economic factors, 
from over 40,000 individuals, were employed alongside regional price data [270]. 
The econometric model employed was the multivariate probit (MVP) model [270].   
Equation (6) described the probit/logit model.  An MVP model can be described as 
a system of probit equations [271], where error terms have a joint distribution [96].  
Equations (8) and (9), below, describe the MVP model estimated by Zhao and 
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Harris, where   
 ,    
  and   
  are underlying propensities to partake in alcohol,  
tobacco and marijuana, respectively  [270, 271]: 
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(9)  
                                             
It is not possible to identify the size of the variance of errors in equations in the 
multivariate probit model, so Zhao and Harris assumed unity, as shown in 
covariance matrix (9).  Crucially, the explanatory variables in    ,    and    
include prices for the three addictive goods, but not the other dependent variables, 
and were assumed to be exogenous.  As such, the MVP model offered efficiency 
gains to Zhao and Harris compared to three separate probit models, assuming a 
joint distribution of error terms, but was bound to produce identical mean 
parameter estimates.   
Probit models require maximum likelihood (ML) estimation. Estimation of the log-
likelihood function for the MVP model though is made complicated by the presence 
of multiple integrals [272].  A technique called maximum simulated likelihood (MSL) 
was employed by Zhao and Harris for estimation [270], whereby probabilities to 
enter the log-likelihood were simulated using the ‘GHK’ algorithm, named after the 
authors who independently developed the method to simulate these probabilities 
[272, 273]. 
The covariance parameters in (9) estimated by Zhao and Harris are positive and 
highly statistically significant [270], indicating that the three participation decisions 
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are positively correlated and that the joint specification was justified on the 
grounds of efficiency.  Other results showed a percentage increase in the price of 
alcohol to significantly reduce the probability of tobacco participation, and 
similarly a percentage increase in tobacco price significantly to reduce the 
probability of drinking [270].  Thus the authors drew the conclusion that alcohol and 
tobacco are complements in participation [270], in contrast to Goodman’s findings 
[269].  
The key criticism of both the MVP model estimated by Zhao and Harris and the 
multinomial logit model estimated by Goodman, relates to the use of cross-
sectional data.  Picone et al recognised that alcohol and tobacco are addictive 
goods; past behaviour is highly predictive of current and future behaviour.  
Without observing past behaviour, the models of Zhao and Harris and Goodman 
lack explanatory power.  Further than this though, their parameter estimates are 
potentially inconsistent.  The influence of addiction and past behaviour upon 
current behaviour is unobserved in static models.  If this unobserved influence is 
correlated with observed explanatory variables, corresponding parameter 
estimates will contain bias.  Extension of the MVP model proposed by Zhao and 
Harris to the dynamic case would be a marked improvement, and possible with 
data such as those available in HILDA.   
Recognising that the participation decisions for alcohol, tobacco and marijuana are 
different to the consumption decisions, Zhao and Harris did extend their analysis 
to estimate the determinants of consumption of the three substances [270].  This is 
important: the decision to smoke (the participation decision) and the choice of 
how much to smoke (the consumption decision) are distinct but possibly related 
mechanisms and should be treated as such.  A study of the determinants of 
cigarette demand using detailed primary data from Greece has in fact found 
evidence that the determinants of smoking participation are not necessarily 
analogous to the determinants of cigarette consumption [274].   
In order to specify consumption equations, Zhao and Harris employed the ordered 
probit model [270].  The ordered probit generalises the concept of the latent-
variable approach of the probit model to the notion of multiple, ordered thresholds 
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[271].  This approach is useful when the dependent variable has numerous 
categorical choices which are ordinal in nature.  Zhao and Harris viewed the 
decision over consumption, among participants in each behaviour, as a decision 
between ordered categories [270].  The alcohol and tobacco consumption decisions 
were each modelled as equations with three categories in the dependent variables, 
ranging from low consumption to high consumption.  As such, the ordered probit 
model for the alcohol consumption decision can be described by equation (10), 
where     and    were threshold values between the three consumption 
categories:               
          (10)  
                                                                                     
               
          
        
          
      
Cross-price results from estimation of the ordered probit equations showed 
alcohol and tobacco to be complements in consumption as well as participation 
[270].   
Other econometric analyses have used individual-level data supplemented by price 
data to estimate the relationship between tobacco and alcohol behaviours [275-277].  
In each of these studies cross-sectional data [276] or pooled cross-sections of 
individual-level surveys [275, 277] were combined with aggregate price data. Two 
sets of authors, Decker and Schwartz [275] and Jimenez and Labeaga [276], estimated 
consumption equations, but all three studies estimated separate participation 
equations to determine interdependencies. 
The results from two of the three studies indicated negative cross-price effects 
between alcohol and cigarettes, suggesting complementarity [276, 277]. In the 
remaining study, Decker and Schwartz found a positive cross-price effect, 
suggesting that alcohol and cigarettes are substitutes in consumption [275].  The 
authors also found that while a rise in alcohol price decreased cigarette 
participation, an increase in the price of cigarettes increased alcohol participation 
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[275].  This suggests the plausible possibility that individuals smoke because they 
drink, but do not drink because they smoke. 
However, as well as relying on cross-price effects for inference about inter-
behavioural relationships in the absence of longitudinal individual-level data, these 
studies have been criticised for attempting to marry individual-level consumer 
data with aggregate price data [278].  Tauchmann et al highlight that as prices are 
not consumer-specific, such analyses are reliant on limited price variation across 
periods and/or across regions for explanatory power [278].   
Tauchmann et al reject cross-price elasticity of demand estimates in favour of 
expressing alcohol (tobacco) consumption as a function of tobacco (alcohol) 
consumption and explanatory variables, and attempt to capture price effects by 
including dummy variables for regional and time effects [278].  Due to concerns over 
endogeneity in their reduced form estimation equations, tobacco consumption and 
alcohol consumption were instrumented by parental tobacco consumption and 
parental alcohol consumption, respectively, in Tauchmann et al’s analysis.  
Tauchmann et al’s approach, therefore, relied on the assumption that parental 
smoking (drinking) does not affect an individual’s drinking (smoking), except 
through their own smoking (drinking) habits  [278].   
The dataset employed comprised consecutive cross sections of individual-level 
non-panel data and reduced form equations for consumption were modelled as 
Tobit models [278]. The Tobit model is similar to the probit model when the 
dependent variable is continuous but limited at zero, and therefore useful for 
applications such as alcohol and tobacco consumption.  The following equation 
describes a simple Tobit model: 
               (11)  
                 
              
Where    is a latent variable and the error term follows a normal distribution.  The 
estimation results found smoking to positively impact the propensity to drink, 
leading the authors to conclude that alcohol and tobacco are complements [278].   
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Other studies have retrospectively analysed the effects of legislative changes on 
individual-level behaviour, to make some inference about the relationship between 
alcohol and tobacco use.  Over the last ten years, in the UK and many other 
countries, smoking cigarettes has become illegal in public places, including public 
houses, bars and restaurants. If comprehensive smoking bans lead to smoking 
cessation, analysing the impact of a smoking ban upon subsequent alcohol use 
could provide insight.  Several American studies have tested the effect on bar sales 
or staffing levels of state-level smoking bans, but while some studies have found 
smoking bans to have a negative effect upon the hospitality industry [279-282], others 
have found that staffing levels and revenue actually increased following a ban [283-
286].  These studies though cannot account for the possibility that individuals 
change their drinking habits away from bars and restaurants following a ban. 
Fewer studies have tried to assess the impact of smoking restriction laws on 
overall alcohol use.  Picone et al, discussed above, found evidence of reduced 
alcohol consumption following a smoking ban [267].  Hyland et al used a cross-
country comparison between The Republic of Ireland, Scotland and the rest of the 
UK to assess whether smoking bans are associated with more drinking inside the 
home [287]. The authors employed ITC study telephone interview data, collected in 
February and March 2006; after the March 2004 Republic of Ireland smoking ban, 
but before bans in England (1st July 2007), Scotland (26th March 2006), Wales (2nd 
April 2007) and Northern Ireland (30th April 2007). The findings showed a lower 
percentage of alcoholic drinks consumed in the home in the Republic of Ireland 
compared to Scotland and the rest of the United Kingdom [287], supporting a 
hypothesis that smoking bans lead to an average reduction in overall drinking. 
These findings of course rest on the assumption that cultural differences in 
drinking habits were not important.  Elsewhere, changes in the proportion of total 
alcohol consumption taking place in pubs and restaurants after a smoking ban 
have been analysed using bimonthly Norwegian data, but no long-term effect was 
found [288].  Overall, the limited evidence available suggests that public smoking 
restrictions have had either a neutral or reducing effect upon drinking at home. 
The picture emerging from this part of the literature is blurred, but suggests that 
smoking bans may lead to an overall reduction in alcohol consumption: suggesting 
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complementarity between alcohol and tobacco. However, it is important to 
consider that the scope of this PhD research is defined as assessing the effect of 
individual-level interventions to change behaviour.  A smoking ban is only relevant 
here as a treatment to the extent that it can be used as an instrument for an 
individual-level smoking cessation strategy.  If smoking bans influence alcohol use, 
the effect may be very different to that of an individual behavioural and drug-
based intervention for smoking cessation.   
5.2.1. Literature Review Conclusions  
Panel data have clear advantages over cross-sectional data for modelling links 
between alcohol use and tobacco use, particularly given that these are addictive 
behaviours.  Nonetheless, only one study has used individual-level panel data to 
model alcohol and tobacco use as dynamic processes [267]. This could reflect 
paucity of suitable data, but such data are available in the HILDA dataset.  Further 
analysis of the dynamic and potentially interrelated processes of alcohol and 
tobacco use is needed, and can be used to inform economic appraisals of behaviour 
change strategies for alcohol and tobacco use.    
Existing study methods have been useful in consideration of appropriate 
methodology for analysis of HILDA data.  Results from Picone et al suggest that 
past use is highly predictive of current use for both alcohol and tobacco 
consumption [267], while Zhao and Harris have highlighted the potential importance 
of a multivariate specification if error terms across alcohol and tobacco use 
equations are jointly distributed [270].  The majority of studies have used price-
elasticity estimates to capture the link between tobacco and alcohol use [267, 269, 270, 
275-277, 289-293].   This has though led to conflicting results across studies with regards 
to whether alcohol and tobacco goods are complements or substitutes.  One author 
has suggested that because prices are aggregated, inference in these studies relies 
on limited price variation across periods and/or across regions [278].  Price 
variation is undoubtedly important in influencing tobacco and alcohol use, and 
price elasticities are useful tools for inference.  Similarly, analyses of the effect of 
clean air laws upon alcohol use are of interest in this area.  However, use of alcohol 
and tobacco is linked in ways that will not be captured in cross-price effects or by 
the influence of smoking restrictions on alcohol use.  When the interest is in 
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informing potential cross-behaviour consequences of smoking cessation treatment, 
or a brief intervention to reduce alcohol consumption, these tools are less 
appropriate. 
Where studies have looked beyond price and policy effects to capture a 
quantitative link between alcohol use and smoking, instrumental variables have 
been used to overcome endogeneity issues when trying to interpret alcohol 
(tobacco) use as a function of tobacco (alcohol) use [278, 294].  This approach has 
drawbacks though, most notably the difficulty of finding appropriate instruments.   
Other important issues raised in this review include the differences between 
decisions relating to alcohol use and smoking.  For both, the decision to participate 
is different to the decision over how much to consume, and may have different 
determinants. With reference to the behaviour change strategies appraised in 
Chapters 3 and 4, the participation decision is of most interest in terms of smoking 
behaviour, where smoking cessation is targeted, whereas reductions in 
consumption of alcohol in those at-risk of health consequences are the general 
aims of interventions to influence alcohol behaviour.  It has also been highlighted 
that the link between behaviours may vary between sub-groups of individuals.  
These are important factors to consider for the analysis of HILDA.  
With knowledge from existing work in mind, the next section sets out the 
theoretical framework for a dynamic and bivariate model to analyse alcohol and 
tobacco use behaviours using data from HILDA. 
5.3.  Theoretical Framework 
Demand in the context of addictive goods has been investigated in the field of 
economics since the early decades of the twentieth century [295, 296], and it is in the 
economic theories of addictive consumption that this analysis lays its theoretical 
grounding. 
Chaloupka and Warner have outlined three separable groups of economic models 
of addiction: imperfectly rational models of addictive behaviour; models of myopic 
addictive behaviour; and models of rational addictive behaviour [295].  The first 
model is characterised by inconsistent short-term and long-term preferences 
within individuals, so that the short-sighted part of an individual that wants 
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present satisfaction from addictive behaviour battles with the long-sighted part 
that wants to avoid the long-run negative consequences of addictive behaviour.  
However, empirical applications to test the imperfect rational addiction model of 
health behaviour are lacking [295].   
In myopic addiction models, individuals recognise the implications of past 
consumption behaviour on present consumption, but ignore the impact of past and 
present consumption on future consumption decisions when making current 
choices [295].  By contrast, in rational addiction models individuals incorporate the 
interdependence between past, present and future addictive consumption into the 
consumption decision to maximise lifetime utility [295].  Though not the first, 
perhaps the most famous model of rational addiction is that proposed by Becker 
and Murphy in 1988 [297].  The authors derived several hypotheses from the basic 
theory of forward-looking rational addiction, including ‘adjacent complementarity’: 
an increase in current consumption of an addictive good will increase future 
consumption of the good for an individual [297]. 
There has been criticism of forward-looking models of addiction.  Akerlof has 
argued that since smokers are fully aware of the future consequences of initiation 
and continuation of smoking when these decisions are made, there should never 
be individuals in the rational addiction model of smoking who regret past 
decisions [298].  However, there is clear evidence of regret about the decision to 
start smoking among the majority of smokers from a selection of countries 
worldwide [299].  Far from being fully aware, adolescent and adult smokers have 
been shown to underestimate personal risk from smoking in several studies [300-
302].  As later noted [303], this apparent inconsistency could also be explained by the 
potential relationship between addiction and time preferences within the 
framework of rational addiction.  The rational addiction model from Becker and 
Murphy implied that people who discount the future more heavily have a greater 
chance of addiction [297, 303]; regret at later time periods could be totally explained 
by high discounting of time.  When the future is discounted heavily, the rational 
addiction framework reduces to the myopic addiction framework. 
  80 
 
Myopic and rational addiction models have been tested empirically, with specific 
applications to tobacco and alcohol demand, separately.  Demand for cigarettes 
was shown to be a function of a ‘stock of past habits’ using aggregate US and 
Western European data [304] and using American survey data [305], supporting the 
myopic model of addiction, but elsewhere alternative US survey data was used to 
show that while smoking is an addictive behaviour, smokers do not behave 
myopically [306].  Analysis of aggregate panel data from forty-two US states over 
thirty-five years has shown the rational addiction framework to be consistent with 
the demand for alcohol [307]. Elsewhere, the assumption imbedded in the full 
rational addiction model that future consequences of addictive behaviours are 
known and understood has been tested and shown to be weak [300-302].   
The literature review demonstrated that a myopic addiction framework has been 
extended to analyse interactions between smoking and drinking [267].  For the 
purpose of informing assumptions about long-run behaviour in economic 
appraisals, the full rational addiction model is impractical.  The model developed 
here will be used to predict behaviour based on individual-level characteristics 
and past behaviour, which are known.  It is not possible to predict behaviour based 
on behaviour further in the future, which is unknown.  A myopic addiction 
framework is the basis for this analysis. 
The initial myopic co-addiction framework outlined here is similar to that used by 
Picone et al [267].  Individuals within the framework aim to maximise their utility 
subject to a finite budget constraint, as follows: 
 
             (                         )                                             (13)  
In this equation,             are respective tobacco and alcohol consumption for 
each individual.     is the composite of non-addictive goods in time t and   is 
monetary income in t that is exhausted by consumption of             in t.  
                  are prices for             in t. 
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A standard assumption used in the literature to derive demand equations from this 
constrained optimisation problem is a quadratic utility function [291].  Taking this 
approach, the following reduced form equations for alcohol and tobacco demand 
for the ith individual are derived: 
 
                                                                
           
(14)  
 
                                                            
             
(15)  
 
In equations (14) and (15), as in equations (4) and (5),     is a time-varying vector 
of observable determinants of alcohol and tobacco consumption,             are 
unobserved time-invariant individual effects and              are error terms 2. 
At this point, this chapter deviates from the work of Picone et al in two key ways.  
Firstly, the dependent variables      and      are binary.  The variable      takes on 
a value of 1 for smokers and 0 for non-smokers; the variable      takes on a value 
of 1 when alcohol consumption is above government recommended alcohol 
consumption thresholds, or ‘at-risk’, and 0 otherwise.  As has been reported within 
this thesis, there is no healthy smoking level, and policy has thus targeted reducing 
the prevalence of smoking, through cessation support for current smokers among 
other strategies.  By contrast, drinking alcohol at low levels is not thought to pose a 
significant health risk, and policy has generally targeted reducing alcohol 
consumption below health-risk thresholds, in non alcohol-dependent populations.  
Consumption is more naturally modelled as a continuous variable and the choice 
to categorise consumption into two groups was made for two reasons.  First, self 
reported alcohol use data is prone to inaccuracy [308].  If an individual reports 
drinking 10 UK units of alcohol weekly one year and 30 units weekly the next year, 
the actual increase in consumption might not be 20 units, but one can be more 
                                                        
2
 Observable determinants of   and   may differ 
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confident that the individual has moved from a safe to an unhealthy level of 
consumption.  Second, a computer programme to estimate parameters for a useful 
and appropriate model which treats the dependent variables as binary was 
available from the literature.  This programme is described in more detail below. 
Given resource constraints, it was not possible to develop a de novo programme to 
estimate parameters for a model treating the dependent variables differently.  It is 
recognised that treating      as a binary variable is a limitation, in that the 
influence of very heavy drinking upon propensity to smoke might be greater than 
the influence of a drinking level just above the guideline threshold, and this 
analysis cannot capture such differences.  This limitation is also of consequence for 
the way alcohol use is modelled in the BIT model in Chapters 7 and 8.  To expand, if 
a patient in the model is predicted to be an ‘at-risk’ drinker at a point in time, their 
risk of alcohol related disease is estimated using equations linking alcohol 
consumption to health events.  Having to make an assumption about where this 
individual’s consumption lies in the distribution of at-risk drinkers means that 
their consumption will very likely be either under- or over-estimated, but it is 
assumed that little bias will result.   The distinction between drinking above 
guideline consumption levels and below is useful for both (i) differences in the link 
to smoking and (ii) consequences for health.         
The other way in which this work deviates from that of Picone et al is that 
equations are jointly estimated. This marks a potential improvement on existing 
work in the area. These specific issues, alongside other econometrics issues, are 
described and analysed below.  First, the characteristics of the HILDA dataset are 
recounted and variables employed in the analysis described.  
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5.4. Data 
5.4.1. The HILDA dataset 
The HILDA dataset was established in Chapter 2 as the best available data source 
for analysis of the interrelated dynamics of smoking and alcohol use.  This chapter 
utilises waves 2 to 10 of the dataset, with the omission of wave 1 data explained by 
the highly limited alcohol data available in the original survey.  The variables used 
are described in this subsection. 
5.4.2. Variables 
Descriptive statistics of the key variables in the HILDA dataset are reported in 
Table 3.  Section 5.4.2 serves describes these variables. 
Table 3: Descriptive statistics; Full, unweighted, unbalanced sample 
Variable Observations Mean Standard 
Deviation 
Minimum Maximum 
Smoker 98447 0.21 0.41 0 1 
At-risk Drinker 97890 0.16 0.37 0 1 
Smoker last year 80250 0.21 0.41 0 1 
At-risk Drinker last 
year 79839 0.16 0.37 0 1 
Age 152517 35.90 22.60 0 93 
Male 152517     0.50 0.50 0 1 
Divorced 110707 0.09 0.29 0 1 
Widowed 110707 0.06 0.23 0 1 
Separated 110707 0.03 0.18 0 1 
Never married, 
cohabiting 110707 0.09 0.28 0 1 
Never married, not 
cohabiting 110707 0.24 0.43 0 1 
Married  
(reference category) 110707 0.49 0.50 0 1 
Child(ren) residing at 
family home 110735 0.36 0.48 0 1 
Graduate Education 110686 0.20 0.40 0 1 
Vocational Further 
Education 110686 0.30 0.46 0 1 
Secondary or No 
Education  
(reference category) 110735 0.50 0.50 0 1 
Price Index Tobacco 152513 121.49 19.53 100 175.47 
Price Index Alcohol 152513 114.55 10.59 100 137.68 
Natural logarithm of 
Household Annual 
Disposable Income 152517 10.89 0.88 0 14.51 
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Variable Observations Mean Standard 
Deviation 
Minimum Maximum 
Poor Health 97959 0.03 0.18 0 1 
Fair Health 97959 0.14 0.35 0 1 
Good Health  97959 0.36 0.48 0 1 
Very good or 
Excellent Health 
(reference category) 97959 0.47 0.50 0 1 
Smoking Ban 152517 0.46 0.50 0 1 
Major City Residence 155430 0.56 0.50 0 1 
 
As described previously, binary variables are used to model tobacco- and alcohol-
related behaviour.  The UK Government daily guideline for safe drinking is no more 
than 2 to 3 units of alcohol for women and no more than 3 to 4 units for men [309].  
Accordingly, ‘hazardous’ drinking has been defined by Purshouse et al as 14 to 34 
units in a week for women and 21 to 49 units in a week for men in a recent UK 
study, while the more consequential ‘heavy’ drinking was defined as at least 35 
units per week for women and at least 50 units per week for men [253].  This 
classification leads to a convenient binary categorisation of ‘hazardous/heavy’ 
drinking, as opposed to non-‘hazardous/heavy’ drinking, to describe ‘risky’ alcohol 
behaviours in contrast to ‘non-risky’ alcohol behaviours. For ease of reference and 
consistency, ‘hazardous/heavy’ is termed ‘at-risk’ throughout this thesis. 
In each of the ten waves of HILDA since and including the first wave of data in 
2001, respondents have been asked details concerning their drinking behaviour 
[310].  In 2001, all respondents eligible to complete the Self-Completion 
Questionnaire, comprising all those aged 16 years and older, were asked ‘How 
often do you drink alcohol?’.  This question was changed in 2002 and for all 
subsequent waves to ‘Do you drink alcohol?’, with eight possible responses: 1. I 
have never drunk alcohol; 2. I no longer drink; 3. Yes, I drink alcohol everyday; 4. Yes, 
I drink alcohol 5 or 6 days per week; 5. Yes, I drink alcohol 3 or 4 days per week; 6. 
Yes, I drink alcohol 1 or 2 days per week; 7. Yes, I drink alcohol 2 or 3 days per month; 
8. Yes, but only rarely [310].  The respondents indicating that they were current 
drinkers were then asked ‘On a day that you have an alcoholic drink, how many 
standard drinks do you usually have?’.  At this stage a standard drink was defined 
to the respondent as ‘a small glass of wine, a 285ml glass of regular beer, a nip of 
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spirits or a mixed drink’ [310]; this equates to just over a UK unit of alcohol3.   The 
respondents could then choose from one of the seven following answers: 1. 13 or 
more standard drinks; 2. 11-12 standard drinks; 3. 9-10 standard drinks; 4. 7-8 
standard drinks; 5. 5-6 standard drinks; 6. 3-4 standard drinks; 7. 1-2 standard 
drinks.   
This format of alcohol behaviour questions is termed ‘quantity/frequency’ 
measurement [308].  Weekly alcohol consumption is defined as the frequency of 
drinking days in a week multiplied by the quantity of drinks consumed on a usual 
drinking day.  A point measure of weekly alcohol consumption is preferable to an 
interval, but the data collected in HILDA is interval data.  Using the mid-point of 
interval values for quantity and frequency of drinking is standard practice in 
analyses of similar data [311-313] . 
Estimated alcohol consumption for an individual in the sample in terms of usual 
number of drinks per week is therefore defined as follows: 
                      (               )            (                )   
The binary variable ‘at-risk drinker’ can therefore be generated, with the value of 1 
if              is greater than the threshold level for hazardous drinking, as 
defined separately for men and women. 
It could be argued that dichotomisation of alcohol data at this stage is unnecessary: 
interval regression can be used to model equations where the dependent variable 
is in interval form, and no data on ‘at-risk’ status would be lost. Similarly, tobacco 
data is in ‘count’ form in the survey; regression techniques designed specifically for 
this type of data are available, such as the zero-inflated negative binomial model 
[314].  However, there is no software currently available to jointly estimate two such 
models and programming would be complex and time consuming.  Treating 
tobacco and alcohol use data as binary choice data at this stage enables joint 
analysis of smoking and alcohol use, within the scope of this research project. 
                                                        
3
 One unit of Australia is defined as 10 grams of pure alcohol, as opposed to the definition of 10 ml of 
alcohol in the UK.  One gram of water is equivalent to 1 gram of water, but the density of alcohol is 
different to that of water.  Allowing for the density of alcohol, 1 Australian unit equates to 1.27 UK units. 
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The Self-Completion Questionnaire has contained questions on tobacco use since 
inception.  In the first survey wave respondents were asked ‘Do you smoke 
tobacco?’, and in subsequent years this was altered slightly to ‘Do you smoke 
cigarettes or any other tobacco products?’ [310].  The potential responses to this 
altered question comprise: 1. No, I have never smoked; 2. No, I no longer smoke; 3. 
Yes, I smoke daily; 4. Yes, I smoke at least weekly (but not daily); 5. Yes, I smoke less 
often than weekly [310].  From these data it was possible to generate the binary 
variable ‘smoker’, equal to 1 when an individual is a current smoker and equal to 0 
for ex- or never-smokers.   
One-wave lagged variables ‘at-risk drinker last year’ and ‘smoker last year’ were 
generated from these variables, in order to model state dependency, as discussed 
in Section 5.5.  Table 4 describes the correlation between last year’s drinking 
status and current drinking status.  There is clear positive correlation; 34.95% of 
responses from those reporting at-risk drinking last year reported current 
smoking, compared to only 17.18% of responses from those not drinking to at-risk 
levels last year.  Table 5 describes correlation between last year’s smoking status 
and current drinking status; the strength of positive correlation is again clear.  Chi-
squared statistics were 1,950 and 2,076 respectively for Table 4 and Table 5 data, 
and clearly reject the null hypothesis of no expect differences between groups at a 
1% significance level.  Tetrachoric correlation coefficients, useful specifically for 
estimating correlation between binary variables and also reported in Table 4 and 
Table 5, further highlight the strength of correlation. 
Table 4: Correlation between smoking status and last year’s drinking status 
  Current smoking status 
  Smoker Non-smoker 
Last year’s 
drinking 
status 
At-risk 4,105 34.95% 7,641 65.05% 
27.80%  12.94%  
Not at-risk 10,659 17.18% 51,400 82.82% 
72.20%  87.06%  
Tetrachoric rho = 0.3087 
Test of null hypothesis last year’s drinking status and current smoking status are independent:  
p = 0.000 
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Table 5: Correlation between drinking status and last year’s smoking status 
  Current drinking status 
  At-risk Not at-risk 
Last year’s 
smoking 
status 
Smoker 4,268 28.30% 10,814 71.70% 
35.86%  17.47%  
Non-
smoker 
7,634 13.00% 51,080 87.00% 
64.14%  82.53%  
Tetrachoric rho = 0.3160  
Test of null hypothesis last year’s smoking status and current drinking status are independent:  
p = 0.000 
 
Theory and simple data analysis (cross-tabulation, Chi-squared tests) of 
correlation between covariates and dependent variables were used to aid decision 
making about appropriate sub-division of covariates for the regression analysis.  
Model fit with different covariate specification was also considered where 
appropriate, using Akaike information criterion (AIC) and Bayesian information 
criterion (BIC) post-estimation [315].  
Four previous analyses found evidence that the level of education achieved by an 
individual to be a significant factor in determining alcohol and tobacco behaviours 
[270, 275, 278, 316].  In these studies, higher education was associated with better health 
behaviours in terms of tobacco [270, 275, 278, 316], but worse health behaviours in 
terms of alcohol [270, 275, 316].  The dichotomous variables ‘none or secondary 
education’, ‘vocational’ and ‘graduate’ were generated from information on the 
highest level of education attained by HILDA respondents.  The variable ‘none or 
secondary education’ signals that an individual achieved no qualifications beyond 
basic secondary educations; ‘vocational’ implies further, non-academic 
qualifications have been achieved; ‘graduate’ signals completion of an 
undergraduate university degree. Responses from the categories ‘vocational’ and 
‘graduate’ showed significantly higher proportions of excessive drinking and 
smoking participation, respectively.  There were no significant differences in 
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smoking and excessive alcohol use status within ‘none or secondary education’ and 
this was used as the reference category. 
Several of the previous analyses identified in the review found marital status to be 
a significant determinant of alcohol and tobacco behaviour [270, 275, 278, 316].  
Marriage has been shown to be negatively associated with smoking [270, 275, 278, 316], 
and evidence points to a weaker negative association with alcohol use [270, 275].  
From the data it was possible to identify separate groups for those that are (i) 
Married; (ii) Widowed; (iii) Divorced; (iv) Separated but not divorced; (v) Never 
married but living with a partner; (vi) Never married and not living with a partner.  
The corresponding dichotomous variables ‘married’, ‘widowed’, ‘divorced’, 
‘separated’, ‘never married but living with someone’ and ‘never married and not 
living with someone’ were generated. The variable ‘married’ was used as the 
reference category.   
Age has been identified as a significant determinant of smoking behaviour and 
drinking behaviour in several of the key studies in the area [270, 275, 276, 278, 316].  The 
age, in years, of a respondent on the 30th of June in the wave year is collected 
routinely in HILDA (e.g. 2002 for wave 2).  The variable ‘age’ was created from 
these data.  
Clarke and Etilé showed that health shocks made smokers more likely to smoke 
less and quit in future years, using BHPS data [317].  HILDA has collected 
information on whether respondents have long-term difficulty breathing or 
shortness of breath every year since the third wave of data, but very few in the 
sample have reported such problems. More general self-reported health measures 
have also been included in each wave through the General Health Questionnaire.   
From these data it was possible to generate binary variables describing own health 
as ‘good but not very good’, ‘fair’, ‘poor’, ‘very good’ or ‘excellent’, and to generate 
binary variables characterising positive or negative changes over the past year.  A 
binary variable signalling long-term chest or breathing problems was also created.   
Prevalence of self-reported chest problems in the overall sample was low (< 3%), 
and tests supported the use of ‘fair health’ and ‘poor health’ as covariates with 
those reporting excellent, very good or good health as the reference category.   
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None of the studies reviewed in section 5.2 controlled for the effect of having 
children upon health behaviour.  However, intuition and evidence suggest that 
having children may reduce the propensity to smoke and drink excessively.  
Analysis of a random sample of nearly 8,000 Canadian drinkers revealed that 
parenthood is associated with reduced heavy drinking for both mothers and 
fathers [318], while a prospective Dutch study found acquisition of a parental role 
was associated with a decrease in heavy drinking and general reduction in 
consumption [319].  Elsewhere, analysis of individual-level survey data from Great 
Britain and America found that having a daughter leads individuals to reduce their 
smoking and drinking, relative to having a son [320].  The HILDA sample supports 
these findings, though the negative correlation between child presence and 
propensity to smoke in the sample is greater. 
The binary variable ‘child resident’ was used as a covariate in the analysis, with a 
value of 1 if a respondent had their own or adopted child currently residing in the 
parental home, and 0 otherwise. 
Price indices for tobacco and alcohol have been used widely in the econometrics 
literature to estimate interdependencies between drinking and smoking habits [275, 
277, 289, 290, 292, 293, 316].  It has been seen though that results have differed across 
studies.  The appeal of using ‘cross-price elasticity’ as a measurement tool is based 
on the assumed exogeneity of price indices as regressors.  As discussed in the 
review above though, the impact of price changes in one good upon use of another 
good only tells part of the story.  Including price indices for tobacco and alcohol as 
covariates may enable some understanding of whether propensity to smoke or 
partake in ‘risky’ alcohol consumption is influenced by changes in real alcohol and 
tobacco prices, and avoid potential ‘omitted variable bias’ problems.  
In order to control for changes in the real price of tobacco and alcohol products, 
Australian Consumer Price Index (CPI) data from the Australian Bureau of 
Statistics (ABS) [321] was appended to the HILDA dataset.  The ABS holds quarterly 
index number data on groups and sub-groups of consumer goods.  ‘Tobacco’ and 
‘Alcoholic Drinks’ are two of nearly 150 categories of consumables recorded [321].   
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The ABS data documents separate CPI information for each of eight cities in 
Australia: Sydney, Melbourne, Brisbane, Adelaide, Perth, Hobart, Darwin and 
Canberra [321].  The HILDA dataset allows identification of the place of residence of 
each respondent by eight regions, and each of these regions includes one of the 
major cities listed above.  These eight regions and their corresponding cities are as 
follows: New South Wales (Sydney); Victoria (Melbourne); Queensland (Brisbane); 
South Australia (Adelaide); Western Australia (Perth); Tasmania (Hobart); 
Northern Territories (Darwin); Australian Capital Territory (Canberra) [310].   
By using the city CPI data from ABS as a proxy for regional price data, it was 
possible to attribute CPI figures for tobacco and alcohol to individuals in the HILDA 
dataset, according to their region of residence.  While ABS CPI data are collected 
quarterly, in March, June, September and December, HILDA respondents 
contribute to the dataset annually [321, 322].  It was important to select the CPI 
figures that most closely matched the time of HILDA data collection.  However, 
data collection for HILDA takes place over a number of months each year.  
Helpfully, documentation of the percentage of interviews collected in each month 
is published in annual reports available from the HILDA website4. 
Using these figures, it was possible to weight the CPI value attributed to 
individuals in the HILDA dataset according to the proportion of interviews 
collected at different time points.  The variables ‘price index alcohol’ and ‘price 
index tobacco’ are therefore wave- and region-specific price index variables with 
values for all respondents in the dataset, and included as scaled-down covariates in 
regression analyses. 
There was some suggestion from previous studies in this area that income is a 
determinant of tobacco and alcohol behaviours, over time [289] and across 
individuals [270, 275].  HILDA contains detailed personal and household income 
information.  The aim of including an income measure as a covariate is to further 
capture the impact of spending power upon propensity to participate in harmful 
health behaviours; household, rather than personal, income is reasoned to better 
represent this power.  A measure of household annual disposable income best 
                                                        
4
 http://www.melbourneinstitute.com/downloads/hilda/Annual_Report/areport2011.pdf (last accessed 
April 2014) 
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captures spending power.  To transform these data into real terms, ABS price index 
data was again used. 
The variable ‘real household annual disposable income’ merited one further 
transformation.  The relationship between disposable income and propensity to 
drink alcohol and smoke is non-linear, increasing with low levels of income before 
tailing off and decreasing with higher income levels. The natural log 
transformation in equation (16) was performed, whereby 1 was added to avoid 
computing the natural log of zero: 
                   
   ((                                       )   )     
(16)  
The variable ‘natural logarithm of real household annual disposable income’ was 
included as a covariate in regression analysis. 
Exploratory data analysis unveiled positive correlation between unhealthy 
behaviours and major city residence. A dummy variable ‘Major City’, with value 1 if 
the respondent resides in Sydney, Melbourne, Brisbane, Adelaide or Perth, and 0 
otherwise, was included as a covariate in regression analysis. 
Though not encountered in the review of the econometrics literature, the panel 
nature of the HILDA data allows estimation of the impact of key temporal events 
upon the variables of interest.    
Initially, it was of interest to analyse how tobacco participation and alcohol 
participation have changed over time.  Cross tabulation of the wave of data with 
the variables ‘smoker’ and ‘at-risk drinker’, respectively, showed that smoking 
prevalence has decreased over the period 2002 to 2009, whereas hazardous 
drinking prevalence has remained almost constant. 
There has been no change in excessive alcohol use prevalence between 2002 and 
2009 among respondents, though this simple analysis could mask changes in the 
distribution of at-risk drinking. There is however clear variation in smoking 
prevalence over time.  This could be viewed as a continuing response to policies 
from regional and central Australian Governments aimed at reducing smoking 
behaviour in the population.  The only key policy change over this period has been 
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the introduction of total enclosed area smoking bans on licensed premises (similar 
to the July 2007 smoking ban in the UK) [323].  The dichotomous variable ‘smoking 
ban’ was generated, with a value of 1 if total bans on smoking in enclosed public 
areas were in place and a value of 0 otherwise. Such bans were in place in all states 
and territories by the end of 2007, bar the Northern Territory, but came in to force 
at different times across Australia.  This is reflected in the variable ‘smoking ban’. 
5.5. Econometric Framework 
Following the theoretical discussion of section 5.3, and existing psychological, 
clinical and economic literature, the decisions to participate in two addictive and 
unhealthy behaviours are assumed to be jointly determined.  Section 5.5 sets out 
the econometric framework to estimate joint participation decisions for smoking 
and excessive drinking.  Specific issues addressed include treatment of state 
dependence and unobserved individual heterogeneity, the initial conditions 
problem in dynamic processes, and parameter estimation. 
The decisions to smoke and participate in excessive drinking are modelled as 
dynamic interdependent processes, and the model used is a dynamic bivariate 
probit with unobserved individual heterogeneity.  A bivariate extension of the 
dynamic probit model was proposed by Alessie et al in 2004 in order to analyse 
the dynamics of ownership of stocks and mutual funds [324].  A similar specification 
has been employed in several analyses since: to investigate social exclusion and 
poverty [325]; to analyse links between spouses in obesity [326] and separately 
spousal links in the decision to smoke [327]; to consider as joint processes migration 
and high school graduation in Mexico [328]; and to jointly model decisions to leave 
home and to enter employment in Britain [329].  One application of a dynamic 
bivariate probit model has used HILDA data.  Lee and Oguzoglu jointly modelled 
positive well being and negative well being (‘ill-being’) using the first five waves of 
HILDA [330].   
Two key econometric issues the dynamic bivariate probit model tackles were first 
addressed in the context of a univariate dynamic probit.  As early as 1981, 
Heckman proposed an econometric framework that dealt with the linked problems 
of unobserved individual heterogeneity and state dependence in econometric 
applications [331, 332].   
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In many situations, experiencing an event in the past increases the probability of 
experiencing that event in the future [332, 333].  This can apply to various different 
contexts, such as the probability of a leg break for a footballer, and is particularly 
relevant for the study of addictive behaviours.  It is well established that past 
alcohol and cigarette use are predictive of future use [267].   
This phenomenon was described by Heckman as ‘state dependence’ [331, 332].  
Heckman was keen to highlight two different forms of state dependence: false and 
true [332].  If experiencing an event in the past changes preferences or probabilities 
relevant to present choices or outcomes, so that behaviour or outcomes now are 
different to an identical individual that did not experience the event, there is true 
state dependence [332].  At the same time, unobserved differences between 
individuals could drive preferences or probabilities relevant to choices or 
outcomes.  If this unobserved individual heterogeneity is linked to past experience 
of the event, past experience could act as a proxy for these unobserved differences, 
and give a false impression that past experience is important [333].  This is false 
state dependence. 
To expand with reference to examples, our footballer’s probability of leg break 
could be increased by a past break as the bone structure is permanently damaged 
(true state dependence), or this could appear to be the case when an unobserved 
genetic calcium deficiency means elevated risk of a leg break at any point in time 
(false state dependence).  For addictive behaviour outcomes, past cigarette 
smoking could be predictive of current cigarette smoking because smoking in the 
past has increased the utility derived from cigarettes (true state dependence), or 
because inherent taste for rebellious behaviour makes an individual more likely to 
smoke at any time (false state dependence). 
Heckman’s proposed model dealt with the problem of distinguishing between true 
and false state dependence [332]. The following model is a simple extension of the 
univariate dynamic probit in that a second equation is added and cross-dynamics 
are introduced [329]: 
    
                                            (17)  
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                                            (18)  
 
               
                                                         
To apply this model to the work at hand,   can be considered a binary variable 
signalling smoking participation,    a binary variable signalling at-risk alcohol use.  
     are exogenous observable explanatory variables,     are time-invariant 
unobservable characteristics and      are random errors.  It is clear that equations 
(17) and (18) are similar to equations (14) and (15), with the key difference the 
problem is now one of discrete choices.     
The unobserved error elements of (17) and (18) can be described by the following 
random effects structure : 
                    (19)  
The time-invariant ‘random’ effects    and     are assumed to follow a bivariate 
normal distribution with variances    
  and    
  and correlation   , while      and 
     are independent over time but also follow a bivariate normal distribution, with 
unit variances and correlation    [325, 334].  With these assumptions, the     , 
conditional on the observed      , are bivariate normal with mean zero and the 
following covariance matrix [326, 329]: 
[
    
    
]    (  [
     
            
                
 ])  
(20)  
 
   (        )     
 (     
 ⁄ )    . 
As the model explicitly accounts for unobserved individual heterogeneity, it is well 
equipped to capture true state dependence.  The coefficients     and     in 
equations (17) and (18) inform whether ‘own’-state dependence is important; that 
is, if smoking in the previous time period actually affects the probability of 
smoking in the current time period.  
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Similarly, the model enables understanding of whether correlation between      
and        (or      and       ) is due to true ‘cross’-state dependence (         ) 
or correlation between unobserved heterogeneity (    ) [325].  This distinction is 
of primary interest.  If there is a significant causal positive effect of previous 
smoking upon the probability of participating in excessive alcohol use, then the 
overriding narrative of strategies to tackle alcohol misuse is blind to an important 
factor.  This analysis of course also has the potential to inform on whether decision 
makers should explicitly consider excessive alcohol use in the development and 
implementation of anti-tobacco strategies. 
It is worth noting that the model described reduces to the univariate case in some 
situations. If           , parameters in equations (17) and (18) can be 
estimated separately as two dynamic probit models with only a potential loss of 
efficiency [325].  If       but there is zero cross-equation correlation between 
unobserved individual effects and between errors (       ), equation (17) 
can be estimated as a univariate model where        is weakly exogenous [325].  
Similar logic applies to equation (16).  For all other cases, joint estimation is 
demanded. 
So far, a problem encountered in dynamic models with unobserved time-invariant 
heterogeneity and limited time periods has been ignored.  In equations (17) and 
(18) the presence of     and     renders own-state dependence variables        
and        endogenous, as seen in the case of Picone et al in Section 5.2 [267] and 
illustrated by implied equations (21) and (22) below:  
      
                                                (21)  
 
      
                                                (22)  
 
Clearly, lagged dependent variables        and        are endogenous in equations 
(17) and (18) as they depend upon     and    , respectively.  For consistent 
estimation, modelling       
  for all  (       ) would be sufficient, but impossible 
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for     given there is no previous data panel [335].    Cross-state dependence 
variables are also endogenous in (17) and (18), as they are correlated with the      
when      [335]. 
A simple solution would be to assume that pre-sample data is exogenous and can 
be ignored [332].  In the present case, this would mean imposing serial 
independence upon the disturbances generating the dynamic process (untrue in 
the presence of time-invariant unobserved heterogeneity) or assuming the 
smoking participation decision each HILDA respondent made in their first wave of 
data collection was truly their first smoking participation decision (highly unlikely).    
Another solution to these problems is to initialise the dynamic process that is 
being generated [331].  With reference to the univariate case, Wooldridge built on an 
approach proposed by Heckman to suggest modelling unobserved individual 
heterogeneity as a function of the endogenous initial value [336].  This approach is 
easily extended to the bivariate case, where the individual-specific unobserved 
effects     and     are each modelled as functions of both initial values      and      
and time-averaged covariates  ̅   as follows: 
                             ̅           (23)  
 
                              ̅           (24)  
 
In equations (23) and (24), the     (       ) are parameters to be estimated 
and     are normally distributed with the following covariance matrix [325]: 
   (      )  [
   
         
           
 ]     
(25)  
 
Substituting equations (23) and (24) into equations (17) and (18) leads to the 
model as follows: 
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                                                     ̅                  (26)  
 
    
                                                     ̅                  
(27)  
 
The underlying propensity to smoke (drink to at-risk levels) is explained by last 
year’s smoking and drinking status, contemporaneous independent variables 
detailed in Section 5.4 and initial smoking (drinking), which is assumed to be a 
function of initial observed behaviour and time-averages of the contemporaneous 
independent variables. Consistent parameter estimates for equations (26) and (27) 
can be obtained using the estimation procedure described below. 
This adaptation of Wooldridge’s solution to the ‘initial conditions’ problem has 
been implemented by several of the existing dynamic bivariate probit model 
studies [325, 327, 329, 335].  Others have used an adaptation of Heckman’s original 
approach [324, 330, 334, 337].  With reference to the univariate case, Heckman proposed 
specifying an auxiliary equation for the process that generated the initial observed 
values, then estimating the model allowing correlation between the initial and 
main equations [329, 331].  Because this amounts to modelling the initial value as a 
function of unobserved individual heterogeneity, it has been described as the 
opposite to Wooldridge’s method [329]. Alessie et al were the first to extend this 
model to the bivariate case [329].  As with the Wooldridge approach, this extension 
is straightforward.   
Because in practice the Heckman approach would mean four integrals in 
comparison to Wooldridge’s two, the Wooldridge approach is less computationally 
expensive [325, 329].  This is the primary reason for using Wooldridge’s solution here: 
reducing estimation time is a practical priority.  In addition though, while one 
group has raised concern over bias in adapted versions of Wooldridge’s solutions 
when few waves of data have been used [338], research has suggested that the 
Wooldridge approach performs at least as well as a Heckman-style approach for 
panel data with five or more waves [339]. 
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Wooldridge argues that for random effects estimation of panel data models, time 
period dummy variables should be included as control variables if they are 
statistically significant: omitting them could cause serial correlation in the 
idiosyncratic error term [340].  Dummy variables for each wave were included in 
static bivariate random effects models, but none were significant at the 10% level 
and were subsequently excluded from final estimation equations. 
5.5.1. The sample and survey non-response and attrition 
Estimation of this dynamic bivariate model requires a ‘compact panel’ [329]. That is, 
observations from each individual must be consecutive and contain no gaps in 
time5.  The obvious approach, and that used in many previous studies [325, 327, 330], is 
to use the balanced panel.  This means dropping all observations from individuals 
with gaps, however: a significant loss of useful data.  In order to use all possible 
data, a sensible and appropriate alternative is to keep the longest consecutive spell 
of observations from each individual. This would mean that as well as all 
observations from an individual with full responses to all variables in each wave 
being used, observations from an individual who joined the sample in wave 4 and 
subsequently responded fully in each wave would be used.  The ‘longest spell’ 
panel contained 44,646 observations from 9,309 men and women for estimation; 
the balanced panel contained 28,665 observations from 4,095 men and women. 
Using the balanced, instead of the ‘longest spell’ panel, is to discard 35% of 
observations and 56% of individuals from the ‘longest spell’ sample.  For 
completeness, the analysis was run for both the balanced panel and the ‘longest 
spell’ unbalanced panel.  Descriptive statistics for key variables in estimation 
samples are reported in Table 44 of Appendix D. 
Using survey panel data to model health-related behaviour creates a potential 
problem of bias from non-response or attrition.  Sampling for the first wave of the 
HILDA survey was designed so that the sample reflected the population of 
households occupying private dwellings in Australia; this sample then formed the 
basis for the panel of households to be followed over subsequent waves [341].  New 
entrants to panel households are added to the sample as temporary or permanent 
                                                        
5
 The estimation code works by estimating the log-likelihood function for each individual and then 
summing across individuals. The code cannot identify missing observations within an individual, 
however: if an individual leaves the sample and then returns, the code is unable to detect this. 
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(births or parents of sample births) sample members, and panel members leave 
the sample either temporarily, perhaps due to ill health, or permanently, because 
they either migrate overseas or die [341].  In this application, if the reason for 
leaving the sample is linked to smoking participation, or at-risk alcohol behaviour, 
then systematic attrition is a threat to the consistency of covariate parameter 
estimates.  Death and ill health can be caused by smoking and at-risk alcohol use, 
and so potential attrition bias deserves attention.  
Continuing panel members may also non-respond to certain or all questions in the 
survey, for some or all years.  Again, if this non-response is related to the 
dependent variables, bias is a concern.  It is easy to imagine such a scenario: a 
respondent might contract a temporary but debilitating respiratory illness caused 
by smoking meaning they cannot respond for one wave; another respondent might 
become embarrassed by their excessive alcohol consumption, and so avoid 
answering specific questions about alcohol use.  In this way, it can be seen that the 
problem of non-response can be similar to that of under-reporting in self-report 
surveys. 
It is important to test for the presence of attrition bias in this study.  However, the 
consequence of attrition bias for cross-state dependence parameter estimates 
(    and     in equations (26) and (27), respectively) is of primary interest. Over-
estimation of cross-state dependence could lead to over-estimation of knock-on 
health benefits of improving smoking (drinking) behaviour.  This would create bias 
in favour of more costly and more effective behaviour-change strategies in 
economic evaluation under the proposed framework.  The consequence of this is 
potentially favouring a ‘wrong’ adoption decision.   
Jones et al have highlighted measures to test for attrition bias in regression models 
[342], first proposed by Verbeek and Nijman [343].  These measures are essentially 
‘variable addition tests’: variables describing the pattern of survey response are 
generated and included as covariates in the regression equations of interest run on 
the full unbalanced sample [342]. Three variables describing survey response are 
suggested [342, 343].  ‘Ti’ is a count variable reflecting the number of survey waves 
individual ‘i’ is in the sample. The dummy variable ‘all waves’ describes presence in 
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the balanced panel.  In this application the balanced panel comprises seven waves6.  
Lastly, ‘next wave’ is a dummy variable indicating presence in the sample in the 
following wave.  Tests of the statistical significance of these survey response 
variables provide tests for attrition bias [342].   
These tests were designed to run on the full unbalanced sample, and as such are 
not suited to the dynamic bivariate random effects probit model: the samples 
available for final model estimation are (i) the balanced panel and (ii) the ‘longest 
spell’ unbalanced panel, as discussed above. However, relaxing assumptions 
imposed upon individual errors and estimating equations (26) and (27) separately 
as (i) pooled static probit models and (ii) dynamic random effects probit models 
using the full unbalanced panel, performing the attrition tests described, gave 
indication of the presence of non-response bias in this study. 
Where non-response bias was indicated to be present from these tests, the 
potential influence of non-response bias for cross-state dependence estimates was 
investigated in reduced specifications of the model. Jones et al prescribe correcting 
for attrition bias using ‘inverse probability weights’[342]; essentially, this involves 
favourably weighting observations from individuals with higher probability of 
non-response.  This method does not easily lend itself to the full model 
specification here though, and has limitations.  To generate ‘inverse probability 
weights’,  equations for response versus non-response at each wave after the first 
wave are estimated, conditional on a set of observable characteristics,    , not used 
elsewhere in the model, that are measured at the first wave [342]. This relies on non-
response being ignorable, conditional on     [342, 344], and so breaks down if non-
response is caused by unobserved health shocks that are systematically linked to 
the outcome.  Practicality is also a consideration. An appeal of the Jones et al 
method in health econometric applications is that it is easy to apply to binary 
outcome models: estimates for a weighted probit model can be generated by 
maximum likelihood using the ‘pweight’ sub-command in recent versions of Stata 
[342, 345].  Interpretation of results from these reduced-specification models was the 
limit of investigation into attrition bias in this chapter.  
                                                        
6
 There are nine waves of data available (waves 2 to 10 of HILDA), but the first two waves are used to 
model initial conditions and lagged explanatory variables. 
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5.5.2. Estimation 
The parameters of the model described were estimated by MSL.  Before setting out 
the likelihood function and describing the MSL process, it is first useful to define 
the probabilistic statements that contribute to the likelihood function [335]. 
Equations (28) and (29) define two        vectors containing the variables on the 
right hand side of equations (26) and (27), while equations (30) and (31) below 
defines two         vectors containing the corresponding parameters, where 
intercept terms     are included in    [326]: 
                                     ̅         (28)  
                                     ̅         (29)  
 
                           ]’       (30)  
                           ]’       (31)  
 
The following conditional probabilistic statements can now be made, where Φ[.,.;.] 
is the cumulative distribution function of the bivariate standard normal 
distribution [335]: 
  (                               )  Φ  (          ) (       
   )           
(32)  
 
  (                               )  Φ  (          )  (       
   )                  
(33)  
 
  (                               )  Φ   (          ) (       
   )            
(34)  
 
  (                               )  Φ   (          )  (       
   )                 
(35)  
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With probabilistic statements for all possible outcomes of the joint decisions over 
whether to smoke and whether to excessively drink captured by equations (32), 
(33), (34) and (35), the probability that a discrete random variable is exactly equal 
to a value can be expressed as follows [335]: 
 (                           )  Φ      (          )     (       
   )                         
(36)  
 
             ,                                             
Outcomes are assumed to be conditionally independent over time, and so their 
joint density for an individual can be written [329, 335]: 
∏  (                           )
 
      
∏ Φ      (          )     (          )            
 
                
(37)  
 
It is now possible to state the likelihood function for the  th individual in equation 
(38), defining the parameters to be estimated as               
    
        ]`, given 
the distributional assumption imposed on     and    : 
  ( )  
∫ ∫ ∏ Φ      (          )     (       
 
       
   )             (      )              
(38)  
 
The log-likelihood function for the entire sample can therefore be written as: 
    ( )  ∑      ( )
 
        (39)  
 
It now remains to calculate parameters  , but the individual likelihood in equation 
(38) contains double integrals.  It is possible to estimate by ML using quadrature or 
MSL, which essentially approximates the individual likelihood, instead of solving 
analytically.  
The MSL procedure adopted works by randomly drawing R values from the 
bivariate normal distribution of the unobserved individual effects   and   , 
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{(   
     
 )    (   
     
 )}, so that for given values of   and   , the individual 
likelihood in (38) is approximated by equation (40) [325, 329, 335]: 
  ̃( )  
 
 
∑ ∑ {∏ Φ      (          
 )     (       
 
   
 
   
     
 
   
     
   
 )            }     
(40)  
Halton draws are well spaced non-random draws contained within the unit 
interval and have been shown to have better coverage than simple pseudo-random 
draws in various discrete choice model simulations [346, 347].   Halton draws were 
therefore used in place of more simple pseudo-random draws in this application.  
The appropriate number of draws was tested by analysing changes in log 
likelihood as the number of draws was increased.  Halton sequence generation and 
simulated likelihood maximisation were performed in Stata, version 11 [345], using 
code written for an earlier application of the bivariate dynamic random effects 
model noted here [325], and made available by the author, Professor Francesco 
Devicienti. 
5.6. Results 
This subsection reports and interprets results from the dynamic bivariate random 
effects probit model described above.  For the purpose of comparison, results from 
univariate dynamic models, a ‘restricted’ version of the dynamic bivariate model 
where        , are also reported in Appendix D.  Problems encountered with 
estimation are described first, before the results are interpreted.  Results of 
investigations into potential attrition bias in the estimates are also presented. 
5.6.1. Estimation Results 
It was necessary to use a compact panel sample, as discussed above, and the 
intention was to estimate the model by gender separately for (i) the ‘longest spell’ 
sample, making maximum use of the data and (ii) the balanced panel, as seen 
elsewhere [336].  However, the complexity of the model meant that the results 
would not converge when balanced samples were used: the estimation procedure 
encountered a flat or discontinuous region in the log-likelihood function.  
Numerous attempts were made to validly overcome this hurdle.  First, within-
variation in covariates was examined, to rule out the possibility of zero or very 
small variation in one or more covariates.  This proved, unsurprisingly, to be the 
case for education variables.  Time-averages of these variables were removed from 
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the initial conditions equations (23) and (24) in an effort to aid estimation.  Second, 
different starting values for the estimation process were used.  The default starting 
point used parameter estimates from the static bivariate random effects probit 
model; estimates from dynamic univariate models and the dynamic bivariate 
model using the ‘longest spell’ sample were also tried.  Third, altering the order of 
the search algorithms was tried.  The default optimisation code started with Stata’s 
modified Newton-Raphson algorithm, switching to the Davidon-Fletcher-Powell 
algorithm and then the Broyden-Fletcher-Goldfarb-Shanno algorithm.  None of 
these attempted solutions led the model to converge. 
There were also problems estimating the model for women using the ‘longest spell’ 
sample. Again, the estimation procedure broke down upon encountering a flat or 
discontinuous region in the log-likelihood function.  The steps described above to 
achieve model convergence were again attempted but were again unsuccessful.   
Results for women were generated, using the full ‘longest spell’ sample from men 
and women, with male included as an additional covariate. 
Figure 8 and Figure 9 show changes in the log likelihood of parameter estimates as 
the number of Halton draws used to generate results was increased incrementally 
from 50 to 300.  It would have been preferable to test results using higher 
numbers of Halton draws, but this was not possible given capacity limitations of 
the available software.  The bivariate dynamic results presented here were 
generated using 300 Halton draws of unobserved individual effects. 
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Figure 8: Change in log-likelihood as number of Halton draws increased, 
male estimation sample 
 
Figure 9: Change in log-likelihood as number of Halton draws increased, 
pooled estimation sample 
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Results from estimation of bivariate dynamic models are shown in Table 6; 
univariate dynamic model results are shown in Table 42 of Appendix D, for 
comparison.  The bivariate model is justified on grounds of consistency, as there is 
evidence of both cross state dependency and correlation between unobserved 
individual heterogeneity, described in more detail below.   
Columns (1) and (2) of Table 6 contain estimates for the male sub-sample; columns 
(3) and (4) contain estimates of results for the pooled sample containing both men 
and women.  It can be seen that while the direction of parameter estimates are 
seldom different across the different samples, the influence of explanatory 
variables upon smoking and drinking outcomes is different for men and women.  
For example, own-state dependence is a stronger determinant of smoking status 
for women than men.  The isolated gender effects in columns (3) and (4) suggest 
being male is an independent predictor of smoking and at-risk drinking. 
True own-state dependence was found for both probability of smoking and 
probability of at-risk drinking, significant at the 1% level across samples.  
Controlling for observed and unobserved person-specific attributes, smoking in 
the previous time period makes an individual significantly more likely be a current 
smoker; at-risk drinking in the previous time period increases the probability of 
current at-risk alcohol use.  This reaffirms results from Picone et al [267], and is the 
expected result given the wealth of literature on the addictiveness of alcohol and 
tobacco encountered in Chapter 2.  This also highlights the limitations of the 
numerous analyses which have relied on cross-sections of data for inference about 
links between alcohol and tobacco use, and have therefore not been able to 
account for addiction in their analyses, clearly a key determinant of smoking and 
drinking behaviour.  
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Table 6: Dynamic Bivariate Probit Model Results  
Variables Men Pooled  
(1) Smoker (2) At-risk Alcohol 
Use 
(3) Smoker (4) At-risk Alcohol 
Use 
Smoker last year 1.527*** 0.209** 1.641*** 0.182*** 
(0.000) (0.016) (0.000) (0.007) 
At-risk Drinker last year 0.060 0.850*** 0.027 0.832*** 
(0.456) (0.000) (0.652) (0.000) 
Smoker initial value 2.558*** 0.164* 2.425*** 0.224*** 
(0.000) (0.067) (0.000) (0.001) 
At-risk Drinker initial value 0.062 2.421*** 0.096 2.441*** 
(0.451) (0.000) (0.121) (0.000) 
Age -1.729*** -0.394 -1.600*** -0.747*** 
(0.000) (0.113) (0.000) (0.000) 
Male   0.177*** 0.317*** 
  (0.000) (0.000) 
Graduate Education -0.017 -0.108 -0.361*** -0.071 
(0.944) (0.640) (0.000) (0.174) 
Vocational Further 
Education 
0.101 0.062** -0.106** 0.005 
(0.611) (0.724) (0.016) (0.902) 
Separated 0.325* -0.136 0.322** -0.066 
(0.083) (0.389) (0.013) (0.570) 
Divorced 0.214 0.033 0.063 -0.104 
(0.279) (0.839) (0.645) (0.389) 
Widowed 0.308 -0.160 0.382* -0.049 
(0.486) (0.547) (0.071) (0.798) 
Never married, cohabiting 0.033 -0.011 0.034 0.025 
(0.863) (0.948) (0.812) (0.844) 
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Variables Men Pooled  
(1) Smoker (2) At-risk Alcohol 
Use 
(3) Smoker (4) At-risk Alcohol 
Use 
Never married, not 
cohabiting 
0.016 0.210 0.015 0.271* 
(0.939) (0.244) (0.925) (0.053) 
Child(ren) in family home -0.156 -0.077 -0.126 -0.029 
(0.125) (0.367) (0.107) (0.672) 
Tobacco Price Index -0.478* -0.209 -0.263 -0.080 
(0.066) (0.295) (0.167) (0.601) 
Alcohol Price Index 0.163 0.386 -0.319 0.200 
(0.806) (0.459) (0.508) (0.613) 
Natural log of Household 
Annual Disposable Income 
0.013 -0.032 0.037 -0.046** 
(0.701) (0.270) (0.134) (0.042) 
Smoking Ban -0.147** 0.058 -0.107** 0.041 
(0.031) (0.280) (0.031) (0.314) 
Good Health 0.149** 0.077 0.140*** 0.067* 
(0.019) (0.128) (0.002) (0.078) 
Fair Health 
  
0.069 0.068 -0.059 0.079 
(0.473) (0.387) (0.396) (0.190) 
Poor Health -0.072 -0.283* -0.287** -0.369*** 
(0.682) (0.067) (0.023) (0.002) 
Major City -0.017 0.121 -0.100 0.121 
(0.913) (0.348) (0.354) (0.203) 
Graduate Education (TA) -0.453* 0.073   
(0.087) (0.768)   
Vocational Further 
Education (TA) 
-0.347 -0.058   
(0.100) (0.758)   
Separated (TA) 0.668** 0.851*** 0.633*** 0.723*** 
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Variables Men Pooled  
(1) Smoker (2) At-risk Alcohol 
Use 
(3) Smoker (4) At-risk Alcohol 
Use 
(0.016) (0.001) (0.001) (0.000) 
Divorced (TA) 0.361 0.047 0.438*** 0.287** 
(0.119) (0.815) (0.005) (0.046) 
Widowed (TA) 0.300 0.857** 0.023 0.223 
(0.572) (0.013) (0.925) (0.331) 
Never married, cohabiting 
(TA) 
0.224 0.112 0.223 -0.101 
(0.325) (0.590) (0.189) (0.528) 
Never married, not 
cohabiting (TA) 
0.529** -0.064 0.514*** -0.059 
(0.031) (0.766) (0.004) (0.718) 
Child(ren) in family home 
(TA) 
0.231* 0.050 0.278*** -0.049 
(0.085) (0.673) (0.004) (0.580) 
Tobacco Price Index (TA) -3.833* 7.567*** -0.016 0.036** 
(0.077) (0.000) (0.271) (0.012) 
Alcohol Price Index (TA) 4.973* -8.975*** 0.028 -0.050*** 
(0.056) (0.000) (0.114) (0.004) 
Natural log of Household  Annual 
Disposable Income(TA) 
-0.004 0.187*** -0.091** 0.232*** 
(0.955) (0.002) (0.037) (0.000) 
Smoking Ban (TA) 0.244 -0.887*** 0.140 -0.381* 
(0.472) (0.005) (0.535) (0.082) 
Good Health (TA) 0.374*** 0.038 0.287*** -0.014 
(0.001) (0.712) (0.000) (0.858) 
Fair Health (TA) 
  
0.239 -0.096 0.321*** -0.178* 
(0.135) (0.505) (0.004) (0.096) 
Poor Health (TA) 0.510* 0.173 0.726*** 0.172 
(0.081) (0.531) (0.000) (0.413) 
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Variables Men Pooled  
(1) Smoker (2) At-risk Alcohol 
Use 
(3) Smoker (4) At-risk Alcohol 
Use 
Major City (TA) -0.031 -0.273* 0.044 -0.247** 
(0.850) (0.055) (0.704) (0.018) 
Intercept -3.079** -2.602** -2.518*** -2.926*** 
(0.020) (0.043) (0.006) (0.002) 
Unobserved time-variant effects 
correlation 
0.192*** 0.149*** 
(0.000) (0.000) 
Unobserved time-invariant effect 
variance 
0.928*** 1.166*** 0.875*** 1.150*** 
(0.000) (0.000) (0.000) (0.000) 
Unobserved time-invariant effects 
correlation 
0.107 0.155*** 
(0.102) (0.000) 
   
Observations; number of 
respondents 
22,162; 4,508 44,646; 9,309 
Average number of waves in 
sample 
4.9 4.8 
Mean age at initial value 43 44 
Log-likelihood -9449.23 -16740.344     
Note: TA = time averaged 
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A key contribution of this analysis, building on Picone et al’s earlier work, is 
estimation of cross-state dependence between smoking and at-risk drinking 
equations.  Cross-state dependence was estimated to be positive and significant in 
determining the probability of at-risk alcohol use, but positive and non-significant 
in determining the probability of smoking participation.  An individual’s 
propensity to drink to at-risk levels is influenced by their recent smoking status. 
These cross-state parameters are fairly small in magnitude, but these are dynamic 
effects and may be powerful over time.  This result is interesting in light of the 
limited evidence reviewed in Chapter 2, where several studies found changes in 
tobacco use to have no influence over alcohol use [63, 90, 94].  These studies used 
longitudinal data, but of only two or three waves, with much smaller samples than 
used here from different populations, and estimated static equations [63, 90, 94].  
Different effects across populations may be expected, but it seems reasonable to 
speculate that these studies failed to identify cross-behaviour effects, rather than 
correctly identifying the absence of effect. 
The importance of initial behaviour in determining ongoing tobacco and alcohol 
use status is discernible from the results.  The variables smoker initial value, at-risk 
drinker initial value and the time-averaged explanatory variables in Table 6 
comprise the observed explanatory variables in initial condition equations (23) 
and (24).  The large, positive and highly statistically significant coefficients of 
smoker initial value in columns (1) and (3) and at-risk drinker initial value in 
columns (2) and (4) of Table 6 indicate that the starting points in the dynamic 
behavioural processes modelled here are very important.  Some of the time-
averaged variables show a strong predictive effect in Table 6, further highlighting 
the importance of the start of the dynamic process for behaviour looking forward.   
Two further points concerning these initial conditions parameter estimates 
require note.  First, the time averaged price index parameter estimates are large in 
columns (1) and (2) of Table 6 in comparison to columns (3) and (4).  This is due to 
these variables not being re-scaled prior to estimation for the pooled subsample.  
The corresponding variable values are around 100 times greater in columns (3) 
and (4) compared to columns (1) and (2), and so the overall effects are similar.  
Second, the initial values for smoking and at-risk drinking are the first observation 
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of each sample member and therefore represent different times in the life cycle 
across respondents and not the true starting points of the dynamic processes (such 
as the ages at which purchasing smoking and alcohol become legal).  This is a 
limitation of the data; the mean ages in years of respondents in the male and 
female estimation samples at which the initial drinking and smoking statuses were 
reported are 43 and 44, respectively. 
Parameter estimates relating to unobserved heterogeneity are reported in Table 6.  
Unobserved person-specific time-invariant characteristics are shown to play a 
crucial role in the dynamic processes modelled.  The proportion of variance in 
unobserved errors attributable to unobservable individual heterogeneity is 
   
  (     
 ) (see equation (20)).  For men, this is 45% of unobserved random 
variation in smoking participation and 53% of random variation in at-risk alcohol 
use.  For the pooled sample, these proportions are 47% and 53%, respectively.  
Permanent characteristics, such as an addictive nature, seem to be roughly as 
important as random shocks, such as the death of a loved one, in determining 
smoking and at-risk drinking status.   
Correlation between time-variant unobserved heterogeneity across the two 
equations is positive, indicating that stochastic shocks which influence the 
propensity to smoke affect the probability of at-risk drinking in the same direction, 
and vice versa.  This may suggest that a particularly effective smoking cessation 
campaign may temporarily reduce the propensity to drink to at-risk levels directly, 
as well as having a potential knock-on effect to future drinking if the campaign 
leads an individual to quit smoking.  
Though positive and highly significant in the pooled sample results, the positive 
correlation between time-invariant unobserved heterogeneity shown in Table 6 is 
statistically insignificant for the male subsample, perhaps surprisingly.  It is 
possible that this is due to a lack of variation in the smaller subsample. Time-
invariant effects are arguably more interesting from a policy perspective than 
time-variant effects because while they are difficult to change, if they can be 
changed for the better then the effect is permanent.  The benefit of a smoking 
cessation intervention which has a high 12-month quit rate may only be temporary 
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for many if time-enduring characteristics are not affected; Table 6 shows that the 
starting point and unobserved characteristics are key drivers of dynamic drinking 
and smoking, even though state dependence is important.  If interventions can 
change these time-enduring characteristics to lower the long-run propensity to 
smoke, they are far more powerful policy tools.  Such an effect is inherently 
difficult to observe however, and so difficult to speculate on.    
Other parameter estimates in Table 6 are of interest from a policy perspective.  
Propensities to smoke and drink to at-risk levels decrease with age.  This is 
reflective of the falling propensity for these unhealthy behaviours as people move 
into retirement age and later life generally observed elsewhere [76, 79, 82, 91], though 
as discussed elsewhere it is not possible to disentangle ageing effects from cohort 
and period effects without making further identifying assumptions [348]; this result 
may not be generalisable to future populations.  This is important as these results 
are used to predict long-run behaviour in Chapter 8, as described in Section 5.7.   
Being subject to an enclosed public space smoking ban was found to decrease the 
probability of being a smoker, as expected, though may again be a cohort effect 
influencing this result.  Being in good health, as opposed to very good health, 
increases the probability of smoking and at-risk drinking participation.  Being in 
poor health, relative to excellent health, reduces the propensity to drink and smoke, 
though this effect is only prominent in the pooled sample results.  These findings 
are sensible, though because health can influence behaviour and behaviour can 
also influence health, the direction of causality is not clear.   
Increases in tobacco prices were found to reduce the propensity to smoke, as 
expected, though the parameter estimate for alcohol price index in alcohol 
equations was, surprisingly, positive.  This suggests that alcohol violates the law of 
demand, but it is far more likely that there is not enough variation in the aggregate 
price data to estimate an accurate effect.   
Among other findings from the model, marital status is found to be a mildly 
important predictor of smoking status: being separated as opposed to married 
increases the propensity to smoke. Higher educational attainment is found to 
reduce the propensity to smoke, while disposable income was negatively 
  114 
 
associated with the probability of at-risk drinking, though this effect is significant 
in the pooled results only. 
5.6.2. Attrition and non-response 
Results from tests of the significance of ‘attrition’ variable coefficients are reported 
in Table 39 and Table 40 of Appendix D.  Attrition appears to be inconsequential in 
determining the probability of ‘at-risk’ drinking behaviour.  By contrast though, the 
attrition test variables ‘number of waves’ and ‘all waves’ are statistically significant 
in smoking participation equations for men and women. The direction of 
coefficients for these variables suggests that the probability of smoking 
participation is higher among those with fewer observations in the sample.  
It was possible to analyse the potential influence of non-response bias to cross-
state dependence estimates in the present application by applying probability 
weights to the static probit model for the smoking participation decision.  Results 
are reported in Table 41 in Appendix D. Average partial effects (APEs) are reported 
as well as regressor coefficients, to give quantitative meaning to the differences 
between weighted and unweighted results. Estimates are fairly similar across 
weighted and unweighted models for men and women. The APE of 0.016 for ‘at-
risk drinker last year’ in the unweighted model for males implies that the 
probability of current smoking is 0.016 higher for those that drank to at-risk levels 
last year, holding other variables in the model at their sample means.  The 
corresponding APE for the weighted model is 0.019. The magnitude of difference 
between the weighted and unweighted estimate is small, but the standard error of 
these APE estimate is also small (0.008 in both unweighted and weighted results), 
suggesting that the difference is statistically important.  Further research into the 
influence of attrition bias and controlling for such bias in future dynamic analyses 
of individual-level smoking behaviour using self-reported longitudinal survey data 
may be of merit. 
5.7. Informing projections of behaviour in an economic appraisal 
model 
This econometric analysis was motivated by the need to inform assumptions about 
long-run patterns of behaviour, and interdependencies between behaviour, in 
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economic appraisals of competing strategies for smoking cessation or alcohol 
reduction.  Chapters 7 and 8 will report an individual-level simulation model to 
appraise competing strategies to aid smoking cessation; the results from this 
chapter informed projections of long-run behaviour in this model.  This brief 
subsection explains how econometric outputs were incorporated into the 
economic appraisal model. 
The first point at which assumptions about behavioural status are needed within 
the economic appraisal model is when the first person in the model reaches the 
trial follow-up end point.  At this moment, certain characteristics of the person are 
known.  Let us assume that this includes the smoking and drinking status of the 
person, as well as information on all observable variables in equations (26) and 
(27).  The estimated parameter values corresponding to these variables are 
reported in Table 6.    
To estimate the propensity of our person to smoke and drink next year, two 
further pieces of information are needed.  Firstly, assumptions about how 
observable covariate values change over time are required.  Propensity to smoke 
and drink next year depends on smoking and drinking status last year, but also 
contemporaneous values for other covariates in the model.  Second, estimates of 
the important unobservable characteristics of our person are needed.  While these 
are not known, using the MSL estimates of     
     
     and     the covariance 
structure of the unobserved terms and random draws from the uniform 
distribution across the interval [0,1], sampled estimates of time-invariant and 
time-variant unobserved effects     and      can be generated.   
With all this information, it is possible to estimate numerical values describing our 
person’s propensities to smoke and drink to an at-risk level the year after final trial 
follow-up, by inputting the information into the linear equations (26) and (27).  If 
the values produced for     
  and     
  are greater than 0, our person will be predicted 
to smoke and drink to at-risk levels.   
Future behaviour for this person can be predicted by updating the relevant 
information, year by year, so that our person’s behaviour twenty years further 
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after trial follow-up will be a function of the pattern of his preceding behaviour and 
other contributory factors.   
In reality, information on many of the person-specific variables in equations (26) 
and (27) is not routinely collected in trials.  In Chapters 7 and 8, assumptions are 
made in lieu of such knowledge.  HILDA estimation sample mean values (Table 44 
and Table 45 in Appendix D) were used for all time-varying covariates bar ‘age’, 
‘male’, state dependence variables, ‘smoking ban’ and price indices.  To recap, these 
time-varying covariates capture income, education status, spousal and parental 
status and whether individuals live in a major city.   
The variable ‘smoker last year’ was defined by smoking status at 12 months 
following smoking cessation treatment, from trial data analysis as described in 
Chapter 6.  Variables for drinking status in the previous year, age and gender were 
sampled for each simulated person from distributions representative of the target 
population, as described fully in Chapter 7.  The variable ‘smoking ban’ was set 
equal to 1 to reflect contemporary society.  Price indices were set to sample means 
and increased annually in line with average price increases in the UK from 2002 to 
2010, based on ONS consumer price index data [349].  Using sample mean values for 
other covariates is not wholly satisfactory, particularly when many covariates are 
binary and the model is nonlinear.  An alternative would have been to sample from 
the distributions of each variable for simulated persons in the individual-level 
model.  This could have also enabled correlation between distributions of variables 
to be accounted for, and may have had some effect upon projected behaviour.  The 
computational burden of this additional complication would have been substantial 
though, and the effect on final economic appraisal outcomes potentially negligible. 
Other variables in equations (26) and (27) not yet accounted for are those 
variables in the initial conditions equations (23) and (24).  It is not possible to 
observe the starting values for smoking and drinking for individuals in a smoking 
cessation trial, though they are more likely to start the dynamic process of 
behaviour as smokers than the general population.  In the cost-effectiveness 
analyses these values were set to attempt to capture the likely values for smoking 
cessation trial participants.  The binary variable ‘smoker initial value’ was set to 1 
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for all simulated individuals, while ‘at-risk drinker initial value’ was assumed equal 
to drinking status upon model entry.  Other time-averaged covariates from initial 
conditions equations (23) and (24) were set equal to HILDA sample means, in the 
absence of other data.  It is not possible to know whether these assumptions best 
represent the target population, but it is reasoned in Chapter 8 that if these 
assumptions are applied consistently across treatment comparators in an 
economic evaluation, the implication for incremental results across comparators is 
likely small.    
Uncertainty around and correlation between parameter estimates in Table 6 is 
incorporated into the economic appraisal in Chapter 8.  Using the mean parameter 
values and the related covariance matrices reported in Appendix D, Table 47 and 
Table 48, sampled sets of parameter estimates were drawn from the distribution 
and used in the probabilistic sensitivity analysis, described further in Chapter 8. 
5.8. Discussion 
This chapter has presented the first known individual-level bivariate and dynamic 
investigation of the relationship between alcohol use and tobacco use, using the 
best available data.  The results shown are of interest for numerous reasons, but a 
key aim of this chapter was to generate output which could be used to project 
patterns of long-run behaviour in an economic appraisal model for competing 
strategies to aid smoking cessation.  It has been set out how this can be achieved, 
but it is possible to infer from the results what the impact for appraisal outcomes 
might be.  As Chapter 3 demonstrated, past appraisals have typically made 
simplistic assumptions about long-term smoking behaviour which imply stability, 
implicitly favouring strategies with greater short-term effectiveness.  Analysis of 
HILDA data has shown smoking behaviour as a dynamic process to be strongly 
influenced by historical behaviour and unobserved time-invariant person-specific 
attributes, suggesting the impact of a smoking cessation intervention will be of less 
consequence that typically assumed in cost-effectiveness models.  The prediction is 
that short-term effectiveness will be of less importance when these dynamic 
results are taken into account in Chapter 8 in comparison to Chapter 6, and this 
will be reflected in smaller incremental differences between outcomes for the 
strategies under comparison.  However, as noted in section 5.6, if smoking 
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cessation interventions affect the unobserved attributes which are important for 
smoking propensity, their influence over long-run behaviour will be greater.  
Comparison of results in Chapters 6 and 8 will highlight the truth of this 
speculation. 
Of the factors that have been shown to influence the decision to smoke, cross-state 
dependence upon past alcohol status was of minor importance.  Cross-state 
dependence was however found to have a positive influence on the propensity to 
drink; being a smoker last year increases the probability of being an at-risk drinker 
next year.  Firstly, this further justifies the focus upon treatments for smoking 
cessation as opposed to strategies to improve alcohol behaviour in subsequent 
chapters. Secondly, this implies that smoking cessation will have a knock-on effect 
to alcohol behaviour which increases the expected health benefits of quitting 
smoking, which should be reflected in Chapter 8 results.   
The finding of positive cross-state dependence between alcohol and tobacco use 
also has potential implications for wider policy.  Should strategies to aid smoking 
cessation include information about the potential knock-on effect of success 
leading to healthier drinking habits? Would this be viewed by the target audience 
as an appealing consequence of smoking cessation? These are questions which 
require further research. 
The findings from this analysis are generally consistent with results from previous 
studies, though little evidence of the interrelated dynamics of smoking and alcohol 
use exists. Only one previous study has used individual-level panel data to model 
dynamic alcohol and tobacco use.  Picone et al estimated equations for alcohol and 
tobacco consumption using American HRS data and results were generally 
consistent with those reported here [267].  Importantly though, there were clear 
differences between Picone et al and this study in terms of data (there were two 
years between each wave of data collection in the HRS) and methods (separate 
versus joint estimation of equations, analysis of consumption versus participation, 
treatment of unobserved time-invariant heterogeneity as ‘fixed’ versus ‘random’), 
which makes it generally difficult to compare results.   
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Cross-price elasticities have often been used in econometric studies to explain the 
link between alcohol and tobacco use, perhaps because of the exogeneity of 
aggregate prices.  Elasticity estimates have generally, though not universally [267, 
289],  suggested complementarity between tobacco and alcohol goods [275, 276, 291, 316].  
However, the results presented here have suggested that insufficient variation in 
aggregate price data may limit the usefulness of such estimates.   A similar 
observation has been made by Tauchmann and colleagues [278].  Though more 
complex than many of the analyses reviewed in section 5.2, dynamic analyses of 
variation in individual-level data, such as that presented here, are possible with 
currently available data and software, and offer far greater explanatory power. 
 
There are limitations to the way alcohol and tobacco use has been modelled in this 
chapter.  Firstly, both tobacco and alcohol behaviours have been modelled as 
binary participation choices that have health consequences. In the case of smoking, 
the choice between being a smoker and a non-smoker is real and clearly policy 
relevant; the NHS Stop Smoking Service exists to help smokers become non-
smokers.  However, smoking behaviour may have been better modelled as count 
data. In the case of alcohol use, the difference between drinking to at-risk levels 
and not is relevant to policy, a clear aim of UK alcohol policy is to reduce alcohol 
consumption levels among hazardous and harmful drinkers to below threshold 
levels [350], but it is not so clearly a decision that individuals make.  In reality, as 
with smoking and other behaviours, there are multiple decisions which contribute 
to the observed drinking behaviour of individuals and numerous ways to measure 
behaviour. The binary decision to drink alcohol is an initial and distinct decision, 
and the level of alcohol use among drinkers can be measured by average volume or 
pattern of drinking (binge drinking) [351].   Defining drinking behaviour here as a 
binary choice between ‘at-risk’ drinking and not ‘at-risk’ drinking  has precedent 
[311, 352], but is somewhat simplistic and an improvement would be to treat HILDA 
drinking data as interval data on frequency and quantity of alcohol use.  There was 
however no software available to jointly estimate two such models and 
programming would have been complex and beyond the feasible scope of this 
project.  Treating tobacco and alcohol use data as binary choice data at this stage 
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enabled joint analysis of smoking and alcohol use, within the scope of this research 
project. 
Secondly, there is a practical limitation in the way the initial conditions problem 
has been treated here.  In the dynamic model described by Wooldridge [336], the 
dynamic process is initiated by the true ‘initial’ values.  This is rarely observed, so 
the first observed value is used instead.  This should be the same point in time for 
all individuals, for example the age at which smoking becomes legal in a smoking 
model.  In cohort studies that follow individuals of the same age over a life cycle 
this is often possible, though even in these studies it is not possible to separate age 
effects and cohort effects.  For the HILDA survey, sampling was designed so that 
the sample reflects the population of households occupying private dwellings in 
Australia, and so the first observed values for smoking and drinking are at varying 
ages across individuals in the sample. Of course, it is not possible to separate age 
effects and cohort effects. 
The HILDA Self-Completion Questionnaire does contain some retrospective 
smoking information, but it is not sufficient to characterise the initial smoking 
state of respondents [310]. Non-smokers are asked if they ever smoked, but smokers 
are not asked about initial behaviour.  The same is true for alcohol use information. 
There was some more detailed questioning on smoking behaviour in wave 7 only.  
In this chapter, the first observed value for each respondent in the sample was 
used as the initial value.  This is a practical approach that has been used in 
previously published applications of dynamic microeconomic panel data models 
[327, 353, 354].    
Thirdly, using survey panel data to model health-related behaviour creates a 
potential problem of bias from non-response or attrition.  Investigation into the 
potential implications for the results presented here indicated that non-response is 
systematically linked to smoking in the HILDA survey, but that any bias in 
estimates will be small in magnitude.  Interestingly, the magnitude of differences in 
estimates between unweighted and weighted models has been small in a range of 
health econometrics applications, even when tests have indicated that non-
response was linked to the outcome measure [342].  Non-response bias has also 
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been shown to have limited influence upon results in applications to income 
dynamics and models of social exclusion [342].  Nevertheless, future research into 
attrition bias in dynamic analyses of individual-level smoking behaviour using self-
reported longitudinal survey data may be of merit. 
Aside from the methodological limitations discussed, there is a question of 
generalisability of the findings here to a UK setting.  The predicted probabilities 
estimated here will be used in the following chapters to quantify the cross-
behavioural effects of smoking cessation for at-risk alcohol use, and consequences 
for health and health care costs in a UK NHS setting.  Though the issue is addressed 
partly by conditioning on variables appropriately when predicting behaviour, 
there is an outstanding issue of whether cross-state dependence in a sample 
representative of Australian households can be assumed equivalent to the target 
population for smoking cessation programmes in the UK.  On the one hand, HILDA 
data was used here in the absence of any equivalent UK data, and the evidence 
produced here is on the basis of the best available information.  On the other hand, 
evidence of similarities between the sample and the target population strengthen 
the validity of the outputs from this chapter for this thesis. Recording of 
demographic characteristics in trials is limited, but recent assessment of 101 
attendees at a stop-smoking clinic in London recorded a mean age of 45 years old 
[355]; only slightly younger than the mean age of 47 of the males in the ‘longest run’ 
unbalanced (estimation) sample as  shown in Table 44. Mean number of cigarettes 
smoked per day was higher in the clinic sample (19 cigarettes) than among 
smokers in the male estimation sample (13 cigarettes).  The prevalence of smoking 
in the estimation sample is almost identical to estimates of smoking prevalence in 
the UK (22%) [356].  Average weekly units of alcohol in the male estimation sample 
(12 UK units) was however lower than recent UK estimates for males (16 UK units) 
[356].  Alcohol consumption might be expected to be higher still among users of 
smoking cessation services, given the results presented here. 
Overall, there are apparent similarities between the sample used to estimate the 
dynamic link between alcohol and tobacco use in this chapter and the UK general 
population and those who use smoking cessation services in the UK, but alcohol 
consumption and consumption of cigarettes among smokers are lower here than 
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can be expected in UK smoking cessation services.  This is a slight limitation, but 
one that the absence of good UK data made necessary. 
 
5.9. Chapter Summary 
The aim of this chapter was to generate evidence on the interrelated dynamics of 
tobacco and alcohol use, using HILDA survey data in the absence of more 
appropriate data, which could be used to better inform projections of long-term 
behaviour in future economic appraisal models.  Though there are limitations to 
the analysis, this aim has been demonstrably achieved.  Tobacco and alcohol use 
are dynamic and interrelated processes and explained not only by past behaviour 
but various other factors both observed and unobserved in survey data.  The 
results are more generally of interest as a study of the co-dependence and 
dynamics of two health-related behaviours, in light of very little evidence in this 
area, and may be of use to policy makers. 
The next chapter reports a ‘standard practice’ cost-utility model for a 
pharmaceutical agent to aid smoking cessation with potential for use in the UK, 
replicating the BENESCO model and incorporating potentially unrealistic 
assumptions about long-run smoking status and links to other behaviour.  
Chapters 7 and 8 will then respectively describe the methods and results from a de 
novo individual-level economic appraisal model to re-assess the expected cost-
utility of this pharmaceutical agent, which incorporates the evidence generate here 
to project patterns of long-run behaviour.
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6. Chapter 6: Standard practice economic appraisal of 
competing strategies to aid smoking cessation 
 
6.1. Introduction 
Chapter 5 demonstrated the interdependence of alcohol use and smoking status, 
yet in Chapter 6 knowledge of this interdependence is to be temporarily put to one 
side, as a ‘standard practice’ economic appraisal of competing strategies to aid 
smoking cessation is presented.  This appraisal follows the methodology of the 
BENESCO model, used widely in previous applications [357-367], as identified in 
Chapter 3.  Though not all appraisals share the assumptions and structure of the 
BENESCO model, it is labelled here as ‘standard practice’ due to the sheer number 
of applications it has been applied to, and decisions it has informed, including the 
decision by NICE to recommend the adoption of varenicline as an aid to smoking 
cessation.  The analysis presented here very recently formed the economic analysis 
for a short review commissioned through the National Institute for Health 
Research (NIHR) HTA programme [368], showing the BENESCO model to be very 
much relevant as a standard practice model in this area. 
 
There are three main motivations and objectives driving this chapter.  The primary 
aim is to analyse the results of an economic appraisal of a relevant resource 
allocation problem using ‘standard practice’ methods, in order to analyse key 
drivers of model outputs and assess the importance of inherent and unrealistic 
modelling assumptions. Secondly, Chapter 6 introduces a contemporary and 
relevant decision problem for healthcare financers, between competing strategies 
to aid smoking cessation attempts.  Thirdly, Chapter 6 serves to describe 
methodology to link smoking status to health, HRQoL and costs.  These methods 
will be retained in the BIT model, described in Chapter 7.  
 
Chapter 6 is structured as follows. First, decision problem, methods and data for 
the model are set out.  This includes description of the decision problem, 
conceptual model, input data and analysis plan.  Second, key probabilistic results 
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are presented, alongside results from probabilistic and various univariate 
sensitivity analyses.  Third, these results and the consequences of limitations of 
this model are discussed and compared to analyses elsewhere and in anticipation 
of those from the BIT model, to be demonstrated in subsequent chapters.  Fourth, 
conclusions are drawn. 
 
6.2. Methods 
6.2.1. The decision problem 
Varenicline was licensed as an aid to smoking cessation in the UK in 2007 and 
subsequently recommended by NICE following a Single Technology Appraisal (STA) 
[366].  Varenicline is a synthetic product manufactured by Pfizer; a nicotine receptor 
partial agonist [368]. These types of drugs aid smoking cessation by abating 
symptoms of nicotine withdrawal through agonist actions, while countering 
reinforcing effects of nicotine through antagonist actions [368, 369].  As reported in 
Chapter 3, varenicline has been shown to have preferential efficacy to licensed 
pharmaceuticals which work upon smoking receptors in different ways, such as 
bupropion and NRT.   
Cytisine is another nicotine partial receptor agonist, with a similar structure to 
varenicline [368].  Cytisine is not currently licensed for use in the UK, but has been 
used as an aid to smoking cessation in Bulgaria (where it is manufactured under 
the brand name Tabex by Sopharma) and various Eastern European countries for 
over forty years [370].  That cytisine is not currently UK licensed can be partly 
attributed to its unusual history of development [370]. Preclinical studies of optimal 
dosing that would normally form part of the drug development process were not 
conducted, and until very recently there were no large, placebo-controlled 
randomised trials that would meet modern regulatory standards [370].  
Cytisine is considerably cheaper than varenicline; though prices vary between 
countries where cytisine is available, the cost of a course of cytisine is generally 
10-20% of the cost of a course of varenicline [370].  The NIHR was therefore 
interested in understanding (i) the estimated cost-utility of cytisine versus 
varenicline, as an aid to smoking cessation for UK patients and uncertainty around 
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this estimate, based on current evidence and (ii) the anticipated value of 
conducting a large scale head to head trial comparing cytisine with varenicline in a 
UK sample of quit-motivated smokers.  The latter was estimated in the NIHR HTA 
short review using advanced value of information analyses [11, 368, 371]; these results 
are not reported here. The aims of this chapter are met presenting analyses 
addressing the problem: ‘What is the cost-utility estimate, and uncertainty around 
this estimate, of cytisine versus varenicline to aid smoking cessation attempts, 
based on current evidence?’ 
The economic analysis was focussed on a population on smokers in England and 
Wales aged 18 years or over who are motivated to quit smoking, and explicitly 
evaluated the cost-effectiveness of a standard 25 day course of cytisine (six 1.5-mg 
tablets per day for 3 days (days 1 through 3), five tablets per day for 9 days (days 4 
through 12), four tablets per day for 4 days (days 13 through 16), three tablets per 
day for 4 days (days 17 through 20), and two tablets per day for the final 5 days 
(days 21 through 25) [372]) with a standard 12 week course of varenicline 
(500 micrograms once daily for 3 days, increased to 500 micrograms twice daily 
for 4 days, then 1 mg twice daily for 11 weeks [373]. 
6.2.2. The conceptual model 
The model structure was based on the existing and widely used BENESCO model 
[357-367], identified in Chapter 3.  The BENESCO model is a state transition model 
designed to capture important long-term outcomes of smoking cessation 
treatments.  
The model was programmed in Microsoft Excel, uses an annual cycle length and 
assumes that all smokers die at age 100 years if death had not been simulated at an 
earlier age.  A hypothetical cohort of 10,000 smokers enters the model with each 
smoker assumed to make a single quit attempt, assisted by either varenicline or 
cytisine. The distribution of the cohort in terms of gender, age (three age 
categories are used: 18-34 (years old); 35-64; 65-100) and chronic smoking-
related diseases (lung cancer, COPD, CHD and stroke) is assumed to be 
representative of smokers in England and Wales. 
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At the start of the model, every cohort member begins in the ‘smoker’ state. At the 
end of the first year, a proportion of smokers successfully cease smoking and 
become ‘quitters’; this proportion is determined by the efficacy of the cessation aid 
treatment received. The model assumes that no further attempts to quit are made 
and that those who fail to quit remain smokers until death. However, there is a 
possibility that quitters may relapse and start smoking again in future years. 
Potential to relapse to smoking is incorporated into the model as a decreasing 
function of time since cessation, and is independent of cessation treatment 
(varenicline or cytisine).  For the four model cycles following cessation, cohort 
members are assigned ‘recent quitter’ status, and risk of relapse is highest. After 
four cycles without relapse, ‘recent quitters’ attain ‘long-run quitter’ status.  The 
annual relapse rate is lower for ‘long-run quitters’ than ‘recent quitters’ in the next 
five cycles, and lower still in subsequent cycles, with this underlying relapse rate 
continuing for the duration of the model. 
At the end of each year, the cohort is distributed into different smoking states 
(smoker, quitter, relapsed smoker) according to their current smoking state and 
relapse rates. Figure 10 details the possible transitions between smoking states. 
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Within these broad smoking states, cohort members are distributed between the 
following disease states: no current morbidity; lung cancer; COPD; CHD; stroke; 
and asthma exacerbation. These health states were selected by the authors of the 
BENESCO model to correspond to the diseases accounting for the greatest 
morbidity, mortality and cost attributable to smoking [363].  The health states are 
mutually exclusive, and death is an absorbing state. The probability of transition 
between disease states at the end of each cycle is dependent on: current disease 
state; smoking status; age; and gender, as these factors have been shown to be 
independent determinants of risk. 
The model has categorised four of the health states as either acute (CHD and stroke) 
or chronic (COPD and lung cancer) conditions. Transitions within acute conditions, 
and within chronic conditions are not allowed, thus it is not possible for a cohort 
member to experience a CHD event following a stroke. Transitions from acute 
disease states to chronic disease states are possible, but not from chronic 
conditions to acute conditions. Asthma exacerbations were transient in nature and 
assumed to resolve within one year, and could only occur from the no current 
Smokers 
Quitters 
Relapsers 
Figure 10: Transitions between smoking states 
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morbidity health state. Figure 11 illustrates possible transitions between health 
states in the model.   
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Each health state is associated with utility and cost values as detailed later. 
Therefore cohort members accumulate costs and health outcomes each cycle until 
death.  Adverse events are not considered within the BENESCO model framework. 
Future costs and benefits were discounted at a rate of 3.5% per annum, and the 
perspective is that of the UK National Health Service for costs and health effects on 
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Figure 11: Transitions between 
health states 
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the individual for outcomes, in line with NICE guidance [6].  Attention now turns to 
parameter values and distributions used in the PSA. Many model inputs are 
derived from a previous manufacturer STA report [366]. Whilst this is a slight 
limitation, this is unlikely to affect the key conclusions regarding the relative cost-
effectiveness of varenicline and cytisine. 
6.2.3. The assumed characteristics of the initial cohort 
The distribution of the cohort across gender and age categories at the start of the 
model was designed to reflect the distribution of smokers in England and Wales. 
Data on the demographics of the cohort, and prevalence and incidence of diseases 
among smokers and non-smokers are assumed to be equal to those reported by 
Pfizer [366].  For convenience these are reproduced in this report together with all 
cause mortality risk along with the original source (Table 7). The proportion of 
male and female adults in each of the three age categories was determined from 
general population data [374].  Smoking prevalence data were applied to this data to 
calculate the distribution across age and gender groups for a representative 
sample of 10,000 smokers [375].  Pfizer [366] used interim life tables calculated by the 
UK Government Actuary’s Department for 2002-2004, weighted by population size 
and averaged to fit the age categories in the model. 
Table 7: Data informing demographic distribution of cohort 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
General 
population 
 
ONS [374]  6,727,400 11,843,600 4,040,000 6,660,700 12,140,100 5,189,300 
Smoking 
prevalence 
 
ONS [375] 
 
36.20% 27.70% 12.70% 28.00% 28.50% 26.70% 
Annual 
risk of all-
cause 
mortality 
Government 
Actuary’s 
Dept [376] 0.09% 0.47% 4.88% 0.04% 0.30% 3.87% 
 
The prevalence of smoking-related diseases in the cohort was estimated by Pfizer 
[366] from data on the prevalence of each disease in the general population. Relative 
risks for the incidence of each disease in the model for smokers were taken from 
the literature and used to calculate the expected number of cases in the cohort of 
smokers [377, 378]. These data are reproduced in Table 8.   
  131  
 
Table 8: Prevalence of disease in simulated cohort of UK smokers7 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
COPD 
 
Soriano et al 
[379] 
0.00% 1.00% 3.00% 0.00% 1.00% 2.00% 
Lung 
Cancer 
 
Forman et al 
[380] 
0.00% 0.10% 0.70% 0.00% 0.06% 0.24% 
History of 
CHD 
 
ONS [381] 0.00% 1.60% 8.00% 0.00% 1.00% 5.90% 
History of 
Stroke 
 
ONS [381] 0.00% 0.50% 3.00% 0.00% 0.30% 2.00% 
Asthma 
Asthma UK 
[382]; 
Hoskins et al  
[383] 
6.00% 5.00% 6.50% 6.40% 5.30% 5.30% 
 
6.2.4. Transition Probabilities  
Annual incidence of disease was estimated by Pfizer [366], divided by age and 
gender categories, for smokers, ‘recent quitters’ and ‘long-run quitters’.  These 
values relied on estimates from the literature in the majority of cases [382, 384-387], 
but for COPD there was a lack of available data and incidence was based on 
mortality data [366].  Office for National Statistics (ONS) data were used to estimate 
stroke incidence, and these data provided a split between first event and all events 
[386].  Table 9, Table 10 and Table 11 show estimates for smokers, recent quitters 
and long-run quitters, respectively, along with original data sources.  Relative risks 
for smokers, short-run quitters and recent quitters were generated from the 
literature [377, 378] and used to generate absolute probabilities of incidence. As can 
be seen, the incidence of smoking-related diseases is at least as high in smokers 
compared with recent quitters, and in recent quitters compared with long-run 
quitters.   
  
                                                        
7
 Pfizer 366. Pfizer UKL. Varenicline: Single Technology Appraisal Submission2007. were not 
consistent in reporting to a set number of decimal places or significant figurers.  In this report, for consistency, 
prevalence, incidence and mortality data, though taken from the manufacturer submission, are reported to at least 2 
decimal places. 
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Table 9: Annual incidence of diseases in smokers by age and gender category 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
COPD 
 
Pfizer [366] 
0.00% 0.02% 0.55% 0.00% 0.02% 0.44% 
Lung Cancer ONS [386] 0.00% 0.10% 1.00% 0.00% 0.08% 0.50% 
CHD (first 
non-fatal) 
British Heart 
Foundation 
[384] 
0.00% 0.10% 1.00% 0.00% 0.05% 0.86% 
CHD 
(subsequent 
non-fatal) 
 
Volmink et al 
[387] 
0.00% 0.19% 1.74% 0.00% 0.05% 1.18% 
Stroke (first 
non-fatal) 
 
ONS [385] 
0.00% 0.26% 0.92% 0.00% 0.20% 0.74% 
Stroke 
(subsequent 
non-fatal) 
 
ONS [385] 
0.00% 0.35% 1.55% 0.00% 0.28% 1.33% 
Asthma 
exacerbation 
Asthma UK 
[382] 
0.08% 0.05% 0.07% 0.08% 0.05% 0.06% 
 
Table 10: Annual incidence of diseases in ‘recent quitters’ by age and gender 
category 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
COPD 
 
Pfizer [366] 
0.00% 0.02% 0.40% 0.00% 0.01% 0.43% 
Lung Cancer ONS [386] 0.00% 0.04% 0.43% 0.00% 0.03% 0.20% 
CHD (first 
non-fatal) 
British Heart 
Foundation 
[384] 
0.00% 0.08% 0.81% 0.00% 0.02% 0.71% 
CHD 
(subsequent 
non-fatal) 
 
Volmink et al 
[387] 
0.00% 0.12% 1.39% 0.00% 0.02% 0.97% 
Stroke (first 
non-fatal) 
 
ONS [385] 
0.00% 0.11% 0.61% 0.00% 0.08% 0.55% 
Stroke 
(subsequent 
non-fatal) 
 
ONS [385] 
0.00% 0.14% 1.03% 0.00% 0.11% 1.00% 
Asthma 
exacerbation 
Asthma UK 
[382] 
0.05% 0.05% 0.06% 0.06% 0.05% 0.06% 
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Table 11: Annual incidence of diseases in ‘long-run quitters’, by age and gender 
category 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
COPD 
 
Pfizer [366] 
0.00% 0.02% 0.05% 0.00% 0.00% 0.04% 
Lung Cancer ONS [386] 0.00% 0.04% 0.43% 0.00% 0.03% 0.20% 
CHD (first 
non-fatal) 
British Heart 
Foundation 
[384] 
0.00% 0.05% 0.68% 0.00% 0.01% 0.50% 
CHD 
(subsequent 
non-fatal) 
 
Volmink et al 
[387] 
0.00% 0.07% 1.16% 0.00% 0.02% 0.69% 
Stroke (first 
non-fatal) 
 
ONS [385] 
0.00% 0.11% 0.61% 0.00% 0.05% 0.46% 
Stroke 
(subsequent 
non-fatal) 
 
ONS [385] 0.00% 0.00% 0.01% 0.00% 0.00% 0.01% 
Asthma 
exacerbation 
Asthma UK 
[382] 
0.05% 0.05% 0.06% 0.06% 0.05% 0.05% 
 
Annual mortality probability by condition was estimated by Pfizer [366] for smokers, 
recent quitters and long-run quitters, by age and gender specific category.  
Mortality associated with asthma exacerbation was assumed to equal all-cause 
mortality (Table 7). Mortality for chronic diseases, COPD and lung cancer, is the 
probability of death from these diseases given the disease state is present.  
Mortality from acute events, CHD and stroke, is the probability of a fatal event that 
differs by smoking status, age and gender.  Table 12, Table 13 and Table 14 show 
disease-specific mortality estimates for smokers, recent quitters and long-run 
quitters, respectively, as reported by the manufacturer's submission for the NICE 
varenicline STA [366], along with the original data sources.  Relative risks of 
mortality for smokers, recent quitters and long-run quitters from the literature 
were used [377, 378]. The probability of smoking-related mortality is equivalent or 
lower for recent quitters compared with smokers and for long-run quitters relative 
to recent quitters. 
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Table 12: Annual mortality for smokers, by age and gender category 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
COPD 
 
ONS [374] 
0.00% 0.98% 10.12% 0.00% 0.70% 9.16% 
Lung Cancer 
 
ONS [374] 
0.00% 26.89% 47.69% 0.00% 40.48% 75.35% 
CHD (first 
event fatal) 
British Heart 
Foundation 
[384] 
0.00% 0.10% 0.81% 0.00% 0.04% 0.69% 
CHD 
(subsequent 
event fatal) 
 
ONS [374] 
0.00% 0.15% 1.39% 0.00% 0.04% 0.94% 
Stroke (first 
event fatal) 
 
ONS [374] 
0.00% 0.02% 0.30% 0.00% 0.02% 0.38% 
Stroke 
(subsequent 
event fatal) 
 
ONS [374] 
0.00% 0.03% 0.50% 0.00% 0.03% 0.56% 
 
Table 13: Annual mortality for ‘recent quitters’, by age and gender category 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
COPD 
 
ONS [374] 
0.00% 0.98% 10.12% 0.00% 0.70% 9.16% 
Lung Cancer 
 
ONS [374] 
0.00% 26.89% 47.69% 0.00% 40.48% 75.35% 
CHD (first 
event fatal) 
British Heart 
Foundation 
[384] 
0.00% 0.06% 0.65% 0.00% 0.02% 0.56% 
CHD 
(subsequent 
event fatal) 
 
ONS [374] 
0.00% 0.09% 1.12% 0.00% 0.02% 0.78% 
Stroke (first 
event fatal) 
 
ONS [374] 
0.00% 0.01% 0.20% 0.00% 0.01% 0.28% 
Stroke 
(subsequent 
event fatal) 
 
ONS [374] 
0.00% 0.01% 0.33% 0.00% 0.01% 0.42% 
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Table 14: Annual mortality for ‘long-run quitters’, by age and gender category 
Data Original 
Source 
Males  
18-34 
Males  
35-64 
Males 
65+ 
Females  
18-34 
Females  
35-64 
Females  
65+ 
COPD 
 
ONS [374] 
0.00% 0.98% 10.12% 0.00% 0.70% 9.16% 
Lung Cancer 
 
ONS [374] 
0.00% 26.89% 47.69% 0.00% 40.48% 75.35% 
CHD (first 
event fatal) 
British Heart 
Foundation 
[384] 
0.00% 0.04% 0.54% 0.00% 0.01% 0.40% 
CHD 
(subsequent 
event fatal) 
 
ONS [374] 
0.00% 0.06% 0.93% 0.00% 0.01% 0.55% 
Stroke (first 
event fatal) 
 
ONS [374] 
0.00% 0.01% 0.20% 0.00% 0.01% 0.24% 
Stroke 
(subsequent 
event fatal) 
 
ONS [374] 
0.00% 0.01% 0.33% 0.00% 0.01% 0.35% 
 
6.2.5. Relapse rates 
In the previous manufacturer's submission for the NICE varenicline STA [366], the 
annual probability of relapse to smoking for the first five years following cessation 
was calculated from a longitudinal US four year follow-up study of a health 
improvement initiative in the workplace (n=1143) [388].  The probability used was 
criticised by the Evidence Review Group, as it was incorrectly derived from 
baseline length of abstinence data [389].  Whilst it was possible to estimate annual 
probability of relapse from this study, using follow-up data for the sub-sample of 
participants that had been abstinent for one to two years at baseline, this sub-
sample comprises only 79 participants. 
A more recent study has used BHPS data to analyse relapse to smoking (n=1578) 
[390].  The article shows numbers relapsing each year among those reporting non-
smoking for at least one year having previously reported smoking, for duration of 
cessation of up to ten years.  These data were used to calculate the annual relapse 
probability for short-run quitters (<5 years since quit) and a proportion of long-
run quitters (more than five years but less than a decade post-quit).  Data on 
annual relapse probability ten or more years post-cessation are scarce and in the 
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absence of more robust data, the same data as used by Pfizer [366] were employed 
here [391]. 
Table 15 shows the probabilities of relapse used in the model.  The probability of 
relapse in the first ten years post 1 year of cessation is higher than estimates used 
in some previous models [357-359, 362, 366] but is in line with other research which 
suggests that around half of those abstinent at one year will relapse to smoking in 
the next seven years [392, 393]. The annual probability of relapse after ten years of 
abstinence was assumed to be 1% in the STA submission and several other 
applications of the BENESCO model [357-359] which all based their estimate on a 
longitudinal study [391].  The authors for this longitudinal study report that ‘the 
(annual) rate of smoking relapse…fell to less than 1% after ten years of abstinence’.  
Using the data reported in the study [391], the annual probability of relapse 
according to the data is much lower than 1%.   Uncertainty around relapse rates is 
modelled in this report as a beta distribution, using event data from the original 
studies [390, 391]. 
 
Table 15: Relapse probabilities, by duration of abstinence 
Data Original 
Source 
Mean 
probability 
95% CI Distribution 
over relapse 
category time 
period 8 
Annual relapse 
probability, >1 & <5 
years post cessation 
(time period 4 years) 
 
Hawkins 
et al [390] 0.129 [0.117, 0.141] Beta (395, 535)  
Annual relapse 
probability, >=5 & 
<10 years post 
cessation 
(time period 5 years) 
 
Hawkins 
et al [390] 
0.0331 [0.0230, 0.0452] Beta (33, 180) 
Annual relapse 
probability, >10 
years post cessation 
(time period 26 
years) 
 
Krall et al 
[391] 
0.00112 [0.000402, 0.00153] Beta (9, 390) 
 
                                                        
8
 Parameter values correspond to total time period in ‘Data’ column: 4 years for relapse 1-5 years post cessation , 5 
years for relapse 6-10 years post-cessation and 26 years for relapse over 10 years post cessation (reflecting the 
follow-up period of Krall (200299)).  Instantaneous relapse rates were first calculated from the data, and then 
converted to one year probabilities. 
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6.2.6. Costs 
Costs included in the model were costs relevant to disease states and intervention 
costs.  The mean costs for COPD, CHD and asthma are those reported in Hind et al 
[394]. The source for COPD cost is the average direct cost of treatment, weighted by 
severity, taken from a study estimating burden of disease in the UK [395].  The 
annual cost of lung cancer was taken from a NICE Rapid Review [396], sourced from 
a UK epidemiology study [397]. The annual patient cost for CHD is an estimate of the 
aggregate cost of CHD to the NHS [398], divided by estimated prevalence.  The cost 
of asthma exacerbations represented a mixture of the estimated cost of an A&E 
attendance and NHS reference cost of inpatient attendance, with the ratio of A&E 
to inpatient admissions estimated taken from a UK an asthma risk factor analysis 
[383].  Costs for stroke were taken from a recent NIHR HTA report [399], and 
incorporates the one-off and ongoing costs of stroke, and the reported difference in 
costs and prevalence of dependent and independent patient states following a 
stroke incident [400].  All costs have been adjusted for inflation to 2011/12 prices 
[401].   
Uncertainty around cost estimates were incorporated into the probabilistic 
analysis. In the absence of data, the standard errors for COPD, lung cancer, CHD 
and asthma exacerbation were assumed to be 10% of the mean estimate. These 
data were assumed to follow a gamma distribution, as is common practice for cost 
data [10].  Confidence intervals around costs following stroke events reported in the 
recent NIHR commissioned Technology Assessment Report [399] informed the 
uncertainty around mean costs for stroke, which was assumed to fit a normal 
distribution. Table 16 reports the source, summary estimates and distributions 
used for the disease state costs used in the model. 
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Table 16: Disease state annual costs 
Data Original 
Source 
Mean Cost 
(£) 
95% CI Distribution 
 
COPD 
 
Britton [395] 
971.31 
[780.93, 
1161.69] 
Gamma (100, 9.71) 
 
Lung Cancer 
 
Sanderson & 
Spiro [397] 
6,524.02 
[5245.31, 
7802.72] 
Gamma (100, 65.24) 
CHD (non-
fatal event) 
 
McMurray et 
al [398] 
1,162.5 
[934.45, 
1390.05] 
Gamma (100, 11.62) 
Stroke (non- 
fatal event) 
 
Simpson et al 
[399] 
5,484.31 
[4996.99, 
5970.85] 
0.741*[Normal(576.51,15.74) 
+ Normal(3398.40,175.83)] + 
0.259*[Normal(3010.17,66.21) 
+ Normal(6792.55,345.70)] 
Asthma 
Exacerbation 
 
Hoskins et al 
[383] 
1,162.25 
[846.73, 
1259.56] 
Gamma (100, 10.53) 
 
Intervention costs comprised the cost of the drug regimen.  Costs of brief 
counselling and support of a health professional are also likely to occur, but not 
likely to differ between drug treatments, thus not impacting relative cost-utility, 
and were not included in the economic analysis.  For the comparator intervention, 
standard treatment with varenicline, British National Formulary (BNF) data on 
dosage and pricing were used [373].  The cost of treatment is the cost of a starter 
pack covering the first two weeks of tapered treatment (£27.30) plus the cost of 
ten weeks at full dose (5 x £27.30), £163.80 in total.  The cost of cytisine treatment 
within a UK setting is not determined. The manufacturers of cytisine were 
contacted but no reply was received. In the absence of firm evidence, it is strongly 
suspected that a course of cytisine will be significantly cheaper than a standard 
course of varenicline [370, 402].  A previous model of the costs and effects of cytisine 
for smoking cessation assumed treatment costs to be US$10 per smoker [402]. As of 
March 2013, it was possible to buy Tabex (active ingredient cytisine) online in the 
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UK for £16.79 for 100 1.5mg tablets [403], which represents approximately a 
standard course, and this cost is used in the model. Table 17 shows the treatment 
costs used in the model. 
 
Table 17: Treatment costs 
Data Original Source Total Cost (£) 
 
Cytisine Treatment Cost 
 
Assumption 16.79 
 
Varenicline Treatment Cost 
 
BNF [373] 163.80 
 
6.2.7. Utilities associated with health states 
Baseline utility for smokers with no current comorbidity were taken from the 
general population utility profile estimated by Ara and Brazier using HSE data [404].  
These data are a function of age and gender.    Disease-specific utility values for 
smoking-related diseases are the same as reported by the manufacturer 
submission team [366].  For lung cancer utility [405], asthma exacerbation utility [406] 
and a second non-fatal stroke event utility [407], a utility multiplier associated with 
the disease was estimated by comparing the reported utility value with the 
expected value for a person of the same age within the general population, 
assuming that age-specific values from the UK were applicable for all populations.  
The average ages of the samples from which utility values were drawn were 62 
years, 49 years and 65 years for lung cancer, asthma exacerbations and a second 
non-fatal stroke, respectively.  The mean ages of the population for which the 
utilities were provided for a first non-fatal stroke event [408], COPD [409] and 
following any CHD event [410], were not reported.  For these disease states, an 
average age of 60 years is assumed with the sensitivity of the results to this 
assumption is explored by altering baseline utility estimates for these diseases to 
correspond to ages 50 and 70 years, respectively.  
Disease state utility was determined using a multiplicative approach, i.e. baseline 
utility is multiplied by an estimate of the impact of the disease. Table 18 displays 
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the mean utility values for health states in the model. Thus a male aged 40 years 
with lung cancer would have an estimated utility of 0.44 (0.88 x 0.50).  
 
Table 18: Health state mean utility values 
Health State Utility Source Mean Age Mean Utility  
Age- and gender-specific utility values 
No current morbidity 
(NCM) Males 18-34 
Ara [404] 26.5 0.94 
NCM Males 35-64 Ara [404] 49 0.88 
NCM Males 65-100 Ara [404] 82.5 0.72 
NCM Females 18-34 Ara [404] 26.5 0.92 
NCM Females 35-64 Ara [404] 49 0.86 
NCM Females 65-100 Ara [404] 82.5 0.70 
Disease-specific utility multipliers 
Lung Cancer Trippoli et al [405] 62 0.50 
COPD Spencer et al [409] 60 0.63 
CHD Hay & Sterling [410] 60 0.63 
Stroke 1st Event Tengs & Lin [408] 60 0.62 
Stroke 2nd Event Gage [407] 65 0.12 
Asthma Exacerbation Szende [406] 49 0.45 
 
Uncertainty around utility estimates is explored in the probabilistic analysis.  
Normally distributed error terms from OLS regressions used to predict baseline 
utility by Ara and Brazier [404] represent uncertainty around utility inputs and were 
used to explore uncertainty in model outputs as part of the PSA.  Uncertainty in the 
values reported for each health state was not considered and therefore the true 
uncertainty will be underestimated.   
6.2.8. Intervention effectiveness 
The NIHR HTA short review included a systematic review and network meta-
analysis of effectiveness data for varenicline and cytisine [368].  Sixteen studies 
comparing pairs, triplets or quintuplets of interventions informed the meta-
analysis, which covered eight drug regimens (NRT patch, cytisine 1.5mg 6 times 
daily, varenicline 0.3mg once daily, varenicline 1.0mg once daily, varenicline 0.5mg 
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twice daily, varenicline 1.0mg twice daily, bupropion 150mg twice daily, placebo) 
[368]. 
The absolute probabilities of cessation at one year for interventions were 
generated by combining the results of the network meta-analysis with an estimate 
of the placebo response, as described in the short review [368].  The median and 
mean probability of one-year continuous abstinence for cytisine and varenicline 
and 95% credible intervals (CrI) are shown in Table 19.  The wide credible 
intervals are reflective of uncertainty around the baseline (placebo) effect.  There 
is much less uncertainty about the treatment effects and the order of the 
effectiveness of the two treatment comparators.  The probability that cytisine 
1.5mg was the most effective treatment of the eight compared in the meta-analysis 
was 0.86. When only cytisine 1.5mg and varenicline 1mg bid are compared, the 
probability that cytisine is the most effective treatment was estimated to be 0.90.  
The 95% credible interval around the difference between effectiveness of the 
interventions (probability of quit with cytisine minus probability of quit with 
varenicline) includes zero [-0.048, 0.389]. 
Table 19: Absolute probability of one year continuous cessation 
 Median Mean 95% CrI 
Cytisine, One-year Continuous Abstinence Probability 0.394 0.449 [0.040, 0.998] 
Varenicline, One-year Continuous Abstinence 
Probability 
0.257 0.330 [0.026, 0.958] 
 
Discussion of key assumptions 
The BENESCO modelling approach involves several assumptions, as noted 
throughout this chapter.  A key assumption implicit in the model is that cohort 
members can only quit after treatment for smoking cessation, within the first 
model cycle, and at no other point until death.  In reality, smokers who are willing 
to quit but fail during one attempt will have a probability of successfully quitting at 
a later stage in their lives.  This assumption is likely to favour interventions with 
greater efficacy.  If the 1-year probability of cessation is significantly higher for one 
treatment than another, that treatment will have greater health outcomes across 
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the cohort over the lifetime horizon.  This assumption is a feature of all previous 
applications of the BENESCO model [357-367]. 
The economic model has relied in part on input data from a previous 
manufacturer's submission for the NICE varenicline STA [366].  It is not known if 
these inputs are the best available as (i) at least five years have elapsed since these 
data were identified and (ii) identification of input studies was not always clearly 
reported.  The majority of cost, utility and relapse data were from the UK, but a 
proportion of these data were from non-UK studies [377, 378, 391]. The model assumes 
transferability of these data to a UK NHS setting.  Additionally, the model assumes 
treatments are not associated with adverse events.    
6.2.9. Analysis of uncertainty 
The uncertainty around key parameter estimates was modelled by the use of 
probability distributions which allowed PSA to be undertaken.  Ten thousand 
draws from distributions of treatment effectiveness, health state utility, disease 
costs and relapse probabilities were used as model inputs.  Furthermore, 
univariate sensitivity analysis was performed to ascertain the key drivers of model 
outputs.  Value of information analyses was also undertaken. This involved the 
calculation of the expected value of perfect information (EVPI) [411].  
6.3. Results 
6.3.1. Mean outcomes associated with each treatment 
The results of the PSA are presented as the primary results of interest, as, unlike 
deterministic estimates, they take into account the distributions of input 
parameters and interaction between parameters, and thus are the more accurate 
estimates. Table 20 shows the primary results of the PSA analysis: per smoker total 
discounted costs, LYs and QALYs for the two treatments. Cytisine is expected to be 
less costly and more effective than varenicline, and so can be said to dominate 
varenicline, based on the expected values.   
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Table 20: Mean Per-Smoker Discounted Total and Incremental Costs, Life Years 
and QALYs from the economic analysis 
Treatment 
Costs Life Years QALYs 
Total  Incr. Total  Incr. Total  Incr. 
Cytisine £      4973 -£251 17.53 0.03 14.55 0.03 
Varenicline £      5225  17.50  14.52  
 
Figure 12 presents the cost-effectiveness acceptability curves [412] for the two 
treatments.  At any threshold willingness to pay of up to £100,000 per QALY 
gained, cytisine was the optimal intervention in over 90% of the simulations 
within the PSA.  This reflects the higher costs associated with varenicline 
treatment.  As the willingness to pay increases, the probability that cytisine is 
preferable falls and the likelihood varenicline is optimal rises.  Given that cytisine 
was estimated to be the more effective treatment in 90% of simulations the value 
for cytisine on the cost-effectiveness acceptability curve will asymptote at 90%. 
 
Figure 12: Cost-effectiveness acceptability curves for cytisine and varenicline 
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Figure 13 shows the distribution of the 10,000 estimated cost-effectiveness pairs.  
There is clear correlation between incremental costs and incremental QALYs: 
health outcomes are important in determining long-term costs.  The wide range of 
per-person health and cost outcomes is reflective of the uncertainty around the 
relative effectiveness of cytisine and varenicline, as illustrated by the univariate 
sensitivity analyses. 
Figure 13: Scatter plot of results from 10,000 PSA runs 
 
6.3.2. Univariate sensitivity analyses 
Table 21 details the results from the univariate sensitivity analyses. In all the 
analyses, bar one, the conclusion that cytisine dominates varenicline is upheld. The 
exception was in altering the relative efficacies of varenicline and cytisine. This 
analysis was operationalised by ranking the output from the network meta-
analysis based on the value in the differences of the absolute quit rates between 
cytisine and varenicline and using the 2.5th and 97.5th percentile. When using the 
value most favourable to varenicline an additional 0.01 QALYs at an additional cost 
of £103 were estimated for varenicline versus cytisine, resulting in a cost per QALY 
gained of just under £8,000 for varenicline which would be typically seen as cost-
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effective under typical NICE thresholds [6], thus leading to a different adoption 
decision to the baseline analysis.  
The assumed treatment cost for cytisine is lower than that for varenicline, but the 
cytisine cost estimate if adopted for use within the NHS is uncertain.  In a threshold 
analysis it was estimated that the price of the cytisine regimen would have to rise 
to over £250 (from an estimate of £16.79, a greater than 14-fold rise) for the total 
expected lifetime cost with cytisine treatment to equal the total expected lifetime 
cost with varenicline treatment. 
 
Table 21: Univariate sensitivity analysis result, per smoker discounted outcomes 
Variable 
Sensitivity 
analysis 
Treatment 
Costs LYs QALYs 
Total  Incr. Total   Incr. Total  Incr. 
Baseline  Cytisine  £   4,973  -£251 17.53 0.03 14.55 0.03 
Varenicline £    5,224  17.50  14.52  
COPD utility Assumed age of 
study sample 
50 years 
Cytisine  £   4,973  -£251 17.53 0.03 14.56 0.03 
Varenicline £    5,224   17.50  14.53  
Assumed age of 
study sample 
70 years 
Cytisine  £   4,973 -£251 17.53 0.03 14.54 0.03 
Varenicline  £   5,224   17.50  14.50  
CHD utility Assumed age of 
study sample 
50 years 
Cytisine  £   4,973 -£251 17.53 0.03 14.57 0.03 
Varenicline  £   5,224   17.50  14.54  
Assumed age of 
study sample 
70 years 
Cytisine  £   4,973 -£251 17.53 0.03 14.52 0.03 
Varenicline  £   5,224   17.50  14.49  
Stroke 1st 
event utility 
  
Assumed age of 
study sample 
50 years 
Cytisine  £   4,973 -£251 17.53 0.03 14.57 0.03 
Varenicline £   5,224   17.50  14.53  
Assumed age of 
study sample 
70 years 
Cytisine  £   4,973 -£251 17.53 0.03 14.53 0.03 
Varenicline £   5,224  17.50  14.50  
Cytisine Cost Double 
 
Cytisine  £   4,990 -£234 17.53 0.03 14.55 0.03 
Varenicline  £   5,224   17.50  14.52  
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Variable 
Sensitivity 
analysis 
Treatment 
Costs LYs QALYs 
Total  Incr. Total   Incr. Total  Incr. 
COPD cost Upper 95% CI 
value 
Cytisine  £   5,037  -£252 17.53 0.03 14.55 0.03 
Varenicline  £   5,289   17.50  14.52  
Lower 95% CI 
value 
Cytisine  £   4,909 -£250 17.53 0.03 14.55 0.03 
Varenicline  £   5,159  17.50  14.52  
Lung Cancer 
cost 
Upper 95% CI 
value 
Cytisine  £   5,062  -£254 17.53 0.03 14.55 0.03 
Varenicline  £   5,317   17.50  14.52  
Lower 95% CI 
value 
Cytisine  £   4,883  -£248 17.53 0.03 14.55 0.03 
Varenicline  £   5,132  17.50  14.52  
CHD event 
cost 
Upper 95% CI 
value 
Cytisine £   5,126 -£252 17.53 0.03 14.55 0.03 
Varenicline  £   5,378   17.50  14.52  
Lower 95% CI 
value 
Cytisine  £   4,820  -£250 17.53 0.03 14.55 0.03 
Varenicline  £   5,070   17.50  14.52  
Stroke event 
cost 
Upper 95% CI 
value 
Cytisine  £   5,273  -£258 17.53 0.03 14.55 0.03 
Varenicline  £   5,531   17.50  14.52  
Lower 95% CI 
value 
Cytisine  £   4,672  -£244 17.53 0.03 14.55 0.03 
Varenicline  £   4,916   17.50  14.52  
Asthma 
event cost 
  
Upper 95% CI 
value 
Cytisine  £   4,975  -£251 17.53 0.03 14.55 0.03 
Varenicline  £   5,226   17.50  14.52  
Lower 95% CI 
value 
Cytisine  £   4,971  -£251 17.53 0.03 14.55 0.03 
Varenicline  £   5,222   17.50  14.52  
Relapse 
probability  
1 to 4 years 
Upper 95% CI 
value 
Cytisine  £   4,992  -£246 17.52 0.03 14.54 0.03 
Varenicline  £   5,238   17.49  14.51  
Lower 95% CI 
value 
Cytisine  £   4,954  -£256 17.54 0.04 14.55 0.03 
Varenicline  £   5,210   17.50  14.52  
Relapse 
probability 5 
to 9 years 
Upper 95% CI 
value 
Cytisine  £   4,989  -£247 17.52 0.03 14.54 0.03 
Varenicline  £   5,236   17.49  14.51  
Lower 95% CI 
value 
Cytisine  £   4,959  -£255 17.53 0.03 14.55 0.03 
Varenicline  £   5,214   17.50  14.52  
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Variable 
Sensitivity 
analysis 
Treatment 
Costs LYs QALYs 
Total  Incr. Total   Incr. Total  Incr. 
Relapse 
probability 
10+ years 
  
Upper 95% CI 
value 
Cytisine  £   4,975  -£251 17.53 0.03 14.55 0.03 
Varenicline  £   5,225   17.50  14.52  
Lower 95% CI 
value 
Cytisine  £   4,972  -£252 17.53 0.03 14.55 0.03 
Varenicline £   5,223   17.50  14.52  
Difference 
between 
treatment 
effectiveness  
(cytisine 
minus 
varenicline) 
Upper 95% CrI 
value 
Cytisine £   4,743 -£504 17.60 0.12 14.62 0.11 
Varenicline £   5,246  17.49  14.51  
Lower 95% CrI 
value 
Cytisine £   5,206 -£103 17.45 -0.01 14.48 -0.01 
Varenicline £   5,309  17.47  14.49  
 
6.3.3. Calculation of the EVPI 
EVPI is defined as the value of eliminating all uncertainty around the adoption 
decision. The value is determined by both (i) the probability that a wrong adoption 
decision will be made and (ii) the costs of forgoing the optimal treatment strategy.   
In order to calculate the EVPI, an estimate of the number of people affected by the 
more accurate information was required. A recent ONS report estimated that 21% 
of the UK adult population smoke, around 10 million people, and the same report 
found that 63% of smokers want to quit smoking [356].  If even half of those with a 
desire to quit attempt assisted cessation while the choice between cytisine and 
varenicline is relevant, the adoption decision will affect more than 3 million UK 
smokers. Elsewhere, it has been estimated that 800,000 smokers currently access 
Stop Smoking Services in England each year [413], supporting the notion that 3 
million smokers could be affected in England and Wales.   
Analysis of US data from the 2003 Tobacco Use Cessation Supplement to the 
Current Population Survey found of those attempting to quit (43.5% of all 
smokers), one third (32.2%; 14.0% of all smokers) used medication [414].   The 
proportion of attempted quitters using medication was lower in the UK at the turn 
of the century, but increasing as NRT and bupropion became available on 
prescription [415].  However, a study into the reasons smokers shy away from 
medications suggests that perceived effectiveness has lessened use of smoking 
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cessation drugs in the past [416].  The high efficacy of the dopamine-inhibitors 
cytisine and varenicline, in comparison to NRT, will likely attenuate this effect.   
Ease of access has also been cited as a factor [416].  This all suggests that with a 
focus on implementation in UK stop smoking services, to overcome these barriers, 
the proportion of quit attempts assisted by medication could rise significantly in 
the next ten years.  The figure of 3 million affected smokers is considered credible, 
but the EVPI was also calculated with the assumption of 1 million smokers affected. 
The INB of cytisine compared with varenicline was calculated per smoker for each 
of the PSA runs for willingness to pay thresholds for an additional QALY of £20,000 
and £30,000. In over 90% of PSA runs the INB was positive indicating that 
varenicline was not cost-effective. However, in the remainder of the PSA runs the 
value was negative, indicating that varenicline was cost-effective. The maximum 
INB was calculated as the sum of all positive INB, divided by the number of PSA 
runs (10,000). The expected INB was calculated as the sum of all INB, divided by 
the number of PSA runs.  The EVPI was calculated as the difference between 
maximum INB and expected INB.  This value was £11.71 per smoker assuming a 
willingness to pay of £20,000 per QALY gained, and £19.99 per smoker assuming a 
willingness to pay of £30,000 per QALY. 
Whilst these are small EVPI values per person the value becomes much greater 
when multiplied by 3 million to represent the likely population affected by the 
decision resulting in EVPI values of £35.13 million and £59.96 million at a 
willingness to pay levels per QALY of £20,000 and £30,000 respectively. Even with 
a conservative value of only 1 million smokers affected by the decision and with 
willingness to pay £20,000 for an additional QALY, the EVPI was £11.71 million.  
6.4. Discussion  
PSA outputs from the model presented in this chapter suggest that cytisine for 
smoking cessation will produce greater mean life years and QALYS, and lower 
mean lifetime costs than varenicline, which was previously considered to be the 
most cost-effective smoking cessation treatment strategy.  At a willingness to pay 
threshold of £20,000 for an additional QALY, the probability that cytisine 
treatment is preferable to varenicline treatment is 0.95, and this probability does 
not fall below 0.9.  Despite this, the value of further information on the relative 
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effectiveness of the two strategies is high because of the very large numbers of 
smokers assumed to be affected by the further information.   
A key driver of the dominance of cytisine treatment over varenicline treatment in 
this economic analysis is the relative effectiveness of cytisine versus varenicline, as 
shown in the univariate sensitivity analysis.  In summary, the treatment which 
generates the greatest number of quitters will have the best long-term health-
related outcomes as efficacious treatment also has the impact of reducing costs 
associated with longer-term conditions associated with smoking. If treatment costs 
were equal for varenicline and cytisine, the probability that cytisine is the optimal 
choice is 0.9 (at any willingness to pay value), reflecting the 0.9 probability that 
cytisine has the greater 1-year continuous cessation probability.   
It was not possible to validate the economic model outputs against results in the 
STA report, as the number in the simulated cohort in the latter was not reported 
and so per smoker values are unknown [389].  Other previous applications of the 
BENESCO model have used non-UK populations and parameter inputs, making 
comparison of total LYs, QALYs and costs difficult [357-367].  However, results across 
these studies and here have been similar, in that the intervention with the greatest 
effectiveness (short-term cessation probability) has consistently had the greatest 
cost-utility. 
The key limitation of the model structure used is the imposed assumption of no 
underlying quit rate, among failed quitters or relapsed smokers, which is likely to 
favour treatments with higher effectiveness.  Other UK analyses of the cost-
effectiveness of smoking cessation interventions have assumed underlying quit 
rates of between 1% and 2.5% [392, 396, 417], but these estimates originated from a 
study that used now dated cross-sectional data [418].  In each of these studies, 
unlike here, the most efficacious strategy had the highest treatment cost, but like 
here, the strategy with greatest short-term effectiveness was the optimal strategy, 
at a willingness to pay threshold of £20,000 per QALY gained.  In these models the 
annual probabilities of relapse to smoking, smoking related disease incidence and 
death have been assumed to be constant [392, 396, 417] compared with the decreases 
related to time since cessation in the present model.  Assuming a sharp fall in 
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probabilities linked to unfavourable health outcomes, rather than a decline over 
time, is less realistic, but further biases results towards those with higher 
effectiveness if the full benefits of smoking cessation are assumed instantly 
obtainable.    
It is difficult to incorporate both an underlying quit rate and transition 
probabilities that vary with time since quit into a state transition model structure, 
without incorporating numerous tunnel states. Individual-level models may be a 
better avenue for accurately quantifying the cost-utility of smoking cessation 
strategies in future.  At least two such models have been built to date [215, 419], and 
the BIT model described in Chapter 7 takes an individual-level approach which 
allows accurate and flexible modelling of predicted smoking status post follow-up, 
as well as incorporation of the link to alcohol use.  
The transition probabilities and some parameter inputs presented here were taken 
from the manufacturer's submission for the NICE varenicline STA [366], and it is not 
known whether these data are the best currently available.  From the results of the 
deterministic sensitivity analysis, model outputs are robust to changes in 
parameter inputs apart from the relative effectiveness of the two treatments.  
Uncertainty around the probabilities of transition to disease states has not been 
explored, but if the relative risks of smoking-related disease incidence and 
mortality can be assumed to decrease after smoking cessation, cytisine for 
smoking cessation will represent a better use of the healthcare budget than 
varenicline using average values given current information. 
6.5. Chapter Summary 
This chapter sought to present and analyse results of a standard practice economic 
appraisal of competing strategies to aid smoking cessation, in order to understand 
the importance of characteristic and unrealistic modelling assumptions of current 
practice models. Appraisal of the cost-utility of cytisine versus varenicline to aid 
smoking cessation, a relevant area of investigation for today’s decision makers, has 
been presented using the BENESCO model structure.   
Choosing the optimal smoking cessation strategy is of great consequence for NHS 
finances, because of the number of current smokers affected.  It is correct that this 
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decision should be based on cost-effectiveness evidence, but it is vital that 
conclusions from the economic analysis are driven by the relative merits of 
competing strategies, and not characteristics of the economic model.  Model results 
are highly driven by effectiveness data: because smoking-related diseases are the 
key driver of both HRQoL and cost differences between comparators, the more 
effective strategy, which leads to the greatest net non-smoker gain in the cohort, is 
shown to be the cost-effective comparator.  Crucially, the BENESCO model 
structure assumes no underlying quit rate post trial follow-up.  This implicitly 
exaggerates the relative effectiveness of the most effective strategy considered.  
Other cohort analyses with differing assumptions and data may have also under-
estimated behavioural changes in the medium and long-run [392, 396, 417].  The more 
recent relapse data employed in this chapter [390] suggested higher relapse than 
previously estimated [418]. The results of many existing analyses may therefore be 
driven, at least partly, by unrealistic assumptions about post-trial behaviour. 
Results from Chapter 5 suggested that smoking status is both more transient than 
previous models have assumed and linked to multiple factors, including level of 
alcohol use.  The next chapter describes an individual-level model to appraise 
competing aids to smoking cessation, which incorporates dynamic projections of 
extrapolated smoking status based on HILDA data, and incorporates the estimated 
inter-temporal link to alcohol use, and its consequences.  The methods and data to 
link smoking behaviour to health, HRQoL and costs presented here will be useful 
model inputs in this individual-level model.  This model provides an alternative 
analytic tool to ‘standard practice’ models such as the BENESCO model.  Analysis 
using this alternative model in Chapter 8 will explore the extent to which standard 
practice models of smoking cessation strategies have produced inaccurate results 
due to unrealistic assumptions and limited data. 
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7. Chapter 7: The Behavioural Interactions in Tobacco 
use (BIT) health economic model  
 
7.1. Introduction 
The previous chapter demonstrated the methods and results of a cost-effectiveness 
model typical of existing economic appraisals of smoking cessation interventions.  
The model made potentially unrealistic assumptions about smoking status post 
trial follow-up and assumed no link between smoking status and alcohol use.   
There are two key objectives of Chapter 7.  The first is to describe the methodology 
of a de novo model of the health economic consequences of smoking cessation 
treatment outcomes, the BIT model.  The model accounts for a link between 
smoking status and alcohol use, using the dynamic equations estimated in Chapter 
5.  By incorporating these dynamic behavioural equations, the BIT model also 
improves on standard practice assumptions about smoking status post trial follow-
up, by allowing for the influence of age, gender and other important factors on the 
propensity to smoke.  The second is to outline the data and methods to link alcohol 
use to health in the BIT model. 
This chapter is split into two parts, relating to these two objectives. The first part 
describes the conceptual model, and should help the reader understand the 
possible pathways of individuals through the model, with reference to a 
hypothetical smoking cessation treatment patient. Methods to predict future 
smoking and alcohol use status have been detailed in previous chapters.  The 
second part of this chapter details methods to capture health and cost 
consequences of alcohol use decisions. 
7.2. The Conceptual Model 
This narrative first describes the software package within which the BIT model 
was constructed, then the workings of the model itself. 
Simul8, a commercial discrete event simulation (DES) software package, was used 
to build the model (www.simul8.com).  In this application, Simul8 was not 
employed for its full DES capabilities, but because of its flexible and user-friendly 
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programming language and interface.  Unlike within a typical DES framework, 
where events occur on a continuous time scale, time is managed through discrete 
cycles.  This framework sits easily with the econometric model outputs from 
Chapter 5. Nevertheless, there is a clear advantage of using Simul8 software over 
Microsoft Excel for a relatively complex state-transition cost-effectiveness model 
such as this.  When dealing with diseases with chronic implications, keeping track 
of patient histories becomes important. In a Microsoft Excel cohort model, this can 
be achieved by creating health states to differentiate between patients with 
different histories.  The number of health states required for this can quickly 
become very large though, and difficult to manage.  In Simul8, it is relatively easy 
to assign labels to patients which keep track of their individual history, and then 
activate logic based on the values within these labels.   
As discussed in Chapter 6, this limitation has played an important role in the way 
economic evaluation models of smoking cessation have been constructed.  Models 
have typically either assumed no future quit attempts after the modelled 
intervention, as is the case with the BENESCO model, reproduced in Chapter 6, or 
have assumed constant underlying quit rates and relapse rates after the first year 
[140, 160, 420].  Evidence from Chapter 5 and Chapter 2 suggests that long-term 
smoking (and drinking) behaviour is variable and influenced by multiple factors, 
but modelling would become unmanageable within a Microsoft Excel cohort state-
transition model framework if appropriate complexity was to be added.  By 
building this economic model within Simul8, smoking status changes and relapse 
rates that vary with time since quit and other factors can be applied, marking 
improvements on existing models.  Similarly, incorporating the consequences for 
alcohol use and alcohol-linked health consequences would have required a number 
of health states that was considered logistically not possible within a Microsoft 
Excel cohort state-transition model framework. 
Building the model in Simul8 has also had the related advantages of ease of 
adaptation, transparency through the user interface and Visual Logic code, and 
relative ease of verification and validation.  
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For readers unfamiliar with Simul8 and requiring a brief introduction, there are 
four main components within a Simul8 model, through which work items (e.g. 
people) travel [421]: 
1. Entry Point(s), where work items arrive in the model 
2. Queues, where work items wait to be processed by the accompanying Work 
Centre 
3. Work Centres, where work is performed 
4. Exit Point(s), where work items leave the model 
Information can be stored during a simulation, in the form of spreadsheets, 
numbers and labels. Labels can be in number form, and are attached to work items 
as they travel through the simulation, and differ between work items.  Numbers 
and spreadsheets are, by contrast, not work item specific.  In a health economic 
individual-level model such as this, labels are well suited to tracking person-
specific attributes such as age, gender and disease presence, whereas numbers can 
be used to record model outputs, such as total costs, life years and QALYs. 
Though it is possible to hold work items within queues and specify a processing 
time for work centres, when there is no competition for resources within the 
model, or interaction between work items, it aids model run time to set processing 
times to zero. Queues are therefore not used in the traditional sense in the model, 
but used only as an aid for validation and verification.  The computational time 
involved in searching for the next event increases disproportionately with the 
number of entities within the system. 
One simulated individual is followed to death before the next enters the model; 
processing one entity at a time also aids verification and validation.  After model 
entry, each simulated individual moves between ‘work centres’, according to 
transition probabilities that reflect both the label characteristics and current work 
centre of the individual, with costs and health outcomes updated within each work 
centre.  Discrete time cycles of 1 year are used. To adjust for bias incurred when 
assuming events occur at the end of each time cycle, a half-cycle correction is 
applied [422]. 
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Figure 14: Flow diagram describing one person’s journey through the model 
 
 
Figure 14 illustrates one simulated person’s journey through the model, in 
simplified terms.   Underpinning movement and tracking of characteristics and 
outcomes for each person, is code written in Simul8’s simulation language, Visual 
Logic (VL).  The following narrative seeks to describe the workings of this code, so 
that the reader can understand the details of the model. 
Before a model run 
One run of the model generates outcomes of interest (costs, LYs, QALYs) for the 
sample of interest, for one configuration of parameters sampled given parameter 
uncertainty.  
Assign person characteristics 
Assign maximum time to morbidity and 
Move to initial behaviour 
Search for next event  
(mortality, morbidity, or behaviour 
Accumulate outcomes 
(costs, LYs, QALYs, time since 
smoking quit if relevant) 
Next event 
death? N 
Y 
Add person outcomes to total 
Move to next event 
Exit model 
 Enter 
model 
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Before each model run, reset logic is called and used to set parameter values to 
appropriate levels. Because the model can be run as probabilistic or deterministic, 
reset logic sets (i) healthcare costs, (ii) utility and (iii) parameters for the 
econometric probability equations to values for the current configuration of 
parameter uncertainty.  This is done in two stages.  To minimise unnecessary 
storage of data within Simul8 and to aid verification and validation, N values of 
parameters tested used in the PSA were sampled a priori in Microsoft Excel. The 
first stage involves retrieving from Excel the draws of PSA input values associated 
with the current parameter uncertainty configuration.  The second stage involves 
setting input parameters to these values.  
7.2.1. Upon entry 
Simulated individuals enter the model at 12 months following smoking cessation 
intervention.   Upon entry, they are assigned age and gender values, in the form of 
labels.  Labels are also used to capture smoking and drinking status.  It is assumed 
that patients do not have any morbidities when entering the model. 
Predicted time to death from causes unrelated to alcohol and tobacco (all other 
cause mortality (AOCM)) is also calculated. Time to AOCM is estimated by 
comparing age and gender specific risk to a random number draw from the 
uniform interval [0, 1] each year until the former is the greater, and then stored as 
a number9.  This number defines the maximum time to death for each individual; 
this can be shortened but not extended as individuals move through the model.   
The individual then leaves the entry point and moves to one of four behaviour-
related work centres.  These work centres are defined by smoking and drinking 
status: 
 ‘NAR, NS’ signals not at-risk drinking and non-smoking 
  ‘NAR, S’ signals not at-risk drinking and smoking 
 ‘AR, NS’ signals at-risk drinking and non-smoking     
 ‘AR, S’ signals at-risk drinking and smoking     
                                                        
9
 For brevity, a random draw from the uniform interval [0, 1] is generally referred to as ‘random number 
draw’ from here on. 
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The drinking and smoking labels of the simulated individual leaving the entry 
point determine to which of these work centres the entity is routed.  This was 
achieved by selecting ‘Routing Out’ options within the entry point, and routing 
according to a label, router, numerically defined by smoking and drinking status. 
To introduce an example simulated individual at this point, assume a 50 year old 
male, ‘Paul’, who enters the model as a smoker and at-risk drinker.  Paul is routed 
to the ‘AR, S’ work centre upon entry. 
7.2.2. Behaviour-related work centres          
The four behaviour-related work centres are broadly similar, so describing Paul’s 
movement through the ‘AR, S’ work centre highlights the mechanics of the other 
three.   
The aims of the code within behaviour-related work centres are to (i) determine 
which event occurs next and route accordingly, (ii) record costs and health 
outcomes incurred whilst in the work centre and (iii) update person-specific label 
values.   
7.2.2.1. (i) Determining the next event and routing 
There are eight possible next events Paul could experience after leaving ‘AR, S’, and 
router is updated accordingly throughout the work station VL.  Box 1 details the 
router values attached to each possible next event. 
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Box 1: Next events for behaviour-related work centres 
 
 
 
 
 
 
 
 
 
 
 
First, the VL code calculates the predicted time to a change in drinking status.  This 
is done using outputs from the econometric model described in Chapter 5.  
Whether Paul changes his drinking status next year is determined by: current 
drinking status; current smoking status; gender; age in a year’s time; unobserved 
time-variant and time-invariant factors that influence the propensity to drink to at-
risk levels; and the remaining independent variables in the econometric at-risk 
drinking equation.  Paul is currently an at-risk drinker.  The output from the at-risk 
drinking equation is the latent propensity for at-risk drinking; as described in 
Chapter 5, if this is less than zero, Paul is predicted to change his drinking 
behaviour to not at-risk next year.  If this is the case, Paul’s time to drinking status 
change is set to 1.  If not, the process is repeated with age and price variables 
appropriately adjusted until either drinking status change is predicted or age 
reaches 100 years, whereby time to drinking status change is recorded.    
router = 1  Next event: Change in drinking status 
router = 2  Next event: Death 
router = 3  Next event: ‘Hospital’ (incidence of smoking or drinking related 
morbidity) 
router = 4  Next event: Change in smoking status 
router = 5  Next event: Simultaneous change in drinking and smoking status 
router = 6 Next event: Change in drinking status and ‘Hospital’ 
router = 7 Next event: Change in smoking status and ‘Hospital’ 
router = 8 Next event: Simultaneous change in drinking and smoking status & 
‘Hospital’ 
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Assuming a change in drinking status is at present the next event, Paul’s router 
label is set to 1, and a number recording time to behaviour change is set to time to 
drinking status change, before time to a change in smoking status is calculated.  The 
method for this is equivalent to calculating time to drink status change, but using 
the smoking equation estimated in Chapter 5.  If time to smoking status change is 
less than time to drinking status change, the next event is now behaviour change to 
non-smoking, time to behaviour change is updated and router is set to 4.  If both 
behaviours are calculated to change in the same year, router is set to 5. 
Next, a number representing time to death is estimated.  There are three broad 
categories of death that Paul is at-risk of every year: alcohol-related disease (ARD) 
mortality; smoking-related disease (SRD) mortality; and AOCM.  Outstanding risk 
estimations are detailed in section 7.3.2.  Time to AOCM is the number calculated 
upon entry, less any time spent in the model; time to death is first set to this 
number. Time to ARD mortality is estimated by comparing age- and gender-
specific risk to a random draw each year until the former is the greater for each 
alcohol-related disease or injury in the model.  If time to ARD death is less than 
time to AOCM, the number tracking time to death is updated.  Time to SRD 
mortality is estimated in a similar fashion only if Paul has one of the four chronic 
SRDs with associated mortality in the smoking model: COPD, lung cancer, previous 
CHD or previous stroke.  Again, if time to SRD death is less than present time to 
death, the time to death number is updated. 
The number time to death is then compared to time to behaviour change, to see if 
behaviour change occurs first.  Importantly, the code prioritises certain events 
over others, if they occur at the same time.  Events are prioritised in order of 
severity, so if death and behaviour change are estimated to occur simultaneously, 
death takes priority.  If time to death is lower or equal to before time to behaviour 
change, the label router is set to 2. A new number, time to next event, is set to 
whichever event occurs soonest. 
Third, the VL code estimates time to morbidity.  There are two broad types of 
morbidity Paul can incur: ARD morbidity and SRD morbidity.  Using familiar 
comparisons of risk estimates to random number draws, time until morbidity is 
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estimated for each ARD in turn, and a new number, time to hospitalisation, is set to 
store the lowest time to morbidity. The term hospitalisation is used loosely to 
capture incidence of all morbidity, though SRD incidence data is not based solely 
on hospital records. Time and cause of morbidity are recorded here, using 
numbers such as time of liver cancer. This is important, as if hospitalisation occurs 
next these numbers are used to assign labels for chronic disease within hospital VL, 
as explained later. Time until SRD morbidity is then estimated for COPD, lung 
cancer, CHD, stroke and asthma using risk data from the smoking model in Chapter 
6.  The number time to hospitalisation is updated if SRD morbidity is estimated to 
occur before ARD morbidity.    
If death is the next event, the VL code then compares time to death to time to 
hospitalisation, to see which occurs first. If it is the latter, time to next event is set to 
time to hospitalisation, and router is set to 3. If both are equal, death takes priority 
over morbidity and behaviour change, as a matter of severity.   
If however, behaviour change is estimated to occur before death, the VL code 
instead compares time to behaviour change to time to hospitalisation. If the latter 
occurs first, time to next event is set to time to hospitalisation, and router is set to 3. 
If both are equal, and drinking status change occurs before smoking status change, 
router is set to 6.  If both are equal, and smoking status change occurs before 
drinking status change, router is set to 7.  If both are equal, and both drinking and 
smoking status changes occur simultaneously, router is set to 8.    
In the smoking model in Chapter 6, risks of SRDs are lower for long-run smoking 
quitters than short-run quitters; this complexity is incorporated into the BIT model 
using VL.  The label ‘quit years’ is updated upon work centre exit.  As Paul is 
currently a smoker, his ‘quit years’ label is set to 0.  If Paul was in a non-smoking 
work centre, his annual risk of death and mortality would reduce after 4 years of 
predictions of no event, by means of the number ‘count quit years’, based on the 
label ‘quit years’ and updated with annual estimations of time to event within non-
smoking work centre VL.   
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7.2.2.2. (ii) Recording costs and health outcomes  
The only costs incurred within behaviour-related work centres are annual costs 
from chronic SRDs.  If one or more chronic SRD is present (as recorded by a label), 
the cost is calculated as the years spent in the work centre multiplied by the annual 
cost.  The discounted cost is calculated by discounting the years spent in the work 
centre before multiplication by the estimated annual cost.  This is done by 
calculating the integral of the exponential survival curve, between work centre 
entry and exit.  The formula for this calculation is as follows: 
                 
 (           )
    
 
 (           )
    
       (41)  
       (    )  
Where    is the annual discount rate,     is the instantaneous discount rate, 
     is time of next event, measured in years, calculated in Paul’s instance as the 
difference between time to next event and model entry, and      is time of last 
event, which in Paul’s case was time at model entry, zero.      is set equal to the 
number of years the entity has been in the model immediately prior to recording of 
health and cost outcomes. The costs and discounted costs incurred are then added 
to the running Total Costs number. 
Simulated individuals like Paul are continually accumulating life years as they 
move through the model.  These are calculated as above, and added to Total LYs 
and Total Discounted Costs, as appropriate.  To calculate the QALYs Paul has 
accrued in the ‘AR, S’ work centre, the age and gender specific general population 
utility value is adjusted for any chronic ARDs or SRDs present, and multiplied by 
life years spent in the work centre.  Discounted QALYs are calculated as discounted 
work centre LYs multiplied by utility, and Total QALYs and Total Discounted QALYs 
are updated accordingly.  
Finally, a new number, years in model, is set equal to TONE. 
7.2.2.3. (iii) Updating person-specific label values 
Lastly, the labels smoker and at-risk drinker are updated according to the next 
event, using the label router.  Let us assume that, unfortunately for Paul, his next 
event is lung cancer at age 60. The labels smoker and at-risk drinker remain at 
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values of 1, and router is set to 3, and Paul travels to the workstation ‘Hospital AR, 
S’. 
7.2.3. Hospital work centres       
As with behaviour-related work centres, the four hospital work centres are 
broadly similar and describing the mechanics of one should be sufficient to convey 
the workings of the other three.   
The aims of the code within hospital work centres are equivalent to the aims listed 
for behaviour-related work centres: (i) determine which event occurs next and 
route accordingly, (ii) record costs and health outcomes incurred between events 
and (iii) update person-specific label values.  However, there are key 
characteristics of hospital work centres that mean the code used to achieve each 
aim requires further description.  
7.2.3.1.  (i) Determining the next event, routing and assigning labels 
The primary difference between behaviour-related and hospital work centres is 
that simulated individuals stay in hospital work centres for, at most, one year.  
Hospital work centres are needed to capture the cost and utility implications of 
morbidity incidence; after one year, labels can be updated to capture any chronic 
disease cost and utility implications for subsequent work centres.   
As Paul enters the ‘Hospital AR, S’ work centre, he is faced with nine possible next 
events, assigned to the router label as detailed in Box 2. 
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Box 2: Next events for hospital work centres 
 
 
 
 
 
 
 
 
 
 
The default next event following a hospital work centre is the previous behaviour-
related work centre; if Paul does not die, return to hospital or change his behaviour 
in the year after morbidity, he returns to ‘AR,S’. At the start of the VL code, router is 
set to 6. 
As in behaviour-related work centres, death takes priority over hospitalisation and 
behaviour change, when these events are predicted to occur at the same time.  The 
code estimates risk of death next.  Instead of estimating time to death, the task in 
hospital work centres is to predict whether death occurs in the next year.  
For Paul, this means comparison of annual death risk with a random number draw, 
for SRDs, ARDs and AOCM, according to his age, gender and chronic disease status.  
There is also a potentially heightened risk of death for 90 days in hospital work 
centres, if hospitalisation was for an alcohol-related condition.  The rationale 
behind this is explained in the description of alcohol behaviour risks in the second 
part of this chapter.  Though Paul’s morbidity was not alcohol-related, 
router = 1  Next event: Change in drinking status 
router = 2  Next event: Death  
router = 3  Next event: ‘Hospital’ (again) 
router = 4  Next event: Change in smoking status 
router = 5  Next event: Simultaneous change in drinking and smoking status 
router = 6  Next event: Previous smoking and drinking status 
router = 7 Next event: Change in drinking status & ‘Hospital’ 
router = 8 Next event: Change in smoking status & ‘Hospital’ 
router = 9 Next event: Simultaneous change in drinking and smoking status & 
‘Hospital’ 
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unfortunately he was predicted to die as a result of heightened mortality risk in the 
year following lung cancer incidence.  
If 90 day death had been predicted, router would have been set to 2 and time to 
next event to 90 days.  As one year mortality was predicted, router is set to 2 and 
time to next event to 1 year. In fact, without a prediction of death, the number time 
to next event could at this point confidently be set to 1 year. 
If death had not been predicted to occur in the next year, whether drinking and 
smoking status changes in the next year would be estimated, comparing predicted 
probabilities to random number draws.  If a change in drinking status is predicted, 
router is set to 1 and at-risk drinker is set to 0.  If a change to smoking status is 
predicted, router is set to 4 and smoker is set to 0, unless drinking status change is 
also predicted, in which case router is set to 5 and at-risk drinker is also set to 0. 
Next, costs and health outcomes accumulated within the workstation are 
calculated.  The costs and utility adjustments incurred through morbidity are 
attributed using numbers recording times of hospitalisation for each model 
disease, as will be described next.  The VL code predicting rehospitalisation 
updates numbers tracking times to and of   hospitalisation by cause, and so must be 
run after costs and health outcomes have been recorded.   
If the next event was not death, hospitalisation code would compare risk for one 
year with a random number draw, for all smoking- and alcohol-related diseases.  
Numbers recording times to hospitalisation and time of condition-specific 
morbidity are reset and updated. If neither death nor a change in behaviour have 
been predicted in the next year (router is currently set to 6), but rehospitalisation 
is predicted, router would be set to 3 and, because behavioural labels were 
potentially changed in this work centre when risk of behaviour change was 
assessed, at-risk drinker and smoker labels would be reset to 1, in Paul’s case.  If a 
change in drinking status was predicted (router is currently set to 1) and 
rehospitalisation was to be also predicted, router would be set to 7 and at-risk 
drinker and smoker labels to 0 and 1, respectively. If a change in smoking status 
was predicted (router is currently set to 4) and rehospitalisation was to be also 
predicted, router would be set to 8 and at-risk drinker and smoker labels to 1 and 0, 
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respectively. If a simultaneous change in drinking and smoking status was 
predicted (router is currently set to 5) and rehospitalisation was to be also 
predicted, router would be set to 9 and at-risk drinker and smoker labels to 0 and 0, 
respectively. 
7.2.3.2. (ii) Recording costs and health outcomes and assigning more labels  
Following prediction of behaviour status change, work centre costs are calculated.  
The costs incurred by a trip to hospital are dependent on the reason for the 
hospital visit.  In the previous work centre, whether it was behaviour-related or a 
hospital work centre, numbers recording time of morbidity for each disease and a 
number tracking time of hospitalisation were calculated.  It is therefore possible to 
determine the morbidity cause, by checking if time of hospitalisation is equal to 
time of morbidity for each SRD and ARD.  If so, a disease specific label can be set to 
1 to track presence of this disease in future, and any disease-specific 
hospitalisation costs can be added to Total Costs. It is important to note that this 
code allows hospitalisation for more than one condition at one time.  Paul is here 
attributed a label for lung cancer, and cost for one year of care with the disease. 
To record health outcomes, first the age and gender specific general population 
utility value is adjusted for any chronic ARDs or SRDs present, as in behaviour-
related work centres.  For Paul, the general population utility for a 60 year old 
male is multiplied by the utility level associated with lung cancer.  This utility value 
would have been multiplied by 90/365 if 90 day death had occurred, but is 
multiplied by 1 otherwise, to calculate work centre QALYs.  Work centre life years 
are either 90/365 or 1.  Then, utility decrements are applied: (i) for two weeks 
upon entry to the hospitalisation work centre, when utility is set to 0 (though SRD 
data are not based on hospital admissions, a sharp temporary fall in utility is 
assumed when learning of a chronic SRD) and (ii) for eight subsequent weeks if the 
reason for hospital admission was acute. These values can be added to Total QALYs 
and Total LYs numbers. 
Annual costs, life years and QALYs are discounted using equation (41), as are 
temporary post-hospital acute condition decrements.  One-off costs of 
hospitalisation and the two week hospitalisation utility decrement are discounted 
using the following formulae, where DR is the annual discount rate, and added to 
  166 
 
Total Discounted Costs, Total Discounted QALYs and Total Discounted LYs, 
respectively: 
                 
     
               
  
                
     
               
  
               
   
               
  
After work centre outcomes have been recorded and rehospitalisation risk 
accounted for, the variable Years in Model can be set equal to TONE, in anticipation 
of the next event.  Unfortunately for Paul, his next event is death and he leaves the 
model. 
7.2.4. After exit and on end run 
As Paul meets the model end point, the next simulated individual enters the model.  
This individual is assigned age, gender and behaviour status, and then travels 
through the model experiencing events according to risk and chance, accumulating 
costs and health outcomes simulating real life, like Paul before them. 
When the entire cohort of simulated individuals have travelled through the model, 
End Run logic enables per patient outcomes to be calculated, and if PSA is being run, 
the model is set to run again using the next sample from parameter uncertainty.  
Reset logic, described at the outset, then starts the process again. 
7.2.5. Limitations 
Despite the flexibility of Simul8 as a modelling platform, there are some limitations 
to this conceptual model.  Firstly, time is modelled as discrete.  This is for practical 
reasons: it sits easily with much of the input data including the dynamic behaviour 
equations.  Though a divergence from reality, it is not expected that the treatment 
of time as discrete will bias any analyses using the model in favour of any 
particular treatment.   
Secondly, the model does not capture health and costs for the first year after 
treatment for smoking cessation.  This is for transparency and efficiency: it enables 
one full run of the model to be analysed posthumously for multiple treatment 
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strategies.  Again, it is not anticipated this limitation will bias any analysis using 
the model.   
Thirdly, the model assumes no interactions between individuals.  For example, if 
two people die in the same car crash that resulted from drink driving, the model 
cannot account for this.  Incorporating such detail into the model, and thus 
assessing the consequences, would require further work, the feasibility of which 
has been assessed in a recently completed doctoral thesis [423]. 
Fourth, the model structure does not explicitly incorporate aided smoking 
cessation attempts after model entry.  The influence of smoking cessation aids 
upon projections of behaviour is implicitly incorporated by the dynamic 
behavioural equations estimated in Chapter 5, as these were generated using data 
from the Australian public collected in the 21st Century, when pharmaceutical aids 
to smoking cessation were available, mirroring the situation in the UK.  It is 
possible that explicit incorporation of smoking cessation attempts would influence 
economic appraisal results.  Consider an appraisal of two competing treatments for 
smoking cessation, where treatment A is more costly and more effective than 
treatment B.  If adopting a treatment means said treatment is used in all future 
cases when a smoker requires treatment to assist a quit attempt, and smokers 
make multiple quit attempts, all future treatment costs and effectiveness rates will 
be higher for treatment A than treatment B.  It is unclear whether not explicitly 
accounting for the costs and effects of subsequent quit attempts would favour 
treatment A or treatment B in this example, but in an appraisal of cytisine versus 
varenicline, the superiority of cytisine may be understated.  
 There are several issues with explicitly and accurately incorporating the costs and 
consequences of future cessation attempts into the model, however.  Firstly, it 
would be difficult to reconcile implicit and explicit incorporation of future quit 
attempts.  Secondly, adoption of one treatment would not mean that treatment 
would be used in all future quit attempts for unsuccessful quitters.  An 
unsuccessful quit attempt with one treatment may actually make another 
treatment more likely in a subsequent attempt [424].  Information would be needed 
as to the probability of quit attempts across time and the probability of each 
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available aid being used in future attempts.  The STOP model study identified in 
Chapter 3 [214] generated estimates for these two parameters using a cross-
sectional survey of US college students (n=1078)  [216].  Aside from the limitations 
of these data in applicability to a contemporary appraisal of competing smoking 
cessation aids, crucially, the survey does not contain data on the use of cytisine.  
Further, knowledge would be required about the effectiveness of subsequent 
treatment using each strategy in individuals who had previously relapsed using 
that treatment.   
7.2.6. Summary of the conceptual BIT model description 
This narrative has hopefully proved useful to the reader in explaining the 
conceptual mechanics of the BIT model, through both a brief account of the 
software platform Simul8, and the travails of our hypothetical hero, Paul, as well as 
setting out limitations of the modelling approach.  The next chapter re-analyses the 
competing cost-effectiveness of cytisine and varenicline for smoking cessation, 
using the BIT model.  However, while much of the data to populate the BIT model 
has been described in previous chapters, the methodology and data to quantify 
health and cost consequences of different levels of alcohol use is yet to be 
explained. The second part of this chapter now details the data used to link alcohol 
use to health and health-related costs in the BIT model. 
7.3. Quantifying risks and outcomes associated with alcohol 
behaviour 
This subsection explains the derivation of BIT model inputs yet to be accounted for.  
Namely, these are alcohol-related condition morbidity and mortality risks, and 
risks of death from causes unrelated to alcohol or tobacco use.  This is achieved in 
three main parts. Firstly, the conceptual pathway of alcohol-related health risks is 
described.  Secondly, the methods used to estimate these risks are explained.  
Thirdly, the method to quantify cost and utility effects related to alcohol 
consumption are set out.  With the aim of this subsection achieved, the limitations 
of these methods to link alcohol use to health are discussed. 
7.3.1. The conceptual care pathway of alcohol-related health risks 
In order to set out how risks of alcohol-related mortality and morbidity are 
captured in the BIT model, it is useful to describe the various alcohol-related 
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health risks faced by simulated individuals. Figure 15 shows a snapshot of these 
risks and how simulated individuals in the BIT model encounter them. This figure 
intentionally highlights the part of the BIT model under current consideration, 
while ignoring other elements of conceptual pathway for simulated individuals, 
such as competing risks of behaviour change, smoking-related health effects and 
AOCM.  
Based on their drinking, age and gender characteristics, each year an individual is 
in any of the work centres in the BIT model, they have a risk of spontaneously 
dying from an alcohol-related condition, and a risk of hospitalisation. If an 
individual is hospitalised with a condition, they then have a heightened risk of 
dying from that condition for a short period afterwards.  If they survive, the next 
year their hospitalisation and death risks will be again determined by their 
drinking, age and gender characteristics. 
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Figure 15: The conceptual care pathway of alcohol-related health risks 
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There are forty-seven alcohol-related conditions in the model, as described below.  
So as well as risks for condition 1, the boastful and faceless individual in Figure 15 
faces risks for forty-six other alcohol-linked conditions, as well as the risk of dying 
from a non-alcohol-related cause.   
With reference to Figure 15, it is apparent that three types of risk estimates are 
needed for each alcohol-related condition in the model, in addition to the risk of 
death from other causes, with sensitivity to alcohol use status, age and gender: 
1. Risk of hospital admission for each condition 
2. Risk of death following hospital admission for each condition 
3. Risk of ‘spontaneous’ death for each condition 
Estimation of risk types 1, 2 and 3 is described next, with continued reference to 
alcohol-linked conditions in the model, to aid clarity.   
7.3.2. Estimating risks for death and hospitalisation 
Accurately estimating the risks identified in Figure 15 is an extremely challenging 
task, for a number of reasons.  The range of health-related events and diseases that 
can be partially or wholly linked to alcohol use is wide, and because of data paucity, 
uncertain.  Linking alcohol consumption patterns to risk of morbidity and 
mortality is also highly difficult, not least because of confounding factors and 
variability in risks across individuals. Further, as discussed in Chapter 2 and 5, 
data on alcohol consumption is in short supply and potentially subject to 
widespread under-reporting.   
Much of the methods and data to estimate risks for death and hospitalisation used 
in the BIT model are adapted from previous studies with these aims [253, 265] and 
are presented here for clarity and completeness.  The first step in estimating risks 
for the model is identifying the conditions that are causally linked to alcohol 
consumption.  The forty-seven conditions defined as fully or partially attributable 
to alcohol in the SAPM [253], as identified in an earlier report from the North West 
Public Health Observatory (NWPHO) [265], are used here.  These conditions can be 
sub-divided as acute or chronic, in terms of their implications for future health, 
and fully or partially attributable to alcohol, and are listed in Table 22. This is the 
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most extensive battery of alcohol-related conditions used in a known economic 
model to date, and exceeds that of previous work [225, 226, 229, 232, 235, 238, 243, 246, 249-252, 
254, 255, 257, 259, 425].   
Table 22: Conditions Included in Mortality and Morbidity Calculations10 
Condition ICD-10 code(s) Source of Alcohol 
Attributable Fraction 
or Relative Risk 
Function 
Road traffic accidents V (many) Ridolfo et al 2001 [426] 
Pedestrian traffic accidents V (many)  
Water transport accidents V90-V94 Single et al 1996  [427] 
Air and space transport 
accidents V95-V97 
English et al 1995 [428] 
Falls W00-W19 Ridolfo et al 2001 [426] 
Work/machine injuries W24-W31 English et al 1995 [428] 
Firearm injuries W32-W34 Single et al 1996  [427] 
Drowning W65-W74 English et al 1995 [428] 
Inhalation of gastric contents W78-W79 Single et al 1996  [427] 
Fire injuries X00-X09  
Accidental excessive cold X31  
Intentional self-harm/Event of 
undetermined intent X60-X84,Y10-Y34 
English et al 1995 [428] 
Assault X85-Y09 Single et al 1996  [427] 
Lip, oral and pharyngeal cancer C00-C14 
Tramacere et al 2010 
[429] 
Oesophageal cancer C15 Corrao et al 2004 [430] 
Malignant neoplasm of colon C18  
Malignant neoplasm of rectum C20  
Liver cancer C22  
Malignant neoplasm of larynx C32 Islami et al 2010 [431] 
Breast cancer C50 Key et al 2006 [432] 
Epilepsy and status epilepticus G40-G41 
Samokhvalov et al 
2010 [433] 
Hypertensive diseases I10-I15 Corrao et al 2004 [430] 
Cardiac arrhythmias I47-I48 Kodama et al 2011[434] 
Haemorrhagic Stroke 
I60-I62, I69.0-
I69.2 Corrao et al 2004 [430] 
Ischemic Stroke  
I63-I66, I69.3-
I69.4  
Oesophageal varices I85  
Gastro-oesophageal laceration- K22.6 Purshouse et al 2009 
                                                        
10
 Table adapted from Purshouse et al, 2009 253. Purshouse R, Brennan A, Latimer N, Yang M, 
Rafia R. Modelling to assess the effectiveness and cost-effectiveness of public health related strategies 
and interventions to reduce alcohol attributable harm in England using the Sheffield Alcohol Policy 
Model version 2.0. Sheffield, UK: School of Health and Related Research (ScHARR), University of 
Sheffield; 2009. 
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Condition ICD-10 code(s) Source of Alcohol 
Attributable Fraction 
or Relative Risk 
Function 
haemorrhage syndrome [253] 
Unspecified liver disease K73, K74 Corrao et al 2004 [430] 
Acute and chronic pancreatitis K85,K86.1  
Psoriasis 
L40 excluding 
L40.5 Gutjahr et al 2001 [435] 
Spontaneous abortion O03  
Diabetes mellitus E11  
Ischemic heart disease I20-I25 Corrao et al 2004 [430] 
Cholelithiasis K80 Gutjahr et al 2001 [435] 
Mental and behavioural 
disorders due to alcohol F10 
100% Attributable 
Ethanol poisoning T51.0  
Methanol poisoning T51.1  
Toxic effect of alcohol, 
unspecified T51.9 
 
Accidental poisoning by and 
exposure to alcohol X45 
 
Alcohol-induced pseudo-
Cushing's syndrome E24.4 
100% Attributable 
Degeneration of nervous system 
due to alcohol G31.2 
 
Alcoholic polyneuropathy G62.1  
Alcoholic myopathy G72.1  
Alcoholic cardiomyopathy I42.6  
Alcoholic gastritis K29.2  
Alcoholic Liver Disease K70  
Chronic pancreatitis (alcohol-
induced) K86.0 
 
 
7.3.2.1. Conditions partially attributable to alcohol 
For over ten years, researchers from around the world have been attempting to 
link mortality and morbidity risks to alcohol use in the context of these challenges, 
with an impetus for research emanating from the World Health Organization 
(WHO) [436, 437].  The method that has become prevalent for events and diseases 
(collectively termed ‘conditions’ in this thesis) partially attributable to alcohol 
involves the use of ‘alcohol-attributable fractions’ (AAFs). An AAF can be defined as 
the proportion of condition risk that would have been absent without exposure to 
alcohol [265].   
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The AAF of a condition is intrinsically linked to the relative risk (RR) of 
experiencing that condition at different levels of alcohol use.  Equation (42) 
describes this relationship [265]: 
 
    
∑   (     )
 
   
∑   (     )
 
     
 
(42)  
  
Here,   (0 to I) are alcohol consumption categories,     is consumption group-
specific relative risk of mortality (exposed versus unexposed groups),    is the 
proportion of the population in the ith consumption category.  If a parameterised 
RR equation is available linking consumption to harm for a condition, it is possible 
to derive a condition AAF estimate.  Equally, it is possible to estimate parameters 
for an RR function with a given functional form, from an AAF estimate. 
With knowledge of an AAF and corresponding RR function for each condition, it 
was possible to estimate the key risks for the model identified above, with access 
to population figures and data on numbers of hospital admissions and deaths by 
condition. Annual numbers of deaths and person specific hospital admissions for 
the 47 conditions in Table 22 were taken directly from the NWPHO report [265], 
derived by the authors from ONS mortality statistics and HES hospital admissions 
data, respectively.  These data, shown in Table 51 and Table 52 of Appendix E, are 
from 2005/2006 and are somewhat dated, but were the most appropriate for a 
combination of reasons.  First, given time restraints, alcohol use data for England 
were only available for this time period, and to link alcohol use to health outcomes 
it was important that data from aligning time periods were used. Second, the data 
are specific to gender and age categories across which risks for alcohol-linked 
diseases vary, and importantly, patient-specific [253, 265].  This level of detail in 
hospital admissions data could only otherwise be acquired in raw form with an 
Extract Services Request, and was considered beyond time resource constraints.   
To describe the process of generating risk inputs for the model, calculations of 
risks for males aged 75 and over for the model condition lip, oral and pharyngeal 
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cancer are shown.  First, the annual risk of hospital admission was calculated, 
using the following equation: 
                     
[
(                          ) (     )
          
]                            
(43)  
For now, let us work with figures of 0.40 for the AAF and 2.65 for the relative risk 
for this group; the rationale of these numbers will become clear in this section.  
ONS population data estimated           men in this age group [438] (Table 53, 
Appendix E) and Table 51 shows 703 condition-specific hospitalisations. The risk 
of hospitalisation for lip, oral and pharyngeal cancer for males aged 75 and over 
that drink to at-risk levels was therefore: 
[
(   ) (      )
         
]               (   ) 
Next, the elevated risk of death following hospitalisation for each condition was 
calculated, based on Hospital Episode Statistics (HES)-ONS linked data which 
captures deaths of people who have been admitted to hospital, up to 90 days after 
a hospital admission, by primary diagnosis upon hospital admission and primary 
cause of death [439]: 
                                
 
                                           
                    
 
(44)  
Limitations of the HES-ONS linked data were the lack of age- or gender-specificity, 
or information on differences in mortality for disease categories within ICD-10 
codes.  To overcome these problems, (i) HES-ONS data were distributed across 
model sex and age categories according to the distribution of morbidity and 
mortality observed in the NWPHO report; (ii) condition-specific mortality was 
assumed consistent within ICD-10 codes.  The HES-ONS linked data were also not 
patient-specific, with the likely implication that the person-specific ninety-day 
death rate was under-estimated. 
To illustrate this method, for lip, oral and pharyngeal cancer, the HES-ONS data 
showed 1,872 ninety day deaths linked to 19,672 admissions (Table 57, Appendix 
E).  The NWPHO report recorded 16.87% of deaths and 11.99% of hospital 
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episodes for lip, oral and pharyngeal cancer to be attributable to males aged 75 
and over.  The death risk after hospitalisation was therefore calculated as follows: 
(    )  (      )
(     )  (      )
        (   ) 
HES-ONS linked data were not available for the partially-attributable acute 
conditions in Table 22, or accidental poisoning by exposure to alcohol. For these 
conditions, defined within ICD-10 documentation as external causes of morbidity 
and mortality [440], data from a recent study of the epidemiology of trauma deaths 
in the UK study was utilised [441].  This study used Trauma Audit and Research 
Network (TARN) Database statistics collected between 2000 and 2010, and found 
43,958 trauma admissions linked to 6,867 deaths in acute care within 93 days.  
Limitations of these data included absence of age- or gender-specificity, and 
information on differences in mortality for disease categories within and between 
ICD-10 codes.  Using a similar approach as for other conditions in the model, the 
trauma data were distributed across model sex and age categories according to the 
distribution of morbidity and mortality observed in the NWPHO report and 
condition-specific mortality was assumed consistent across external causes of 
morbidity and mortality. 
For some conditions, the death risk after hospitalisation predicted by ONS-HES 
linked or TARN data implied more deaths than recorded in Table 52.  This was 
explicable for many cases, given the limitations of the ONS-HES and TARN data for 
this purpose.  In these cases, the death risk following hospitalisation was estimated 
as the number of age, gender and disease specific deaths in Table 52, divided by 
the corresponding number of person-specific hospital admissions in Table 51. 
The risk of spontaneous death for each condition can now be calculated. First, the 
estimated annual number of spontaneous deaths is calculated: 
                                
             (                          )  (                                )  
(45)  
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For our elderly males, the recorded total deaths in a year for lip, oral and 
pharyngeal cancer is 254 (Table 52), the number of condition-specific 
hospitalisations is 703 (Table 51) and the risk of condition-specific hospital death 
has been calculated as 0.1339. The estimated annual number of spontaneous 
deaths caused by lip, oral and pharyngeal cancer is therefore calculated as just 
under 160: 
                      (   ) 
Finally, the annual risk of spontaneous death, differing by alcohol use status, can be 
estimated using population data and knowledge of relative risks: 
                           
 [
(                            )  (     )
          
]                       
(46)  
Again, let us work with figures of 0.40 for the AAF and 2.65 for the relative risk for 
lip, oral and pharyngeal cancer among men aged 75 and over. Recalling the 
population figure of 1,477,700 for this group,  the following annual risk of dying 
from lip, oral and pharyngeal cancer, when they haven’t been hospitalised for the 
condition in the past year is calculated: 
[
(      )  (      )
         
]               (   ) 
The remaining health risk faced by simulated individuals is that of dying from 
causes that aren’t linked to alcohol, or smoking.  Risks of other cause mortality are 
calculated, by age and gender, from the ONS population and mortality statistics, as 
follows: 
                          
                                    
          
  (47)  
Where the number of alcohol deaths is the total number of deaths attributed to the 
47 alcohol-linked conditions in Table 52 and the number of additional smoking 
deaths is the total number of deaths attributed to lung cancer and COPD, the two 
mortality-linked smoking related diseases in the model which are not also 
captured in Table 22, in ONS death by cause data for the corresponding time 
period [442].   
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Equations (43) to (46), (47), the accompanying text and worked example have 
explained the derivation of the hospitalisation and death risks for the thirty-four 
conditions in the model partially attributable to alcohol.  The devil is in the detail, 
though, and derivation of RR functions and AAFs for each of these conditions now 
warrants explanation. 
Generating and using RR functions and AAFs 
The existing literature was of use in linking alcohol consumption patterns to risk of 
morbidity and mortality.  Leading work in this area has been in the form of meta-
analyses of epidemiological studies (case-control or cohort) focusing largely on 
partially-attributable conditions with chronic implications [429-435]. Functions 
linking average daily alcohol intake to risk have been estimated in these meta-
analyses using random effects models, as reported in Table 50 of Appendix E.  
Typically, these functions are linear, or linear on a logarithmic scale, with the 
exception of diseases more strongly linked to alcohol (various neoplastic 
conditions including liver cancer, as well as oesophageal varices and liver disease 
and cirrhosis) where risk flattens out at higher doses, and diseases where there is 
thought to be a J shaped relationship between consumption and harm (ischaemic 
heart disease, diabetes mellitus, cholelithiasis) [430, 431, 435].   
Using the distribution of alcohol consumption reported above and the published 
risk functions in Table 50, it was possible to derive AAFs for partially-attributable 
chronic conditions using the relationship described in equation (42).  To illustrate 
this process, let us refer again to the familiar example of lip, oral and pharyngeal 
cancer, and explain in turn the    figure of 2.65 and AAF of 0.40 used in the above 
calculations of disease mortality.   A meta-analysis of alcohol drinking and oral and 
pharyngeal cancer provided the following function linking average daily grams of 
alcohol consumption ( ) to disease risk [429]:   
  (  )                     
(48)  
The AAF for lip, oral and pharyngeal cancer was then calculated using this 
equation and the estimated distribution of alcohol use in the sub-population at 
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hand, using the relationship between relative risk and the alcohol-attributable 
fraction, described in equation (42).   
The profile of alcohol use used in estimation of mortality and morbidity risks is 
based on GHS 2006 data.  The GHS, later the GLS and identified in Chapter 2, was 
an annual individual-level survey of UK households aiming to capture data on a 
range of topics including health and lifestyle, as well as income, education, 
migration, and other demographic information [443].  The survey ran from 1972 to 
2012; the 2006 dataset was the latest available at the time of analysis without a 
Special Access Licence [443], and importantly was aligned with available detailed 
hospital admissions and mortality data [265].  
Two key variables were utilised from the dataset: ‘estimated weekly units’ was used 
to capture mean alcohol consumption; ‘total units on the day in which the most 
alcohol was drunk’ was used to represent peak consumption.  A total of 13,894 
adults had data for both key variables, excluding outliers (those reporting >300 
units per week or >60 units peak daily consumption).  Different measures were 
generated from these data: mean and peak alcohol consumption estimates for at-
risk drinkers and those that are not at risk were needed for the analysis, by age 
category and gender.  Table 54, describing these data, can be found in Appendix E.   
Our elderly men (aged 75 years and over) are assumed to have a distribution of 
mean alcohol consumption as described by the GHS 2006 data, and shown in Table 
23: 
Table 23: Distribution of mean alcohol consumption, males 75 years and 
older, GHS 2006 
Mean daily 
units 
None 
Less than 
4 
4 to less 
than 8 
8 to less 
than 12 
12 to less 
than 16 
16 or 
more 
Percentage 
of sample 
15.99% 72.05% 9.94% 1.40% 0.31% 0.31% 
 
Converting mid-point intake for the categories in Table 23 into grams, and using 
abstainers as the reference group (    ), the relative risk of lip, oral and 
pharyngeal cancer was calculated for each of these categories using equation (48).  
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This produced estimates of    1.49 for drinking up to 3.99 units per day, 
   2.99 for drinking 4 to 7.99 units per day,    5.33 for drinking 8 to 11.99 
units a day,    8.40 for drinking 12 to 15.99 units a day and    13.19 for 
drinking 16 to 23.99 units a day.  Given there are 8g in a UK unit of alcohol, and the 
mid-point of the 0 to 3.99 units per day category is 16g per day, equation (49) 
describes the    calculation for elderly male drinkers who consume under 4 units 
a day: 
        (  )        (  
 )       (   ) 
 
The AAF for lip, oral and pharyngeal cancer for males aged 75 and over 
was then calculated as 0.40 as follows, using equation (42) and with 
reference to data in Table 23.  The denominator of equation (42) was 
calculated as 1.67 as follows: 
 
              (   )        (      )        (      )  
     (      )        (     )        (       )   
 
The AAF for lip, oral and pharyngeal cancer for males aged 75 and over 
was then estimated to be 0.40 using the following calculations: 
 
      (      )
    
        
      (      )
    
        
      (      )
    
        
      (      )
    
        
      (       )
    
        
 
                                               (   ) 
(49)  
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Mean and peak alcohol consumption across the GHS sample by age, gender and 
drinking status is shown in Table 55 and Table 56 of Appendix E. For males aged 
75 and over, the average daily intake of alcohol was 41.99g among at-risk drinkers.  
According to the relationship described by equation (48), this corresponds to a 
relative risk of 2.65: 
        (     )        (     
 )       (   ) 
In line with NHS guidelines on safe drinking [444], it was assumed that individuals 
drinking under the current average daily drinking guidelines (three units a day for 
men; two for women) were not at an increased risk of chronic conditions.      
For partially-attributable acute conditions, there is a general lack of 
epidemiological studies linking different alcohol consumption levels to harm for 
each condition [445].  In the absence of such data, it was possible to estimate RR 
functions from the distribution of alcohol consumption across the population and 
AAF estimates, again using the relationship described in equation (42).    
The AAF estimates for the thirteen partially-attributable acute conditions in the 
model were taken from the NWPHO report [265].  GHS data was again used to 
capture the distribution of alcohol use in the English population, but because these 
conditions are more closely linked to binge drinking behaviour, and following 
Purshouse et al [253], peak, rather than mean alcohol consumption was used.  
Increased risk of acute conditions was assumed to start from peak consumption 
levels of three units in a day for women; four units in a day for men.  This is 
somewhat lower than the ‘loose’ marker for binge drinking used in the UK of more 
than double the recommended daily intake in one session [446, 447].  However, these 
thresholds were reasoned as appropriate with the belief that heightened risk for 
many acute conditions begins before six and eight units in a session, respectively 
for women and men.  The legal blood alcohol content for being in charge of a 
vehicle is difficult to translate into binge units as it depends on physiological 
factors, but quick ingestion of four units of alcohol will likely increase the risk of 
acute conditions for an average male. Similar thresholds for acute condition risks 
were used in the SAPM [253]. 
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The functional forms of the estimated relative risk equations for acute partial 
conditions were assumed to be linear, in the absence of evidence in the literature 
[445], and following previous work [253].  The generic equation for a relative risk 
function of this type can be defined as follows: 
      (   )               
                                                 
(50)  
where   represents peak consumption and   is the risk threshold; these equations 
were estimated in Microsoft Excel using the Solver tool.   
 
7.3.2.2. Conditions wholly attributable to alcohol 
For the thirteen wholly alcohol-attributable conditions in the model, the risk of 
hospitalisation and death is zero if no alcohol is consumed.  The approach to 
estimating these risks was therefore necessarily different to the approach used for 
partially-attributable condition risks. Absolute, rather than relative risk functions 
were needed to link alcohol use to morbidity and mortality risk.  As for partially-
attributable conditions, three types of risks were needed: 
1. Risk of hospital admission for each condition 
2. Risk of death following hospital admission for each condition 
3. Risk of ‘spontaneous’ death for each condition 
Published work quantifying the link between alcohol use and wholly-attributable 
alcohol condition harm is limited [265, 448, 449].  The risk of hospitalisation for each of 
the thirteen conditions was estimated using the hospital admissions data in Table 
51 and the distribution of alcohol consumption in the GHS data.  As above, mean 
consumption was used for chronic conditions, peak consumption for acute 
conditions.  Risk functions were again assumed to be linear, in line with previous 
work [253], and can be described by the following equation: 
        (   )               
                                                   
(51)  
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where   and   again represent consumption and the risk threshold, respectively, 
and   and   are parameters to be estimated.  The Solver tool in Microsoft Excel was 
used to estimate equation parameters, by age group, gender and condition.   
Alcoholic liver disease (ALD) is one of the more prevalent conditions wholly 
attributable to alcohol, with 12,373 patient-specific hospital admissions in the year 
ending March 2006 (Table 51).  For ALD, the HES-ONS data showed 3,298 ninety-
day deaths linked to 14,886 admissions.  The NWPHO report recorded 3.59% of 
deaths and 4.22% of hospital episodes for ALD to be attributable to males aged 75 
and over.  The death risk after hospitalisation was therefore calculated as follows: 
(     ) (      )
(      ) (      )
      (   ) 
The number of spontaneous deaths could then be estimated using equation (45), in 
an identical manner to partially-attributable conditions.  Absolute risk for 
spontaneous death could then be estimated as a linear function, using this number 
and the distribution of alcohol consumption, using the same process as described 
equation (51) and the accompanying text. 
This concludes the description of the many alcohol-related risks faced by 
simulated individuals in the BIT model, and the methods used to estimate these 
risks.  It remains to describe quantification of cost and health outcomes in the 
model. 
7.3.3. Costs  
Costs of hospital admissions for each alcohol-related disease in Table 22 were 
taken from the SAPM report, and were originally derived from work by the 
Department of Health on the cost to the NHS of alcohol-linked diseases [450].  These 
costs comprise the costs of: hospital inpatient and outpatient visits; accident and 
emergency visits; ambulance services; GP and Practice Nurse consultations; 
dependency prescribed drugs; specialist treatment services; and other health care 
[253]. These costs were inflated to 2011/2012 levels using the Unit Costs of Health 
and Social Care index for Hospital & Community Health Services Prices [451] and are 
shown in Table 59 of Appendix E. 
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7.3.4. Utilities 
Baseline utility for patients with no current comorbidity were taken from the 
general population utility profile estimated by Ara and Brazier using Health Survey 
for England data [452]. 
The Health Outcomes Data Repository (HODaR) contains data EQ-5D scores for 
around 2,000 diagnoses, and was used to incorporate utility values into the SAPM 
[253].  The HODaR is the first to supplement routine clinically coded data from one 
UK Hospital Trust (Cardiff and Vale) with survey data including demographic 
information and utility values [453].  Using this one source to capture utility for all 
47 alcohol-linked conditions in the model has the clear advantage of avoiding bias 
and variability between studies.  Mean utility for each condition was taken from 
this resource. 
Where utility data were not available, mean utility was assumed to be that of 
similar conditions, following the SAPM [253].  The mean utility for mental and 
behavioural disorders and alcohol-induced Cushing’s syndrome were assumed 
similar to alcoholic polyneuropathy; utility for methanol poisoning as assumed 
similar to ethanol poisoning; utilities for air, space and water transport accidents 
were assumed similar to road traffic accidents; utilities for firearm injuries, fire 
injuries, drowning and excessive cold were assumed similar to pedestrian traffic 
accident [253]. 
In HODaR, the mean age was 59 among inpatient, and 58 among outpatient, 
respondents [453]. EQ-5D scores generally decreased with age and number of 
comorbidities [453].  
In HODaR, utility values are at 6 weeks post-discharge.  The first two weeks 
following hospital admission are assumed to have zero utility. Following this, the 
HODAR utility values are applied for the next ten weeks for acute conditions and 
are used to represent ongoing utility for chronic model conditions.  The absence of 
other time points in the dataset is a limitation of HODaR for this purpose, and it is 
not clear whether this will over- or under-estimate health gains from avoiding 
model conditions, particularly acute conditions.  Condition-specific utility values 
are shown alongside costs in Table 59. 
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7.3.5. Limitations 
Though based on established work in the field, there are some limitations of these 
methods to link alcohol use to health.  Firstly, there is uncertainty around RR 
functions for conditions partially attributable to alcohol.  For partially attributable 
conditions, RR functions from the literature were used.  These were often based on 
meta-analyses using data from populations outside of the UK, and the 
transferability of these estimates to a UK population is unclear.  But further, there 
will be uncertainty around the parameters of these RR functions, as well as 
uncertainty around the functional forms of the RR equations fitted.  This 
uncertainty will be reflected in uncertainty around AAF estimates generated from 
the relationship described in equation (42), risk estimates of hospitalisation and 
and death that are inputs in the BIT model, and ultimately model outputs.  This is a 
limitation of this work, previous leading economic evaluations of alcohol strategies 
[253, 425] and has been a limitation of the established field of work linking alcohol 
use to health [454].  Recent research has developed methods to estimate uncertainty 
around AAFs [454]; this should improve the usefulness of future economic 
evaluations in the area. 
Secondly, the alcohol-related morbidity data is based on hospital admissions only, 
and does not account for the burden of patients treated for alcohol-related 
conditions in primary care alone. The greater burden will come from more serious 
diseases which require hospital admission, so this is considered a minor limitation, 
and should lead to conservative estimates as the overall benefit of reducing alcohol 
use.     
Thirdly, the appraoch taken does not account for relationships between risks for 
the various conditions in Table 22.  Diabetes is known to increase the risk of 
chronic liver disease [455]; there are likely to be numerous links between risks for 
conditions in the model that are not accounted for.  For the case of diabetes and 
liver disease, ignorance of an interaction in risk will lead to underestimation of the 
benefits of reductions in alcohol use.  In other cases there might be an inverse 
relationship between risks: suffering the effects of a stroke often impairs ability to 
drive, and non-driving may lower the risk of a road traffic accident [456]. 
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Fourthly, there were several limitations to the methods to link hospitalisation to 
temporary heightened risk of death. As noted above,  the HES-ONS linked data and 
TARN data linking hospital admissions to mortality were not age-, gender-, or 
patient-specific, and not always specific to the disease categories in Table 22. Lack 
of patient specificity means while there can only be one recorded death per patient, 
there could have been multiple hospital admissions for every patient in the data.  
The 90-day death rate is likely underestimated for some conditions; this should 
understate the mortality gains from alcohol use reduction.  Lack of disease-
specificity in the TARN database meant the same 90-day mortality rate was 
assumed across all partially attributable acute conditions; this may have led to 
overestimation of the 90-day mortality for some, or even all of these conditions, if 
other conditions classified as trauma conditions in the TARN database have higher 
mortality after hospital admission.   
Ninety-day death statistics were conservatively read as ‘death at 90 days after 
admission’, when all that is known is death occurred in the first 90 days after 
admission.  This was considered a minor and conservative assumption, as the 
mortality benefits of alcohol use reductions will be slightly understated as a 
consequence. 
Greater efforts could have been made to accurately capture the heightened health 
risks for each condition in Table 22, but understanding the prognoses of patients 
hospitalised for alcohol-related conditions is far from simple.  The first challenge is 
the range of conditions: there are twenty nine chronic and eighteen acute 
conditions listed in Table 22; understanding prognosis following hospitalisation 
for each would be an expensive task.  The second challenge is that many of the 
conditions are actually groups of conditions, with varying prognosis by type.  
Alcoholic liver disease, for example, is an umbrella term incorporating fatty liver 
disease, alcoholic hepatitis and the more serious form of the disease, alcoholic 
cirrhosis.  Time to death for alcoholic liver disease patients is further mediated by 
age and future alcohol use, among other factors  [457]. Malignant neoplasm of colon 
is one of the more specific condition categories in Table 22, but published evidence 
shows prognosis to vary significantly by treatment which is applicable to only the 
10-20% of all patients who develop hepatic involvement of colorectal origin [458].   
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There are numerous factors determining prognosis in cancers, including cancer 
stage and type and treatment options, which are often interrelated, making it 
difficult to characterise average prognosis.  Hypertensive diseases, to use another 
example, can lead to death from cardiovascular disease or kidney damage, with a 
varied prognosis that is influenced by the behaviour of a patient [459, 460].  It is 
unclear whether taking a more simplistic approach to capture heightened death 
risk after hospitalisation has led to under- or over-estimation of the mortality 
benefits of alcohol use reduction; the import for the results of the cost-
effectiveness analysis in Chapter 8 will likely be minor. 
7.3.6. Summary 
This section has described calculation of alcohol-related condition morbidity and 
mortality risks, and risks of death from causes unrelated to alcohol or tobacco use, 
for use in the BIT model described previously.  This approach is largely based on 
established methods, from publications that have been used to inform UK 
Government decision makers [253], but has several limitations, discussed above.  
Overall, it is believed that these methods are useful and detailed and sufficiently 
capture the link between alcohol use and health consequences for the purposes of 
this thesis. 
7.4. Chapter Summary 
This chapter has been largely descriptive; the chapter aims of describing to the 
reader (i) the BIT model and (ii) the data and methods to link alcohol use status to 
health, have hopefully been achieved. 
The strengths and limitations of the methods described have been detailed.  The 
BIT model is an improvement on existing models of the health economic 
consequences of smoking cessation strategies reviewed in Chapter 3 and including 
the smoking model recreated in the Chapter 6, in that individual patients are 
followed through a flexible modelling platform, allowing more flexibilityand 
accuracy in capturing long-term behaviour and interaction between alcohol use 
and smoking status.  The model still bears limitations, such as assumptions about 
future quit attempts, the treatment of time as discrete and the assumption of no 
interaction between indviduals. 
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The methods to link alcohol use to health consider a wide and established battery 
of conditions with links to alcohol use, and follow established methods from the 
field.  Limitations have been noted, including the absence of assessment of 
uncertainty around estimates, and ignorance of the effect of alcohol use upon 
patients who seek primary care but are not admitted to hospital. 
The mechanism and model inputs for the BIT model should now be clear.  Chapter 
5 established the method to predict ‘next year’ smoking status and at-risk drinking 
status for an individual, using the bivariate dynamic econometric equations 
estimated therein.  Chapter 6 described the methods and data to link smoking 
status to health and health related costs and quality of life. Chapter 7 has 
established the data and methods to link alcohol use to health, healthcare costs and 
health related quality of life, and described a simulation model to incorporate all of 
these inputs.  The next and penultimate chapter of this thesis sets out the plan of 
analysis of the BIT model, and reports results.  Within Chapter 8, the answers to 
the key research questions of this thesis should become clear.     
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8. Chapter 8: Economic appraisal of competing 
strategies to aid smoking cessation using the BIT 
model 
 
8.1. Introduction 
The methods and data of the BIT model now described, Chapter 8 presents and 
analyses results from an economic appraisal of competing strategies to aid 
smoking cessation, using the BIT model.  The decision problem is identical to that 
posed in Chapter 6; the competing strategies assessed are standard courses of 
cytisine and varenicline. 
The key aim of this chapter is to explore the consequences of using projections of 
long-run behavioural patterns from panel survey data, which incorporate inter-
behavioural links, within an individual-level simulation modelling framework for 
economic appraisal outcomes.  This is achieved with comparison of BIT model 
results with standard practice model results from Chapter 6.   
Chapter 8 begins with a note on performing economic appraisals using the BIT 
model.  Results from the BIT model are then presented.  Evidence from internal 
validation tests set out the mechanics of the model, before key results from the 
economic appraisal are analysed.  The implications of assumptions about long-
term behaviour for model results are shown to be substantial.  The penultimate 
section of this chapter discusses the results and their implications for future work, 
before the findings are summarised.  
8.2. Performing cost-utility analyses with the BIT model 
When the model is used to compare competing interventions, for transparency and 
efficiency, one full run of the model comprises four separate runs of model 
“branches”, where in each branch individuals enter the model as either (i) non-
smokers and not at-risk drinkers; (ii) smokers but not at-risk drinkers; (iii) non-
smokers but at-risk drinkers; (iv) smokers and at-risk drinkers.  The behaviour 
characterised by individuals in these four branches as they enter the model is 
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labelled “NAR, NS”, “NAR, S”, “AR, NS” and “AR, S” respectively in Table 24, as in the 
previous chapter. 
 
Table 24: Group labels for behaviour upon entry 
Smoking and drinking status on model entry Entry Group 
1, Not an at-risk drinker, Non-smoker NAR, NS 
2, Not an at-risk drinker, Smoker NAR, S 
3, At-risk drinker, Non-smoker  AR, NS 
4, At-risk drinker, Smoker  AR, S 
 
Effectiveness data can then be applied to set the proportions of the cohort in each 
of the four behavioural categories, subject to the effectiveness of the intervention.  
Accordingly, for an aid to smoking cessation with a 12 month quit rate of 50%, one 
would apply weights of 0.5 to results from non-smoking starting points, and 0.5 to 
results from smoking starting points.  To weight the results appropriately for 
smoking and drinking starting points according to groups 1 to 4 in Table 24, the 
distribution of drinking across at-risk and not at-risk categories is taken from GHS 
2006 data [461]. Among adult smokers, 35.78% drink to at-risk levels.  In this 
hypothetical situation therefore, a weight of 0.179 (=0.3578 x 0.5) would be 
applied to group 3 results and group 4 results, and a weight of 0.321 (= (1-0.3578) 
x 0.5) would be applied to group 1 results and group 2 results.   
Evidence detailed in Chapter 2 suggests dopamine-inhibitor drugs such as cytisine 
and varenicline make alcohol less enjoyable [67, 68].  Chapter 5 results suggested 
that a smoking cessation intervention may have a direct negative influence upon 
the propensity to drink to at-risk levels, whether the intervention is successful or 
not.  However, as neither of these effects would influence the relative proportion of 
at-risk drinkers in each arm of the appraisal, adjustments were not made to the 
model. 
To account for the different age profiles of those above and below at-risk drinking 
thresholds, age distributions for smokers by gender and drinking status are used 
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and drawn from as individuals enter the model.  These distributions are reported 
and described in Table 49 of Appendix E and the accompanying text.  Of course, 
once this ‘age profiling’ adjustment is made, patients are no longer identical across 
the four groups in Table 24.  Age, and consequently time to death from causes not 
linked to alcohol use or smoking, differ for the nth individual across the four 
groups.  This introduces variability across the four Table 24 model entry groups, 
but is necessary for the incremental analysis.  To validate the model, introducing 
such variability was not necessary, and during model validation the nth individual 
to enter the model was identical across the four model entry groups.  The next 
subsection reports some results from this validation process. 
8.3. Model Results 
8.3.1. Model Validation  
The validation process involved two key stages.  First, key results were generated 
at various restricted model specifications, using 10,000 simulated persons, to test 
the mechanics of the model.  Following this, the number of simulated persons 
needed to generate sufficiently accurate results from a model run was analysed.   
8.3.1.1. Testing aspects of the model mechanics 
To test and internally validate the BIT model, key outputs were assessed across 
different specifications.  Four validation checks were made, beginning with 
Validation 1.  For the initial validation, it was useful to restrict movement across 
behavioural groups.  Initially, the two key behaviour-related consequences in the 
model, behaviour-related morbidity and behaviour-related mortality, were also 
nullified.  Table 25 shows key per-person results from the ‘Validation 1’ 
specification.  As expected, simulated individuals incur no morbidity-related costs.  
Similarly, as behaviour-related health consequences have been nullified, life years 
and QALYs are identical across the four entry groups.  Average utility is high, at 
0.89, as expected in the absence of morbidity decrements.  
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Table 25: Per Person Discounted Model Results, Validation 1 
No behaviour change, no behaviour-related morbidity, no behaviour-related 
mortality 
 Model Entry Group 
 NAR, NS NAR, S AR, NS AR, S 
Costs £               - £               - £               - £               - 
Life Years 20.17 20.17 20.17 20.17 
QALYs 17.88 17.88 17.88 17.88 
 
Validation 2 differs from Validation 1 only in that behaviour-related morbidity was 
incorporated.  As our simulated individuals were now subject to behaviour-related 
illness, it was expected that (i) overall utility would fall, (ii) per patient costs would 
be highest in the least healthy model entry group and lowest in the most healthy 
model entry group and (iii) per patient QALYs would be lowest in the least healthy 
model entry group and highest in the most healthy model entry group. 
Table 26 shows key results from Validation 2.  The results are as expected.   Utility 
across the four model entry groups is significantly lower than in Table 25, despite 
LYs remaining constant.  QALYs are highest and costs lowest in the healthy “NAR, 
NS” model entry group, who in this specification abstained from smoking and 
drinking over guidelines levels throughout their simulated lives after entering the 
model.  The model entry group who smoked and drank above guideline levels for 
the remainder of their simulated lives paid the price, with the lowest utility and 
highest healthcare costs of the four groups.    
Per person QALYs in the “AR, NS” entry group are lower than in the “NAR, S” entry 
group.  This is explained by the extensive range of alcohol-related health 
conditions incorporated, in comparison to the limited key smoking-related chronic 
diseases included in the analysis, and does not necessarily imply that at-risk 
drinking is on average more dangerous than smoking.  The imbalance between 
coverage of alcohol-related health conditions and smoking-related health 
conditions in this analysis is a limitation, but it is not expected to bias results of an 
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economic appraisal of aids to smoking cessation.  Underestimation of the health 
consequences of smoking may understate the relative effectiveness of more 
effective smoking cessation strategies; this is also the case for the many economic 
appraisals reviewed in Chapter 3. 
 
Table 26: Per Person Discounted Model Results, Validation 2 
No behaviour change, no behaviour-related mortality 
 Model Entry Group 
 NAR, NS NAR, S AR, NS AR, S 
Costs £  16,854.12 £21,780.37 £  18,200.46 £  23,390.68 
Life Years 20.17 20.17 20.17 20.17 
QALYs 13.93 13.62 13.44 13.18 
 
Validation 3 differs from Validation 2 in that behaviour-related mortality was 
incorporated.  Simulated individuals were still restricted to the behavioural states 
they entered the model in, but now also faced the most severe health consequences 
of their alcohol use and smoking status.   It was expected that per patient LYs 
would reduce in all four model entry groups, and be highest in the healthiest group.  
In addition, it was expected that per patient QALYs would reduce further in 
comparison to the results from Validation 2, reflecting fewer life years.  Per patient 
costs were expected to be lower in each group than in Validation 2, as the 
simulated individuals’ shortened life span restricted their time accumulating 
healthcare costs.    
Table 27 shows results from Validation 3.  Results are again as anticipated.  There 
are smaller differences between entry group-specific costs in Table 27 than in 
Table 26.  This is explained by those in healthier model entry groups living longer 
than those in less healthy model entry groups, allowing them more time for 
behaviour-related condition incidence.  Differences in per patient QALYs between 
entry groups are slightly greater in Table 27 than in Table 26, due to the higher per 
person LYs in healthier groups in Table 27.      
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Table 27: Per Person Discounted Model Results, Validation 3 
No behaviour change 
 Model Entry Group 
 NAR, NS NAR, S AR, NS AR, S 
Costs £  9,858.96 £  11,789.88 £  11,023.74 £12,887.23 
Life Years 17.95 17.67 17.65 17.46 
QALYs 13.25 12.89 12.70 12.45 
 
Validation 4 is the full model specification, and differs from Validation 3 in that 
individuals were no longer restricted to the behavioural states in which they 
entered the model.  It was anticipated that the results would be similar to those in 
Table 27 in that results from those in healthier model entry groups would have 
better outcomes than those in less healthy model entry groups, but that differences 
between model entry groups would be smaller.   
Table 28 shows results from Validation 4.  The results are generally as expected; 
those in the “NAR, NS” model entry group have the lowest costs and the best health 
outcomes, while those in the “AR, S” model entry group have the highest costs and 
worst health outcomes.  Differences between “NAR, NS” and “NAR, S” and between 
“AR, S” and “AR, NS” are small, implying that the lifetime health benefit of entering 
the model as a smoker as opposed to a non-smoker is small.   
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Table 28: Per Person Discounted Model Results, Validation 4 
Unrestricted model 
 Model Entry Group 
 NAR, NS NAR, S AR, NS AR, S 
Costs £  10,791.55 £     10,983.04 £   11,448.68 £11,755.97 
Life Years 17.76 17.75 17.61 17.6 
QALYs 12.82 12.79 12.47 12.42 
 
8.3.1.2. Appropriate numbers of simulated individuals for the analysis 
At this point, results of the economic appraisal problem comparing cytisine to 
varenicline as an aid to smoking cessation come in to focus.  Consequently, the ‘age 
profiling’ adjustment described above was used to account for the differing age 
distributions of at-risk drinkers and others in results presented from here 
onwards.  As this introduces necessary variability across individuals run through 
the four model entry groups in Table 24, comparison of results across these groups 
becomes less meaningful.  Results are from here presented separately for different 
smoking cessation strategies only. 
Before generating final model results to make inference about policy for the target 
population, it was necessary to establish the number of simulated individuals 
needed before results stabilised.  There is a trade-off between accuracy and 
feasibility in that both accuracy and model run time increase with the number of 
simulated persons run through the model.  Key results of interest presented are 
the discounted per person costs, QALYs and NB of cytisine versus varenicline as an 
aid to a smoking cessation attempt, assuming a willingness to pay of £20,000 for an 
additional QALY.  Figure 16, Figure 17 and Figure 18 show the relationship 
between number of individuals run through the model and these three respective 
results.   
The results are highly variable up to around 7,000 simulated persons, then 
stabilise somewhat.  Per person costs do though continue to increase very 
gradually as more per-patient results are added, while per person QALYs fall very 
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gradually, up to around 22,000 persons.   Reflecting these trends, the INB of 
cytisine over varenicline is fairly stable after 7,000 simulated persons but 
increases up to the point where results for 22,500 simulated individuals have been 
collected.  After this point, the results in Figure 16, Figure 17 and Figure 18 do 
seem to stabilise. For all results of the economic appraisal presented in the next 
subsection, 23,000 simulated persons were run through each model entry group. 
 
Figure 16: Relationship between Per Person Total Discounted Costs and Number 
of Simulated Persons 
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Figure 17: Relationship between Per Person Total Discounted QALYs and Number 
of Simulated Persons 
 
Figure 18: Relationship between Per Person INB of Cytisine and Number of 
Simulated Persons, at a willingness to pay threshold of £20,000 per QALY gained 
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This validation has foremost demonstrated that the BIT model described in 
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and 23,000 people per model run were believed to be appropriate.  Results from 
the economic appraisal of cytisine as an aid to smoking cessation using the BIT 
model can now be presented.  
 
8.3.2. Economic Appraisal Results 
8.3.2.1. Probabilistic Results 
Table 29 shows mean PSA results from the economic appraisal of cytisine versus 
varenicline as an aid to smoking cessation, using the BIT model.  As in Chapter 6, 
the results of the PSA are presented as the primary results of interest, as unlike 
deterministic estimates, they take into account the distributions of input 
parameters and interaction between parameters, and thus are the more accurate 
estimates.  One run of the individual-level BIT model was far more computationally 
expensive than one run of the standard practice model of Chapter 6; it was 
therefore not possible to perform a vast number of PSA runs.  The results in Table 
29 are based on 750 PSA runs.   
Table 29: Mean PSA discounted results, compared to equivalent results from 
Chapter 6 
Treatment 
Costs Life Years QALYs 
Total  Incr. Total  Incr. Total  Incr. 
BIT Model Results 
Cytisine £   11,700  -£164  18.471 0.002 13.119 
 
0.003 
 
Varenicline £   11,865   18.469  13.116  
Chapter 6 Results 
Cytisine £      4973 -£251 17.53 0.03 14.55 0.03 
Varenicline £      5225  17.50  14.52  
 
As in Chapter 6, the mean PSA results show cytisine to dominate varenicline, 
producing a higher number of per person LYs and QALYs and lower person total 
lifetime costs. Incremental LY, QALY and cost benefits of cytisine are much smaller 
than estimated by the standard practice cohort model, however.  This is reflective 
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of relatively lower importance of model entry smoking status upon long-run 
behavioural patterns in the BIT model.  Mean incremental HRQoL benefit of 
cytisine of 0.003 QALYs per person is slight, and a tenth of the estimated HRQoL 
benefit of cytisine from the standard practice model.   Mean total cost difference 
between treatments is £164, a higher proportion of the corresponding estimate 
from the standard practice model, £251.  However, these figures include a 
treatment cost difference of £147.  Ignoring treatment costs, the per person total 
cost difference between strategies is £17 in the BIT model, compared with £104 in 
the standard practice model. 
The mean ICER of cytisine versus varenicline is -£58,229.  To estimate a confidence 
interval (CI) around the mean ICER, jackknifing was used.  Jackknifing is a method 
for dealing with the bias caused by ratios [462]; the jackknifed 95% CI for the mean 
ICER is [-£67,560, -£48,027].  The jackknifed CI narrows as the number of PSA runs 
informing the mean increases, and so is also useful as a guide as to whether the 
number of PSA runs used is sufficient, which in this case it appears to be.   
Figure 19 shows cost-effectiveness acceptability curves [412] for the two strategies.  
The probability cytisine is optimal is over 0.95 up to a willingness to pay threshold 
of £30,500 per additional QALY.  This probability falls as the willingness to pay 
threshold increases.  The curves appear similar to the corresponding CEACs from 
the standard practice economic appraisal.   
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Figure 19: Cost-effectiveness acceptability curves for cytisine and varenicline 
 
 The distribution of the 750 PSA ICER estimates is shown in Figure 20.  Nearly 70% 
of the estimates are in the south east quadrant, indicating that cytisine dominates 
varenicline.  The remaining estimates are in the south east quadrant, indicating 
cytisine is less costly and less effective than varenicline. Over 95% of estimates are 
to the right of the £20,000 willingness to pay threshold for an additional QALY, 
favouring cytisine over varenicline at this threshold.  Every ICER estimate in Figure 
20 shows cytisine to produce lower total costs compared to varenicline.  This is 
influenced by the relative treatment costs of the two strategies.  Ignoring 
treatment costs, 17.5% of PSA ICER estimates show varenicline to be less costly 
than cytisine. 
The correlation between incremental costs and incremental QALYs is not as strong 
as in the equivalent Figure 13 from Chapter 6.  This is a consequence of the small 
QALY and non-treatment cost differences between those entering the model as 
smokers and those entering the model as non-smokers.  In the standard practice 
appraisal deterministic sensitivity analysis, intervention effectiveness was shown 
to be the key determinant of model outcomes.  As treatment effectiveness has a 
weaker association with long-term outcomes when HILDA data on longitudinal 
behaviour is used in place of simple assumptions which favour high short-term 
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effectiveness, this parameter appears to have less influence over BIT model 
outcomes.   
Figure 20: Scatter plot of results from 750 PSA runs 
 
8.3.2.2. Sensitivity to Treatment Cost 
Due to the way the BIT model is structured, whereby treatment cost data are 
retrospectively applied to model output in order to calculate economic appraisal 
outcomes, it was possible to analyse the sensitivity of results to treatment cost 
using the probabilistic output.   This is particularly pertinent to the appraisal of 
cytisine for smoking cessation as the cytisine cost estimate if adopted for use 
within the NHS is uncertain.   
Figure 21 illustrates how the mean PSA ICER changes as the assumed treatment 
cost of cytisine increases.  At the estimated treatment cost of £16.79, cytisine 
dominates varenicline as the cost saving and more effective alternative.  However, 
the mean incremental cost savings for cytisine at this treatment cost are only £164, 
as shown in Table 29.  As the assumed treatment cost of cytisine rises in Figure 21, 
the incremental cost savings of cytisine falls by the same amount.  Cytisine 
treatment need only cost £18 more than varenicline (just over £181) for the 
estimated mean cost saving of cytisine (due to better health outcomes) to be 
eradicated.  Were cytisine treatment to cost £240, varenicline would be preferable 
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to cytisine at a willingness to pay threshold of £20,000 for an additional QALY; 
were cytisine treatment to cost £270, varenicline would be preferable to cytisine at 
a willingness to pay threshold of £30,000 for an additional QALY. 
Of course, the treatment cost of cytisine, were it to be adopted for use within the 
NHS, is likely to be well below the treatment cost of varenicline. As reported in 
Chapter 6, as of March 2013 it was possible in the UK to buy a standard course of 
Tabex (active ingredient cytisine) online for £16.79 [403].  Figure 21 is mostly useful 
in demonstrating that as treatment effectiveness differences between smoking 
cessation strategies lead to only small differences in mean health and health-
related cost outcomes in the BIT model, the respective treatment costs of 
strategies are important in influencing strategy appraisal decisions. 
 
Figure 21: Relationship between cytisine treatment cost and cost-effectiveness 
 
 
8.3.2.3. Deterministic Sensitivity Analysis 
The importance of other model inputs was tested with univariate sensitivity 
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mean PSA estimates, though the deterministic incremental cost and health benefits 
of cytisine are slightly higher. 
 
Table 30: Deterministic Sensitivity Analysis Results 
Variable 
Sensitivity 
analysis 
Treatment 
Costs LYs QALYs 
Total  Incr. Total   Incr. Total  Incr. 
Baseline  Cytisine £11,666  -£174 18.456 0.008 13.109 0.010 
Varenicline £11,840   18.448  13.099  
Difference 
between 
treatment 
effectiveness  
(cytisine 
minus 
varenicline) 
Upper 95% CI 
value 
Cytisine £11,608 -£237 18.473 0.027 13.131 0.033 
Varenicline £11,845  18.447  13.088  
Lower 95% 
CI value 
Cytisine £11,725 -£136 18.439 -0.003 13.088 -0.004 
Varenicline £11,861  18.442  13.092  
Assuming 
cytisine 
intervention 
affects 
unobserved 
time-invariant 
attributes 
which 
determine 
propensity to 
smoke 
Alpha shifts 
10% left 
Cytisine £11,617 -£224 18.479 0.031 13.124 0.025 
Varenicline £11,840  18.448  13.099  
Alpha shifts 
20% left 
Cytisine £11,621 -£220 18.535 0.087 13.170 0.071 
Varenicline £11,840  18.448  13.099  
Alpha shifts 
50% left 
Cytisine £11,528 -£313 18.568 0.120 13.196 0.097 
Varenicline £11,840  18.448  13.099  
Ignoring interrelation 
between behaviours 
Cytisine £11,546 -£157 18.475 0.005 13.153 0.006 
Varenicline £11,704  18.470  13.147  
Ignoring dynamics Cytisine £11,313 -£175 18.557 0.009 13.256 0.012 
Varenicline £11,488  18.548  13.245  
 
 
Of the various specifications of the standard practice model tested in Chapter 6, 
only analysis of uncertainty around the relative effectiveness of cytisine affected 
the adoption decision.  This analysis was repeated using BIT model results.  As 
Table 30 shows, at the upper 95% CI of the relative effectiveness of cytisine, 
incremental gains from cytisine are over three times greater than baseline.  At the 
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lower 95% CI of the relative effectiveness of cytisine, varenicline is more effective 
than cytisine, and this is reflected in greater total LYs and QALYs for varenicline.  
The relative effectiveness is still an important determinant of model outcomes.  
However, the ICER for varenicline at this specification is £33,574; cytisine is still 
preferable at willingness to pay thresholds below this level.  In the corresponding 
specification in Chapter 6, the ICER for varenicline was under £8,000, indicating 
varenicline to be preferable at current UK willingness to pay thresholds.   
The results presented up to now have shown short-term treatment effectiveness to 
have a diminished impact on long-run treatment cost-effectiveness when the 
former only has implications for state dependence in dynamic behaviour equations, 
in comparison to the standard practice model in Chapter 6 and numerous 
applications of a similar model structure where smoking status following a 
cessation attempt was assumed to be a stronger indicator of long-run behaviour 
[357-367].  However, as discussed in Chapter 5, smoking cessation interventions could 
have a greater influence over long-run smoking status and health outcomes, if the 
person-specific, time-invariant, unobserved characteristics which influence the 
propensity to smoke, termed alpha here for brevity, are affected by an intervention.  
Due to the flexibility of the dynamic equations and BIT model, it was possible to 
test the implications of such an effect here.   
The person-specific alphas of the 23,000 simulated people in the model were 
reduced by (i) 10%; (2) 20%; and (3) 50%, in the cytisine treatment arm only, in 
three deterministic runs of the model. The results are shown in Table 30.  If 
cytisine treatment was to permanently reduce the propensity to smoke by 
reducing alpha as well as leading to more short-run smoking quits than varenicline 
treatment, its relative superiority in terms of cost-effectiveness would be greater, 
and increasingly so as the effect upon alpha is increased.  If smoking cessation 
interventions can permanently reduce the propensity to smoke, their value is 
greatly improved 
The results so far have demonstrated implications of assumptions about long-term 
behaviour for the cost and health consequences of competing smoking cessation 
strategies.  However, this has involved a contrast between simplistic modelling 
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assumptions about long-term behaviour, and more complex assumptions about the 
dynamics of smoking and its interrelation with alcohol use, based on longitudinal 
individual-level data.  The key aim of this thesis was to better understand the 
consequence of a link between alcohol use and smoking for economic appraisals of 
competing behaviour change strategies.  In an attempt to isolate this consequence, 
a deterministic run of the model was performed while setting the cross-state 
dependence variables in the dynamic behaviour equations, the variable relating to 
last year’s smoking status in the drinking equation and the variable relating to last 
year’s drinking status in the smoking equation, equal to HILDA sample means.  
This did not totally isolate the link between smoking and alcohol use, as the 
correlation between unobserved effects in the two dynamic equations captures 
part of the relationship.  Nevertheless, due to the positive cross-state dependence 
parameters found in Chapter 5, it was anticipated that this would reduce the 
estimated incremental net benefit of cytisine relative to varenicline. Table 30 
shows this to be the case; incremental health and health related cost gains are 
reduced in comparison to baseline.   Total costs and QALYs are slightly lower in 
both treatment arms compared to baseline, suggesting some random variation 
affecting results, though as patients characteristics are fixed across interventions, 
this is less likely to influence incremental results.  Of course, if a smoking cessation 
intervention can change the person-specific time-invariant characteristics which 
influence the propensity to drink to at-risk levels, its implications for long-run 
healthcare costs and HRQoL will be magnified.  Chapter 5 suggested that these 
effects are positively correlated with person-specific time-invariant characteristics 
which influence the propensity to smoke, so this is plausible. 
Using output from the dynamic analysis of longitudinal data on smoking and 
alcohol use in Chapter 5 to inform projections of long-run behaviour in this 
economic appraisal has influenced results, relative to results from the standard 
practice model in Chapter 6.  There was a labour and computational cost to the 
econometric analysis presented in Chapter 5 however, which must be considered 
in the context of the applicability of the framework proposed in Chapter 1 for 
future work.  For future economic appraisals of competing behaviour change 
strategies to investigate and quantify links to related health behaviours in the 
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absence of available data, the requisite skills and other resources will be required.  
This may form a practical barrier.  It was therefore of interest to test the 
consequence of using simplistic analyses of the HILDA data to inform transitions 
between behaviour states, in place of the dynamic equations. 
Confounded behaviour transition parameters were estimated by first sub-dividing 
the unbalanced panel of HILDA data, summarised in Table 3, Chapter 5, into gender 
and age-specific categories.  Next, the distribution across smoking and non-
smoking groups was summarised for those in each of the four behavioural 
categories in the BIT model in the last time period, for each age- and gender-
specific category.  The percentage of ‘smoker’ (‘at-risk drinker’) responses in a 
lagged-behaviour-, age- and gender-specific subgroup then comprised the 
probability of being a smoker (at-risk drinker) next year for that sub-group.  To 
illustrate with an example, among men aged 19-25 who reported non-smoking and 
safe drinking last year, 228 of 2,419 responses reported current smoking. The 
probability of smoking next year for 18-24 year old male safe drinkers and non-
smokers was therefore (228/2,419 =) 0.076.  These confounded transition 
probabilities are reported in full in Appendix F, Table 60 and Table 61.  
It was anticipated that using confounded transition probabilities would lead to 
broadly similar results to baseline, but show a greater incremental health benefit 
for cytisine.  This was reasoned as the underlying data are driving the baseline 
behavioural projections, but results so far have indicated that unobserved 
heterogeneity was highly important in determining behavioural patterns over time 
in the baseline analysis.  Table 30 shows incremental results using confounded 
transition probabilities to be very similar to baseline, with only marginally higher 
incremental health and financial gains for cytisine predicted.  Again total costs and 
QALYs in both treatment arms are lower than baseline, suggesting random 
variation influencing results, though again this is less likely to influence 
incremental findings.  These results suggest that using outputs from simple data 
analysis generates results that are a good approximation of results using full 
dynamic behavioural equations, in this case.  However, the generalisability of this 
finding is not known, and the deterministic sensitivity analyses explored here have 
demonstrated the flexibility afforded by an appropriate dynamic and multivariate 
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approach to modelling longitudinal survey data, when applied to a flexible 
individual-level simulation cost-effectiveness model.    
 
8.3.2.4. Calculation of the EVPI 
The EVPI was calculated as the difference between the maximum INB obtainable 
and the expected INB of cytisine, as in Chapter 6, for willingness to pay thresholds 
of £20,000 and £30,000 for an additional QALY.  Table 31 shows the per person 
EVPI for these thresholds, and the total EVPI assuming 1 million or 3 million 
smokers affected, across both the BIT model and the standard practice model of 
Chapter 6.  The EVPI is lower in BIT model results, reflecting less uncertainty about 
the adoption decision at the willingness to pay thresholds considered, yet still high 
when applied to the total population likely to be affected by a decision regarding 
NHS aids to smoking cessation.  
Table 31: EVPI for the adoption decision 
 Expected Value of Perfect Information 
 BIT Model Standard Practice Model 
 
£20,000 
threshold 
£30,000 
threshold 
£20,000 
threshold 
£30,000 
threshold 
Per person £2.23 £6.37 £11.71 £19.99 
1 million 
affected 
£2.23 million £6.37 million £11.71 million £19.99 million 
3 million 
affected 
£6.69 million £19.1 million £35.13 million £59.96 million 
 
8.4. Discussion 
Treatment effectiveness has been shown to have less influence over long-run costs 
and QALYs under BIT model assumptions than under standard practice model 
assumptions about long-run behaviour, demonstrated in the model presented in 
Chapter 6 and used in various published analyses [357-367].  This resulted in slight 
QALY gains and long-run cost savings for cytisine, in comparison to the less 
effective alternative varenicline.  If the assumptions of the BIT model are robust, 
this may have implications for future modelling practice in appraisals of smoking 
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cessation strategies and for the validity of past economic evaluation studies.  The 
differing methods and data in Chapters 6 and 8 have not changed the appraisal 
decision, but this is in large part because the evidence suggests cytisine has higher 
effectiveness and a lower treatment cost compared to varenicline; it is clearly the 
preferable alternative.  Historically, novel pharmaceutical aids to smoking 
cessation have coupled evidence of higher 12 month cessation rates with higher 
treatment costs in comparison to existing alternatives, as was the case when 
varenicline emerged as a more expensive alternative to bupropion and NRT [366].  
In such cases, recommendations from analysis using the BIT model may clash with 
recommendations from a standard practice model analysis.  Given that standard 
practice assumptions about long-run behaviour have been shown to be based on 
limited evidence, it is important that assumptions and methods used in future 
models for the economic appraisal of competing smoking cessation interventions 
are robust and tested. 
While the BIT model is designed to account for dynamic changes in behaviour, the 
model does not account for the difference in costs and consequences across 
treatment arms of subsequent aided quit attempts in simulated individuals who 
relapse to smoking, when the treatments available across arms may be different.  
As discussed in Chapter 7, because cytisine has a lower treatment cost and greater 
effectiveness than varenicline, the INB of cytisine may have been underestimated 
in this analysis.  In cases where a novel smoking cessation strategy is more 
effective and more expensive than its comparators, it is unclear whether BIT model 
assumptions would favour one alternative over another.  The importance of 
differences between treatment effectiveness and cost across strategies would 
assume more importance for appraisal results.  Evidence on the effectiveness of 
pharmaceuticals in smokers who have previously relapsed after attempting to quit 
with the pharmaceutical aids would be welcome, and better data are also needed 
on risks for repeated quit attempts and choice of cessation aid in repeated quit 
attempts. 
In the analysis, treatment effectiveness was an important predictor of cost-
effectiveness, though other differences between treatments assumed more 
importance in determining appraisal results in comparison to the analysis of 
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Chapter 6.  Sensitivity analysis showed cytisine need only cost £75 more than 
varenicline for varenicline to be preferable at a willingness to pay of £20,000 for an 
additional QALY.  Aside from treatment cost, adverse events associated with 
competing treatments also assume greater consequence.  Adverse events were not 
considered here, nor in past analyses, but there is some evidence of negative side 
effects from smoking cessation drugs.  Cytisine compared with varenicline was 
found to have slightly lower risk of both headache and nausea in a recent meta-
analysis of evidence [368].  There may be greater call to establish and utilise such 
evidence in future modelling studies. 
The validation process highlighted an imbalance between coverage of alcohol-
related health conditions and smoking health conditions in the model.  Whereas 
the catalogue of alcohol-linked conditions established by the NWPHO is 
comprehensive [265], the five smoking-related diseases considered are a sub-sample 
of related conditions with great implications for healthcare burden [363].  Other 
diseases including bladder, pancreatic, kidney and stomach cancers, as well as hip 
fracture and periodontal disease have been linked to smoking for some time [463].  
Omission of links to these diseases in the model will have understated the health 
benefit of smoking cessation, thus underestimating the importance of treatment 
effectiveness for smoking cessation.  If greater emphasis is placed on justifying 
long-run behaviour assumptions in future NICE technology appraisals, any 
pharmaceutical company submitting evidence on the cost-utility of their novel aid 
to smoking cessation may be increasingly keen to highlight these links in their 
analysis.  
Deterministic sensitivity analyses, exploiting the flexibility of the model, produced 
several interesting results.  The importance of alcohol use for model outcomes was 
assessed, suggesting the relative cost-effectiveness of strategies with superior 
short-term effectiveness are under-estimated if the interrelated dynamics of 
alcohol and tobacco use are ignored.  Uncertainty around relative treatment 
effectiveness was shown to be a key driver of results, though less important than in 
Chapter 6, where smoking status upon model entry was assumed to have greater 
implications for long-run tobacco use.  The relative cost-effectiveness of one 
strategy versus another could however be great if those unobserved, time-
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invariant, person-specific characteristics which are not observed in survey data 
but influence the propensity to smoke are changed to reduce said propensity 
permanently.  This was demonstrated assuming cytisine had such an effect but 
varenicline treatment did not; however, this sensitivity analysis was not motivated 
by evidence to suggest that cytisine treatment should influence time-invariant 
characteristics to a greater extent than varenicline treatment.  For this result to be 
meaningful in practice, information would be needed about the relative degree to 
which factors that may contribute to these characteristics are affected by different 
smoking cessation strategies.  Strategies involving psychological motivation and 
support may be candidates to produce a permanent effect, though short-term 
evidence has suggested that strength of beliefs about the benefits and harms of 
smoking are unimportant for quit success [464, 465].    
Enthusiasm for projections of behaviour based on survey data should be tempered 
by caution concerning the limitations and applicability of such data.  There is well 
documented concern about bias and uncertainty surrounding self reports of 
behaviour [342], though exploration of attrition bias in Chapter 5 highlighted no 
clear cause for concern in this case study.  In addition, survey questions are framed 
with the aim of minimising bias, and high levels of accuracy from self-reported 
smoking data have been found elsewhere [466].   
There is further issue as to whether it is possible to accurately represent the target 
population with output from analysis of survey data used here.  Though it is 
possible to set variables in the dynamic behavioural equations with the aim of 
representing UK smokers likely to receive cessation treatment, data on 
appropriate values for many variables will not be routinely collected in practice.  In 
lieu of such information, assumptions must be made, as have been here for many 
variables, including those capturing initial behaviour.  However, when 
assumptions are applied consistently across treatment arms, the importance of 
such assumptions for incremental results may be small.   
 
Criticism may generally be levelled at the use of survey data instead of trial follow-
up data to capture long-run behavioural patterns, but sufficient trial follow-up data 
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for this purpose, for alcohol and tobacco use at least, appears from Chapters 2, 3 
and 4 to be scarce.  Such data are needed, and long-run large scale follow-up 
studies with regular data collection should be actively encouraged.  In the 
meantime, longitudinal individual-level survey data to capture long-run 
behavioural patterns is available for use. 
Given the practical obstacles to estimating dynamic equations in future economic 
appraisals of competing behaviour change strategies, the consequences of using 
relatively simple analysis of HILDA data to inform behavioural transition 
probabilities was tested as part of the sensitivity analysis.  Results were similar to 
baseline in this case, implying that appraisal results based on simple analysis of the 
appropriate data are a good approximation of results when using dynamic 
equations estimated using the same data, and could be used in their stead with 
little consequence.  Of course, dynamics and confounding factors not accounted for 
in simple analysis could be important for economic appraisal outcomes in other 
applications, and this author is cautious about recommending against correct 
practice.  Further, the dynamic equations offer greater flexibility in terms of 
capturing individual-level characteristics when such data are available and 
exploration of the importance of these characteristics for cost-effectiveness results.   
However, when resource limitations mean that undertaking dynamic analysis of 
appropriate data is not possible, simple analysis of such data may be preferable to 
simplistic assumptions about long-term behaviour in existing studies which have 
been at best based on limited trial follow-up data.  For future economic appraisals 
of competing aids for smoking cessation, where data are sufficiently transferable, 
the mean dynamic equation parameters reported in Table 6 and the accompanying 
covariance matrix in Table 47 and Table 48 can be utilised. 
It is possible that the importance of treatment cost has been understated in the 
analysis.  If an individual relapses to smoking or fails in a quit attempt, they are 
likely to make assisted attempts again in the future [467].   The BIT model does not 
explicitly account for future quit attempts, in the manner of the recent simulation 
model identified in Chapter 3 [214].  However, the HILDA respondents upon whom 
projections of long-term behaviour are based have been living in a society where 
aids to smoking cessation have been available in a similar situation to the UK [166, 
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424].  Though use of smoking cessation medication is not recorded in HILDA, the 
propensity to change smoking status after an assisted quit attempt will be 
captured by observed transitions between behaviour states.  The cost of such quit 
attempts however, is not accounted for.  Cheaper treatment options may be more 
preferable than the BIT model would suggest. 
The analysis is subject to the limitations of contributory input data and methods 
from Chapters 5, 6 and 7, some of which have already been discussed.  Aside from 
these, the data to link smoking status to health was taken from a manufacturer’s 
submission to the STA process and may not represent the best data available [366].  
Methods and data to link alcohol use to health were also subject to limitations, and 
uncertainty around morbidity and mortality rates has not been explored.  Despite 
these limitations, the analysis represents an improvement on what have become 
standard practice economic appraisals of competing strategies for smoking 
cessation, and has demonstrated the feasibility and consequences of incorporating 
dynamic movements in smoking status and their link to alcohol use status in an 
economic appraisal framework. 
 
8.5. Chapter Summary 
The aim of this chapter was to explore the consequences of using dynamic and 
bivariate behavioural equations to project long-run behavioural patterns within an 
individual-level health economic simulation model framework.  The analyses 
presented here have demonstrated that cost-effectiveness results for behaviour 
change intervention comparisons are sensitive to assumptions about the link 
between short-run observed behaviour and long-run unobserved behaviour.  
These assumptions should be justified and based on sound analysis of the best 
available data, which may be longitudinal survey data such as that available from 
the HILDA survey.  Previous analyses using potentially unrealistic assumptions 
may have overestimated the cost-effectiveness of smoking cessation strategies 
with high short-term effectiveness [357-367].  However, this chapter has highlighted 
that if cessation strategies can permanently reduce the propensity to smoke, their 
value is greatly increased.  In the absence of information on this, further important 
assumptions are necessary.   
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These issues merit further consideration in the concluding chapter of this thesis.  
Chapter 9 discusses the findings of this research and the potential implications for 
future work, including assessment of the merit of the framework for appraisal of 
behaviour change strategies set out in Chapter 1, in light of the evidence presented 
on the case study of smoking and alcohol use in the intervening chapters. 
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9. Chapter 9: Discussion 
This thesis has investigated bias in economic evaluations of behaviour change 
strategies caused by omission of links between behaviours.  The investigation 
focused on the relationship between two behaviours with importance for public 
health, tobacco use and alcohol use, and the implications for cost-effectiveness 
estimates of competing interventions to aid smoking cessation.  Though there is 
extensive literature in the area, current knowledge on long-term patterns of 
tobacco use and alcohol use, and their interrelation, has been shown to be limited.  
This is reflected in the data and methods used to capture long-term behaviour and 
its consequences in the numerous economic appraisals in the area to date, which 
have been potentially inaccurate.   
Analysis of alcohol and tobacco use in the HILDA dataset has suggested that use of 
these substances is both dynamic and interrelated.  Analysis of these data provided 
suitable alternative inputs to potentially more accurately project long-term 
behaviour in future economic appraisals.  Due to the nature of these data, an 
individual-level simulation modelling framework is necessary to accurately 
account for long run patterns of behaviour.  Appraisal outcomes have been shown 
to be substantially affected by assumptions about long-run behaviour, and it is 
possible that reimbursement decisions have been misinformed by inappropriate 
historical economic appraisals. 
9.1. Summary of key contributions, findings and limitations 
A key contribution of this thesis is the dynamic, bivariate analysis of tobacco and 
alcohol use presented in Chapter 5.  This contribution to a limited field of evidence 
may help understanding of the determinants of alcohol and tobacco use, from the 
importance of addiction, to the influence of person-specific characteristics which 
are difficult to observe in survey and trial data but should not be ignored.  In 
addition, the results from this analysis were suitable to predict behaviour beyond 
trial endpoints in an economic evaluation of competing smoking cessation 
interventions.   
The BIT model itself is another sizeable contribution of this thesis.  Despite the 
multitude of economic models to evaluate the cost-effectiveness of competing 
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smoking cessation strategies published to date, and the appropriateness of an 
individual-level simulation model type to capture long-run smoking behaviour, the 
author is aware of only one other individual-level model in the field [214].  This 
might be explained by a scarcity of long-run follow-up data from smoking 
cessation trials. Incorporation of dynamic, bivariate equations estimated using 
large-scale longitudinal data in this thesis to predict long-run behaviour further 
strengthens the contribution of the BIT model to the field in this context,. 
The previous chapter provided a useful insight into the potential mis-estimation of 
cost-effectiveness results in historical economic evaluations of smoking cessation 
interventions. If a smoking cessation intervention produces a high 12-month quit 
rate but does not change time-invariant person-specific characteristics which 
determine a person’s propensity to smoke, their long-run health and healthcare 
cost benefit may have been exaggerated in past models. If, however, smoking 
cessation interventions can permanently reduce the propensity to smoke, their 
benefit for future health and health-care costs may be great. This finding is a 
further contribution of this thesis to the knowledge base, but ultimately, without 
knowledge of the relationship between smoking cessation interventions and their 
influence on these characteristics, the bias in historic economic evaluations with 
potentially unrealistic assumptions about long-run behaviour is unknown.  
However, it is likely that the differential effect upon these characteristics between 
competing drugs to aid cessation attempts is small, and so historic economic 
evaluations have probably exaggerated the cost-effectiveness of pharmaceutical 
aids to smoking cessation which have high 12-month cessation rates.  This may 
have led to incorrect resource allocation decisions, potentially including the 
recommendation of varenicline for smoking cessation in the UK.   
 A fourth contribution of this work, and a key aim set out in Chapter 1, is evidence 
on the practicality, feasibility and merit of considering links between behaviours in 
economic evaluations of behaviour change strategies.  This discussion now turns to 
reflective analysis of the usefulness of the framework for economic evaluations of 
behaviour change strategies proposed in Chapter 1, in light of the key findings and 
limitations of each subsequent chapter.   
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From Figure 1, shown in Chapter 1, which describes the proposed framework, five 
separable stages to appropriate economic appraisal can be discerned.  First, 
methods and data to perform an economic appraisal without consideration of 
inter-behavioural links must be established.  Second, evidence on links to other 
health behaviours must be researched, which includes establishing whether past 
economic appraisals in the area have considered cross-behavioural consequences.  
Third, data to quantify evidence-supported links to other behaviours need to be 
either sourced or generated.  Fourth, data and methods to connect changes in 
related behaviours to changes in health, and cost and quality of life outcomes must 
be established.  Fifth, and finally, an analytical tool to accommodate all of these 
data in order to perform a robust economic appraisal which considers inter-
behavioural links must be developed for use, and the analysis run.  An overarching 
aim of subsequent chapters was to test the feasibility and merit of this framework, 
with a case study focusing on the link between tobacco and alcohol use and its 
implications for economic appraisal of competing strategies to aid smoking 
cessation. 
Chapter 2 investigated existing evidence on the link between alcohol and tobacco 
use, thus targeting the second identified stage of the framework.  The overriding 
narrative of the literature is of a complementary relationship between tobacco use 
and alcohol use, but a relationship that is complex and influenced by confounding 
factors such as age and gender [76, 79, 82, 91].  Despite the wealth of literature in the 
area, very little evidence was available on the interaction between alcohol use and 
tobacco use over time.  Exploration of available survey data highlighted a potential 
lack of data on inter-temporal patterns of alcohol and tobacco use within the same 
sample, though the HILDA survey was identified as a source of rich longitudinal 
individual-level data on both alcohol and tobacco use. 
The implications from Chapter 2 for wider use of the framework are that while 
links between behaviours have been the focus of past work and can be useful in 
determining the importance of inter-behavioural relationships, longitudinal data 
on linked behaviours may be limited.  Without knowledge of patterns of inter-
linked behaviours over time, it is not possible to accurately incorporate 
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consequences of behavioural links into economic appraisals, where long-term 
health consequences are of great importance.   
Chapters 3 and 4 also targeted the second identified stage of the framework, by 
investigating whether inter-behavioural links have been incorporated into 
previous economic evaluations of competing strategies for (i) smoking cessation 
and (ii) alcohol reduction.  They have not.  These chapters also highlighted data 
and methods to link behaviour change to long-run health-related consequences, 
and were thus useful exploring the first and fourth identified stages of the 
framework.  Many economic evaluations studies were identified in chapters 3 and 
4, but the overwhelming majority of modelling studies have used cohort model 
structures and made potentially unrealistic assumptions about long-term 
behaviour which are not supported by the best available data.  Improvements in 
modelling practice in these areas are merited, aside from consideration of inter-
behavioural effects, with a movement towards individual-level models which can 
handle the complexity of patterns of behaviour over time as well as appropriate 
analysis of longitudinal data to accurately inform assumptions about long-term 
behaviour.   For future use of the framework, the implications are that economic 
appraisals of behaviour change strategies are numerous and a search and review 
of evidence may be cumbersome, but improvements on existing data and methods 
used will likely be warranted and past incorporation of inter-behavioural effects is 
unlikely.  
Chapter 5 tested the third stage of the framework, by estimating parameters for 
dynamic equations to quantify the link between smoking status and alcohol use in 
an economic evaluation model, in the absence of existing data.  The parameterised 
equations are powerful in that they can be used to predict dynamic patterns of 
behaviour based on nine consecutive years of data from a large sample and flexible 
in that they control for many important factors which influence smoking and 
drinking behaviour.  Limitations include the potential for bias in self-reported data 
and the generalisability of Australian general population data to other settings.  
There are implications from Chapter 5 for future use of the framework, in terms of 
the practical feasibility of undertaking dynamic and multivariate analysis of survey 
data in cost-effectiveness projects.  The analysis presented in Chapter 5 required a 
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skill set not typically necessary in economic evaluation projects, and inclusion of 
such analyses in future economic evaluations may increase the cost of such 
projects.  Further, this case study has considered the case of two inter-related 
health behaviours; if fully implemented, the framework may warrant analysis of 
interactions between more than two behaviours.  This will be perfectly feasible if 
the data are available, but would increase the computational burden of estimation, 
and require programming skills in Stata or alternative software.   Nevertheless, 
dynamic analyses of data on health-related behaviour can contribute substantially 
to the knowledge base, improving understanding of the complexities and 
determinants of behaviour, as well as providing useful and flexible evidence for 
extrapolation of behaviour in cost-effectiveness analyses, as demonstrated here.  
Efforts to improve understanding of the interrelated dynamics of different health-
related behaviours may represent a highly worthwhile use of resources. 
Chapter 6 presented results from a standard practice economic appraisal of 
competing strategies to aid smoking cessation and in doing so established methods 
and data to perform an economic appraisal without consideration of inter-
behavioural links.  This was necessary to achieve the first identified stage of the 
framework for this case study, but the chapter was also useful in providing 
encouraging evidence on the potential for cytisine as a cost-effective alternative to 
varenicline for smoking cessation.  The economic model was based on a widely 
used modelling framework, the BENESCO model [363], but the limitations of the 
analysis were numerous.  Paramount among these was the assumption that 
smokers who fail to successfully quit following treatment at the start of the model, 
or relapse to smoking following a successful quit, have zero chance of smoking 
cessation in the future.  This is an unrealistic assumption which favours strategies 
with higher short-term effectiveness.  Aside from this, many model parameters 
were taken from an earlier manufacturer’s submission to the NICE appraisal 
process [366] and may not represent the best available data.  Given the depth of 
research on the economics of smoking, systematically identifying the most 
appropriate cost, utility and probability parameters to link tobacco use to cost and 
HRQoL outcomes would be a significant task, though one demanded by NICE 
guidance [6].  If the framework is to be implemented in future, this would need to 
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be replicated for each related health behaviour identified as important: a 
potentially substantial burden. 
Chapter 7 established the structure and remaining inputs for the BIT model; 
Chapter 8 reported results from a re-analysis of the cost-effectiveness of cytisine 
versus varenicline using this de novo individual-level simulation model.  Together, 
these chapters comprise the final identified stage of the framework, in developing 
and testing an analytical tool to perform a robust economic appraisal which 
considers inter-behavioural links.  There are limitations to the BIT model, 
including the omission of costs of future NHS-funded smoking cessation attempts, 
but its structure and key input data represent a clear improvement upon standard 
practice health economic models in the field. Though the economic appraisal 
results from Chapter 8 aligned with those of Chapter 6 in that cytisine was shown 
to be preferable to varenicline for adoption based on current evidence, there were 
clear differences in incremental outcomes between comparators across the two 
chapters, driven by different assumptions about long-term behaviour across the 
BIT and BENESCO models.  Cost-effectiveness analyses using modelling structures 
and assumptions similar to those in the BENESCO model have likely been biased to 
favour strategies with superior short-term effectiveness.  This may have led to 
misallocation of resources in the past.  The risk of resource mis-allocation would 
be reduced with appropriate assumptions and data used in future models. 
There are implications from Chapters 7 and 8 for future use of the framework in 
terms of the practical feasibility of (i) developing, (ii) populating and (iii) running 
an individual-level multi-behaviour cost-effectiveness model, which sit alongside 
the implications from previous chapters.  To expand with respect to point (i), the 
human resources required to build a health economic model are driven by the 
complexity of the model, which is driven by the complexity of the disease and the 
availability of data [7].  When multiple behaviours with links to numerous diseases 
are incorporated into one model, model building will likely be a substantial task. As 
stated above, data and methods to accurately link behaviour to health-related 
outcomes are required for every behaviour considered, and these should be 
identified through a systematic search and review of existing evidence according 
to NICE guidelines [6].  The resource cost of this may be significant.  With respect to 
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point (iii), due to the scope for increased complexity relative to cohort models, 
individual-level simulations may be more computationally expensive than cohort 
analyses, and this has been highlighted in the past as a potential problem for wide 
use of individual-level simulations for health economic modelling, particularly with 
respect to undertaking PSA [10].  However, with methodological progress in this 
area and increases in computing power, this argument is waning [468].    
Though difficult to quantify, a valuable lesson from this thesis for similar work in 
the future is the importance of good communication and understanding within a 
multidisciplinary team. It is foreseeable, were the framework to be used elsewhere, 
that skills in econometrics and cost-effectiveness modelling may not be common to 
any one member of the project team.  Care, attention to detail and clear 
communication across disciplines will be crucial.      
Overall, while key findings from this thesis have shown that modelling practice in 
the field of economic evaluation of behaviour change strategies may require 
improvement, full implementation of the framework for appraisal proposed in 
Chapter 1 may not always represent the best use of resources.  On the basis of this 
case study, this author recommends that decisions about the merit of 
incorporating links between health behaviours into future economic evaluations of 
behaviour change strategy should be made on a case-by-case basis, perhaps 
through a scoping exercise to ascertain (i) the potential importance of inter-
behavioural links for the appraisal decision (ii) the availability of longitudinal, 
individual-level data on the behaviours in question.  Behavioural links which may 
have particular importance for appraisal decisions include those in which an 
improvement in one behaviour leads to a worsening in another behaviour, those in 
which there is are differential inter-behavioural implications across comparator 
interventions, and those in which there is high uncertainty around the appraisal 
decision.  The link between smoking and diet may for example be of consequence 
for economic appraisals of smoking cessation strategies, particularly if one 
strategy is an appetite suppressant, or if the decision between competing 
strategies is uncertain.  
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9.2. Recommendations for future research 
There is a clear need for further evidence on long-term patterns of health 
behaviour.  The analysis of HILDA data presented here contributes to evidence on 
the dynamics of tobacco and alcohol use and their interrelation, but is subject to 
limitations and would be strengthened by verification through analysis of data 
from different populations.  While further analysis of existing data would be 
welcome, the availability of such data may be limited.  Priority should potentially 
be given to collecting further data as well as analysing the information that 
currently exists.  Large-scale longitudinal general population surveys with a format 
similar to HILDA are well suited to this purpose, and the Understanding Society 
survey in the UK could be a rich source of ongoing information for the UK general 
population, if the right data were collected [110]. Currently, the survey contains very 
few questions on alcohol use and detailed information pertaining to weekly 
consumption for adults only if they are or have been pregnant [110].  Smaller, 
behaviour-specific studies with regular data collection should also be encouraged, 
while trials for interventions for behaviour change might be incentivised to collect 
information on related health behaviour at baseline and follow-up, which will 
preferably be regular and continue for multiple years in order to capture the 
dynamics of behaviour. 
Dynamic analyses of available longitudinal data on health behaviour are of merit 
and will hopefully be encouraged, for their important explanatory power, and also 
as a resource to inform projections of behaviour in cost-effectiveness analyses.  
Analyses considering networks of behaviour as interrelated outcomes would be of 
great use, where data are available.  Full dissemination of parameter estimates 
including covariance matrices should be strongly promoted, while analysts who 
make their estimation code publicly available can not only demonstrate 
transparency in their work, but help a wider network of researchers with varying 
skill sets contribute to work in this area. 
A move away from cohort state-transition models and towards individual-level 
simulation models to inform appraisals of competing behaviour change strategies 
may be merited.  This thesis has demonstrated the importance of assumptions 
about long-term behaviour for economic evaluation outcomes.  Potentially 
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unrealistic assumptions in historical models have at least partly been 
consequences of inappropriate model structures.  Individual-level behaviour is 
complex and dynamic, and the model structures used, as well as the data to 
populate them, should ideally reflect this. 
 
9.3. Policy implications 
Appraisal of the cost-effectiveness of cytisine as an aid to smoking cessation has 
shown the drug to have great potential as an alternative to varenicline, currently 
recommended for use in the UK.  The analysis reported in Chapter 6 has 
contributed to a recommendation for a large-scale trial directly comparing cytisine 
to varenicline in a sample of UK smokers [368].   
Re-estimation of the relative cost-effectiveness of cytisine and varenicline using 
the BIT model in Chapter 8 did not change the policy recommendations from 
Chapter 6.  However, it has been shown that assumptions in previous analyses 
using the BENESCO model and other models with similar simplistic assumptions 
about long-run behaviour may have led to misallocation of resources in the past. 
There are further potential policy implications from the dynamic bivariate analysis 
of tobacco and alcohol use in Chapter 5.    Smoking and drinking behaviours are 
best understood as time-persistent, reinforcing and dynamic behaviours; 
interventions which target short-term improvements in behaviour may only lead 
to temporary behavioural improvements.  Further research into the time-invariant 
characteristics which affect the propensity to smoke and drink may aid policy 
decisions, though these characteristics are inherently difficult to observe.     
 
9.4. Concluding Remarks 
Links between health behaviours are potentially of great importance for cost-
effectiveness estimates in economic evaluations of competing behaviour change 
strategies.  This thesis has presented an investigation into assumptions about 
behavioural projections in economic evaluations of smoking cessation strategies.  
Common assumptions about post-trial behaviour are based on few data and 
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potentially inaccurate, and have not considered inter-behavioural links.  This 
thesis has provided evidence on the dynamics and interrelation of tobacco and 
alcohol use in a form that can be used to inform assumptions about behaviour in 
future cost-effectiveness models, demonstrated potential bias in historical 
economic evaluations and provided insight into the feasibility and merit of 
considering links between behaviours in future economic evaluations of behaviour 
change strategies.  The thesis concludes by recommending consideration of the 
merit of incorporating inter-behavioural links on a case by case basis in economic 
evaluations; but also with a call for robust and tested assumptions about long-term 
behaviour in future economic evaluations of behaviour change strategies and for 
further evidence on the dynamics and interrelation of health-related behaviours to 
be actively encouraged. 
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11. Appendices 
11.1. Appendix A: Appendix to Chapter 2 
Table 32: Summary of studies analysing links between alcohol use and tobacco use 
Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
Correlation between alcohol and tobacco use 
Anthony 2000 [76] To determine the extent of 
concurrent use of alcohol and 
tobacco in the US population 
NHSDA and NCS cross-
sectional data; 
General US adult population 
(n>8,000 NCS; n>17,000 
each cross-section of 
NHSDA, three cross-sections 
analysed separately)  
Analysis of 
correlation 
Patterns of co-occuring 
use of alcohol and tobacco, 
with decreasing 
prevalence after age 25 
years 
Chiolero 2006 [78] To assess clustering of risk 
behaviours (including high 
alcohol consumption) with 
level of cigarette 
consumption 
SHS cross-sectional data; 
General Swiss adult 
population 
(n>18,000) 
Logistic regression Odds of multiple risk 
behaviours higher for 
smokers than non-
smokers and increases 
with cigarette 
consumption 
Falk 2006 [79] To update findings of 
Anthony [76] assessing the 
extent of concurrent use of 
alcohol and tobacco in the US 
NESARC cross-sectional 
data; 
General US adult population 
(n>42,000) 
Analysis of 
correlation 
Tobacco use increases 
with alcohol consumption; 
use of both peaks in young 
adults and decreases 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
population  thereafter 
Gupta 2005 [80] To determine the association 
between concurrent alcohol 
and tobacco use in an ageing 
Indian male population 
Cross-sectional interview 
questionnaire of men 
age >=45 years in Mumbai 
(n>35,000) 
Analysis of 
correlation 
Pattern of co-occurrence, 
controlling for age, 
religion and education. 
Harrison 2008 [81] To investigate the association 
of alcohol use with non-daily 
smoking in young adults 
NESARC cross-sectional 
data; 
sub-sample of Wave 1 aged 
18-25 years  
(n>5,500) 
Logistic regression Daily and nondaily 
smokers more likely to be 
current 
drinkers, to drink more 
alcohol, and to drink more 
frequently 
than non-smokers 
John 2003 [82] To investigate associations of 
different measures of alcohol 
misuse with tobacco use 
TACOS  cross sectional data; 
sub-sample of German 
smokers (n>2,400) 
Logistic regression Tobacco dependence and 
being male independent 
predictors of alcohol 
dependence 
McKee 2007  [98] To investigate smoking 
status as a clinical indicator 
for alcohol misuse 
NESARC cross-sectional 
data; 
General US adult population 
(n>42,000) 
Logistic regression Daily and non-daily 
smokers at heightened 
risk for hazardous 
drinking and clinical 
alcohol misuse, compared 
to non-smokers 
ONS 2012 [85] To analyse inter-relation GLS cross-sectional data; Analysis of Smokers drink more than 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
between alcohol use and 
tobacco use 
General UK adult population 
(n>16,000) 
correlation non-smokers, but this is 
driven by never-smokers. 
Ex-smokers drink nearly 
as much as smokers 
Role of alcohol use in determining tobacco use 
Auguston 2008 
[86] 
To identify factors associated 
with smoking cessation 
Finnish longitudinal 
nutritional intervention 
study with assessment 
every 4 months for 5 to 8 
years; Finnish male smokers 
aged 50 to 69 years at 
baseline 
(n>20,000) 
Logistic regression Smoker who drink over 
15g alcohol per day less 
likely to have a sustained 
quit as opposed to 
relapsing than smokers 
who do not  
Breitling 2010 [77] To examine importance of 
alcohol consumption for 
probability of smoking 
cessation 
German cross-section data; 
German individuals aged 
50-74 years presenting for 
general health screening; 
sub-sample of ‘ever 
smokers’  
(n>4,500) 
Cox regression 1-99g/week is predictive 
of smoking cessation, 
relative to alcohol 
abstinence 
Dawson 2000 [88] To explore the relationship 
between drinking and 
smoking cessation 
NLAES two waves of 
longitudinal data; 
smoker subsample of 
Logistic regression Smokers who engage in 
heavy drinking less likely 
to quit than smokers who 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
general US adult population  
(n>12,500) 
do not 
Dollar 2009 [56] To explore importance of 
own and spousal alcohol and 
tobacco use for smoking 
cessation 
Prospective study of 
American couples  
(n>600) 
Cox regression Drinking >6 drinks or to 
intoxication ‘several times’ 
a month reduces hazard of 
smoking cessation in 
married men  
Hughes and Callas 
2003 [60] 
To investigate whether past 
alcohol problems predict 
smoking cessation outcomes 
American study of smokers 
randomised to varying 
strengths of nicotine patch 
(n>1000) 
Logistic regression Past alcohol problems do 
not predict smoking 
cessation outcomes 
Hughes 2006 [104] To investigate whether past 
alcohol problems predict 
smoking cessation outcomes 
using existing evidence 
17 articles analysing 
nicotine dependence 
between those with and 
without alcohol problems 
Review Past alcohol problems do 
not predict smoking 
cessation outcomes but 
smokers with current or 
past alcohol problems are 
less likely to quit in their 
lifetime 
Hughes and 
Oliveto 1993 [61] 
To investigate alcohol as a 
predictor of smoking 
cessation and tobacco 
withdrawal 
Follow-up study Individuals 
attempting quitting smoking 
without pharmaceutical aid 
in America (n>600)  
Survival curve 
analysis 
Alcohol use not important 
in predicting smoking 
cessation success; 
cigarette craving levels 
decreased two weeks after 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
cessation for those who 
did not increase their 
alcohol intake 
Hymowitz 1997 
[91] 
To identify predictors of 
smoking cessation in a cohort 
of smokers followed for 5 
years 
Telephone survey of 
American and Canadian 
cigarette smokers 
interviewed at baseline and 
after 5 years 
(n>13,400) 
Logistic regression Alongside being male, 
older and having a desire 
to quit, lower frequency of 
alcohol intake predicts 
smoking cessation. 
Kahler 2008 [83] To investigate the role of 
lifetime alcohol involvement 
in different smoking 
decisions such as initiation, 
progression to daily smoking 
and then dependence 
TTURC: NEFS cross-
sectional data; 
General New England adult 
population 
(n>1,600) 
Logistic regression   Levels of alcohol 
involvement increase the 
risk of ever smoking and 
progression to daily 
smoking, but are not 
important for smoking 
persistence  
Kahler 2009 [92] To investigate different 
alcohol use measures as 
predictors of quitting 
smoking 
ITC-4 two waves of 
longitudinal data from US, 
UK, Canadian and Australian 
adult smokers 
(n>4800) 
 
Logistic regression Neither drinking 
frequency nor weekly 
quantity of consumption 
showed robust 
associations with quitting 
smoking. Alcohol use 
measures similar across 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
Australia and UK; both 
bigger users of alcohol 
than US. 
Kahler 2010b [102] To examine alcohol use and 
its association with smoking 
lapses in heavy non-
dependent drinkers in 
smoking cessation treatment 
26 week follow-up of 
American heavy drinking 
smoking cessation 
treatment participants 
(n=236) 
Cox regression  Moderate drinking days 
associated with almost 4 
times greater risk of 
relapse to smoking than 
non-drinking days 
Leeman 2007 [105] To understand the effect of 
alcohol upon smoking 
cessation with and without 
smoking cessation aids, and 
the effect of smoking 
cessation on alcohol use 
Data  from 149 smoking 
cessation trials involving 
nicotine replacement 
therapy, bupropion or 
varenicline 
Narrative Review The majority of 11 trials 
reporting alcohol problem 
history find no effect. Only 
two trials that specifically 
recruited past alcohol 
dependence patients 
reported effect of smoking 
cessation on alcohol use. 
Leeman 2008 [66] To investigate the 
relationship between 
smoking cessation treatment 
failure and current and 
lifetime alcohol use and 
problems 
Data from an American RCT 
of two types of motivational 
interventions both with 
bupropion for smoking 
cessation with 12 week 
follow-up 
(n=249) 
Logistic regression Probability of smoking 
highest on heavy drinking 
days; relapse to smoking 
slightly more likely for 
hazardous drinkers than 
non-hazardous drinkers.  
Alcohol use disorder 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
history did not predict 
smoking cessation relapse. 
McClure 2002 [93] To examine whether 
smokers’ drinking levels 
predict smoking abstinence 
4 year follow-up study of 
working smokers in south 
eastern US 
(n=728) 
Logistic regression Participants who had quit 
smoking at follow-up 
drank less at baseline than 
continued smokers. 
Osler 1999 [95] To analyse determinants of 
spontaneous smoking 
cessation 
Longitudinal data on adult 
smokers in Copenhagen, re-
interviewed after 5 and 10-
16 years 
(n>6000) 
Logistic regression High alcohol consumption 
and being female were 
independent predictors of 
non-quitting. 
Zimmerman 1990 
[84] 
To analyse the role of alcohol 
use in smoking cessation 
Cross-section of the Florida 
adult general population 
(n>2100) 
Logistic regression Heavy drinkers less likely 
to have attempted quitting 
smoking; individuals who 
enjoy smoking and alcohol 
concurrently more likely 
to quit smoking than those 
who do not use the two 
concurrently 
King 2009 [65] To investigate alcohol’s effect 
on various aspects of 
smoking behaviour 
Double blind trial of US non-
dependent heavy drinking 
smokers randomised to 
either alcohol (n=29) or 
Analyses of 
variance 
Alcohol, compared with 
placebo beverage, 
increased smoking urge, 
puff count, volume and 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
placebo (n=13) beverage duration in men and 
women. 
McKee 2006 [70] To examine the role of 
alcohol use in smoking lapse 
behaviour 
Within-subject trial of US 
smokers (age 21-55) who 
drink at least 2 days a week 
but not alcohol dependent 
(n=16)  
Hypothesis testing 
(t distribution) 
After consuming alcohol, 
subjects less able to resist 
the first cigarette, initiated 
smoking sessions sooner 
and smoked more, 
compared to placebo 
beverage. 
McKee 2010 [69] To examine how alcohol 
alters the subjective effects of 
smoking in heavy drinking 
young US adults (age 21-25) 
who are experimental 
smokers 
Within-subject trial of 
alcohol’s effect on subjective 
responses to smoking and 
amount smoked in heavy 
drinking young US adults 
(age 21-25) who are 
experimental smokers 
(n=19) 
Analyses of 
variance 
Expectation of alcohol 
increased satisfaction and 
calm with smoking and 
taste of cigarettes, and 
alcohol decreased nausea 
associated with smoking. 
Mintz 1985 [71] To identify a causal link 
between drinking alcohol 
and smoking cigarettes 
Trial of US narcotic addicts 
who were smokers and 
social drinkers, given 
alcohol and then orange 
juice in separate sessions  
(n=14)  
Hypothesis testing 
(t distribution) 
The hypothesis that 
alcohol consumption 
would increase smoking 
was supported. 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
Role of tobacco use in determining alcohol use 
Non-alcohol dependent drinkers    
Carmelli 1993 [87] To investigate the 
relationship between 
changes in smoking and 
drinking over 16 years of 
adult life 
Data from a twin registry on 
war veterans with 16 year 
follow-up 
(n>5500) 
Analyses of 
variance 
There was an increase in 
alcohol consumption in 
smoking quitters and 
continuing smokers, but 
no change in alcohol 
consumption in continuing 
non-smokers 
Dawson 2012 [97] To assess correlates of 
drinking cessation 
NESARC two waves of 
longitudinal data 3 years 
apart; subsample of 
participants in both waves 
consuming alcohol at least 
once a month in the year 
before the first wave 
(n>14850) 
Logistic regression Lifetime smoking 
cessation associated with 
increased odds of lifetime 
drinking cessation across 
all ages 
Gordon 1986 [90] To examine the relationship 
between changes in alcohol 
consumption and other 
factors 
Follow-up study of 
employed US men 18 years 
after initial interview 
(n>850)  
Linear regression There was no association 
between changes in 
smoking habits and 
changes in drinking habits 
Kahler 2010a [63] To examine longitudinally 
whether quitting smoking is 
ITC-4 three waves of annual 
longitudinal data, from US, 
Logistic regression Low rates of quitting 
smoking for those who 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
associated with decreased 
alcohol consumption 
UK, Canadian and Australian 
adult smokers 
(n>3300) 
drank heavily more than 
once a week. Little 
evidence of sustained 
smoking cessation 
changing drinking 
behaviour. 
McKee 2008 [67] To examine whether nicotine 
replacement therapy alters 
alcohol use 
Within-subject trial of US 
smokers (age 21-55) who 
drink at least 3 days a week 
but not alcohol dependent 
(n=19) 
Hypothesis testing 
(t distribution) 
Nicotine replacement 
compared to mild nicotine 
deprivation attenuated 
subjective and 
physiological alcohol 
responses and delayed the 
initiation of drinking 
McKee 2009 [68] To test whether varenicline 
reduces alcohol craving and 
consumption 
Double-blind placebo-
controlled two-arm trial of 
non-alcohol dependent US 
heavy drinkers who smoke 
(n=20) 
Analyses of 
variance 
Varenicline significantly 
reduced alcohol self-
administration in heavy-
drinking smokers 
Murray 1996 [72] To test whether changes in 
smoking are followed by 
changes in drinking 
LHS data on US adult 
smokers (age 35-
60)randomised to either 
motivational smoking 
cessation intervention or 
Logistic regression Higher smoking cessation 
in intervention group but 
no difference between 
intervention and control 
in alcohol use after one 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
control  
(n>5887) 
year 
Murray 2002 [94] To assess the evidence that 
changes in smoking over 
time are related to changes in 
drinking or that changes in 
drinking over time are 
related to changes in 
smoking 
Two waves of longitudinal 
data on US adults 
representative of the  
general population, about 2 
years apart  
(n=344) 
 
Structural equation 
modelling 
No significant 
relationships found 
between changes in 
smoking and changes in 
drinking 
Alcohol dependent drinkers    
Cosgrove 2011 
[108] 
To review evidence 
suggesting nicotine and 
tobacco smoke modulate the 
effects of alcohol on neuronal 
function and implications for 
recovering alcoholics 
Various previous 
publications 
Review Tobacco smoking during 
alcohol withdrawal 
attenuates negative 
alcohol withdrawal effects 
Dawson 2007 [89] To examine longitudinal 
changes among individuals  
recovering from alcohol 
dependence 
NESARC two waves of 
longitudinal data 3 years 
apart;  subsample in 
remission from alcohol 
dependence 
(n>1750) 
Logistic regression Positive association 
between baseline smoking 
and risk of relapse to 
alcohol, only significant 
for those who continued 
smoking across waves 
Friend 2005 [57]  To examine the relationship Sub-sample of smokers in Kaplan-Meier Smokers whose cigarette 
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Lead Author, 
Year 
Study aim Data, population Main Statistical 
Approach 
Findings 
between cigarette 
consumption and alcohol use 
outcomes over time 
US study of interventions 
for alcohol abuse 
(n>950) 
survival analysis consumption decreased 
less likely to relapse to 
alcohol than those whose 
consumption increased or 
remained unchanged 
Gulliver 2000 [59] To investigate the 
longitudinal relationships 
between alcohol and tobacco 
use variables in alcoholics in 
treatment for alcoholism 
6 month follow-up study of 
US alcoholics in treatment 
for alcoholism 
(n=116) 
Analysis of 
variance 
Pre-treatment smoking 
history did not predict 
post-treatment drinking; 
the rate of smoking 
declined following 
treatment for alcoholism, 
independent of relapse 
status 
Gulliver 2006 [106] To review the evidence 
relating smoking cessation 
and alcohol abstinence in 
alcohol dependent and 
tobacco dependent persons 
Various previous 
publications 
Narrative Review smoking cessation does 
not disrupt alcohol 
abstinence and may 
actually enhance the 
likelihood of longer-term 
sobriety 
Prochaska 2004 
[107] 
To assess the effectiveness of 
smoking cessation 
interventions for individuals 
in substance addictions 
19 randomised controlled 
trials of smoking cessation 
interventions for individuals 
in substance abuse 
Meta-analysis Smoking cessation 
interventions provided 
during addictions 
treatment associated with 
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Study aim Data, population Main Statistical 
Approach 
Findings 
treatment or recovery treatment or recovery 
(n>2000) 
increased likelihood of 
long-term abstinence from 
alcohol  
Schmidt 2001 [74] To investigate the role of 
tobacco smoking in the 
rehabilitation process of 
alcoholics who smoke 
Data from a double-blind 
placebo-controlled trial of 
German alcoholics with 12 
months follow-up 
(n=70) 
Kaplan-Meier 
survival analysis 
No difference in 
abstinence rates between 
smokers and non-
smokers, though smokers 
tended to be abstinent 
longer than non-smokers 
Toneatto 1995 [75] To investigate the link 
between alcohol abusers’ 
smoking status when treated 
for alcohol abuse and 
patterns of drinking before 
and after treatment 
Data from Canadian alcohol 
abusers who had received 
outpatient treatment for 
alcoholism with 12 months 
follow-up 
(n=155) 
Analysis of 
variance 
Non-smokers and ex-
smokers had more 
abstinent days than 
smokers, but smoking 
groups did not differ at 
follow-up on other 
drinking variables 
Assessments of validity of concurrent treatment for tobacco and alcohol misuse 
Grant 2007 [58] To assess bupropion and 
nicotine patch as smoking 
cessation aids in alcoholics 
being treated for their 
alcoholism 
Data from a double blind 
placebo controlled study of 
sustained release bupropion 
as a smoking cessation 
aid in US alcoholics 
undergoing treatment for 
Hypothesis testing 
(Chi-squared 
distribution) 
Cessation rates with 
nicotine patch similar to 
general population. 
Alcohol outcomes 
improved in those who 
stopped smoking 
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Study aim Data, population Main Statistical 
Approach 
Findings 
their alcoholism, 6 months 
follow-up 
(n=58) 
Josephs 2002 [62] To compare the effectiveness 
of smoking intervention 
delivered concurrently with 
intensive alcohol treatment 
with smoking intervention 
that is delayed until 6 months 
after alcohol treatment 
US Alcohol dependence 
patients who smoke and 
have desire to quit smoking 
at some point, nicotine 
replacement therapy, 18 
month follow-up 
(n>450) 
Comparison of 
percentages  
Smoking cessation 
treatment successful in 
alcohol treatment patients. 
Timing of smoking 
cessation intervention not 
important for treatment 
outcomes 
Nieva 2010 [73] To evaluate the effect of 
intensive tobacco cessation 
treatment simultaneously 
with alcohol dependence 
treatment versus delayed 
treatment (first alcohol and 6 
months later tobacco) upon 
alcohol and tobacco 
consumption 
Spanish alcohol dependent 
smokers, being treated for 
alcohol dependence, 
randomised between 
smoking cessation 
treatment alternatives 
(simultaneous versus 
delayed) 
(n=92) 
Survival curves No differences were in 
alcohol abstinence rates in 
time-to-first relapse or in 
cumulative abstinence at 6 
months. Smoking 
cessation rates were low 
overall 
Kalman 2001 [64] To assess smoking cessation 
treatment early in inpatient 
alcohol treatment versus 
shortly after an inpatient stay 
US smoking patients in a 
substance abuse treatment 
program randomised to 
smoking cessation 2 weeks 
Hypothesis testing 
(t distribution and 
Chi-squared 
distribution) 
Low smoking cessation 
rates at follow-up. Timing 
of treatment not 
important for smoking 
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Study aim Data, population Main Statistical 
Approach 
Findings 
or 6 weeks after admission, 
20 weeks follow-up 
(n=36)  
cessation outcome 
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11.2. Appendix B: Appendix to Chapter 3 
 
Figure 22: Search Strategy, Chapter 3 
All searches performed 28th February 2011 
 
Database: HMIC (1979-present), Econlit (1969-present) 
 
1. (zyban or bupropion or wellbutrin or amfebutamone or buproprion).mp. [mp=heading words, abstract, title, country as subject] 
2. nicotine replacement therap*.mp. [mp=heading words, abstract, title, country as subject] 
3. (nicotine adj3 (patch* or gum or inhaler* or spray* or tablet* or transdermal or lozenge*)).mp. [mp=heading words, abstract, title, 
country as subject] 
4. 1 or 2 or 3 
5. (cost* or econom* or pharmacoeconom* or price* or pricing).mp. [mp=heading words, abstract, title, country as subject] 
6. 4 and 5 
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Database: NHS EED 
1. zyban or bupropion or wellbutrin or amfebutamone or buproprion 
2. nicotine (w) replacement (w) therap$ or nrt 
3. nicotine (3w) (patch$ or gum or inhaler$ or spray$ or tablet$ or transdermal or lozenge$) 
4. 1 or 2 or 3 
 
Database: HTA 
1. zyban or bupropion or wellbutrin or amfebutamone or buproprion 
2. cost$ or econom$ or pharmacoeconom$ or price$ or pricing 
3. nicotine 
4. 2 and 3 
5. 1 or 4 
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Database: MEDLINE 
1. Economics/ 
2. exp "Costs and Cost analysis"/ 
3. "Value of Life"/ 
4. Economics, Dental/ 
5. exp Economics, Hospital/ 
6. Economics, Medical/ 
7. Economics, Nursing/ 
8. Economics, Pharmaceutical/ 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab. 
11. (expenditure$ not energy).ti,ab. 
12. (value adj1 money).ti,ab. 
13. budget$.ti,ab. 
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14. 10 or 11 or 12 or 13 
15. 9 or 14 
16. letter.pt. 
17. editorial.pt. 
18. historical article.pt. 
19. 16 or 17 or 18 
20. 15 not 19 
21. Animals/ 
22. Humans/ 
23. 21 not (21 and 22) 
24. 20 not 23 
25. (metabolic adj cost).ti,ab. 
26. ((energy or oxygen) adj cost).ti,ab. 
27. 24 not (25 and 26) 
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28. zyban or bupropion or wellbutrin or amfebutamone or buproprion 
29. nicotine replacement therap* 
30. (nicotine adj3 (patch* or gum or inhaler* or spray* or tablet* or transdermal or lozenge*)) 
31. 28 or 29 or 30 
32. 27 and 31 
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Table 33: Data Extraction Table, Chapter 3 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Modelling 
Studies 
     
Akehurst 1994a UK; 
Not clear; 
CEA 
Healthcare Payer; 
36 years;  
General 
population of 
adult smokers 
12 month cessation 
rate; 
Cost/LY gained; 
0% 
1. GP BA [3.7%] 
2. GP BA + NRT patch 
[11.7%] 
Intervention 
cost; 
 
No clearly 
reported 
assumption 
about number of 
quit attempts 
Akehurst 1994b UK; 
Not clear; 
CEA 
Healthcare Payer; 
36 years; 
Heavy adult 
smokers (>22 
cigarettes per 
day) 
Cessation rate 
(length of abstinence 
or from intervention 
unclear); 
Cost/LY gained; 
0% 
1. GP BA [3.7%] 
2. GP BA + NRT spray 
[26.0%] 
Intervention 
cost, SRDMC; 
 
Intervention 
impacts remain 
continuous as 
people enter and 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
leave the model 
Annemans 2009 Belgium; 
Pfizer; 
CUA 
Healthcare Payer; 
Lifetime; 
General 
population of 
adult smokers 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
6.8% annually years 
1 to <6, 2% annually  
years 6 to <10,  1% 
annually years 10 
onwards 
1. Self Quit [5.0%] 
2. BC [9.4%] 
3. BC + NRT [14.8%] 
4. BC + Bupropion (12 
weeks) [15.4%] 
5. BC + Varenicline 
[22.5%] 
Intervention 
cost, SRDMC; 
 
Single quit 
attempt at the 
start of the 
model 
Bae 2009 South Korea; 
Pfizer; 
CUA 
Societal; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
Cessation rate 
(length of abstinence 
or from intervention 
unclear); 
Cost/QALYs gained; 
6.8% annually years 
1 to <6, 2% annually 
years 6 to <10, 1% 
annually years 10 
onwards 
1. Willpower [10.6%] 
2. NRT [17.2%] 
3. Bupropion [17.8%] 
4. Varenicline [25.2%] 
Intervention 
cost, SRDMC; 
 
No clearly 
reported 
assumption 
about number of 
quit attempts 
Bauld 2011 UK; Healthcare Payer; 12 months 1. Self Quit [1.5%] Intervention 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Glasgow Centre 
for Population 
Health, NHS 
Greater Glasgow 
and Clyde and 
NHS Health 
Scotland; 
CUA 
Lifetime; 
Smokers aged 16 
years and over 
with a desire to 
quit 
continuous cessation 
rate, biochemically 
confirmed; 
Cost/QALY gained; 
24% years 1 to <3, 
10% years 3 to <5, 
2% years 5to <8, 0%  
onwards 
 
2. Pharmacy-based BC + NRT 
[2.5%] 
3. GC + NRT + pharmacy 
follow up [5.5%] 
cost (including 
overhead cost); 
 
Single quit 
attempt at the 
start of the 
model 
Bertram 2007 Australia; 
Australian 
National Health 
and Medical 
Research Council 
(NHMRC); 
CUA 
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month cessation 
rate (ORs); 
Cost/DALY gained; 
10-48% annually 
years 1 to 4; 0% year 
5 onwards 
1. Self Quit [8.6%] 
2. NRT [OR: 1.73] 
3. Bupropion [OR: 2.54] 
4.Bupropion [OR: 2.54], 
followed by NRT at 12 
months if Bupropion not 
successful [OR: 1.73] 
Intervention 
cost, SRDMC; 
 
No clearly 
reported 
assumption 
about number of 
quit attempts 
Bolin 2006 Sweden; 
GlaxoSmithKline; 
CUA 
Societal; 
20 years; 
General 
population of 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
35% over time 
1. NRT patch + MS [15.0%]; 
2. NRT gum + MS [15.6%]; 
3. Bupropion + MS [18.9%] 
Intervention 
cost, SRDMC 
 
30% of smokers 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
adult smokers horizon attempt to quit 
each year 
Bolin 2008 Sweden; 
Pfizer; 
CUA 
Societal; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month continuous 
cessation rate; 
Cost/QALY gained 
6% annually years 1 
to <6,  
2% annually years 6 
to <10, 1% annually 
years 10 onwards 
1. MS + Bupropion [15.7%] 
2. Optional MS + 
Varenicline [22.5%] 
Intervention 
cost, SRDMC; 
 
Single quit 
attempt at the 
start of the 
model 
Bolin 2009 Sweden; 
Pfizer; 
CUA 
Healthcare Payer; 
Societal; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
6% annually years 1 
to <6,  
2% annually years 6 
to <10, 1% annually 
years 10 onwards 
1. MS + Varenicline + 
Placebo (additional 12 
weeks) if abstinent at 12 
weeks [23.2%] 
2. MS + Varenicline + 
Varenicline (additional 12 
weeks) if abstinent at 12 
weeks [27.4%] 
Intervention 
cost, SRDMC; 
 
Single quit 
attempt at the 
start of the 
model 
Bolin 2009a Sweden, UK, 
France, Belgium; 
Healthcare Payer; 
Lifetime; 
12 month continuous 
cessation rate; 
1. NRT patch [20.3%] 
2. Varenicline [26.1%] 
Intervention 
cost, SRDMC; 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Pfizer; 
CUA 
General 
population of 
adult smokers 
Cost/QALY gained; 
Considered but not 
reported in the text 
 
Single quit 
attempt for 25% 
of smokers at 
the start of the 
model.   
Cornuz 2003 Switzerland; 
Swiss Federal 
Office for Public 
Health; 
CEA 
Healthcare Payer; 
Lifetime; 
Dependent adult 
smokers (average 
20 cigarettes per 
day) 
12 month cessation 
rate (ORs); 
Cost/LY saved; 
35% over time 
horizon 
 
1. GP BC [OR*:1.73] 
2. GP BC + NRT gum 
[OR**:1.63] 
3. GP BC + NRT patch 
[OR**:1.79] 
4. GP BC + NRT spray 
[OR**:2.35] 
5. GP BC + NRT inhaler 
[OR**:2.14] 
6. GP BC + Bupropion 
[OR**:2.30] 
 
Intervention 
cost; 
 
25% of current 
smokers are in 
the preparation 
stage for 
quitting; 
No reported 
assumption 
about number of 
quit attempts 
Cornuz 2006 Switzerland, 
Canada, France, 
Spain, USA, UK; 
Healthcare Payer; 
Lifetime; 
Dependent adult 
12 month point 
prevalence cessation 
rate (ORs); 
1. GP BC [OR*:1.73] 
2. GP BC + NRT gum 
[OR**:1.66] 
Intervention 
cost; 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Not clear; 
CEA 
smokers (average 
20 cigarettes per 
day) 
Cost/LY gained; 
35% over time 
horizon 
 
3. GP BC + NRT patch 
[OR**:1.80] 
4. GP BC + NRT spray 
[OR**:2.35] 
5. GP BC + NRT inhaler 
[OR**:2.14] 
6. GP BC + Bupropion 
[OR**:2.51] 
 
25% of current 
smokers are in 
the preparation 
stage for 
quitting;              
No reported 
assumption 
about number of 
quit attempts 
Cromwell 1997 USA; 
US Department 
of Health and 
Human Services 
(HHS); 
CUA 
Healthcare Payer; 
Not explicitly 
reported; 
General 
population of 
adult smokers 
5 months minimum 
cessation rate; 
Cost/QALY saved; 
45% over time 
horizon 
1. Self quit [5%] 
2. BA [5.9%] 
3. BA + NRT patch [11.7%] 
4. BA + NRT gum [8.7%] 
5. Brief BC [6.9%] 
6. Brief BC + NRT patch 
[13.4%] 
7. Brief BC + NRT gum 
[10.0%] 
8. BC [11.2%] 
9. BC +NRT patch [21.0%] 
10. BC + NRT gum [15.9] 
Intervention 
cost (includes 
cost of 
motivating 
unwilling 
smokers to 
quit); 
 
Single quit 
attempt for 75% 
of smokers at 
the start of the 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
11. Intense BC [11.6%] 
12. Intense BC + NRT patch 
[21.6%] 
13. Intense BC + NRT gum 
[16.5%]  
model 
Feenstra 2005 The 
Netherlands; 
Dutch Public-
Private 
Partnership to 
reduce tobacco 
dependence; 
CUA 
Healthcare Payer; 
Lifetime; 
Smokers aged 10 
years and older 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
Considered, but 
values not fully 
reported in text 
 
1. Willpower (with access to 
the interventions below, 
using uptake rates) [3.4%] 
2. GP BA [7.9%] 
3. GP BA + NRT [12.7%] 
4. BC + NRT [15.1%] 
5. BC + Bupropion [17.2%] 
6. TC [7.6%] 
Intervention 
cost; 
 
Interventions for 
25% of smokers 
each year 
Fiscella 1996 USA; 
Not clear; 
CUA 
Healthcare Payer; 
Not explicitly 
reported; 
Adult smokers 
receiving primary 
care 
 
12 month cessation 
rate, biochemically 
validated; 
Cost/QALY saved; 
35% over time 
horizon 
1. Self quit [2.5%] 
2. GP BC [4.0%] 
3. GP BC + NRT patch 
[7.9%] 
Intervention 
cost; 
Single 
intervention at 
the start of the 
model 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Flack 2007 UK; 
NICE Rapid 
Reviews; 
CUA 
Healthcare Payer; 
Lifetime; 
General 
population of 
smokers aged 16 
years and older 
12 month cessation 
rates; 
Cost/QALY gained; 
35% over time 
horizon 
1. Self quit [2.0%] 
2. GP BA [3.0%] 
3. GP BA + SHM [4.0%] 
4. BA + SHM + NRT [6.0%] 
5. BA + SHM + NRT + 
Specialist Clinic [15.0%] 
6. Brief BC + Bupropion 
[24.0%] 
7. BC + Bupropion [31.0%] 
8. NRT patch [12.0%] 
9. GC + NRT patch [21.0%] 
10. BC + NRT patch [16.0%] 
11. Pharmacist Consultation 
+ NRT patch [24.0%] 
12. BC + Pharmacist 
Consultation + NRT patch 
[35.0%] 
Intervention 
cost, SRDMC; 
Single quit 
attempt at the 
start of the 
model; 
underlying quit 
rate 
Gilbert 2004 The Seychelles; 
Not clear; 
CEA 
Healthcare Payer; 
Lifetime; 
General 
population of 
12 month continuous 
cessation rate (ORs); 
Cost/LY gained; 
35% over time 
1. BC [OR*:1.73] 
2. BC + NRT gum (3 months) 
[OR**:1.66] 
3. BC + NRT patch (3 
Intervention 
cost; 
 
25% of current 
  
  
 
2
8
0 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
adult smokers horizon months) [OR**:1.80] 
4. BC + NRT spray (3 
months) [OR**:2.35] 
5. BC + NRT inhaler (3 
months) [OR**:2.14] 
6. BC + Bupropion (3 
months) [OR**:2.51] 
 
smokers 
prepared to 
make a quit 
attempt; 
No reported 
assumption 
about number of 
quit attempts 
 
Godfrey 2005 UK; 
 DoH Policy 
Research 
Programme; 
CEA 
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
4 week cessation 
rate, biochemically 
confirmed; 
Cost/LY gained; 
65% from 4 weeks to 
52 weeks, 54% from 
52 weeks to 8 years 
1. Background cessation 
[2.0%] 
2. Specialist smoking 
cessation services 
[13.56%] 
Intervention 
cost (including 
overhead cost), 
SRDMC; 
 
Background quit 
rate 2% 
Halpern 2000* USA; 
Glaxo Wellcome; 
CBA 
Healthcare Payer, 
Insurers, 
Employers; 
Lifetime; 
General 
12 month cessation 
rate; 
Benefit-to-cost ratio; 
Considered, but 
values not reported in 
1. Bupropion  
2. Bupropion + BA  
3. Bupropion + BC 
4. Bupropion + NRT patch 
5. Bupropion + BA + NRT 
Intervention 
cost, cost of a 
smoking 
employee 
(including 
   
 
2
8
1 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
population 
 
text patch 
6. Bupropion + BC + NRT 
patch 
7. NRT patch 
8. NRT patch + BA 
9. NRT patch + BC 
10. BA 
11. BC 
12. Self Quit 
productivity 
cost and 
SRDMC); 
 
34% of smokers 
attempt to quit 
each year 
Halpern 2007 USA; 
Pfizer; 
CEA/CBA 
Healthcare Payer; 
Employers; 
10 years; 
General 
population 
12 month continuous 
cessation rate; 
Cost per additional 
quitter;                                                     
14% 1 to <2 years, 10.3% 
2 to <3 years, 3.4% 3 to <4 
years; 3.0% 4 to <5 years; 
1.5% 5 to <11 years; 0% 
11 years onwards 
1. Self Quit [3.2%]                                     
2. BC + NRT patch [9.8%]                                    
3. BC + Bupropion [15.5%]                    
4. BC + Varenicline 
[22.5%] 
Intervention 
cost, Future 
general medical 
costs; 
 
43% of smokers 
attempt to quit 
each year, but 
the intervention 
was only 
available in the 
first year 
  
  
 
2
8
2 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Heitjan 2008 USA; 
National Cancer 
Institute and  
National 
Institute on Drug 
Abuse; 
GlaxoSmithKline; 
CEA 
Healthcare Payer; 
Lifetime; 
General 
population of 
adult smokers 
6 month minimum 
continuous cessation 
rate; 
Cost/LY gained; 
50% across time 
horizon for 
temporary quitters 
(temporary quitters 
comprise 40% of 
total quitters) 
1. Self Quit [5.0% at 12 
months] 
2. BC + NRT patch [23.0% at 
6 months] 
3. BC + Bupropion [17.0% at 
6 months] 
4. Varenicline [35% at 12 
months] 
5. Test for genotype; assign 
either to Bupropion [27.0% 
at 6 months] or NRT patch 
[19.0% at 6 months] 
Intervention 
cost; 
 
50% attempt to 
quit each year 
 
 
 
 
 
Hind 2009 UK; 
NIHR HTA 
Programme; 
CUA 
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
6.3% annually years 
1 to <6, 2% annually 
years 6 to <10, 1% 
annually years 10 
onwards 
1. Placebo [9.4%] 
2. NRT [14.9%] 
3. Bupropion [15.5%] 
4. Varenicline [22.5%] 
Intervention 
cost, SRDMC; 
 
Single quit 
attempt at the 
start of the 
model 
Hoogendoorn The Healthcare Payer; 12 month cessation 1. Self Quit [5.0%] Intervention 
   
 
2
8
3 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
2008 Netherlands; 
Pfizer; 
CUA 
Lifetime; 
General 
population of 
adult smokers 
rate; 
Cost/QALY gained; 
6.8% years 1 to <6,  
0% years 6  onwards 
 
2. NRT (type weighted by 
use) [14.8%] 
3. Nortriptyline [17.0%] 
4. Varenicline [22.4%] 
cost, SRDMC; 
 
Single quit 
attempt for 25% 
of smokers at 
the start of the 
model 
 
Howard 2008 USA; 
Pfizer; 
CUA 
Healthcare Payer; 
Lifetime; 
General 
population of 
adult smokers 
12 month cessation 
rate, biochemically 
confirmed;  
Cost/QALY gained; 
6.3% annually years 
1 to <6,  2% annually 
years 6 to <11,  1% 
annually years 10 
onwards 
1. Self Quit [5%] 
2. NRT (type weighted by 
use) [15.4%] 
3. Bupropion (12 weeks) 
[15.4%] 
4. Varenicline [22.4%] 
Intervention 
cost, SRDMC; 
 
Single quit 
attempt for 25% 
of smokers at 
the start of the 
model 
Igarashi 2009 Japan; 
Pfizer; 
CUA 
Healthcare Payer; 
Lifetime; 
General 
population of 
12 month continuous 
cessation rate, 
biochemically 
confirmed; 
1. BC + Placebo [men 25.5%; 
women 16.1%] 
2. BC + Varenicline [men 
37.9%; women 22.2%] 
Intervention 
cost, 
administration 
cost; 
  
  
 
2
8
4 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
smokers that 
started smoking 
at age 20 years 
Cost/QALY gained; 
Not considered 
 
Single 
intervention at 
the start of the 
model 
Javitz 2004 USA; 
National Cancer 
Institute; 
CBA 
Employer; 
5 years; 
Adult smokers 
with a desire to 
quit 
Self-reported 7 day 
point prevalence 
cessation rate at 12 
months; 
Net monetary 
benefit; 
Not considered 
1. Proactive TC + Bupropion 
[20.4%] 
2. SHM + Bupropion [12.6%] 
3. Proactive TC + High Dose 
Bupropion [22.2%] 
4. SHM + High Dose 
Bupropion [14.7%] 
Intervention 
cost; 
 
Employees 
entered the 
program on a 
continuing basis 
Javitz 2004a USA; 
National Cancer 
Institute; 
CUA 
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
Self-reported 7 day 
point prevalence 
cessation rate at 12 
months; 
Cost/QALY saved; 
37% over time period 
1. Proactive TC + Bupropion 
[20.4%] 
2. SHM + Bupropion [12.6%] 
3. Proactive TC + High Dose 
Bupropion [22.2%] 
4. SHM + High Dose 
Bupropion [14.7%] 
Intervention 
cost; 
 
Single 
intervention in 
first year of the 
model 
Kaper 2006 The Societal; 7 day point 1. Reimbursement for Intervention 
   
 
2
8
5 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Netherlands; 
STIVORO (Dutch 
smoking 
cessation 
foundation) and 
the Dutch 
Asthma 
Foundation; 
CUA 
Lifetime; 
General 
population of 
adult smokers 
prevalence 
abstinence at 12 
months, 
biochemically 
confirmed; 
Cost/QALY gained; 
25% lifetime relapse  
NRT, bupropion and BC for 
6 months [5.5%] 
2. No reimbursement [2.8%] 
cost (including 
overhead cost), 
travel costs, 
productivity 
losses; 
 
No reported 
assumption 
about number of 
quit attempts 
Knight 2010 USA; 
Pfizer; 
CUA 
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
0% 
1. Self Quit [5.0%] 
2. Placebo [9.3%] 
3. NRT [15.4%] 
4. Bupropion [15.9%] 
5. Varenicline [22.9%] 
6. Varenicline + second 
course or Varenicline if 
abstinent at 12 weeks 
[27.7%] 
Intervention 
cost, SRDMC; 
 
Single quit 
attempt at the 
start of the 
model 
Levy 2002 USA; 
US HHS; Robert 
Insurer; 
1 year; 
12 month cessation 
rate; 
1. No coverage [4.5%] 
2. Prescription NRT + 
Intervention 
cost; 
  
  
 
2
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6 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Johnson Wood 
Foundation; 
CEA 
General 
population of 
adult smokers 
Cost/quitter; 
N/A 
Bupropion [10.7%**] 
3. Prescription NRT + 
Bupropion + OTC NRT 
[16.9%**] 
4. BC [5.9%**] 
5. BC + Prescription NRT + 
Bupropion [17.9%**] 
6. BC, Prescription NRT, 
Bupropion, OTC NRT, alone 
or in conjunction [28.6%**] 
 
 
No more than 2 
quit attempts in 
a year;                                             
45% of smokers 
attempt to quit  
Levy 2006 USA; 
National 
Institutes of 
Health; 
CBA 
Employer; 
Insurer; 
20 years; 
General 
population 
 
Cessation rate 
(length of abstinence 
or from intervention 
unclear); 
Benefit-to-cost ratio; 
20% annually years 0 
to <2 after quitting,  
2% annually years 2 
to <5 after quitting,  
1% annually years 5 
1. No smoking cessation 
coverage program [4.3%] 
2. Smoking cessation 
coverage program [5.9-
28.6% **] 
Intervention 
cost, Future 
general medical 
expenditure; 
 
Every year there 
was a chance 
current smokers 
would quit 
   
 
2
8
7 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
after quitting 
onwards 
Linden 2010 Finland; 
Pfizer; 
CUA 
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month continuous 
cessation rate, 
biochemically 
confirmed; 
Cost/QALY gained; 
6% annually years 1 
to <6, 2% annually 
years 6 to <10, 1% 
annually years 10 
onwards 
 
1. Self quit [5.0%] 
2. Bupropion [15.7%] 
3. Varenicline [22.5%] 
Intervention 
cost, SRDMC; 
 
Single quit 
attempt at the 
start of the 
model 
McGhan 1996 USA; 
Lederle 
Laboratories; 
CBA 
Employer; 
1 year; 
Smoking 
employees 
6 month minimum 
cessation rate; 
Net monetary 
benefit; 
N/A 
1. Self Quit + SHM [15.0%] 
2. Intense BC [26.0%] 
3. Brief BC + NRT patch 
[15.0%] 
4. Intense BC + NRT patch 
[20.0%] 
5. Group BC + NRT patch 
[26.0%] 
Intervention 
cost, cost of a 
smoking 
employee 
(including 
productivity 
cost), Future 
general medical 
  
  
 
2
8
8 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
6. Pharmacist Consultation + 
NRT patch [31.0%] 
7. Pharmacist Consultation 
+ Intense BC + NRT patch 
[44.0%] 
costs; 
 
Single 
intervention at 
the start of the 
model  
Nielsen 2000 USA; 
Glaxo Wellcome; 
CBA 
Employer;  
1 year; 
Population of 
adult smokers 
(socio-
demographic and 
mean smoking 
rate figures 
reported) 
12 month point 
prevalence cessation 
rate, biochemically 
confirmed; 
Net monetary 
benefit; 
Not considered 
1. Placebo [15.6%] 
2. Bupropion [30.3%] 
3. NRT patch [16.4%] 
4. NRT patch + Bupropion 
[35.5%] 
Intervention 
cost, cost of a 
smoking 
employee 
(including 
productivity 
cost); 
 
Single 
intervention at 
the start of the 
time horizon 
Ong 2005 USA; 
National Cancer 
Institute; Health 
Healthcare Payer; 
Lifetime; 
Dependent adult 
6 month continuous 
cessation rate; 
Cost/QALY gained; 
1. Self Quit [10.6%] 
2. OTC NRT gum or patch 
[7.5%**] 
Intervention 
cost; 
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8
9 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Resources and 
Services 
Administration; 
CUA 
smokers (>14 
cigarettes per 
day) 
35% over time 
horizon 
64% of smokers 
ready for 
attempt to quit ;  
No more than 2 
quit attempts in 
the first year 
and all failed 
quitters would 
try NRT again;    
No clearly 
reported 
assumption 
about number of 
quit attempts in 
the long run                                             
 
Orme 2001 UK; 
Glaxo Wellcome; 
CEA  
Healthcare Payer; 
20 years; 
General 
population of 
adult smokers 
Cessation rate 
(length of abstinence 
or from intervention 
unclear); 
Cost/LY gained; 
1. Willpower [1.0%] 
2. GP BA [3.0%] 
3. Group Therapy [9.0%] 
4. NRT or Bupropion 
[13.0%] 
Intervention 
cost, SRDMC; 
 
Interventions 
only available in 
  
  
 
2
9
0 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
6.9% annually at 1 
year, falling by 1% 
increments to 0% 
(timing or increments 
not reported) 
first year of the 
model 
 
Oster 1986 USA; 
Merrel Dow 
Pharmaceuticals; 
National 
Institutes of 
Health; 
CEA 
Healthcare Payer; 
Lifetime; 
Adult smokers 
receiving primary 
care 
12 month cessation 
rate; 
Cost/LY gained; 
0% 
1. GP BA [4.5%] 
2. GP BA + NRT gum [6.1%] 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
model 
Parrott 1998 UK; 
UK Health 
Education 
Authority; 
CEA 
Healthcare Payer, 
Societal; 
43 years; 
General 
population 
6 month minimum 
cessation rate; 
Cost/LY gained; 
Not considered 
1. Self Quit [1.0%] 
2. BA + Willpower [3.0%] 
3. BA + SHM [4.0%] 
4. BA + NRT [6.0%] 
5. Smokers’ clinic + NRT 
[20%] 
Intervention 
cost (including 
training cost); 
 
40% of those 
advised to cease 
made a quit 
attempt each 
year 
   
 
2
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1 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Shanahan 2003 Australia; 
Not clear; 
CEA 
Healthcare Payer; 
1 year; 
General 
population of 
adult smokers 
12 month cessation 
rate; 
Narrative 
comparison of 
relative costs and 
effectiveness; 
N/A 
1. OTC NRT patch [Not 
reported] 
2. GP BC + NRT patch [14.0-
21.0%] 
3. GP BA + Bupropion [21.0-
35.0%] 
Intervention 
cost; 
 
No clearly 
reported 
assumption 
about number of 
quit attempts 
 
Shearer 2006 Australia; 
Australian 
Government 
Department of 
Health and 
Ageing; 
CEA 
Healthcare Payer; 
6 months; 
General 
population of 
adult smokers 
6 month continuous 
cessation rate; 
Cost/additional 
quitter; 
N/A 
1. BA + SHM [6.0%] 
2. TC + SHM [9.0%] 
3. TC + SHM + NRT patch 
[17.0%] 
4. Proactive TC + SHM + NRT 
patch [27.0%] 
5. TC + SHM + Bupropion 
[19.0%] 
6. Proactive TC + SHM + 
Bupropion [32.0%] 
7. TC + SHM + NRT patch + 
Bupropion [19.0%] 
Intervention 
cost; 
 
No clearly 
reported 
assumption 
about number of 
quit attempts 
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2 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Song 2002 UK;                                                                  
Not clear, but 
based on study 
funded by NHS 
R&D HTA 
Programme; 
CUA 
Healthcare Payer;
Lifetime; 
General 
population of 
adult smokers 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
40% over time 
horizon 
1. BC [10.0%] or BA [4.0%] 
2. BC or BA + NRT [OR: 1.67] 
3. BC or BA + Bupropion 
[OR: 2.1] 
4. BC or BA + NRT + 
Bupropion [OR: 2.8] 
 
(ORs all versus placebo) 
Intervention 
cost; 
 
Single quit 
attempt at the 
start of the 
model; 
underlying quit 
rate 
Stapleton 1999 UK; 
MRC; Pharmacia 
and Upjohn; 
CEA 
Healthcare Payer; 
Not explicitly 
reported; 
Dependent adult 
smokers (>13 
cigarettes per 
day) with a desire 
to quit 
12 month cessation 
rate, biochemically 
confirmed;  
Cost/LY saved; 
40% over time 
horizon 
1. GP BA [4.5%] 
2 GP BA + NRT patch 
[9.6%] 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
model 
Thavorn 2008 Thailand; 
Thailand 
Research Fund & 
Thai Pharmacy 
Healthcare Payer; 
Lifetime; 
Adult smokers 
that regularly 
12 month continuous 
cessation rate; 
Cost/LY gained; 
Not considered 
1. Dependence and 
motivation discussion, BA, 
provision of therapy [2.7%] 
2. Community cessation 
Intervention 
cost, SRDMC; 
 
Single 
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3 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Network for 
Tobacco Control 
CEA 
smoke 10 to 20 
cigarettes per day 
program with Dependence 
and motivation discussion, 
BA, provision of 
appropriate therapy with 
SHM, follow up care 
[14.3%] 
intervention 
over the time 
horizon 
 
Tran 2010 Canada; 
Health Canada 
and the 
governments of 
Alberta, British 
Columbia, 
Manitoba, New 
Brunswick, 
Newfoundland 
and 
Labrador, 
Northwest 
Territories, Nova 
Scotia, Nunavut, 
Prince Edward 
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month continuous 
cessation rate, 
biochemically 
confirmed; 
Cost/QALY gained; 
8.7% annually years 
1 to <6, 3.8% 
annually years 6 to 
<8, 2.1% annually 
years 8 to <11, 0.5% 
annually year 11 
onwards 
1. Self Quit [3.4%] 
2. NRT patch [5.9%] 
3. NRT gum [5.6%] 
4. NRT inhaler [7.3%] 
5. NRT lozenge [7.5%] 
6. Bupropion [6.4%] 
7. Varenicline [8.8%] 
Intervention 
cost, SRDMC; 
 
Single 
intervention at 
the start of the 
model 
 
 
  
  
 
2
9
4 
Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
Island, 
Saskatchewan, 
and Yukon; 
CUA 
Vemer 2010 The Netherlands, 
Germany, 
Sweden, UK, 
Belgium, France; 
Pfizer; 
CUA 
Healthcare Payer; 
Lifetime; 
General 
population of 
adult smokers 
12 month continuous 
cessation rate; 
Cost/QALY gained; 
Considered but not 
reported 
1. Self Quit [5.0%] 
2. BC + NRT [14.8%] 
3. BC + Bupropion [17.0%] 
4. BC + Varenicline 
[22.4%] 
Intervention 
cost, SRDMC 
 
Single quit 
attempt for 25% 
of smokers at 
the start of the 
model 
Wang 2008 UK; 
NHS R&D HTA 
Programme; 
CUA 
Healthcare Payer;  
Lifetime; 
Current UK 
smokers 
(targeting those 
unwilling or 
unable to make an 
abrupt attempt to 
quit) 
12 month minimum 
continuous cessation 
rate; 
Cost/QALY gained; 
30% over time 
horizon 
1. CDTQ: NRT OTC [2.2%] 
2. CDTQ: NRT prescription 
[2.0%] 
3. CDTQ: NRT prescription + 
BC or GBC [5.3%] 
4. NRT OTC [6.6%] 
5. NRT prescription [5.9%] 
6. NRT prescription + BC or 
GBC [16.0%] 
Intervention 
cost; 
 
Single quit 
attempt 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
 7. Self Quit [4.0%] 
Warner 2004 USA; 
Robert Wood 
Johnson 
Foundation; 
CEA/CBA 
Insurer; Societal; 
30 years; Lifetime 
General 
population  
Lifetime cessation 
rate; 
Cost/LY gained; Net 
monetary benefit; 
Not considered 
1. Self Quit; 
2. Smoking cessation 
services [15%****] 
Intervention 
cost, Future 
general medical 
expenditure, 
Membership 
premium (CBA 
only); 
 
Each year the 
model gives a 
smoker a chance 
of quitting 
 
Wasley 1997 USA; 
Merrel Dow 
Pharmaceuticals; 
CEA 
Healthcare Payer; 
Not explicitly 
reported; 
Heavy adult 
smokers (>19 
cigarettes per 
day) receiving 
12 month cessation 
rate; 
Cost/LY gained; 
35% over time 
horizon 
1. GP BA [4.5%] 
2. GP BA + NRT patch 
[17.6%] 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
model 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
primary care 
Welton 2008 UK; 
Medical Research 
Council; 
CUA  
Healthcare Payer; 
Lifetime; 
Adult smokers 
with a desire to 
quit 
12 month cessation 
rate; 
Cost/QALY gained 
(Incremental Net 
Benefit); 
Beta distribution 
(38,57) 
1. BA [5.1%] 
2. NRT [19%] 
3. Bupropion [21%] 
4. NRT + Bupropion [27%] 
5. BA for CC genotype  
[5.1%], NRT for CT and TT 
genotypes [21%] 
6. BA for CC genotype 
[5.1%], Bupropion for CT 
and TT genotypes [17%] 
7. NRT for CC genotype 
[18%] or BA for CT and TT 
genotypes [5.1%] 
8. NRT for CC genotype 
[18%] or Bupropion for CT 
and TT genotypes [17%]  
9. Bupropion for CC 
genotype [24%] or BA for CT 
and TT genotypes [5.1%]  
10. Bupropion for CC 
Intervention 
cost; 
 
No clearly 
reported 
assumption 
about number of 
quit attempts 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
genotype [24%] or NRT for 
CT and TT genotypes [21%] 
Woolacott 2002 UK; 
NHS R&D HTA 
Programme; 
CUA 
Healthcare Payer; 
Lifetime; 
General 
population of 
smokers 
12 month continuous 
cessation rate; 
Cost/QALY saved; 
40% over time 
horizon 
1. MS or BC [4.0%]; 
2. NRT + MS [6.5%]; 
3. Bupropion + MS [8.1%]; 
4. Bupropion + NRT + MS 
[9.9%] 
Intervention 
cost;  
 
30% of smokers 
attempt to quit 
and can only use 
one 
intervention; 
Background quit 
rate 1% 
Primary 
Studies 
     
An 2006 USA; 
Not clear; 
CEA 
Healthcare Payer; 
6 months; 
Adult smokers 
(consuming >4 
cigarettes per 
day) with a desire 
Self-reported 30 day 
point prevalence 
cessation rate at 6 
months; 
Cost/quit; 
N/A 
1. Cessation service without 
pharmacology [10.0%] 
2. Cessation service + NRT 
patch or gum [18.2%] 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
to quit time horizon 
Boyd 2009 UK; 
Glasgow Centre 
for Population 
Health, NHS 
Greater Glasgow 
and Clyde and 
NHS Health 
Scotland; 
CEA 
Healthcare Payer; 
4 weeks; 
Smokers aged 16 
years and over 
with a desire to 
quit 
4 week cessation 
rate, biochemically 
confirmed; 
Cost/additional 
quitter; 
N/A 
1. Self Quit (10.0%) 
2. Pharmacy support + NRT 
[17.0%] 
3. GC + NRT + pharmacy 
follow up [31.0%] 
Intervention 
cost (including 
overhead 
costs); 
 
Single 
intervention at 
the start of the 
time horizon 
Hall 2005 USA; 
US HHS; 
CEA 
Healthcare Payer; 
12 months; 
Adult smokers 
with a desire to 
quit and 
willingness to 
participate in a 
clinical trial 
12 month cessation 
rates, biochemically 
confirmed; 
Average cost/12 
month cessation 
rate; 
N/A 
1. BA + SHM [13%] 
2. BA + SHM + Nortriptyline 
[23%] 
3. BA + SHM + Bupropion 
[29%] 
4. BA + SHM + GC [21%] 
Intervention 
cost (including 
overhead 
costs); 
 
Single 
intervention at 
the start of the 
time horizon 
Halpin 2006 USA; Insurers; Self-reported 7 day 1. Bupropion (12 weeks) or Intervention 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
California 
Tobacco-Related 
Disease Program; 
CEA 
8 months; 
Insured adult 
smokers (at least 
1 cigarette in last 
7 days) willing to 
participate in a 
clinical trial 
point prevalence 
cessation rate at 8 
months; 
Costs and cessation 
rates reported 
separately; 
N/A 
NRT (patch, inhaler, or nasal 
spray) [19%] 
2. Proactive TC + Bupropion 
(12 weeks) or NRT (patch, 
inhaler, or nasal spray) 
[13%] 
3. Proactive TC + Bupropion 
(12 weeks) or NRT (patch, 
inhaler, or nasal spray) if 
participant enrolled in the 
TC [18%] 
cost; 
 
Single 
intervention at 
the start of the 
time horizon 
Hollis 2007 USA;  
National Cancer 
Institute; 
GlaxoSmithKline; 
CEA 
Healthcare Payer; 
1 year; 
Adult smokers 
(consuming >4 
cigarettes per 
day) with a desire 
to quit 
30 day point 
prevalence cessation 
rate at 12 months; 
Cost/Quit; 
N/A 
1. Brief TC [11.7%] 
2. TC [13.8%] 
3. Intense TC [14.3%] 
4. Brief TC + NRT patch 
[17.1%] 
5. TC + NRT patch [20.1%] 
6. Intense TC + NRT patch 
[21.2%] 
Intervention 
cost (including 
training cost); 
 
Single 
intervention at 
the start of the 
time horizon 
Jackson 2007 USA; 
Pfizer; 
Employer; 
1 year; 
12 month continuous 
cessation rates, 
1. Brief BC + Placebo [8.4%] 
2. Brief BC + Bupropion (12 
Intervention 
cost, cost of a 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
CBA Smoking 
employees 
biochemically 
confirmed; 
Net monetary 
benefit; 
N/A 
weeks) [16.1%] 
3. Brief BC + Varenicline 
[21.9%] 
smoking 
employee; 
 
Single 
intervention at 
the start of the 
time horizon 
McAfee 2008 USA; 
Oregon 
Department of 
Human Services; 
CEA 
Healthcare Payer; 
6 months; 
Adult smokers 
(consuming >4 
cigarettes per 
day) with a desire 
to quit 
Self-reported 30 day 
point prevalence 
cessation rate at 6 
months; 
Cost/additional 
quitter; 
N/A 
1. TC + NRT patch (2 weeks) 
[10.4%] 
2. TC + NRT patch (8 
weeks) [15.8%] 
Intervention 
cost (including 
overhead 
costs); 
 
Single 
intervention at 
the start of the 
time horizon 
Salize 2009 Germany; 
German Federal 
Ministry for 
Education and 
Research; 
Health Insurer; 
1 year; 
Adult smokers 
receiving primary 
care 
12 month cessation 
rate, biochemically 
confirmed; 
Cost/additional 
percentage point 
1. No intervention [2.7%] 
2. GP training and incentives 
[3.5%] 
3. GP training + NRT or 
Bupropion [12.1%] 
Intervention 
cost (including 
overhead 
costs); 
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Study  
1st Author and Year; 
Study Quality 
Country; 
Sponsorship;  
Study Design 
Study 
perspective;  
Time Horizon; 
Study population 
Effectiveness 
measure;                         
Main outcome 
measure; 
Relapse Rate 
Alternatives [Effectiveness 
Rates]  
Optimal Alternative 
Highlighted  
Resources; 
 
Key 
Assumptions 
 
CEA abstinent 
participants; 
N/A 
4. GP training and incentives 
+ NRT or Bupropion [14.6%] 
Single 
intervention at 
the start of the 
time horizon 
 
Key 
BC = Behavioural counselling 
TC= Telephone Counselling 
GC= Group Counselling 
MS= Motivational Support 
BA= Brief Advice 
SHM= Self Help Material 
CDTQ= Cut Down to Quit 
SRDMC= Smoking-related disease medical costs 
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OTC = Over the Counter 
OR= Odds Ratio versus placebo 
OR*= Odds Ratio versus no intervention 
OR**= Odds Ratio versus BC 
 
Usual courses: NRT 12 weeks (If Nasal Spray, longer), Bupropion 7-10 weeks, Varenicline 12 weeks 
 
* Nonsensical cessation rates reported 
** Increase in quit rate in relation to comparator 
**** Percentage of the study population ceasing smoking because of the intervention 
 
Table 34: Quality Appraisal of Modelling Studies, Chapter 3 
Study  
1st Author and Year 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 
Akehurst 1994 Y Y Y Y N N N/A Y N N N N N Y Y 
Akehurst 1994a Y Y Y Y Y Y N/A Y Y N Y N N Y Y 
Annemans 2009 Y Y Y Y Y N Y Y Y Y Y N N N Y 
Bae 2009 Y N Y Y N N Y Y Y Y Y N N Y Y 
Bauld 2011 Y Y Y Y Y N Y N Y N Y N Y Y Y 
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Study  
1st Author and Year 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 
Bertram 2007 Y Y Y Y Y Y Y N Y Y N N N N Y 
Bolin 2006 Y N Y Y Y N Y N Y Y Y Y Y N Y 
Bolin 2008 Y N Y Y Y N Y Y Y Y Y Y Y N Y 
Bolin 2009 Y Y Y Y Y N Y Y Y Y Y Y Y N Y 
Bolin 2009a Y N Y Y Y N Y Y Y Y Y N N N Y 
Cornuz 2003 Y Y Y Y N N N/A N Y N Y N N N Y 
Cornuz 2006 Y Y Y Y N N N/A N Y N Y N N N Y 
Cromwell 1997 Y Y Y N N N Y Y Y N Y N N N Y 
Feenstra 2005 Y Y N/A Y Y N Y N Y N Y N N Y Y 
Fiscella 1996 Y Y Y Y N N Y Y Y Y Y N Y N Y 
Flack 2007 Y Y Y Y Y Y Y Y Y N N N N Y Y 
Gilbert 2004 Y Y Y Y N N N/A N Y N Y N Y N Y 
Godfrey 2005 Y Y Y Y N N N/A Y Y N Y N N N Y 
Halpern 2000 Y Y Y Y Y N N/A Y N N N N N Y Y 
Halpern 2007 Y N Y Y Y N N/A Y N N Y N N N Y 
Heitjan 2008 Y Y N/A Y Y N N/A Y Y N Y N N Y Y 
Hind 2009 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Hoogendoorn 2008 Y Y Y Y Y N Y Y Y Y Y N N N Y 
Howard 2008 Y Y Y Y Y N Y Y Y Y Y N N Y Y 
Igarashi 2009 Y Y Y Y Y N Y Y Y Y Y N Y Y Y 
Javitz 2004 Y Y Y N N N N/A N Y N Y N N Y Y 
Javitz 2004a Y Y N N N N N N Y N Y N N N Y 
Kaper 2006 Y Y Y N N N Y Y Y Y N N N N Y 
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Study  
1st Author and Year 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 
Knight 2010 Y N N/A Y  Y N Y Y Y Y N N N Y Y 
Levy 2002 Y N Y Y Y N N/A N Y N N Y N N Y 
Levy 2006 Y N Y Y Y N N/A Y Y N Y N Y N Y 
Linden 2010 Y Y N Y Y N Y Y Y Y Y N N Y Y 
McGhan 1996 Y Y Y Y Y N N/A N Y N N N N Y Y 
Nielsen 2000 Y Y Y Y Y N N/A Y Y N N N N N Y 
Ong 2005 Y Y Y N N N Y Y Y Y N N Y Y Y 
Orme 2001 Y N Y Y Y N N/A Y Y N Y N N Y Y 
Oster 1986 Y Y Y N N Y N/A Y Y N Y N N N Y 
Plans-Rubio 1998 Y Y N N N N N/A N Y N Y N N N Y 
Parrott 1998 Y Y Y Y Y Y N/A Y N N Y N N Y Y 
Shanahan 2003 Y Y Y N N N N/A N N N N N N Y Y 
Shearer 2006 Y Y Y N N Y N/A Y Y N N N N N Y 
Song 2002 Y Y Y N Y Y Y N Y N N N N N Y 
Stapleton 1999 Y Y Y N N N N/A Y Y N Y N N N Y 
Thavorn 2008 Y Y Y Y Y N N/A Y Y Y Y N N N Y 
Tran 2010 Y Y Y Y Y Y Y Y Y Y Y N Y Y Y 
Vemer 2010 Y N Y Y Y N Y Y Y N Y N N N Y 
Wang 2008 Y Y Y Y Y Y Y N Y N N N Y N Y 
Warner 2004 Y N Y Y Y N N/A Y Y N Y N N N Y 
Wasley 1997 Y Y Y N N N N/A Y Y N Y N Y N Y 
Welton 2008 Y N N/A N N N Y Y Y Y N Y N N Y 
Woolacott 2002 Y Y Y N Y Y Y N Y N N N N Y Y 
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Description of questions [15, 136]: 
Q1: Was a well-defined question posed in answerable form, in response to a clearly stated decision problem? 
Q2: Were the alternatives clearly and fully described (i.e. was treatment length reported?)? 
Q3: Were model inputs consistent with the study perspective and scope of the model? 
Q4: Was the model type stated? 
Q5: Was the model structure clearly described and were structural assumptions clear?  (If a model schematic was not reported was the 
model structure otherwise described?  Were health states in state-transition models reported?) 
Q6: Were data identification and selection methods appropriate (i.e. systematic)? 
Q7: Were the sources for utility weights referenced and appropriate? 
Q8: Was an incremental analysis of costs and consequences of alternatives performed? 
Q9: Was parameter uncertainty addressed? 
Q10: Were the methods used to assess parameter uncertainty appropriate (i.e. probabilistic)? 
Q11: Were methodological uncertainties assessed in the sensitivity analysis? 
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Q12: Were structural uncertainties assessed in the sensitivity analysis? 
Q13: Was heterogeneity addressed using sub-group analysis? 
Q14: Did the presentation and discussion of study results include all issues of concern to users (i.e. were total costs and outcomes 
reported?) 
Q15: Were conclusions valid, given the data presented? 
 
Table 35: Reasons for Final Stage Exclusions, Chapter 3 
Study First Author and Year Exclusion Reason 
Abdullah (2004)[469] Study Design  
Abdullah (2008)[470] Population  
Akers (2007)[471] Alternatives 
Apelberg (2010)[472] Study Design 
Barnett (2008)[473] Population 
Bolin (2007)[474] Study Design 
Brandon (2004)[475] Alternatives 
Buck (2000)[121] Alternatives 
Burns (2007)[476] Study Design 
Carpenter (1998)[477] Population 
Cheung (1997)[478] Study Design 
Chirikos (200)[479] Alternatives 
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Study First Author and Year Exclusion Reason 
Cohen (1998)[480] Other 
Coleman (2010)[481] Alternatives 
CRD Report (1998)[482] Study Design 
Crealey (1998)[122] Alternatives 
Croghan (1997)[123] Alternatives 
Croghan (1998)[483] Study Type  
Cummings (2006)[484] Study Design 
Cummings (1989)[125] Alternatives 
Curry (1998)[126] Alternatives 
Davis (1994)[485] Study Design 
Dey (1999)[486] Study Design 
DiFranza (2001)[487] Alternatives 
Ershoff (1990)[488] Population 
Fellows (2007)[489] Alternatives  
Fosnocht (1998)[490] Study Design 
Godfrey (2002)[491] Study Design 
Gomel (1998)[492] Alternatives 
Hawk (2006)[493] Study Design 
Hill (2006)[189] Other  
Hoogendoorn (2010) [494] Study Design 
Hudmon (1997)[495] Population 
Hueston (1994)[496] Population 
Jiminez (2003)[497] Other 
Johansson (2005)[498] Alternatives  
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Study First Author and Year Exclusion Reason 
Jones (1998)[499] Alternatives 
Kahende (2009)[500] Study Design  
Keating (2010)[501] Study Design  
Keating (2010b)[502] Study Design  
Keiding (2009)[503] Study Design 
Krumholz (1993)[129] Alternatives 
Lickteig (1993)[504] Study Design 
Meenan (1998)[505] Alternatives 
Miller (1996)[506] Population 
Pinget (2007)[507] Alternatives 
Plans (1995)[508] Other 
Pollack (2001)[509] Population 
QIS (2001)[510] Study Design  
Ranson (2002)[511] Alternatives 
Raw (2005)[512] Study Design 
Raw (1998)[513] Study Design 
Ronckers (2003) [514] Alternatives 
Ronckers (2005) [515] Study Design 
Ruger (2008)[516] Population 
Ruger (2008b)[517] Alternatives 
Saeterdal (2010)[518] Other  
SCTAHC (2002) [519] Other  
Secker-Walker (2005) [520] Alternatives 
Slatore (2009)[521] Alternatives 
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Study First Author and Year Exclusion Reason 
Solberg (2006)[522] Alternatives 
Stevermer (1996)[523] Study Design 
Tillgren (1993)[524] Alternatives  
Tomson (2004)[525] Alternatives  
Tran (2002)[526]  Population 
Tsevat (1992)[527] Study Design 
Warner (1997)[528] Study Design 
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11.3. Appendix C: Appendix to Chapter 4 
 
Figure 23: Search Strategy, Chapter 4 
Medline: Performed 28th February 2011; limited to studies published after 31st 
December 2008 
 1. Economics/ 
2. exp "Costs and Cost analysis"/ 
3. "Value of Life"/ 
4. Economics, Dental/ 
5. exp Economics, Hospital/ 
6. Economics, Medical/ 
7. Economics, Nursing/ 
8. Economics, Pharmaceutical/ 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab. 
11. (expenditure$ not energy).ti,ab. 
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12. (value adj1 money).ti,ab. 
13. budget$.ti,ab. 
14. 10 or 11 or 12 or 13 
15. 9 or 14 
16. letter.pt. 
17. editorial.pt. 
18. historical article.pt. 
19. 16 or 17 or 18 
20. 15 not 19 
21. Animals/ 
22. Humans/ 
23. 21 not (21 and 22) 
24. 20 not 23 
25. (metabolic adj cost).ti,ab. 
26. ((energy or oxygen) adj cost).ti,ab. 
27. 24 not (25 and 26) 
28. *Alcohol Drinking/ 
29. exp Alcohol-Related Disorders/ 
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30. *Temperance/ 
31. Alcohol Deterrents/ 
32. exp Self-Help Groups/ 
33. "alcohol drinking".mp. 
34. Alcoholism.mp. 
35. dipsomania.mp. 
36. "alcohol consumption".mp. 
37. (drink$ adj Excess$).tw. 
38. (drink$ adj binge).tw. 
39. (drink$ adj heavy).tw. 
40. (drink$ adj hazard$).tw. 
41. (drink$ adj problem$).tw. 
42. (drink$ adj abuse).tw. 
43. (drink$ adj dependen$).tw. 
44. (drink$ adj harm$).tw. 
45. (alcohol$ adj excess$).tw. 
46. (alcohol$ adj binge).tw. 
47. (alcohol$ adj heavy).tw. 
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48. (alcohol$ adj hazard$).tw. 
49. (alcohol$ adj problem$).tw. 
50. (alcohol$ adj abuse).tw. 
51. (alcohol$ adj misus$).tw. 
52. (drink$ adj misus$).tw. 
53. (alcohol$ adj dependen$).tw. 
54. (alcohol$ adj harm$).tw. 
55. "alcohol intake".tw. 
56. or/28-55 
57. 27 and 56 
58. Rehabilitation Centers/ 
59. Health Behavior/ 
60. Health Education/ 
61. Preventive Health Services/ 
62. Preventive Psychiatry/ 
63. Directive Counseling/ 
64. exp Behavior Therapy/ 
65. exp Cognitive Therapy/ 
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66. exp Evidence-Based medicine/ 
67. Hospitalization/ 
68. (Referral and Consultation).mp. 
69. Health Promotion/ 
70. Health Maintenance Organizations/ 
71. "relapse prevention".mp. 
72. "harm reduction".mp. 
73. (naltrexone or acamprosate or disulfiram or opioid-antagonist or antabuse or vivitrol).tw. 
74. campral.mp. 
75. anti?craving.tw. 
76. dis?lfiram.tw. 
77. disulfiram.tw. 
78. dissulfiram.tw. 
79. disulfuram.mp. 
80. "brief intervention".tw. 
81. "motivational interviewing".tw. 
82. "motivational enhancement therapy".tw. 
83. "social behavio?r".tw. 
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84. "cognitive behavio?ral therapy".tw. 
85. "aversion therapy".tw. 
86. "relapse prevention".tw. 
87. "skills training".tw. 
88. treatment.mp. 
89. or/58-88 
90. 57 and 89 
 
NHS EED (via CRD), performed February 2011, limited to studies published after 31st December 2008; HTA (via CRD), 
performed February 2011, no time restriction imposed 
1. MeSH Alcohol-Related Disorders EXPLODE 1 2 
2. MeSH Alcohol Drinking EXPLODE 1 
3. MeSH Temperance EXPLODE 1 
4. MeSH Alcohol Deterrents EXPLODE 1 
5. "alcohol drinking" 
6. alcoholism 
7. dispomania 
8. "alcohol consumption" 
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9. drink* NEAR excess* 
10. drink* NEAR binge 
11. drink* NEAR heavy 
12. drink* NEAR hazard* 
13. drink* NEAR problem* 
14. drink* NEAR abuse 
15. drink* NEAR misus* 
16. drink* NEAR dependen* 
17. drink* NEAR harm* 
18. alcohol* NEAR excess* 
19. alcohol* NEAR binge 
20. alcohol* NEAR heavy 
21. alcohol* NEAR hazard* 
22. alcohol* NEAR problem* 
23. alcohol* NEAR abuse 
24. alcohol* NEAR misus* 
25. alcohol* NEAR dependen* 
26. alcohol* NEAR harm* 
27. "alcohol intake" 
28. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 
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or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27                                                                    
29. acamprosate OR antabuse OR disulfiram OR vivitrol OR naltrexone                                                                 
 30. #29 OR #30 
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Table 36: Extracted Data from Economic Evaluation Studies in the Review, Chapter 4 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Modelling 
Studies 
     
Barbosa 2010a UK; 
Various author-
specific research 
funding; 
CUA; 
State-transition 
cohort 
 
Healthcare Payer; 
Lifetime;  
Problem drinkers 
seeking treatment 
(hazardous and 
harmful) 
aged >=16 years; 
3.5% p.a.  
12 month 
probabilities of 
transition between 
consumption-
specific health states; 
Cost/QALY gained; 
Epidemiological data 
for health effects; 
‘long-term follow-up 
trial data to inform 
long run alcohol use’ 
 
1. ME Therapy (3x50 
minutes) 
2. SB&N Therapy (8x50 
minutes) 
(taken from Russell et al) 
 
Intervention 
cost, ARDC 
 
Lifetime 
exposure to 
alcohol 
interventions 
equal across 
consumption-
specific health 
states 
Cobiac 2009 Australia; 
Alcohol 
Healthcare payer, 
patient; 
Reduction of alcohol 
intake per day 
1. BI + follow up [6.3g] 
2. Residential detoxification 
Intervention 
cost, patient 
   
 
3
1
9 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Education and 
Rehabilitation 
Foundation; 
CUA; 
State-transition 
cohort 
Lifetime; 
Hazardous and 
harmful drinkers 
aged 18-79 years 
(Alternative 1); 
Dependent 
drinkers aged 18-
79 years 
(Alternatives 2 & 
3); 
3% p.a. 
(grams); 
Cost/DALY gained; 
Epidemiological data 
for health effects; 
relapse data for 
alcohol status post 
follow-up 
 
(3 weeks) [13g, 50% 
relapse/year] 
3. Residential detoxification 
+ Naltrexone (12 weeks) 
[13g, 18% relapse/year] 
travel and time 
costs, ARDC; 
 
Authors target 
2% of study 
population for 
Alternative 1, 
4% for 
Alternatives 2 
and 3, but 
make no 
explicit 
assumptions 
about patient 
motivation; 
Single 
intervention at 
the start of the 
model 
Corry 2004 Australia; Government; Unspecific 1. Contact with a health Intervention 
  
  
 
3
2
0 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Australian 
Health and 
Medical 
Research 
Council; 
Australian 
Commonwealth 
Department of 
Health and 
Ageing; 
CUA; 
Decision Tree 
12 months; 
Alcohol use 
disorder (ICD-10) 
(principal 
complaint) 
individuals 
reporting 
previous contact 
with the health 
system for mental 
problems such as 
stress, depression 
or substance 
dependence; 
N/A 
 
consumption-related 
symptom change; 
Cost/Years Lived 
with Disability 
averted; 
Disability weights 
professional including BC for 
harmful users and 
medication for dependent 
users 
2. Optimal care for harmful 
and dependent users 
including inpatient 
detoxification for those with 
dependency 
cost; 
 
Single 
intervention at 
the start of the 
model 
Doran 2004 Australia; 
Not clear; 
CEA; 
Decision tree 
Healthcare payer; 
12 months; 
Primary care 
patients 
Detection rate, 
Patient coverage, BI 
effectiveness in 
modifying drinking; 
1. GP screening + BI for at-
risk drinkers 
2.Improved at-risk drinker 
detection rate 
Intervention 
cost, detection 
cost; 
 
   
 
3
2
1 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
aged >=14 years; 
N/A 
Cost/number of 
individuals who have 
modified their 
drinking; 
N/A 
3. Improved patient 
coverage of BI 
4. Improved effectiveness of 
BI 
5. Joint increases in 
detection of at-risk drinkers, 
coverage and effectiveness 
of BI 
Single 
intervention for 
each individual, 
occurring 
throughout the 
time horizon 
 
Gentilello 2005 USA; 
Robert Wood 
Johnson 
Foundation; 
CBA; 
State-transition 
cohort 
Healthcare payer; 
3 years; 
Trauma centre 
patients 
aged >=18 years 
with high blood-
alcohol or an 
alcohol disorder 
as defined by a 
standard 
questionnaire; 
3% p.a. 
Reduction in injuries 
requiring hospital 
admission over 3 
years of follow-up; 
Net Benefit; 
N/A 
1. No intervention [N/A] 
2. BI [48%] 
Intervention 
cost, detection 
cost, cost of 
emergency 
visits and 
hospitalisation; 
 
Single 
intervention for 
each individual 
in year one;  
Acceptance 
  
  
 
3
2
2 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
rate for 
treatment of 
76%  
Lindholm 1998 Sweden; 
Swedish Institute 
for Public Health; 
CEA; 
State-transition 
cohort 
Healthcare payer; 
30 years; 
Males aged 40 
years comprising 
‘heavy’ drinkers;  
5% p.a. 
Change in 
consumption from 
‘heavy’ to ‘moderate’; 
Cost/Life Year 
gained; 
Epidemiological data  
on mortality from 
‘heavy’ and 
‘moderate’ drinking 
assumption used: 
double mortality risk 
for heavy drinkers 
versus everyone else 
age 40-70; simple 
assumptions about 
duration of 
consumption effect 
1. No Intervention 
2. 5 GP visits involving BI 
(12 months) 
3. 25 GP visits involving BI 
(5 years) 
 
 
Intervention 
cost, detection 
cost, Future 
general 
medical costs; 
 
Interventions in 
first five years 
of the model 
   
 
3
2
3 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Mortimer 2005 Australia; 
Australian 
Government 
Department of 
Health and 
Ageing; Monash 
University; 
CUA; 
State-transition 
cohort 
Healthcare payer; 
Lifetime; 
Heavy drinkers >= 
19 years old and 
hazardous 
drinkers not 
physically 
dependent 17-70 
years old 
(Alternative 1); 
Patients seeking 
help for alcohol 
problems and 
drinkers 15-59 
years old 
(Alternative 2); 
Detoxified 
patients with 
history of severe 
dependence but 
Change in proportion 
of patients drinking 
at 12 months 
(typical); 
Cost/QALY gained; 
Movement between 
drinking level health 
states adjusted for 
HRQoL using 
disability weights; 
‘pessimistic’ 
assumptions about 
duration of effect 
from limited follow-
up data post 1 year 
1. BI for problem drinking; 
2. Psychotherapy for mild to 
moderate dependence; 
3. Drug therapy + 
counselling for detoxified 
dependent drinkers 
Intervention 
cost, ARDC in 
sensitivity 
analysis only; 
 
Single 
intervention at 
the start of the 
model 
  
  
 
3
2
4 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
no other 
substance 
dependence 
(Alternative 3); 
5% p.a. 
Neighbors 2010 USA; 
NIAAA; National 
Cancer Institute; 
CUA; 
Decision Tree 
Healthcare payer; 
Societal; 
Lifetime; 
Emergency 
department 
hospital patients 
aged 18-19 years 
admitted for 
alcohol-related 
injuries; 
3% p.a. 
Drink driving 
incidence rate, 
alcohol-related 
injury rate, traffic 
ticket rate; 
Cost/QALY gained; 
National mortality 
tables to estimate 
death rates from 
drink driving and 
population-level 
utility data; alcohol 
level itself not linked 
directly to health 
1. BA 
2. Motivational Interview 
Intervention 
cost, accident 
fatality costs; 
 
Single 
intervention at 
the start of the 
model; 
Acceptance 
rate for 
treatment of 
67%; no 
consideration 
of long term 
effects, just 
   
 
3
2
5 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
simple 
extrapolation 
assumption. 
NICE 2010 UK; 
NHS NICE; 
CUA; 
Decision Tree 
Healthcare payer; 
End of Hospital 
admission; 
Hospital patients 
with acute alcohol 
withdrawal; 
3.5% p.a. 
Difference in length 
of hospital stay 
compared to 
Placebo; 
Cost/QALY gained; 
N/A; 
Utility scores from 
effectiveness trials 
1. Placebo 
2. Oxazepam 
3. Chlordiazepoxide 
4. Clomethiazole 
5. Lorazepam 
Intervention 
cost; 
 
Ongoing 
treatment for 
each individual 
throughout 
time horizon 
NICE 2011 UK; 
NHS NICE; 
CUA; 
Decision Tree 
(from Schadlich 
et al) 
Healthcare payer; 
12 months; 
Individuals in 
recovery from 
alcohol 
dependence; 
N/A 
 
Abstinence rate at 12 
months; 
Cost/QALY gained; 
Utility scores from 
published studies 
1. Psychological therapy to 
prevent relapse [10.44%] 
2. Psychological therapy + 
Acamprosate [17.47%] 
3. Psychological therapy + 
Naltrexone [18.24%] 
Intervention 
cost, Relapse 
cost; 
 
Single 
intervention at 
the start of the 
model 
  
  
 
3
2
6 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Palmer 2000 Germany; 
Not clear; 
CEA; 
State-transition 
cohort 
Healthcare payer; 
Lifetime; 
Male detoxified 
alcoholic patients, 
80% with fatty 
liver, 15% with 
cirrhosis, 22% 
with chronic 
pancreatitis, 1% 
with 
cardiomyopathy; 
5% p.a. 
Abstinence rate; 
Cost/Life Year 
gained; 
Incidence of ARD 
among abstinent and 
relapsed patients 
translated to survival 
rates; 
abstinence rates 
reduce according to 
unreported function 
after 2 years and 
remain constant after 
five years 
 
1. BC 
2. BC + Acamprosate (48 
weeks) 
Intervention 
cost, ARDC; 
 
Single 
intervention at 
the start of the 
model 
Purshouse 2008 UK; 
NHS NICE; 
CUA; 
State-transition 
cohort 
Healthcare payer; 
30 years; 
General English 
population; 
3.5% p.a. 
Reduction in mean 
consumption at 12 
months; 
Cost/QALY gained; 
Assumptions about 
1. Screening at next GP 
registration for 10 years 
2. Screening at next primary 
care appointment for 10 
years 
Intervention 
cost, ARDC; 
 
Uptake of 
interventions; 
   
 
3
2
7 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
 duration of effect and 
statistical equations 
linking consumption 
to harm 
3. Screening in emergency 
care for 10 years 
long run 
effectiveness 
Quanbeck 2010 USA; 
Various author-
specific research 
funding; 
CBA; 
State-transition 
cohort  
Employer; 
4 years; 
Individuals aged 
18-65 years in 
primary care 
screening positive 
for problem 
drinking; 
3.5% p.a. 
Alcohol consumption 
change (7 days), 
binge drinking 
episode rate (30 
days); 
Net monetary 
benefit; 
Estimates of 
absenteeism 
attributable to 
alcohol abuse 
1. General health booklet 
2. BI + reinforcement 
telephone call 
Intervention 
cost, cost of 
problem 
drinking to an 
employer; 
 
Not clear if 
intervention 
was available 
throughout 
time horizon or 
solely at the 
start of the 
model 
Schadlich 1998 Germany; 
Lipha 
Healthcare payer; 
96 weeks; 
Abstinence rate at 96 
weeks; 
1. BC + Placebo (48 weeks) 
[17.3%] 
Intervention 
cost, ARDC; 
  
  
 
3
2
8 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Arzneimittel 
GmbH; 
CUA; 
Decision tree  
Alcohol 
dependent (DSM-
III) psychiatric 
outpatients 
abstinent for 14-
28 days; 
5% p.a. 
Cost per additional 
abstinent patient; 
N/A 
2. BC + Acamprosate (48 
weeks) [39.9%] 
 
Single 
intervention at 
the start of the 
model 
Slatterly 2003 UK; 
NHS Scotland; 
CEA; 
Decision tree 
Healthcare payer 
and patient; 
20 years; 
Newly abstinent 
and detoxified 
alcohol dependent 
individuals; 
6% p.a. for costs 
only; 
 
Number of patients 
with abstained or 
controlled drinking 
at close to 12 month; 
Cost/abstinent or 
controlled drinker at 
20 years; 
Relapse rate 
estimates 
 
1. Placebo or No 
Intervention [OR: 1.00] 
2. Coping / Social Skills 
Training [OR: 2.11] 
3. BC (Self Control) [OR: 
1.75] 
4. ME Therapy [OR: 1.88] 
5. Marital / Family Therapy 
[OR: 1.94] 
6. Acamprosate (12 months) 
[OR*: 1.73] 
7. Naltrexone (6 months) 
[OR*: 1.46] 
Intervention 
cost, ARDC; 
 
Single 
intervention at 
the start of the 
model 
   
 
3
2
9 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
8. Disulfiram (6 months) 
[OR*: 1.31] 
Tariq 2009 Netherlands; 
Ministry of 
Health, Welfare 
and Sport of the 
Netherlands; 
CUA; 
State-transition 
cohort 
Healthcare payer; 
Lifetime; 
Primary care 
patients aged 20 
to 65 years; 
4% p.a. for costs, 
1.5% p.a. for 
benefits; 
 
Decrease in 
consumption at 12 
months; 
Cost/QALY gained; 
Risk ratios for ARDs 
to estimate survival 
among different 
drinking groups, 
national disability 
weight data; 
mysterious ‘long term 
maintenance 
fraction’ for long 
term reduction in 
alcohol consumption 
1. No intervention  
2. Screening + BI for 
excessive drinkers 
Intervention 
costs, Future 
general 
medical 
expenditure; 
 
Single 
intervention in 
year one of the 
model 
Wutzke 2001 Australia; 
National Health 
and Medical 
Healthcare payer; 
Lifetime; 
Hazardous and 
Number of ‘at risk’ 
drinkers identified; 
Decrease in alcohol 
1. No training or support 
(for health practitioners 
implementing BI) 
Cost of 
marketing to 
health 
  
  
 
3
3
0 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Research Council 
of Australia; 
CEA; 
State-transition 
cohort 
harmful drinkers 
aged >=16 years; 
3% p.a. 
consumption among 
‘at  risk’ drinkers; 
Cost/Life Year 
gained; 
Implicit assumption 
of sustained 
consumption effect 
2. Training (5 minutes) only 
3. Training + fortnightly 
advice 
4. Training + fortnightly 
telephone or personal visits 
professionals, 
Training and 
support costs, 
Intervention 
costs; 
 
Single 
intervention in 
first three 
months of the 
model 
Primary 
Studies 
     
Alwyn 2004 UK; 
Not clear; 
CEA; 
N/A 
Healthcare payer; 
12 months; 
Home 
detoxification 
patients; 
N/A 
Number of days 
abstinent, 
drinks/day total 
consumption.  Other 
measures included; 
Costs and outcomes 
1. Home detoxification with 
medication  
2. Home detoxification with 
medication + Psychological 
Therapy 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
   
 
3
3
1 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
reported separately; 
N/A 
time horizon 
Babor 2006 USA; 
Robert Wood 
Johnson 
Foundation; 
CEA; 
N/A 
Healthcare payer; 
12 months; 
At-risk drinkers 
undergoing home 
detoxification; 
N/A 
Number of 
drinks/week; 
Costs and outcomes 
reported separately; 
N/A 
1. BI in ‘usual care’ 
2. BI delivered by licensed 
practitioners 
3. BI delivered by mid-level 
health professionals 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
time horizon 
Barrett 2006 UK; 
Alcohol 
Education and 
Research Council; 
CEA; 
N/A 
Societal; 
12 months; 
Hazardous 
drinkers in an 
accident and 
emergency 
department of a 
general hospital; 
N/A 
Units of alcohol 
consumed/week; 
Cost/unit reduction 
in alcohol 
consumption/week; 
N/A 
 
1. Information Leaflet 
2. BI from an Alcohol 
Health Worker 
Intervention 
cost, social 
care costs, 
criminal justice 
costs, 
productivity 
costs; 
 
Single 
intervention at 
the start of the 
  
  
 
3
3
2 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
time horizon 
Bischof 2008 Germany; 
German Federal 
Ministry of 
Research and 
Education; 
CEA; 
N/A 
Healthcare payer; 
12 months; 
At-risk, 
dependent, 
alcohol abusing 
and heavy 
episodic drinkers 
aged 18-64 years 
in primary care; 
N/A 
Alcohol 
consumption/day, 
number of binge 
episodes; 
Costs and outcomes 
reported separately; 
N/A 
1. No Intervention 
2. Computerized 
intervention + BC (up to 
3x30 mins) 
3. Computerized 
intervention + BC (fixed 
4x30 mins) 
 
Intervention 
cost 
(counsellor 
cost only); 
 
Single 
intervention at 
the start of the 
time horizon 
Drummond 
2009 
UK; 
Wales Office for 
Research and 
Development; 
CUA; 
N/A 
Societal; 
6 months; 
Male hazardous 
drinkers who had 
not received 
treatment for an 
alcohol use 
disorder in at 
least 180 days; 
Total alcohol 
consumed (over 180 
days), mean number 
of drinks per 
drinking day, 
percentage of days 
abstinent; 
Cost/QALY gained;                                   
EQ-5D published 
1. Minimal Nurse 
Intervention 
2. Stepped Care: BC + MET 
(4x50 mins) + referral to 
alcohol treatment agency 
 
Intervention 
cost, Training 
cost, general 
healthcare 
costs, social 
care costs, 
criminal justice 
costs, costs 
associated 
   
 
3
3
3 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
N/A estimates                                    
 
 
with accidents; 
 
Single 
intervention at 
the start of the 
time horizon 
Dunlap 2010 USA;  
NIAAA; 
CEA; 
N/A 
Patient; 
16 weeks; 
Individuals with 
alcohol 
dependence 
(DSM-IV) 
abstinent for 4-21 
days; 
N/A 
Percent of days 
abstinent, 
proportion avoiding 
heavy drinking, 
proportion achieving 
‘good’ clinical 
outcome; 
Cost/additional 
percentage point or 
patient positive for 
each of the 3 primary 
outcome measures; 
N/A 
1. Placebo + MM 
2. BC 
3. Naltrexone (16 weeks) + 
MM 
4. Acamprosate (16 weeks) + 
MM 
5. Placebo + MM + BC 
6. Naltrexone (16 weeks) + 
Acamprosate + MM 
7. Naltrexone (16 weeks) + 
MM + BC 
8. Acamprosate (16 weeks) + 
MM + BC 
9. Naltrexone (16 weeks) + 
Patient time, 
medication and 
travel costs; 
 
Single 
intervention at 
the start of the 
time horizon 
  
  
 
3
3
4 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Acamprosate (16 weeks) + 
MM + BC 
Fals-Stweart 
2005 
USA; 
National 
Institute on Drug 
Abuse; NIAAA; 
Alpha 
Foundation; 
CEA; 
N/A 
Healthcare payer 
and patient; 
12 months; 
Alcohol 
dependent (DSM-
IV) male aged 20-
60 years who has 
a partner; 
N/A; 
Percentage of Days 
of Heavy Drinking; 
Change in 
Percentage of Days 
of Heavy 
Drinking/Cost 
weight; 
N/A 
1. Brief Relationship 
Therapy  
2. Shortened standard 
Behavioural Couples 
Therapy 
3. Individual-based 
Treatment 
4. Psycho-educational 
Attention Control Treatment 
Intervention 
cost, Patient 
time and travel 
costs; 
 
Single 
intervention at 
the start of the 
time horizon 
Fleming 2002 USA; 
Robert Wood 
Johnson 
Foundation; 
NIAAA; National 
Institutes of 
Health; 
CEA; CBA; 
N/A 
Healthcare payer 
and patient; 
Societal; 
2 years; 
Individuals aged 
18-65 years in 
primary care 
screening positive 
for problem 
Alcohol consumption 
change (7 days), 
binge drinking 
episode rate (30 
days); 
Net monetary 
benefit; 
Utilisation of health 
care, motor vehicle 
1. General health booklet 
2. BI + reinforcement 
telephone call 
Intervention 
cost, Patient 
time cost 
(Healthcare 
payer and 
patient 
perspective 
only), Health 
service 
   
 
3
3
5 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
drinking; 
0% p.a. 
events and legal 
events 
utilisation cost 
(Societal 
perspective 
only), Legal 
and motor 
vehicle 
accident costs 
(Societal 
perspective 
only); 
 
Single 
intervention at 
the start of the 
time horizon 
 
Humphreys 
1996 
USA; 
NIAAA; 
Department of 
Veterans Affairs; 
Healthcare payer; 
3 years; 
Individuals 
seeking help for 
Number of days 
intoxicated in past 
month, ounces of 
ethanol consumed 
1. Professional outpatient 
alcoholism treatment 
2. AA self-help and mutual 
aid programme 
Treatment 
costs 
(excluding 
costs for major 
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6 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
 CEA; 
N/A 
alcoholism with 
no previous 
treatment; 
5% p.a. for costs 
on a typical drinking 
day. Other measures 
included; 
Costs and outcomes 
reported separately; 
N/A 
surgical 
procedures 
related to 
alcoholism) for 
Alternative 1 
only; 
 
Single 
intervention at 
the start of the 
time horizon 
Kunz 2004 USA; 
NIAAA; National 
Institutes for 
Health; 
CEA; 
N/A 
Healthcare payer; 
3 months; 
Hospital 
emergency 
department 
patients screening 
positive for 
alcohol problems; 
N/A 
AUDIT score, 
average 
drinks/week, 
percentage of 
patients heavy 
drinking; 
Cost/each primary 
outcome measure; 
N/A 
1. Information packet 
2. Information packet + BI 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
time horizon 
   
 
3
3
7 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Lock 2006 UK; 
NHS;  
CEA; 
N/A 
Healthcare payer 
and patient; 
12 months; 
Patients 
aged >=16 years 
screened for 
alcohol use 
disorders in 
primary care; 
N/A 
Number of 
drinks/drinking day, 
Drinking Problems 
Index, SF-12 HRQoL 
questionnaire; 
Costs and outcomes 
reported separately; 
N/A 
1. Information Leaflet + BA 
2. BI 
 
 
Intervention 
cost, Patient 
time, travel, 
accident and 
property 
damage costs; 
 
Single 
intervention at 
the start of the 
time horizon 
Long 1998 UK; 
Not clear; 
CEA; 
N/A 
Healthcare payer; 
12 months; 
Alcohol 
dependent (ICD-
10) individuals; 
N/A 
Proportion of 
abstinent days, 
consumption. Other 
measures included; 
Costs and outcomes 
reported separately; 
N/A 
1. Residential programme (5 
weeks) 
2. In- and day-patient 
programme (2 weeks) 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
time horizon 
Moraes 2010 Brazil; 
State of Sao 
Societal 
(healthcare payer 
Abstinence rate.  
Other measures 
1. Outpatient detoxification 
involving 20 group sessions 
Intervention 
cost, Patient 
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8 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Paolo Research 
Foundation; 
CEA; CUA; 
N/A 
+ patient costs); 
3 months; 
Alcoholic patients 
aged 20-66 years 
N/A 
included such as SF-
36; 
Incremental 
Cost/Incremental 
Abstinence; 
N/A 
(3 months) [43.1% (3.4% at 
baseline)] 
2. Outpatient 
detoxification involving 20 
group sessions (3 months) 
+ 4 Home Visits to enhance 
patient and family 
adherence [58.11% (1.6% 
at baseline)] 
travel and time 
(productivity) 
costs; 
 
Single 
intervention at 
the start of the 
time horizon 
 
Nalpas 2003 France; 
French Ministry 
of Health; Fonds 
d’Intervention en 
Santé Publique; 
the LIPHA group; 
CEA; 
N/A 
Healthcare payer 
and employer; 
12 months; 
Alcohol 
dependent (DSM-
IV) patients 
aged >=18 years 
admitted to 
specialist centres 
for detoxification; 
N/A 
Number of months 
without relapse; 
Costs and outcomes 
reported separately; 
N/A 
1. Detoxification + follow up 
(Centre 1) 
2. Detoxification + follow up 
(Centre 2) 
3. Detoxification + follow up 
(Centre 3) 
4. Detoxification + follow up 
(Centre 4) 
Intervention 
cost, 
Productivity 
costs; 
 
Single 
intervention at 
the start of the 
time horizon 
   
 
3
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Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
O’Farrell 1996 USA; 
NIAAA; 
Department of 
Veterans Affairs; 
the Smithers 
Foundation; 
CEA; 
N/A 
Societal; 
3 years (1 year 
pre-intervention, 
2 years post-
intervention); 
Newly abstinent 
married males 
(with non-
alcoholic spouses) 
under outpatient 
counselling for 
alcoholism; 
0% p.a. 
Percent of days 
abstinent, marital 
satisfaction; 
Units of 
improvement for 
each outcome 
measure/Weighted 
Cost; 
N/A 
1. Individual BC 
2. Individual BC + 
Behavioural Marital Therapy 
(involving Antabuse 
Contract) 
3. Individual BC + 
Interactional Couples 
Therapy (not involving 
Antabuse Contract)  
Intervention 
cost, ARDC, 
criminal justice 
costs; 
 
Single 
intervention at 
the start of the 
time horizon 
 
Parrott 2006 UK; 
Department of 
Health; 
CEA; CUA; 
N/A 
Societal; 
6 months; 
Individuals with 
alcohol 
dependence; 
N/A 
Reduction in ethanol 
consumption at 60 
days; 
Cost/QALY gained; 
EQ-5D questionnaire 
scores 
1. Partially-hospitalised NHS 
daytime detoxification 
service (3 days) 
2. Inpatient charity-funded 
detoxification service (10 
days) 
 
Intervention 
cost, social 
service costs, 
criminal justice 
system costs; 
 
Single 
  
  
 
3
4
0 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
intervention at 
the start of the 
time horizon 
Pettinati 1999 USA; 
NIAAA; 
CEA; 
N/A 
Healthcare payer; 
12 months; 
Alcohol 
dependent (DSM-
III) patients with 
no other 
substance 
dependencies; 
N/A 
‘Significant drinking’ 
of 3 or more drinks 
per day rates; 
Cost/probability of 
returning to 
‘Significant drinking’; 
N/A 
1. Inpatient AA treatment (4 
weeks) 
2. Outpatient AA treatment 
(6 weeks) 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
time horizon 
Russell 2005 UK; 
Medical Research 
Council; NHS 
Executive in 
England; Wales 
Office for 
Research & 
Development in 
Healthcare payer 
and public sector; 
12 months; 
Individuals 
seeking treatment 
for alcohol 
problems 
aged >=16;  
EQ-5D health 
outcomes; 
Cost/additional 
QALY; 
N/A 
1. ME Therapy (3x50 
minutes) 
2. SB&N Therapy (8x50 
minutes) 
 
Healthcare and 
alcohol 
treatment 
costs, social 
service costs, 
criminal justice 
system costs; 
 
   
 
3
4
1 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Health and Social 
Care; 
CUA; 
N/A 
N/A 
 
Single 
intervention at 
the start of the 
time horizon 
Rychlik 2003 Germany; 
Merck KGaA; 
CEA; 
N/A 
Healthcare payer 
and patient; 
12 months; 
detoxified alcohol 
dependent (DSM-
IV) patients aged 
18-65 years; 
N/A 
 
Abstinence rate at 12 
months; 
Cost/Abstinence 
rate; 
N/A 
1. Psychosocial 
Rehabilitation Program 
2. Psychosocial 
Rehabilitation Program + 
Acamprosate  
Intervention 
cost, Cost of 
lost salary 
from time 
spent out of 
work, Travel 
costs; 
 
Single 
intervention at 
the start of the 
time horizon 
Shakeshaft 2002 Australia; 
National 
Health and 
Medical Research 
Service provider; 
6 months; 
Individuals 
attending a free 
AUDIT questionnaire 
outcomes, weekly 
and binge 
consumption.  Other 
1. Pamphlet + BI 
2. Cognitive BT 
Intervention 
cost; 
 
Single 
  
  
 
3
4
2 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Council; 
CEA; 
N/A 
community-based 
substance abuse 
counselling 
service; 
N/A 
measurements 
included; 
Cost/Mean 
effectiveness across 
outcome measures 
index; 
N/A 
intervention at 
the start of the 
time horizon 
Sobell 2002 Canada; 
NIAAA; 
CEA; 
N/A 
Healthcare payer; 
12 months; 
Alcohol abusers 
(more than 12 
drinks per week 
or over 4 drinks 
on over 4 days in 
the past week) 
who had never 
sought help or 
treatment; 
N/A 
Alcohol 
consumption/week, 
number of days 
drinking and binge 
drinking.  Other 
measures included. 
Costs and outcomes 
reported separately; 
N/A 
1. Pamphlets 
2. BA + feedback 
Recruitment 
costs, 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
time horizon 
 
Walters 2009 Australia; Healthcare payer; Abstinence rate 1. BC (12 weeks) Intervention 
   
 
3
4
3 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
Internal Funds; 
CUA; 
N/A 
12 weeks; 
Alcohol 
dependent (DSM-
IV) adults with no 
other substance 
dependencies; 
N/A 
(medically 
confirmed); 
Cost/successful 
treatment [No 
statistical difference 
in SF-6D scores 
between groups]; 
N/A 
2. BC + Naltrexone (12 
weeks) 
costs; 
 
Single 
intervention at 
the start of the 
time horizon 
 
Zarkin 2008 USA; 
NIAAA; 
CEA; 
N/A 
Healthcare payer; 
16 weeks; 
Individuals with 
alcohol 
dependence 
(DSM-IV) 
abstinent for 4-21 
days; 
N/A 
Percent of days 
abstinent proportion 
avoiding heavy 
drinking, proportion 
achieving ‘good’ 
clinical outcome; 
Cost/additional 
percentage point or 
patient positive for 
each of the 3 primary 
outcome measures; 
N/A 
1. Placebo + MM 
2. BC 
3. Naltrexone (16 weeks) + 
MM 
4. Acamprosate (16 weeks) + 
MM 
5. Placebo + MM + BC 
6. Naltrexone (16 weeks) + 
Acamprosate + MM 
7. Naltrexone (16 weeks) + 
MM + BC 
8. Acamprosate (16 weeks) + 
Intervention 
cost; 
 
Single 
intervention at 
the start of the 
time horizon 
  
  
 
3
4
4 
Study  
1st Author and Year; 
 
Country; 
Sponsorship;  
Study design; 
Model Type 
Study 
perspective;  
Time horizon; 
Study 
population; 
Discount rate 
Effectiveness 
measure;                         
Main outcome 
measure; 
Long Term 
Extrapolation 
Alternatives [Effectiveness 
Rates]  
Economically optimal 
alternative highlighted  
Resources; 
 
Key 
Assumptions 
 
MM + BC 
9. Naltrexone (16 weeks) + 
Acamprosate (16 weeks) + 
MM + BC 
 
  
   
 
3
4
5 
Key 
ARDC = Alcohol-Related Disease Costs 
ME = Motivational Enhancement 
SB&N = Social Behaviour & Network 
NIAAA = National Institute on Alcohol Abuse and Alcoholism 
BA = Brief Advice 
BC = Behavioural Counselling 
MM = Medical Management 
AA = Alcoholics Anonymous 
OR= Odds Ratio versus placebo 
OR*= Odds Ratio versus no intervention 
DALY = Disability-Adjusted Life Year 
p.a. = per annum 
  
  
  
 
3
4
6 
 
Table 37: Quality Appraisal, Chapter 4 
Study  
1st Author and Year 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 
Barbosa 2010 Y Y Y Y Y N Y Y Y Y Y N N Y Y 
Cobiac 2009 Y Y Y Y N N N N Y Y N N N Y Y 
Corry 2004 Y Y Y Y N N Y N Y Y N N N Y Y 
Doran 2004 Y Y N/A Y Y N N/A N Y N N N N Y Y 
Gentilello 2005 Y Y Y Y Y NC N/A Y Y Y N N N Y Y 
Lindholm 1998 Y Y Y Y N N N/A N Y N N N N Y Y 
Mortimer 2005 Y Y NC Y Y N Y Y Y N Y N N Y Y 
Neighbors 2010 Y Y Y N N N N/A Y Y Y N N N Y Y 
NICE 2010 Y Y Y N N Y Y Y Y Y N N N Y Y 
NICE 2011 Y Y Y Y Y Y Y Y Y Y Y N N Y Y 
Palmer 2000 Y Y Y Y Y N N/A Y Y N N N N Y Y 
Purshouse 2008 Y Y Y Y Y Y Y N Y N Y N Y Y Y 
Quanbeck 2010 Y Y Y Y N N N/A Y Y N N N N Y Y 
Schadlich 1998 Y Y Y Y Y N N/A Y Y N N N N Y Y 
Slatterly 2003 Y Y Y Y Y Y N/A N Y N Y N N Y Y 
Tariq 2009 Y Y Y Y Y N Y Y Y Y N N N Y Y 
Wutzke 2001 Y Y Y Y N N N/A N Y N Y N N Y Y 
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Table 38: Reasons for Final Stage Exclusions, Chapter 4 
Study First Author and Year Exclusion Reason 
Berglund (2001)[529] Other  
Gifford (2010) [530] Population 
Harwood (2009)[531] Population 
HAYES (2009a)[532] Other  
HAYES (2009b)[533] Other  
HAYES (2010)[534] Other  
Kapoor (2009)[535] Alternatives 
Mitchell (2009a)[536] Other  
Mitchell (2009b)[537]  Other  
Mitchell (2009c)[538] Other  
Olmstead (2010)[539] Population 
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11.4. Appendix D: Appendix to Chapter 5 
Table 39: Attrition bias test results, At-risk drinking participation equation, full unbalanced sample 
Tests for attrition bias 
Equations modelling the probability of participation in ‘at risk’ drinking 
Men Static Probit Number of waves participant present Chi2(1) 2.65 
Probability > 
Chi2 
0.1038 
Participant present in all waves Chi2(1) 1.67 
Probability > 
Chi2 
0.1963 
Participant present in next wave Chi2(1) 0.25 
Probability > 
Chi2 
0.6194 
Dynamic probit model with 
random effects 
Number of waves participant present Chi2(1) 0.52 
Probability > 
Chi2 
0.4717 
Participant present in all waves Chi2(1) 0.13 
Probability > 
Chi2 
0.7235 
Participant present in next wave Chi2(1) 0.32 
Probability > 0.5727 
   
 
3
4
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Tests for attrition bias 
Equations modelling the probability of participation in ‘at risk’ drinking 
Chi2 
Women Static Probit Number of waves participant present Chi2(1) 0.70 
Probability > 
Chi2 
0.4013 
Participant present in all waves Chi2(1) 1.50 
Probability > 
Chi2 
0.2208 
Participant present in next wave Chi2(1) 2.72 
Probability > 
Chi2 
0.0992 
Dynamic probit model with 
random effects 
Number of waves participant present Chi2(1) 1.37 
Probability > 
Chi2 
0.2415 
Participant present in all waves Chi2(1) 1.88 
Probability > 
Chi2 
0.1705 
Participant present in next wave Chi2(1) 2.15 
Probability > 
Chi2 
0.1423 
 
  
  
  
 
3
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Table 40: Attrition bias test results, Smoking participation equation, full unbalanced sample 
Wald test for attrition bias 
Equations modelling the probability of smoking participation 
Men Static Probit Number of waves participant present Chi2(1) 5.39 
Probability > 
Chi2 
0.0202 
Participant present in all waves Chi2(1) 3.13 
Probability > 
Chi2 
0.0768 
Participant present in next wave Chi2(1) 0.90 
Probability > 
Chi2 
0.3431 
Dynamic probit model with 
random effects 
Number of waves participant present Chi2(1) 13.59 
Probability > 
Chi2 
0.0002 
Participant present in all waves Chi2(1) 9.51 
Probability > 
Chi2 
0.0020 
Participant present in next wave Chi2(1) 1.29 
Probability > 
Chi2 
0.2561 
Women Static Probit Number of waves participant present Chi2(1) 7.23 
   
 
3
5
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Wald test for attrition bias 
Equations modelling the probability of smoking participation 
Probability > 
Chi2 
0.0072 
Participant present in all waves Chi2(1) 3.14 
Probability > 
Chi2 
0.0762 
Participant present in next wave Chi2(1) 1.30 
Probability > 
Chi2 
0.2548 
Dynamic probit model with 
random effects 
Number of waves participant present Chi2(1) 16.95 
Probability > 
Chi2 
0.0000 
Participant present in all waves Chi2(1) 8.67 
Probability > 
Chi2 
0.0032 
Participant present in next wave Chi2(1) 0.74 
Probability > 
Chi2 
0.3883 
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Table 41: Comparison of model estimates before and after re-weighting for attrition 
Probability of smoking 
participation  
Univariate static probit 
model 
Men Women 
Un-weighted Weighted Un-weighted Weighted 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Explanatory variables         
Smoker last year 2.098*** 0.585*** 2.095*** 0.593*** 2.209*** 0.572*** 2.221*** 0.582*** 
(0.000) (0.000) (0.000) (0.000) (0.000) (0.000) (0.000) (0.000) 
At-risk drinker last year 0.090** 0.016** 0.099** 0.019** 0.049 0.006 0.069 0.009 
(0.027) (0.027) (0.018) (0.018) (0.370) (0.370) (0.221) (0.221) 
Initial value smoker 1.110*** 0.263*** 1.088*** 0.267*** 1.074*** 0.203*** 1.040*** 0.198*** 
(0.000) (0.000) (0.000) (0.000) (0.000) (0.000) (0.000) (0.000) 
Initial value at-risk drinker -0.008 -0.001 0.002 0.000 0.057 0.007 0.048 0.006 
(0.852) (0.852) (0.958) (0.958) (0.356) (0.356) (0.444) (0.444) 
Age -0.005 -0.001 -0.006 -0.001 -0.011 -0.001 -0.012* -0.001* 
(0.410) (0.410) (0.290) (0.290) (0.102) (0.102) (0.074) (0.074) 
Age squared -0.000 -0.000 -0.000 -0.000 0.000 0.000 0.000 0.000 
(0.230) (0.230) (0.371) (0.371) (0.887) (0.887) (0.785) (0.785) 
Highest qualification - vocational -0.010 -0.002 0.023 0.004 0.127 0.016 0.171 0.022 
(0.932) (0.932) (0.852) (0.852) (0.294) (0.294) (0.158) (0.158) 
Highest qualification - graduate -0.074 -0.013 -0.040 -0.007 -0.046 -0.005 -0.019 -0.002 
   
 
3
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Probability of smoking 
participation  
Univariate static probit 
model 
Men Women 
Un-weighted Weighted Un-weighted Weighted 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
(0.606) (0.606) (0.789) (0.789) (0.722) (0.722) (0.881) (0.881) 
Marital status - separated 0.210* 0.041* 0.183 0.037 0.238** 0.033** 0.246** 0.035** 
(0.074) (0.074) (0.111) (0.111) (0.038) (0.038) (0.040) (0.040) 
Marital status - divorced 0.159 0.030 0.139 0.028 -0.006 -0.001 -0.039 -0.005 
(0.179) (0.179) (0.227) (0.227) (0.954) (0.954) (0.709) (0.709) 
Marital status - widowed 0.236 0.047 0.228 0.048 0.226 0.031 0.221 0.031 
(0.243) (0.243) (0.254) (0.254) (0.124) (0.124) (0.137) (0.137) 
Marital status – never married 
and not cohabiting 
0.266** 0.052** 0.260** 0.053** 0.037 0.004 0.118 0.015 
(0.016) (0.016) (0.021) (0.021) (0.773) (0.773) (0.427) (0.427) 
Marital status – never married 
but cohabiting 
0.201** 0.039** 0.197* 0.040* 0.076 0.009 0.112 0.015 
(0.047) (0.047) (0.059) (0.059) (0.538) (0.538) (0.446) (0.446) 
Child resident -0.065 -0.011 -0.051 -0.009 -0.004 -0.000 -0.027 -0.003 
(0.242) (0.242) (0.375) (0.375) (0.956) (0.956) (0.708) (0.708) 
Tobacco price index -0.001 -0.000 -0.001 -0.000 0.001 0.000 0.001 0.000 
(0.609) (0.609) (0.595) (0.595) (0.718) (0.718) (0.628) (0.628) 
Alcohol price index 0.001 0.000 0.001 0.000 -0.008* -0.001* -0.008* -0.001* 
(0.769) (0.769) (0.745) (0.745) (0.052) (0.052) (0.058) (0.058) 
Real household disposable 
income (natural logarithm) 
0.011 0.002 0.006 0.001 0.021 0.002 0.022 0.003 
(0.622) (0.622) (0.784) (0.784) (0.406) (0.406) (0.389) (0.389) 
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Probability of smoking 
participation  
Univariate static probit 
model 
Men Women 
Un-weighted Weighted Un-weighted Weighted 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Raw 
coefficients 
Average 
partial 
effects 
Public place smoking ban in 
operation 
-0.085* -0.015* -0.085* -0.016* 0.036 0.004 0.037 0.005 
(0.059) (0.059) (0.070) (0.070) (0.460) (0.460) (0.458) (0.458) 
Own-health subjective measure – 
good or very good health 
0.103** 0.018** 0.115*** 0.022*** 0.042 0.005 0.058 0.007 
(0.014) (0.014) (0.009) (0.009) (0.334) (0.334) (0.190) (0.190) 
Own-health subjective measure – 
fair health 
0.045 0.008 0.057 0.011 -0.078 -0.009 -0.046 -0.005 
(0.462) (0.462) (0.377) (0.377) (0.242) (0.242) (0.509) (0.509) 
Own-health subjective measure – 
poor health 
-0.104 -0.017 -0.114 -0.020 -0.175 -0.018 -0.102 -0.012 
(0.319) (0.319) (0.292) (0.292) (0.161) (0.161) (0.416) (0.416) 
Constant -1.805**  -1.709**  -1.201*  -0.934  
(0.011)  (0.019)  (0.090)  (0.235)  
         
Observations 31,210 31,210 30,564 30,564 32,904 32,904 32,083 32,083 
Note:  P-values in parenthesis; parameter estimates for time-averaged explanatory variables not reported 
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Table 42: Results from Dynamic Univariate Random Effects Probit Models 
Variables Men Pooled 
(1) Smoker (2) At-risk Alcohol 
Use 
(3) Smoker (4) At-risk Alcohol 
Use 
Smoker last year 1.519*** 0.210*** 1.628*** 0.231*** 
(0.000) (0.002) (0.000) (0.000) 
At-risk Drinker last year 0.087 0.848*** 0.104** 0.830*** 
(0.159) (0.000) (0.029) (0.000) 
Smoker initial value 2.568*** 0.154* 2.441*** 0.187*** 
(0.000) (0.055) (0.000) (0.002) 
At-risk Drinker initial value 0.029 2.425*** 0.040 2.440*** 
(0.696) (0.000) (0.487) (0.000) 
Age -1.723*** -0.421* -1.609*** -0.733*** 
(0.000) (0.091) (0.000) (0.000) 
Male   0.184*** 0.318*** 
  (0.000) (0.000) 
Graduate Education 0.106 0.086 -0.114 -0.107 
(0.593) (0.626) (0.501) (0.463) 
Vocational Further 
Education 
0.005 -0.102 0.161 0.078 
(0.983) (0.657) (0.232) (0.532) 
Separated 0.327* -0.141 0.328** -0.065 
(0.081) (0.372) (0.011) (0.577) 
Divorced 0.225 0.040 0.073 -0.096 
(0.255) (0.808) (0.595) (0.424) 
Widowed 0.309 -0.159 0.387* -0.044 
(0.489) (0.551) (0.069) (0.820) 
Never married, cohabiting 0.051 0.208 0.041 0.019 
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Variables Men Pooled 
(1) Smoker (2) At-risk Alcohol 
Use 
(3) Smoker (4) At-risk Alcohol 
Use 
(0.812) (0.247) (0.776) (0.879) 
Never married, not 
cohabiting 
0.057 -0.009 0.037 0.267* 
(0.765) (0.955) (0.818) (0.055) 
Child(ren) in family home -0.153 -0.080 -0.128 -0.029 
(0.135) (0.353) (0.103) (0.668) 
Tobacco Price Index -0.464* -0.205 -0.259 -0.080 
(0.074) (0.304) (0.176) (0.600) 
Alcohol Price Index 0.126 0.379 -0.407 0.207 
(0.850) (0.467) (0.402) (0.600) 
Natural log of Household 
Annual Disposable Income 
0.011 -0.034 0.033 -0.045** 
(0.739) (0.239) (0.178) (0.042) 
Smoking Ban -0.148** 0.058 -0.109** 0.040 
(0.031) (0.279) (0.029) (0.324) 
Good Health 0.148** 0.077 0.140*** 0.068* 
(0.020) (0.133) (0.002) (0.075) 
Fair Health 
  
0.073 0.072 -0.055 0.083 
(0.446) (0.365) (0.429) (0.166) 
Poor Health -0.061 -0.278* -0.279** -0.364*** 
(0.728) (0.072) (0.027) (0.002) 
Major City -0.006 0.123 -0.093 0.120 
(0.968) (0.338) (0.386) (0.209) 
     
Intercept -3.060** -2.673** -2.518*** -2.822*** 
(0.021) (0.037) (0.006) (0.002) 
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Variables Men Pooled 
(1) Smoker (2) At-risk Alcohol 
Use 
(3) Smoker (4) At-risk Alcohol 
Use 
Natural logarithm of 
variance of random effect 
-0.150 0.305*** -0.259** 0.270*** 
(0.332) (0.001) (0.028) (0.000) 
     
Observations; number of 
respondents 
22,162; 4,508 22,162; 4,508 44,646; 9,309 44,646; 9,309 
Average number of waves in 
sample 
4.9 4.9 4.8 4.8 
Log-likelihood -3515.80    -5950.82   -6461.84 -10309.759 
Note:  Parameter estimates for time-averaged explanatory variables not reported 
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Table 43: Results from Dynamic Univariate Random Effects Probit Model, 
female sub-sample only 
Variables Women 
(1) Smoker (2) At-risk Alcohol 
Use 
Smoker last year 1.765*** 0.266*** 
(0.000) (0.001) 
At-risk Drinker last year 0.143* 0.794*** 
(0.059) (0.000) 
Smoker initial value 2.283*** 0.220** 
(0.000) (0.016) 
At-risk Drinker initial value 0.054 2.454*** 
(0.553) (0.000) 
Age -1.410*** -1.289*** 
(0.000) (0.000) 
Graduate Education -0.238 -0.089 
(0.321) (0.636) 
Vocational Further 
Education 
0.215 0.062 
(0.242) (0.727) 
Separated 0.309* -0.023 
(0.090) (0.896) 
Divorced -0.059 -0.260 
(0.757) (0.145) 
Widowed 0.384 0.033 
(0.115) (0.907) 
Never married, cohabiting -0.017 0.071 
(0.939) (0.727) 
Never married, not 
cohabiting 
-0.020 0.358 
(0.935) (0.107) 
Child(ren) in family home -0.070 0.047 
(0.584) (0.691) 
Tobacco Price Index 0.011 0.090 
(0.970) (0.702) 
Alcohol Price Index -1.112 0.010 
(0.119) (0.987) 
Natural log of Household 
Annual Disposable Income 
0.060 -0.069* 
(0.112) (0.059) 
Smoking Ban -0.058 0.019 
(0.427) (0.760) 
Good Health 0.135** 0.062 
(0.045) (0.290) 
Fair Health 
  
-0.212** 0.114 
(0.040) (0.220) 
Poor Health -0.498*** -0.513*** 
(0.006) (0.009) 
Major City -0.185 0.108 
(0.226) (0.447) 
   
Intercept -1.718 -2.863** 
(0.181) (0.032) 
Natural logarithm of 
variance of random effect 
-0.424** 0.203* 
(0.020) (0.063) 
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Variables Women 
(1) Smoker (2) At-risk Alcohol 
Use 
   
Observations; number of 
respondents 
22,484; 4,801 22,484; 4,801 
Average number of waves in 
sample 
4.7 4.7 
Log-likelihood -2915.36 -4325.54 
Note:  Parameter estimates for time-averaged explanatory variables not reported 
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Table 44: Sample characteristics, ‘compact’ estimation sample, males only 
Variable Observations Mean Standard 
Deviation 
Minimum Maximum 
Smoker 22162 0.22 0.41 0 1 
At-risk Drinker 22162 0.22 0.42 0 1 
Age 22162 48.76 16.33 17 93 
Divorced 22162 0.08 0.27 0 1 
Widowed 22162 0.02 0.15 0 1 
Separated 22162 0.03 0.18 0 1 
Never married, 
cohabiting 22162 0.07 0.26 0 1 
Never married, not 
cohabiting 22162 0.16 0.37 0 1 
Child(ren) residing at 
family home 22162 0.38 0.48 0 1 
Graduate Education 22162 0.40 0.49 0 1 
Vocational Further 
Education 22162 0.24 0.42 0 1 
CPI Tobacco 22162 125.19 17.67 107.48 175.47 
CPI Alcohol 22162 117.28 8.80 104.32 137.68 
Natural logarithm of 
Household Annual 
Disposable Income 22162 10.93 0.89 0 13.68 
Poor Health 22162 0.03 0.18 0 1 
Fair Health 22162 0.15 0.35 0 1 
Good Health  22162 0.38 0.48 0 1 
Smoking Ban 22162 0.55 0.50 0 1 
Major City Residence 22162 0.55 0.50 0 1 
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Table 45: Sample characteristics, ‘compact’ estimation sample, pooled 
sample of men and women 
Variable Observations Mean Standard 
Deviation 
Minimum Maximum 
Smoker 44646 0.19 0.39 0 1 
At-risk Drinker 44646 0.17 0.37 0 1 
Age 44646 0.49 0.16 17 93 
Male 44646 0.50 0.50 0 1 
Divorced 44646 0.10 0.30 0 1 
Widowed 44646 0.06 0.23 0 1 
Separated 44646 0.03 0.18 0 1 
Never married, 
cohabiting 44646 0.06 0.25 0 1 
Never married, not 
cohabiting 44646 0.15 0.36 0 1 
Married 44646 0.59 0.49 0 1 
Child(ren) residing at 
family home 44646 0.38 0.49 0 1 
Graduate Education 44646 0.24 0.42 0 1 
Vocational Education 44646 0.33 0.47 0 1 
CPI Tobacco 44646 1.25 0.18 107.48 175.47 
CPI Alcohol 44646 1.17 0.09 104.32 137.68 
Natural logarithm of 
Household Annual 
Disposable Income 44646 10.88 0.89 0.00 13.79 
Poor Health 44646 0.03 0.18 0 1 
Fair Health 44646 0.15 0.36 0 1 
Good Health  44646 0.37 0.48 0 1 
Smoking Ban 44646 0.55 0.50 0 1 
Major City Residence 44646 0.55 0.50 0 1 
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Table 46:Covariance matrices parameter reference table 
Male Sub-sample Estimates Pooled Sample Estimates 
Smoking equation Smoking equation 
1. L .Smoker 1. L .Smoker 
2. L. At-risk Drinker 2. L. At-risk Drinker 
3. Smoker Initial Condition 3. Smoker Initial Condition 
4. At-risk Drinker Initial Condition 4. At-risk Drinker Initial Condition 
5. Age 5. Age 
6. Vocational Education 6. Vocational Education 
7. Graduate Education 7. Graduate Education 
8. Separated 8. Separated 
9. Divorced 9. Divorced 
10. Widowed 10. Widowed 
11. Never married, not cohabiting 11. Never married, not cohabiting 
12. Never married, cohabiting 12. Never married, cohabiting 
13. Child(ren) residing at family home 13. Child(ren) residing at family home 
14. CPI Tobacco 14. CPI Tobacco 
15. CPI Alcohol 15. CPI Alcohol 
16.ln( Annual Disposable Income) 16.ln( Annual Disposable Income) 
17. Smoking Ban 17. Smoking Ban 
18. Good Health 18. Good Health 
19. Fair Health 19. Fair Health 
20. Poor Health 20. Poor Health 
21. Major City Residence 21. Major City Residence 
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Male Sub-sample Estimates Pooled Sample Estimates 
22. TA_ Vocational Education 22. Male 
23. TA_ Graduate Education 23. TA_ Separated 
24. TA_ Separated 24. TA_ Divorced 
25. TA_ Divorced 25. TA_ Widowed 
26. TA_ Widowed 26. TA_ Never married, not cohabiting 
27. TA_ Never married, not cohabiting 27. TA_ Never married, cohabiting 
28. TA_ Never married, cohabiting 28. TA_Child(ren) residing at family home 
29. TA_Child(ren) residing at family home 29. TA_ CPI Tobacco 
30. TA_ CPI Tobacco 30. TA_ CPI Alcohol 
31. TA_ CPI Alcohol 31. TA_ ln( Annual Disposable Income) 
32. TA_ ln( Annual Disposable Income) 32. TA_ Smoking Ban 
33. TA_ Smoking Ban 33. TA_ Good Health 
34. TA_ Good Health 34. TA_ Fair Health 
35. TA_ Fair Health 35. TA_ Poor Health 
36. TA_ Poor Health 36. TA_ Major City Residence 
37. TA_ Major City Residence 37. Constant 
38. Constant  
Drinking equation Drinking equation 
39. L .Smoker 38. L .Smoker 
40. L. At-risk Drinker 39. L. At-risk Drinker 
41. Smoker Initial Condition 40. Smoker Initial Condition 
42. At-risk Drinker Initial Condition 41. At-risk Drinker Initial Condition 
43. Age 42. Age 
44. Vocational Education 43. Vocational Education 
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Male Sub-sample Estimates Pooled Sample Estimates 
45. Graduate Education 44. Graduate Education 
46. Separated 45. Separated 
47. Divorced 46. Divorced 
48. Widowed 47. Widowed 
49. Never married, not cohabiting 48. Never married, not cohabiting 
50. Never married, cohabiting 49. Never married, cohabiting 
51. Child(ren) residing at family home 50. Child(ren) residing at family home 
52. CPI Tobacco 51. CPI Tobacco 
53. CPI Alcohol 52. CPI Alcohol 
54.ln( Annual Disposable Income) 53.ln( Annual Disposable Income) 
55. Smoking Ban 54. Smoking Ban 
56. Good Health 55. Good Health 
57. Fair Health 56. Fair Health 
58. Poor Health 57. Poor Health 
59. Major City Residence 58. Major City Residence 
60. TA_ Vocational Education 59. Male 
61. TA_ Graduate Education 60. TA_ Separated 
62. TA_ Separated 61. TA_ Divorced 
63. TA_ Divorced 62. TA_ Widowed 
64. TA_ Widowed 63. TA_ Never married, not cohabiting 
65. TA_ Never married, not cohabiting 64. TA_ Never married, cohabiting 
66. TA_ Never married, cohabiting 65. TA_Child(ren) residing at family home 
67. TA_Child(ren) residing at family home 66. TA_ CPI Tobacco 
68. TA_ CPI Tobacco 67. TA_ CPI Alcohol 
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Male Sub-sample Estimates Pooled Sample Estimates 
69. TA_ CPI Alcohol 68. TA_ ln( Annual Disposable Income) 
70. TA_ ln( Annual Disposable Income) 69. TA_ Smoking Ban 
71. TA_ Smoking Ban 70. TA_ Good Health 
72. TA_ Good Health 71. TA_ Fair Health 
73. TA_ Fair Health 72. TA_ Poor Health 
74. TA_ Poor Health 73. TA_ Major City Residence 
75. TA_ Major City Residence 74. Constant 
76. Constant  
Other parameters Other parameters 
77.  Unobserved time-variant effects correlation 75.  Unobserved time-variant effects correlation 
78.  Unobserved time-invariant effect variance, smoking equation 76.  Unobserved time-invariant effect variance, smoking equation 
79.  Unobserved time-invariant effect variance, drinking equation 77.  Unobserved time-invariant effect variance, drinking equation 
80.  Unobserved time-invariant effects correlation 78.  Unobserved time-invariant effects correlation 
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Table 47: Parameter covariance matrix, male estimates 
Parameters 1 2 3 4 5 6 7 8 9 10 11 
1 5.49E-03           
2 -3.30E-04 6.39E-03          
3 -9.71E-03 -8.77E-05 2.68E-02         
4 -1.46E-05 -3.94E-03 5.65E-05 6.80E-03        
5 4.36E-03 -1.57E-04 -1.07E-02 -1.52E-03 7.25E-02       
6 -9.07E-04 2.43E-04 2.24E-03 -5.39E-05 9.26E-05 3.90E-02      
7 -8.79E-04 2.78E-04 2.29E-03 -3.64E-05 2.07E-04 1.41E-02 5.95E-02     
8 -2.20E-06 -2.49E-04 5.61E-04 1.31E-04 9.76E-05 2.55E-04 -2.81E-04 3.50E-02    
9 -3.81E-04 -1.72E-04 9.05E-04 2.38E-05 4.72E-04 -9.33E-05 7.60E-04 1.75E-02 3.90E-02   
10 -1.31E-03 -2.40E-04 2.05E-03 2.78E-04 -9.31E-04 4.94E-04 9.35E-04 9.44E-03 1.57E-02 1.95E-01  
11 -3.46E-04 -4.04E-05 4.50E-04 2.33E-05 -2.53E-03 8.24E-04 9.75E-04 1.92E-03 1.35E-03 1.01E-04 4.44E-02 
12 -4.29E-04 2.85E-05 8.38E-04 -1.86E-05 -3.08E-03 -9.44E-04 -1.01E-03 1.17E-03 8.34E-04 -1.04E-04 3.12E-02 
13 3.07E-04 6.17E-05 -7.86E-04 -1.19E-04 9.83E-04 -2.78E-04 -1.78E-04 4.24E-03 3.07E-03 1.29E-03 3.98E-03 
14 5.81E-04 -4.45E-04 -2.30E-03 2.41E-04 -2.69E-04 3.30E-04 4.96E-04 -2.58E-04 -2.34E-04 -1.72E-03 1.75E-03 
15 2.29E-03 4.29E-04 -4.06E-03 -1.03E-04 -9.95E-03 -7.25E-03 -9.86E-03 -1.66E-03 -2.34E-03 -6.92E-04 4.01E-03 
16 2.96E-05 -5.39E-05 -3.09E-05 1.89E-05 -1.27E-04 1.63E-04 -6.81E-06 2.75E-04 1.83E-04 3.79E-04 4.16E-04 
17 1.81E-04 -4.48E-05 -6.60E-04 1.77E-05 -1.65E-04 -1.82E-04 -4.61E-04 -8.68E-07 -1.22E-04 -5.51E-04 4.30E-04 
18 -1.49E-04 -9.43E-05 5.20E-04 6.07E-05 -1.48E-04 -3.35E-05 2.32E-04 2.49E-04 2.56E-04 4.68E-04 -1.07E-05 
19 5.21E-06 -4.12E-05 -5.21E-05 3.33E-05 2.15E-04 4.56E-05 4.15E-04 1.83E-04 6.08E-04 2.74E-04 4.52E-05 
20 -2.47E-04 -2.20E-04 2.28E-04 1.51E-04 3.29E-04 1.19E-04 6.72E-04 1.00E-03 1.34E-03 2.06E-04 -7.69E-05 
21 1.83E-04 1.93E-04 -6.05E-04 -1.40E-04 2.52E-05 2.02E-04 7.07E-04 -3.17E-04 -6.81E-04 -1.35E-03 -1.29E-03 
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Parameters 1 2 3 4 5 6 7 8 9 10 11 
22 1.70E-03 -2.63E-04 -4.42E-03 -5.67E-05 2.88E-04 -3.96E-02 -1.45E-02 -4.23E-04 -1.88E-05 -5.74E-04 -7.29E-04 
23 2.16E-03 -4.09E-04 -5.51E-03 3.21E-05 2.47E-04 -1.43E-02 -6.08E-02 5.57E-05 -9.85E-04 -1.27E-03 -8.14E-04 
24 -2.90E-03 -3.95E-04 6.84E-03 3.79E-04 6.36E-05 3.82E-04 1.35E-03 -3.60E-02 -1.93E-02 -9.50E-03 -2.51E-03 
25 -1.32E-03 1.29E-04 3.18E-03 -2.03E-04 -1.32E-04 6.67E-04 -1.82E-04 -1.72E-02 -3.96E-02 -1.51E-02 -1.90E-03 
26 8.50E-05 -4.32E-04 2.41E-03 3.84E-04 -1.09E-02 -3.06E-04 -8.03E-04 -9.97E-03 -1.68E-02 -2.09E-01 -3.55E-04 
27 -1.32E-03 -9.16E-05 4.32E-03 1.37E-04 1.68E-02 -5.86E-04 -8.43E-04 -1.78E-03 -1.11E-03 2.85E-04 -4.57E-02 
28 -5.17E-04 4.75E-05 7.53E-04 -1.95E-04 1.48E-02 8.13E-04 1.10E-03 -1.34E-03 -8.47E-04 2.70E-04 -3.07E-02 
29 -6.41E-04 5.77E-05 1.55E-03 2.90E-04 4.63E-03 5.39E-04 5.55E-04 -4.32E-03 -3.17E-03 -1.46E-03 -4.54E-03 
30 8.13E-03 -7.28E-03 -2.05E-02 -1.74E-03 1.53E-02 -2.07E-03 -3.83E-03 -3.54E-03 -4.45E-04 -1.10E-03 2.50E-04 
31 -1.45E-02 7.09E-03 3.53E-02 4.06E-03 -2.06E-03 8.94E-03 1.38E-02 6.50E-03 2.39E-03 1.54E-03 -5.08E-03 
32 -1.36E-05 -3.84E-05 2.75E-04 -2.16E-04 3.15E-03 -1.22E-04 6.62E-05 -1.77E-04 -1.63E-05 1.07E-05 -5.69E-04 
33 -1.83E-04 1.12E-03 3.54E-04 -2.29E-04 -4.68E-04 4.26E-04 1.09E-03 6.62E-04 4.89E-04 1.79E-03 -2.18E-04 
34 -1.21E-03 1.13E-04 2.46E-03 -3.45E-04 -3.99E-03 4.20E-04 2.69E-04 -6.44E-05 -5.87E-05 -2.18E-04 3.65E-07 
35 -8.68E-04 6.08E-05 1.82E-03 1.04E-04 -8.93E-03 1.82E-04 -6.80E-05 1.11E-04 -3.38E-04 4.01E-05 1.23E-04 
36 -7.39E-04 6.91E-04 1.10E-03 -1.60E-04 -7.22E-03 5.00E-04 -2.25E-04 -8.57E-04 -1.26E-03 -3.70E-04 5.40E-05 
37 8.67E-05 6.26E-05 -1.33E-04 2.21E-04 -5.04E-05 -3.43E-04 -7.86E-04 3.80E-04 5.36E-04 1.49E-03 1.38E-03 
38 6.08E-03 7.73E-04 -2.07E-02 -6.88E-04 -6.65E-02 -1.76E-03 -2.93E-03 -2.69E-03 -1.72E-03 -2.92E-03 1.93E-03 
39 5.89E-04 2.75E-03 -1.52E-03 -1.88E-03 6.29E-04 1.02E-04 -4.74E-05 -2.53E-04 -2.31E-04 -3.47E-04 3.65E-05 
40 -2.26E-05 3.24E-04 1.51E-05 -2.05E-04 -1.54E-05 1.81E-05 2.46E-05 -1.27E-05 -1.85E-05 -6.99E-06 2.02E-05 
41 -4.33E-04 -2.11E-03 1.36E-03 1.41E-03 -3.42E-04 -9.10E-05 1.75E-05 1.89E-04 1.71E-04 1.99E-04 -5.48E-05 
42 2.83E-05 -5.68E-04 -1.98E-05 6.09E-04 -9.55E-05 -2.22E-05 -2.64E-05 2.92E-05 3.99E-05 9.02E-05 -4.60E-05 
43 -4.18E-06 1.70E-04 1.24E-04 -2.47E-04 3.53E-03 -6.14E-06 2.98E-05 -3.28E-05 -2.74E-05 -3.16E-04 -1.16E-04 
44 -3.18E-05 -2.89E-04 1.13E-04 2.14E-04 -7.06E-05 1.84E-03 6.45E-04 3.34E-05 3.53E-05 8.81E-05 4.10E-05 
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Parameters 1 2 3 4 5 6 7 8 9 10 11 
45 -2.29E-05 -2.63E-04 1.01E-04 1.85E-04 5.05E-08 6.15E-04 2.82E-03 4.64E-05 5.86E-06 6.94E-05 4.51E-05 
46 5.92E-06 2.17E-04 -4.60E-05 -1.45E-04 1.04E-05 2.35E-05 1.25E-05 1.22E-03 5.52E-04 1.87E-04 8.07E-05 
47 -5.36E-06 -1.15E-04 2.32E-05 7.82E-05 -1.67E-05 1.49E-05 -9.11E-06 5.73E-04 1.21E-03 2.91E-04 4.44E-05 
48 4.46E-06 -6.45E-05 -2.49E-05 9.30E-05 -1.01E-04 2.03E-05 2.43E-05 2.31E-04 3.34E-04 4.54E-03 -1.20E-05 
49 2.79E-05 -7.68E-06 -9.00E-05 8.61E-06 -7.98E-05 2.71E-05 4.17E-05 7.82E-05 4.41E-05 -3.07E-05 1.64E-03 
50 2.08E-05 2.38E-05 -6.86E-05 -6.76E-06 -9.36E-05 -4.30E-05 -1.82E-05 4.35E-05 2.52E-05 -2.02E-05 1.01E-03 
51 1.27E-05 6.55E-05 -3.26E-05 -4.44E-05 5.02E-05 -4.29E-06 -1.47E-06 1.29E-04 7.29E-05 1.35E-06 1.41E-04 
52 2.43E-05 1.47E-05 -7.20E-05 -1.31E-05 -2.03E-05 3.43E-06 5.19E-06 1.89E-06 1.48E-06 -2.03E-06 3.18E-06 
53 6.87E-05 4.31E-04 -1.99E-04 -2.62E-04 -4.92E-04 -1.54E-04 -2.59E-04 -5.32E-05 -6.82E-05 -2.50E-04 2.46E-04 
54 -2.40E-06 1.35E-05 4.37E-06 -8.86E-06 -8.53E-06 3.45E-06 -5.95E-06 1.43E-05 3.81E-06 4.25E-06 1.66E-05 
55 6.56E-06 -8.46E-07 -1.33E-05 3.59E-07 -2.96E-05 -8.23E-06 -1.11E-05 -6.82E-06 -3.86E-06 -1.03E-05 7.95E-06 
56 1.46E-06 5.56E-06 -1.01E-05 -5.15E-06 1.11E-05 1.22E-06 3.33E-07 1.57E-06 2.12E-06 -3.55E-06 9.51E-07 
57 2.36E-06 -7.92E-07 -1.28E-05 -3.96E-06 1.66E-05 5.91E-06 6.74E-06 1.25E-06 8.90E-06 -1.26E-05 9.52E-07 
58 -1.95E-07 -8.41E-06 -1.46E-05 3.45E-06 2.05E-05 1.02E-05 1.97E-05 8.29E-06 1.55E-05 -4.10E-06 -5.20E-07 
59 2.10E-05 -9.73E-06 -5.99E-05 5.17E-06 4.31E-05 -1.91E-05 2.90E-05 -1.65E-06 -1.17E-05 -4.05E-05 -3.54E-05 
60 4.83E-05 3.24E-04 -1.36E-04 -2.65E-04 4.35E-05 -1.84E-03 -6.49E-04 -3.22E-05 -4.14E-05 -1.36E-04 -3.58E-05 
61 1.91E-05 3.36E-04 -6.14E-05 -2.41E-04 -8.00E-05 -5.97E-04 -2.84E-03 -5.66E-05 -1.07E-05 -7.52E-05 -7.20E-06 
62 -6.92E-05 -9.09E-04 2.12E-04 6.24E-04 5.08E-05 -6.10E-05 9.59E-07 -1.20E-03 -5.33E-04 -7.90E-05 -1.18E-04 
63 -3.15E-05 -8.07E-06 2.79E-06 -2.04E-05 1.29E-04 1.06E-05 2.81E-05 -5.43E-04 -1.19E-03 -3.20E-04 -6.32E-05 
64 5.89E-05 -4.63E-04 -3.15E-05 3.23E-04 -4.49E-04 -5.05E-05 -5.27E-05 -1.75E-04 -2.74E-04 -4.11E-03 -1.40E-05 
65 -7.73E-05 -3.16E-04 2.38E-04 2.10E-04 8.94E-04 -3.31E-05 -5.67E-05 -5.72E-05 -2.66E-05 -4.20E-05 -1.71E-03 
66 -6.39E-05 -1.14E-04 1.05E-04 4.02E-05 8.57E-04 -1.27E-05 9.65E-06 -5.00E-05 -2.90E-05 -4.30E-05 -9.98E-04 
67 -2.45E-05 -1.43E-04 5.77E-05 1.22E-04 3.15E-04 8.71E-07 8.01E-06 -1.30E-04 -7.55E-05 -2.35E-06 -1.65E-04 
  
 
3
6
9 
Parameters 1 2 3 4 5 6 7 8 9 10 11 
68 4.23E-04 -2.08E-03 -2.76E-04 1.23E-03 7.96E-05 9.26E-04 2.64E-04 6.17E-04 4.25E-04 5.88E-04 -1.90E-04 
69 -6.97E-04 1.21E-03 1.05E-03 -6.02E-04 3.18E-04 -8.76E-04 -8.62E-06 -6.45E-04 -4.97E-04 4.77E-04 2.53E-05 
70 -1.06E-05 3.65E-06 3.62E-05 -3.47E-05 2.37E-04 8.51E-06 9.76E-06 -1.92E-05 -4.07E-06 -1.45E-04 -3.40E-05 
71 -4.79E-05 2.50E-04 4.01E-05 -1.54E-04 5.52E-05 -8.91E-05 -3.73E-06 -2.62E-05 6.00E-06 -5.37E-05 2.68E-05 
72 -2.56E-05 -8.29E-05 1.48E-05 8.12E-05 -3.14E-04 1.82E-05 1.26E-05 1.79E-05 2.26E-05 8.76E-05 -1.83E-05 
73 -2.74E-05 -3.23E-05 3.52E-05 4.32E-05 -3.99E-04 2.18E-05 1.25E-05 9.45E-06 -1.24E-06 -1.43E-05 -1.28E-05 
74 -1.09E-04 1.33E-04 1.58E-04 -8.65E-05 -4.15E-04 3.64E-05 1.49E-05 -2.44E-06 -1.53E-05 -1.03E-04 1.66E-05 
75 -7.50E-06 1.63E-04 4.21E-06 -1.12E-04 -5.34E-05 9.62E-06 -3.28E-05 -5.12E-06 -3.56E-06 2.12E-06 3.55E-05 
76 3.23E-04 4.32E-04 -1.08E-03 9.81E-06 -4.24E-03 -1.85E-05 -5.56E-05 1.21E-04 1.34E-04 8.12E-04 2.04E-04 
77 -5.36E-05 1.40E-03 -1.36E-04 -8.72E-04 6.33E-05 1.17E-04 -4.80E-05 -1.34E-04 -1.26E-04 -2.19E-04 -5.48E-06 
78 -3.96E-03 -1.28E-04 1.08E-02 3.78E-04 -5.21E-03 1.00E-03 1.12E-03 1.53E-04 3.76E-04 7.08E-04 2.54E-04 
79 -1.10E-05 -3.50E-04 7.50E-05 2.26E-04 -2.70E-05 -2.81E-05 -1.52E-05 2.74E-05 3.18E-05 4.06E-06 -3.40E-05 
80 -1.13E-04 -3.33E-03 7.30E-04 2.32E-03 -4.10E-04 -1.97E-04 -5.09E-05 2.96E-04 2.50E-04 4.67E-04 -6.27E-05 
 
Parameters 12 13 14 15 16 17 18 19 20 21 22 
12 3.53E-02           
13 2.39E-03 1.04E-02          
14 1.01E-03 1.04E-04 6.74E-02         
15 3.78E-03 5.02E-04 -1.39E-01 4.40E-01        
16 7.06E-05 -2.40E-04 1.80E-04 -1.41E-03 1.06E-03       
17 3.72E-04 -5.52E-05 4.22E-03 -2.77E-02 -4.28E-05 4.65E-03      
18 -1.38E-04 -7.79E-05 -1.68E-04 5.11E-04 -3.69E-07 -1.08E-04 3.99E-03     
  
 
 
3
7
0 
Parameters 12 13 14 15 16 17 18 19 20 21 22 
19 -2.17E-04 -9.12E-05 -5.31E-05 -7.87E-04 2.42E-05 -2.17E-05 3.28E-03 9.11E-03    
20 -1.29E-04 -4.67E-05 -8.53E-04 8.50E-04 7.57E-05 -3.11E-04 3.16E-03 7.30E-03 3.10E-02   
21 -1.10E-03 2.23E-04 2.53E-04 3.94E-04 2.71E-05 6.90E-05 -4.87E-05 -3.11E-04 -5.74E-04 2.35E-02  
22 1.07E-03 3.62E-04 -1.01E-04 7.72E-03 -1.39E-04 2.35E-04 -2.80E-05 -7.62E-05 -1.91E-04 -2.26E-04 4.46E-02 
23 1.09E-03 2.13E-04 -8.18E-05 1.05E-02 3.45E-05 5.68E-04 -3.09E-04 -3.92E-04 -8.16E-04 -4.62E-04 1.72E-02 
24 -1.69E-03 -4.58E-03 -3.99E-04 -3.95E-04 -2.82E-04 -2.27E-04 7.22E-06 -1.32E-04 -9.68E-04 1.02E-04 -1.07E-03 
25 -1.37E-03 -3.16E-03 -2.83E-04 1.22E-03 -1.83E-04 -4.14E-05 -1.90E-04 -6.18E-04 -1.33E-03 4.75E-04 -1.09E-03 
26 7.50E-05 -1.85E-03 1.58E-03 1.76E-03 -3.82E-04 5.03E-04 -3.68E-04 -2.97E-04 -3.57E-04 1.08E-03 7.01E-04 
27 -3.24E-02 -4.12E-03 -2.55E-03 -7.17E-03 -4.33E-04 -6.77E-04 1.74E-04 3.07E-05 2.30E-04 1.24E-03 7.86E-04 
28 -3.51E-02 -2.71E-03 -1.45E-03 -6.31E-03 -8.91E-05 -4.93E-04 1.73E-04 1.52E-04 7.02E-05 7.70E-04 -1.07E-03 
29 -2.92E-03 -1.07E-02 -2.52E-04 -1.51E-03 2.57E-04 -6.39E-05 1.16E-04 1.02E-04 7.15E-05 -3.38E-04 -8.48E-04 
30 6.37E-04 1.51E-03 -7.68E-02 1.76E-01 -5.31E-04 -4.72E-03 2.15E-04 1.38E-03 1.31E-03 5.59E-03 1.28E-03 
31 -3.52E-03 -3.67E-03 1.47E-01 -4.97E-01 1.77E-03 3.08E-02 1.96E-04 -2.13E-04 3.94E-05 -5.02E-03 -7.93E-03 
32 -2.31E-04 3.09E-04 -2.73E-04 8.26E-04 -1.14E-03 3.67E-05 -1.08E-05 -4.22E-05 -1.44E-04 -1.02E-04 -1.31E-04 
33 2.13E-04 -1.77E-04 -6.73E-03 3.66E-02 1.55E-04 -5.82E-03 4.42E-05 -1.12E-04 5.61E-04 -8.05E-04 -6.25E-04 
34 4.21E-05 -5.29E-05 -1.76E-04 -2.26E-04 -2.65E-05 -2.25E-05 -4.00E-03 -3.33E-03 -3.17E-03 -1.02E-04 -6.49E-04 
35 3.14E-04 1.05E-04 8.10E-05 1.68E-03 -1.42E-05 -8.81E-07 -3.19E-03 -9.26E-03 -7.23E-03 4.44E-04 -7.74E-05 
36 5.22E-05 9.67E-05 9.02E-04 -4.22E-04 -1.57E-04 2.80E-04 -3.09E-03 -7.29E-03 -3.26E-02 3.48E-04 -6.21E-04 
37 1.19E-03 -1.30E-04 -1.80E-04 -2.87E-04 -4.03E-05 -6.38E-05 7.60E-05 3.48E-04 6.07E-04 -2.37E-02 2.49E-04 
38 8.60E-04 1.13E-03 6.28E-03 2.52E-02 8.01E-04 -1.50E-03 -1.03E-03 -2.91E-04 -1.14E-03 -6.99E-06 2.33E-03 
39 2.24E-05 2.53E-05 -1.23E-04 3.94E-04 -2.25E-05 1.21E-05 -5.93E-05 -1.85E-05 -1.44E-04 9.37E-05 1.04E-05 
40 1.47E-05 -1.66E-06 -2.12E-05 1.43E-08 9.62E-07 -3.42E-06 -1.95E-06 -4.05E-06 4.96E-06 1.06E-05 -3.42E-05 
41 -3.79E-05 -2.31E-05 8.87E-05 -3.15E-04 1.66E-05 -8.17E-06 4.51E-05 1.43E-05 9.62E-05 -8.12E-05 2.87E-05 
  
 
3
7
1 
Parameters 12 13 14 15 16 17 18 19 20 21 22 
42 -3.13E-05 1.78E-06 3.46E-05 1.21E-05 -3.77E-06 6.64E-06 3.19E-06 4.37E-06 -1.01E-05 -2.15E-05 3.61E-05 
43 -1.18E-04 4.17E-05 -7.64E-05 -5.70E-04 -8.86E-08 -3.70E-05 8.35E-07 -5.94E-07 -8.73E-06 2.06E-05 -3.91E-05 
44 -3.59E-05 -9.80E-06 4.36E-05 -2.35E-04 5.26E-06 -8.87E-06 1.21E-05 1.23E-05 3.84E-05 -2.56E-05 -1.85E-03 
45 -1.92E-05 1.86E-06 2.24E-05 -2.87E-04 -2.64E-06 -1.11E-05 1.15E-05 1.26E-05 3.92E-05 4.10E-05 -6.31E-04 
46 5.03E-05 1.33E-04 -1.85E-05 3.30E-05 1.30E-05 -8.22E-06 -1.90E-07 1.91E-06 -3.28E-06 3.07E-06 -1.58E-05 
47 2.91E-05 7.46E-05 1.75E-05 -4.27E-05 5.01E-06 -1.97E-06 4.70E-06 9.82E-06 2.18E-05 -1.44E-05 -1.34E-05 
48 -1.21E-05 1.44E-05 -1.16E-05 -1.01E-04 6.01E-06 -1.16E-05 4.43E-06 2.56E-06 7.09E-06 -2.27E-05 -3.88E-05 
49 1.02E-03 1.41E-04 1.31E-05 2.46E-04 1.76E-05 1.09E-05 -7.08E-07 1.84E-06 -5.12E-06 -2.71E-05 -1.68E-05 
50 1.22E-03 8.08E-05 1.18E-05 2.16E-04 3.15E-06 7.30E-06 -2.47E-06 -1.63E-06 -1.78E-07 -1.37E-05 5.06E-05 
51 8.45E-05 3.37E-04 -5.49E-08 5.27E-06 -8.51E-06 5.18E-07 -6.23E-08 3.38E-06 3.51E-06 -8.25E-06 1.24E-06 
52 6.33E-06 7.31E-06 1.89E-03 -3.97E-03 3.08E-06 1.25E-04 -6.33E-06 -2.95E-06 -8.18E-06 -1.44E-06 -7.21E-07 
53 2.06E-04 -1.86E-06 -4.01E-03 1.29E-02 -4.23E-05 -8.16E-04 -1.65E-05 -4.35E-05 -9.55E-05 8.42E-05 1.78E-04 
54 2.86E-06 -8.39E-06 1.00E-06 -3.64E-05 3.59E-05 -1.81E-06 -5.71E-07 3.81E-07 1.48E-06 -5.16E-06 -3.83E-06 
55 5.10E-06 6.54E-07 1.23E-04 -8.13E-04 -1.67E-06 1.38E-04 -9.52E-07 -1.29E-06 -3.12E-06 -1.36E-06 1.07E-05 
56 -2.74E-06 1.88E-07 -2.49E-06 -7.28E-06 -4.80E-07 -4.88E-07 1.25E-04 1.06E-04 1.02E-04 -1.79E-06 1.00E-06 
57 -3.37E-06 4.12E-06 3.65E-06 -4.64E-05 2.27E-07 -1.04E-06 1.06E-04 2.97E-04 2.49E-04 -5.50E-06 -3.02E-06 
58 -2.29E-07 7.76E-06 1.06E-05 -9.26E-05 2.64E-06 -2.55E-06 1.05E-04 2.52E-04 1.05E-03 -4.04E-06 -1.71E-05 
59 -2.25E-05 -6.28E-06 3.32E-06 7.03E-05 -5.36E-06 3.19E-08 -4.04E-06 -5.14E-06 -7.02E-06 7.92E-04 2.43E-05 
60 4.38E-05 8.80E-06 -4.01E-05 2.36E-04 -4.76E-06 1.02E-05 -1.12E-05 -1.13E-05 -4.68E-05 2.64E-05 2.10E-03 
61 5.61E-05 -2.34E-06 -1.83E-05 2.79E-04 2.57E-06 1.00E-05 -1.10E-05 -1.16E-05 -4.33E-05 -2.91E-05 7.38E-04 
62 -8.66E-05 -1.20E-04 5.16E-05 -1.32E-04 -1.03E-05 1.11E-05 1.49E-05 4.23E-06 2.49E-05 -2.45E-05 4.34E-05 
63 -5.34E-05 -6.80E-05 -1.27E-05 -8.24E-06 1.51E-06 -2.43E-06 -6.06E-06 -5.14E-06 -5.59E-06 1.31E-05 -4.84E-05 
64 -7.70E-06 -1.63E-05 5.78E-05 2.36E-04 -1.97E-05 2.60E-05 6.18E-07 1.14E-05 -1.53E-06 1.57E-06 7.92E-05 
  
 
 
3
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Parameters 12 13 14 15 16 17 18 19 20 21 22 
65 -1.08E-03 -1.34E-04 -1.86E-05 -4.18E-04 -1.60E-05 -1.42E-05 -3.05E-08 -4.18E-06 1.34E-05 1.91E-05 4.71E-05 
66 -1.21E-03 -8.93E-05 4.71E-06 -4.33E-04 4.58E-07 -1.50E-05 1.13E-05 5.68E-06 1.10E-05 1.21E-06 -2.03E-05 
67 -1.05E-04 -3.41E-04 -3.40E-06 -5.08E-05 9.91E-06 -7.15E-06 1.20E-07 -3.78E-06 -2.52E-07 2.70E-06 -4.21E-06 
68 -2.14E-04 -2.40E-05 -1.98E-03 4.54E-03 -5.25E-05 2.00E-06 6.51E-05 1.53E-04 6.32E-05 2.04E-04 -6.29E-04 
69 1.28E-04 -3.08E-05 4.05E-03 -1.39E-02 9.53E-05 7.63E-04 -5.12E-06 -7.18E-05 9.29E-05 -3.94E-04 6.62E-04 
70 -1.89E-05 1.10E-05 -1.03E-05 -5.58E-06 -3.78E-05 -1.13E-06 -1.43E-07 -4.49E-06 -9.74E-06 5.30E-06 -1.49E-05 
71 5.82E-05 -2.54E-06 -2.36E-04 1.11E-03 9.45E-06 -1.84E-04 -1.23E-05 -2.49E-05 -1.10E-05 2.42E-06 1.96E-05 
72 -1.19E-05 4.78E-07 7.33E-06 4.69E-05 -1.57E-06 1.72E-06 -1.26E-04 -1.07E-04 -9.80E-05 -1.50E-05 -6.74E-06 
73 -6.45E-06 -1.23E-05 1.39E-05 6.50E-05 9.88E-07 5.61E-06 -1.04E-04 -3.07E-04 -2.48E-04 1.29E-06 -1.14E-05 
74 1.08E-05 -1.46E-05 -3.04E-05 9.82E-05 -4.23E-06 1.39E-06 -1.03E-04 -2.53E-04 -1.13E-03 2.36E-05 -2.39E-06 
75 2.47E-05 1.16E-05 -1.30E-05 -4.43E-05 5.99E-06 -1.26E-06 1.91E-06 5.70E-06 7.23E-06 -7.94E-04 -2.96E-05 
76 1.23E-04 5.45E-06 2.65E-04 1.06E-03 1.77E-05 -1.58E-05 -3.41E-05 3.77E-06 4.91E-05 1.15E-04 -1.44E-04 
77 -1.06E-05 -1.61E-05 -2.11E-04 2.89E-04 -6.33E-06 -1.09E-05 -1.04E-05 -2.86E-05 -1.24E-04 4.30E-05 -1.10E-04 
78 4.04E-04 -2.98E-04 -9.64E-04 -1.70E-03 5.90E-06 -2.89E-04 1.99E-04 -6.76E-05 7.62E-05 -2.98E-04 -1.93E-03 
79 -2.65E-05 2.21E-06 1.60E-05 -2.21E-05 -8.35E-07 2.85E-06 3.34E-06 2.00E-06 -5.80E-06 -1.38E-05 4.92E-05 
80 -7.04E-05 -8.21E-06 1.62E-04 -1.18E-04 2.72E-05 1.17E-05 5.45E-05 8.05E-06 1.26E-04 -7.46E-05 1.48E-04 
 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
23 6.99E-02           
24 
-2.69E-
03 7.63E-02          
25 9.64E-05 2.15E-02 5.36E-02         
  
 
3
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3 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
26 1.36E-03 1.47E-02 1.99E-02 2.83E-01        
27 6.38E-04 8.25E-03 6.25E-03 2.46E-03 5.99E-02       
28 
-1.62E-
03 6.32E-03 4.85E-03 4.68E-04 3.71E-02 5.17E-02      
29 
-7.58E-
04 7.17E-03 5.58E-03 3.44E-03 9.75E-03 5.67E-03 1.80E-02     
30 7.95E-03 8.43E-03 
-1.48E-
03 2.71E-03 -1.37E-04 -2.79E-03 -6.00E-03 4.71E+00    
31 
-2.27E-
02 
-9.32E-
03 1.21E-03 -1.73E-03 1.50E-02 6.15E-03 1.20E-02 
-
4.99E+00 6.76E+00   
32 
-8.27E-
04 9.08E-04 8.46E-04 1.62E-03 1.65E-03 8.88E-04 -1.04E-03 -3.55E-03 2.67E-04 3.82E-03  
33 
-7.69E-
04 
-1.81E-
03 
-1.22E-
03 -1.41E-03 -6.33E-05 -2.12E-03 3.30E-04 -5.06E-01 3.44E-01 -9.68E-05 1.15E-01 
34 1.44E-04 1.51E-03 1.02E-03 1.10E-03 6.60E-04 6.49E-04 -3.22E-04 -6.43E-03 8.68E-03 2.40E-04 2.15E-04 
35 4.94E-04 
-7.06E-
04 4.59E-04 9.49E-04 -5.72E-04 -3.79E-04 -8.35E-04 4.74E-03 -6.96E-03 7.37E-04 -7.05E-04 
36 5.99E-04 2.57E-03 2.59E-03 2.26E-03 5.25E-04 7.40E-04 -2.21E-04 1.26E-02 -1.67E-02 1.73E-03 -1.85E-03 
37 2.08E-05 
-1.16E-
05 
-5.53E-
04 -1.53E-03 -2.00E-03 -9.60E-04 4.27E-04 -1.28E-02 8.33E-03 -2.63E-04 2.69E-03 
38 1.41E-02 
-1.26E-
02 
-1.27E-
02 -1.81E-02 -3.49E-02 -1.42E-02 -3.17E-03 1.94E-01 
-
1.51E+00 -2.72E-02 1.34E-01 
39 7.41E-05 -3.67E- -3.31E- -1.80E-04 -2.90E-04 -3.45E-05 3.88E-05 -3.72E-03 2.87E-03 9.61E-06 7.44E-04 
  
 
 
3
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Parameters 23 24 25 26 27 28 29 30 31 32 33 
04 05 
40 
-4.57E-
05 
-4.21E-
05 1.51E-05 -5.50E-05 -4.80E-05 -8.70E-06 2.03E-06 -3.76E-04 3.15E-04 -6.08E-06 5.54E-05 
41 8.33E-06 2.05E-04 
-1.26E-
05 1.96E-04 2.53E-04 -3.63E-06 -3.51E-05 2.94E-03 -2.24E-03 1.91E-05 -5.88E-04 
42 5.78E-05 1.01E-04 
-4.01E-
05 7.27E-05 1.18E-04 5.53E-06 1.85E-05 4.07E-04 -2.67E-04 -5.42E-06 -7.43E-05 
43 
-1.03E-
04 1.76E-04 1.81E-04 -4.00E-04 9.99E-04 9.01E-04 3.57E-04 -3.49E-04 1.23E-03 2.28E-04 1.07E-04 
44 
-6.40E-
04 1.93E-05 1.13E-05 -1.51E-05 -2.52E-05 8.93E-06 6.48E-06 1.05E-03 -8.23E-04 3.46E-06 -1.57E-04 
45 
-2.85E-
03 1.91E-05 2.59E-05 -2.18E-05 -5.29E-05 1.04E-05 2.37E-06 6.19E-04 -3.02E-04 5.06E-06 -8.86E-05 
46 
-1.54E-
05 
-1.29E-
03 
-5.43E-
04 -2.21E-04 -9.60E-05 -5.63E-05 -1.34E-04 1.14E-05 -4.98E-05 -1.41E-05 3.54E-05 
47 1.47E-05 
-5.92E-
04 
-1.20E-
03 -2.50E-04 -4.02E-05 -3.71E-05 -8.43E-05 5.33E-04 -5.76E-04 2.35E-07 -5.59E-05 
48 
-1.67E-
05 
-2.20E-
04 
-3.77E-
04 -4.42E-03 -3.96E-05 -1.71E-05 -2.98E-05 3.02E-04 6.08E-05 -5.54E-05 -1.99E-05 
49 
-3.28E-
06 
-1.27E-
04 
-7.82E-
05 1.14E-05 -1.71E-03 -1.02E-03 -1.67E-04 3.57E-05 -2.21E-04 -3.21E-05 5.26E-06 
50 4.37E-05 
-8.76E-
05 
-5.96E-
05 1.32E-05 -1.07E-03 -1.22E-03 -1.00E-04 -2.16E-04 8.74E-05 -1.63E-05 6.84E-05 
  
 
3
7
5 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
51 7.57E-07 
-1.33E-
04 
-7.48E-
05 -2.28E-05 -1.41E-04 -8.72E-05 -3.39E-04 -3.36E-04 3.14E-04 1.12E-05 3.91E-05 
52 7.60E-06 
-2.58E-
05 
-1.77E-
05 8.16E-06 -3.16E-05 -1.24E-05 -1.12E-05 -2.67E-03 4.77E-03 -9.70E-06 -1.46E-04 
53 2.57E-04 
-6.12E-
05 9.88E-06 2.54E-04 -3.96E-04 -3.52E-04 -5.74E-05 5.20E-03 -1.51E-02 1.55E-05 1.15E-03 
54 4.67E-06 
-1.40E-
05 
-2.47E-
07 -1.19E-05 -1.77E-05 -3.19E-06 8.82E-06 -3.33E-05 7.02E-05 -3.81E-05 6.27E-06 
55 1.33E-05 5.81E-06 2.06E-07 2.17E-05 -1.55E-05 -1.19E-05 -4.16E-06 -1.24E-04 9.28E-04 -1.29E-06 -1.76E-04 
56 2.10E-06 
-3.29E-
06 
-5.27E-
06 -4.57E-07 -4.48E-06 5.03E-06 -1.01E-06 6.52E-06 1.76E-05 9.41E-07 -1.17E-06 
57 
-2.88E-
06 3.56E-06 
-6.76E-
06 1.21E-05 7.70E-07 6.40E-06 -3.53E-06 3.41E-05 1.52E-05 -7.32E-07 -8.41E-07 
58 
-1.97E-
05 
-1.16E-
05 
-1.74E-
05 -4.21E-06 -3.55E-06 3.21E-07 -4.93E-06 5.05E-05 9.99E-06 -6.73E-06 -2.00E-06 
59 
-6.71E-
06 
-1.91E-
05 1.38E-06 3.14E-05 3.12E-05 7.86E-06 1.11E-06 3.46E-04 -4.79E-04 2.52E-06 -1.81E-05 
60 7.72E-04 
-3.66E-
05 
-4.30E-
05 2.74E-05 4.63E-05 -3.89E-05 -8.39E-06 -8.33E-04 7.36E-04 -1.10E-05 9.76E-05 
61 3.18E-03 
-3.45E-
05 
-1.16E-
05 3.83E-05 3.24E-05 -5.53E-05 7.20E-06 -9.39E-05 -4.69E-04 -4.33E-05 4.48E-05 
62 
-1.29E-
05 3.32E-03 6.35E-04 4.51E-04 3.88E-04 2.62E-04 1.89E-04 9.66E-04 -7.56E-04 7.28E-05 -2.20E-04 
  
 
 
3
7
6 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
63 
-2.20E-
05 6.60E-04 1.89E-03 3.55E-04 2.51E-04 2.20E-04 1.88E-04 -3.66E-04 1.25E-04 4.99E-05 -1.12E-05 
64 1.07E-04 4.05E-04 3.80E-04 6.81E-03 8.43E-05 -3.99E-05 4.11E-05 1.38E-03 -1.41E-03 7.01E-05 -2.14E-04 
65 2.88E-05 3.79E-04 2.70E-04 1.07E-04 2.52E-03 1.30E-03 4.02E-04 3.63E-04 8.33E-05 1.10E-04 -4.95E-06 
66 
-5.05E-
05 3.02E-04 2.38E-04 -9.69E-06 1.30E-03 2.18E-03 2.46E-04 -6.45E-04 9.25E-04 5.76E-05 -1.57E-04 
67 
-2.82E-
06 2.37E-04 1.93E-04 7.70E-05 4.16E-04 2.41E-04 6.99E-04 4.26E-04 -2.53E-04 -5.60E-05 -3.19E-05 
68 6.16E-04 
-5.38E-
04 
-4.95E-
04 4.57E-04 2.30E-04 -7.97E-04 -7.61E-05 2.65E-01 -2.81E-01 -2.02E-04 -2.91E-02 
69 
-1.21E-
03 8.42E-04 3.94E-04 -6.56E-04 2.13E-04 9.68E-04 2.64E-04 -2.81E-01 3.66E-01 -3.39E-05 2.13E-02 
70 
-4.69E-
05 8.23E-05 6.07E-05 1.02E-04 1.16E-04 6.57E-05 -5.42E-05 -2.89E-04 9.46E-05 2.04E-04 2.04E-06 
71 
-8.39E-
05 1.83E-05 
-3.35E-
05 -1.06E-04 5.22E-05 -1.07E-04 4.18E-05 -2.86E-02 2.10E-02 -8.72E-06 6.00E-03 
72 3.16E-05 5.75E-05 2.18E-05 9.82E-05 1.28E-05 -2.15E-07 -5.26E-05 1.06E-04 8.12E-05 7.18E-06 -3.52E-05 
73 4.21E-05 
-3.78E-
05 
-1.45E-
05 -9.75E-06 -4.20E-05 -3.75E-05 -4.53E-05 6.58E-04 -6.90E-04 5.00E-05 -9.71E-05 
74 3.90E-06 1.15E-04 1.04E-04 1.31E-04 2.16E-05 6.56E-06 3.28E-05 4.57E-04 -1.05E-03 5.66E-05 8.87E-05 
75 
-2.44E-
05 
-5.35E-
06 
-1.27E-
05 -7.16E-05 -8.03E-05 -1.50E-05 4.98E-06 -9.92E-04 8.14E-04 -1.45E-05 1.62E-04 
76 6.93E-04 -1.24E- -6.96E- -1.05E-03 -1.94E-03 -9.85E-04 1.25E-07 1.37E-02 -8.00E-02 -1.65E-03 6.85E-03 
  
 
3
7
7 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
03 04 
77 6.39E-06 
-2.82E-
05 9.91E-05 1.07E-06 -2.95E-05 3.95E-05 5.72E-05 -1.49E-03 1.35E-03 2.08E-06 2.59E-04 
78 
-2.63E-
03 3.32E-03 1.57E-03 8.42E-04 1.76E-03 5.75E-04 6.78E-04 -8.57E-03 1.45E-02 5.42E-06 2.24E-04 
79 3.05E-05 6.83E-05 
-2.73E-
06 6.24E-05 9.40E-05 2.60E-05 -2.51E-06 3.60E-04 -2.65E-04 1.56E-05 -6.02E-05 
80 1.29E-04 1.69E-04 
-1.44E-
04 1.73E-04 1.64E-04 -6.95E-05 -1.14E-04 6.79E-03 -6.32E-03 -3.26E-05 -1.14E-03 
 
Parameters 34 35 36 37 38 39 40 41 42 43 44 
34 1.32E-02           
35 5.80E-03 2.55E-02          
36 8.72E-03 5.69E-03 8.57E-02         
37 1.41E-04 -3.77E-04 -8.83E-05 2.76E-02        
38 -7.89E-03 -7.52E-03 -1.51E-02 6.46E-03 1.74E+00       
39 2.47E-06 -8.26E-05 2.77E-04 6.75E-05 9.41E-04 7.49E-03      
40 1.26E-05 2.56E-05 8.71E-07 3.21E-06 1.35E-04 -1.37E-04 2.68E-03     
41 -6.57E-05 4.04E-06 -2.41E-04 -4.34E-05 -1.11E-03 -5.46E-03 -3.38E-04 8.05E-03    
42 -1.08E-05 -3.03E-05 9.11E-06 -4.16E-06 -1.05E-04 8.95E-05 -3.50E-03 2.40E-04 1.05E-02   
43 -2.73E-04 -3.65E-04 -2.77E-04 -4.99E-05 -4.62E-03 9.48E-04 1.69E-04 1.33E-03 -2.03E-03 6.19E-02  
44 1.59E-05 1.88E-05 -2.97E-05 -6.64E-06 -1.43E-04 -4.96E-04 1.79E-04 3.45E-04 -2.59E-04 6.32E-04 3.10E-02 
  
 
 
3
7
8 
Parameters 34 35 36 37 38 39 40 41 42 43 44 
45 1.26E-06 5.77E-06 -4.81E-05 -6.04E-05 -1.24E-04 -5.37E-04 3.10E-04 2.97E-04 -4.72E-04 1.29E-03 8.66E-03 
46 1.17E-05 -2.43E-06 4.43E-05 1.48E-05 2.20E-05 2.64E-04 -1.70E-04 -1.06E-04 1.47E-04 2.07E-04 2.57E-04 
47 5.26E-06 -1.87E-05 -2.34E-05 3.09E-06 1.77E-05 -2.37E-04 -2.87E-04 1.78E-04 5.18E-04 2.98E-04 -4.86E-05 
48 3.26E-05 -1.28E-05 -5.87E-05 2.04E-05 3.16E-04 -3.96E-04 2.34E-04 1.31E-04 -3.89E-04 1.53E-04 4.26E-04 
49 -2.24E-05 -1.87E-05 8.61E-07 3.00E-05 1.81E-04 -1.24E-04 7.29E-06 -4.64E-05 2.40E-05 -2.05E-03 5.43E-04 
50 -1.47E-05 -8.94E-06 -1.06E-05 1.80E-05 1.18E-04 9.61E-06 4.70E-05 -1.45E-04 -1.28E-04 -2.48E-03 -9.88E-04 
51 -5.93E-07 -1.26E-05 -2.37E-06 1.37E-05 -1.86E-05 2.54E-04 1.32E-06 -2.27E-04 -4.98E-05 6.48E-04 -7.35E-05 
52 5.82E-06 -6.82E-06 1.72E-05 6.89E-06 1.73E-04 1.33E-06 -4.77E-05 -1.02E-04 -1.48E-04 -9.47E-04 2.58E-04 
53 5.92E-05 1.28E-04 1.83E-04 -5.38E-05 1.41E-03 1.14E-03 -5.78E-04 -8.66E-04 1.41E-03 -1.08E-02 -4.82E-03 
54 2.60E-06 2.34E-06 -4.06E-07 6.17E-06 2.05E-05 2.81E-05 3.76E-06 -5.34E-05 -3.49E-05 -1.75E-04 4.46E-05 
55 -1.22E-06 2.39E-06 2.48E-06 4.53E-07 -5.05E-05 4.89E-05 -3.05E-05 -2.81E-05 1.03E-04 -4.38E-04 -6.33E-05 
56 -1.30E-04 -1.07E-04 -9.84E-05 2.63E-06 -2.03E-05 -3.02E-05 -5.36E-05 4.39E-05 1.10E-04 8.65E-05 -1.00E-04 
57 -1.09E-04 -3.04E-04 -2.47E-04 6.02E-06 -4.90E-06 -2.95E-05 -1.15E-04 5.61E-05 2.01E-04 7.64E-05 1.34E-05 
58 -1.07E-04 -2.63E-04 -1.11E-03 5.38E-06 7.26E-05 -2.38E-04 1.56E-04 1.06E-04 -6.12E-04 2.90E-04 1.03E-04 
59 -1.60E-05 -5.71E-06 1.23E-05 -8.00E-04 1.11E-04 -9.49E-05 6.80E-05 5.11E-05 5.43E-05 -2.80E-06 -1.39E-04 
60 -4.09E-06 -4.01E-06 8.42E-05 -9.60E-06 -7.48E-06 6.66E-04 -1.72E-04 -3.73E-04 1.40E-04 -1.03E-03 -3.12E-02 
61 5.69E-05 6.17E-05 1.13E-04 1.52E-05 6.86E-04 8.27E-04 -2.51E-04 -1.16E-04 3.46E-04 -2.28E-03 -8.56E-03 
62 1.77E-05 -3.78E-05 -5.77E-05 -2.88E-05 -1.05E-03 -1.32E-03 -6.46E-04 1.19E-04 1.81E-03 3.84E-03 -3.98E-04 
63 2.48E-05 -9.07E-06 5.56E-05 -2.87E-05 -4.28E-04 -1.72E-04 1.19E-04 -5.10E-04 -3.86E-04 3.14E-03 1.30E-04 
64 5.77E-05 -2.78E-05 2.95E-05 -5.70E-05 -7.16E-04 -9.00E-05 -1.16E-03 8.03E-04 2.46E-03 -7.71E-03 -5.24E-04 
65 3.62E-06 -3.95E-05 -2.33E-05 -7.67E-05 -1.84E-03 -4.37E-04 -3.29E-04 5.39E-04 7.08E-04 1.84E-02 -7.50E-04 
66 -5.42E-06 -4.01E-05 -1.60E-05 -1.68E-05 -9.95E-04 -2.91E-04 -9.35E-05 -4.60E-04 9.05E-05 1.52E-02 8.04E-04 
67 -5.08E-05 -3.99E-05 -2.50E-06 -5.56E-06 3.98E-06 -3.59E-04 3.88E-06 1.16E-04 2.81E-04 6.08E-03 2.19E-04 
  
 
3
7
9 
Parameters 34 35 36 37 38 39 40 41 42 43 44 
68 -1.27E-04 3.96E-04 7.84E-04 -7.71E-04 1.32E-02 3.65E-03 -8.59E-03 2.29E-03 1.84E-02 4.33E-03 2.47E-03 
69 3.04E-04 -4.43E-04 -1.60E-03 6.44E-04 -7.96E-02 -7.43E-03 1.02E-02 8.73E-04 -2.18E-02 1.36E-02 1.57E-03 
70 2.88E-06 4.98E-05 6.53E-05 -1.59E-05 -1.67E-03 4.14E-05 -2.00E-04 2.85E-04 2.46E-04 3.60E-03 -7.37E-05 
71 9.82E-06 -4.06E-05 6.20E-05 1.13E-04 6.86E-03 -1.08E-04 9.02E-04 -6.94E-04 -1.95E-03 5.49E-04 -4.96E-05 
72 5.64E-04 2.38E-04 3.29E-04 2.86E-05 -4.01E-04 -3.41E-04 -5.99E-05 -5.93E-04 -4.74E-05 -2.41E-03 1.19E-04 
73 2.38E-04 1.14E-03 1.36E-04 -9.10E-06 -5.91E-04 -1.93E-04 5.97E-05 -5.71E-04 -7.62E-05 -6.28E-03 4.58E-05 
74 3.74E-04 1.72E-04 4.41E-03 4.86E-05 -2.06E-04 1.46E-05 6.35E-05 -1.40E-03 3.31E-04 -4.77E-03 3.64E-04 
75 3.54E-05 -1.10E-08 6.19E-05 9.99E-04 2.63E-04 2.46E-04 1.62E-04 -2.49E-04 -4.15E-04 -4.02E-04 1.24E-04 
76 -3.71E-04 -5.87E-04 -2.05E-04 2.30E-04 9.10E-02 1.39E-03 2.59E-03 -6.22E-03 -4.05E-03 -7.78E-02 6.66E-04 
77 3.53E-05 2.26E-05 2.56E-04 1.53E-05 3.31E-05 1.72E-03 1.55E-05 -1.26E-03 -1.11E-04 1.76E-04 -3.14E-04 
78 1.35E-03 1.12E-03 1.04E-03 -1.12E-05 -7.48E-03 -6.95E-04 -3.64E-06 5.17E-04 3.62E-05 -1.57E-05 5.88E-05 
79 -1.52E-05 -2.34E-05 1.95E-05 -3.49E-06 -2.81E-04 -9.31E-05 -1.86E-03 6.10E-04 4.40E-03 -4.05E-04 -2.15E-04 
80 -1.14E-04 4.66E-05 -4.44E-04 -1.01E-04 -3.68E-04 -3.46E-03 -1.71E-04 2.66E-03 4.34E-04 -1.79E-04 3.32E-04 
 
Parameters 45 46 47 48 49 50 51 52 53 54 55 
45 5.30E-02           
46 -2.50E-04 2.49E-02          
47 3.88E-04 1.13E-02 2.70E-02         
48 5.52E-04 3.89E-03 6.44E-03 7.08E-02        
49 9.94E-04 1.24E-03 8.72E-04 -2.65E-04 3.24E-02       
50 -3.42E-04 7.83E-04 5.74E-04 -2.99E-04 2.25E-02 2.66E-02      
51 -1.05E-04 2.57E-03 1.85E-03 1.96E-04 2.90E-03 1.88E-03 7.38E-03     
  
 
 
3
8
0 
Parameters 45 46 47 48 49 50 51 52 53 54 55 
52 4.40E-04 3.60E-04 -1.19E-04 -2.28E-04 3.02E-04 1.70E-04 1.43E-04 3.97E-02    
53 -5.94E-03 -1.70E-03 -6.87E-04 -2.50E-03 4.32E-03 3.53E-03 8.14E-05 -8.39E-02 2.71E-01   
54 -1.47E-04 3.24E-04 1.33E-04 4.23E-04 3.01E-04 2.41E-05 -1.55E-04 1.95E-04 -1.08E-03 8.19E-04  
55 -1.92E-04 -2.63E-05 -1.00E-04 -3.03E-04 2.78E-04 2.19E-04 5.70E-06 2.59E-03 -1.72E-02 -3.61E-05 2.90E-03 
56 -5.55E-05 3.56E-05 8.20E-05 1.64E-04 -1.04E-04 -2.18E-04 6.53E-06 -2.88E-04 4.71E-04 -1.24E-05 -6.09E-05 
57 6.02E-05 -3.82E-06 2.37E-04 1.53E-04 -1.38E-04 -2.38E-04 -3.83E-05 -2.67E-04 -2.66E-04 9.53E-06 -3.17E-05 
58 1.77E-04 1.68E-04 1.58E-04 3.10E-04 -3.24E-04 -3.30E-04 -2.62E-04 -1.46E-04 -6.69E-04 5.85E-05 -1.76E-04 
59 9.07E-05 -1.69E-04 -7.50E-04 4.77E-04 -6.83E-04 -5.02E-04 -2.28E-04 -9.05E-05 1.25E-03 -8.89E-05 5.19E-06 
60 -8.78E-03 -2.87E-04 -5.86E-07 -4.56E-04 -4.53E-04 1.09E-03 7.80E-05 -2.42E-04 4.96E-03 -2.58E-05 6.27E-05 
61 -5.37E-02 1.66E-04 -4.44E-04 -5.70E-04 -8.34E-04 4.74E-04 5.03E-05 -4.38E-04 6.23E-03 1.90E-04 1.92E-04 
62 5.15E-04 -2.57E-02 -1.21E-02 -4.13E-03 -1.62E-03 -1.27E-03 -2.54E-03 -3.49E-04 8.99E-04 -3.54E-04 3.87E-05 
63 -2.75E-04 -1.10E-02 -2.72E-02 -6.46E-03 -1.23E-03 -1.02E-03 -1.78E-03 -1.04E-04 4.17E-04 -1.42E-04 7.06E-05 
64 -6.99E-04 -3.98E-03 -6.66E-03 -7.39E-02 2.40E-04 3.19E-04 -3.71E-04 1.30E-04 4.25E-03 -4.46E-04 4.05E-04 
65 -1.32E-03 -1.23E-03 -8.22E-04 2.21E-04 -3.33E-02 -2.34E-02 -2.81E-03 -6.34E-04 -6.66E-03 -3.48E-04 -3.82E-04 
66 2.68E-04 -9.27E-04 -6.31E-04 2.81E-04 -2.23E-02 -2.64E-02 -1.93E-03 -4.92E-04 -5.48E-03 -8.48E-05 -2.66E-04 
67 3.76E-04 -2.58E-03 -1.92E-03 -2.86E-04 -3.29E-03 -2.31E-03 -7.47E-03 -1.99E-04 -1.23E-03 1.42E-04 -7.94E-05 
68 3.24E-04 -1.44E-03 -3.53E-04 -4.15E-03 -3.85E-04 -1.14E-03 -1.38E-03 -5.02E-02 1.07E-01 -4.31E-04 -2.42E-03 
69 4.96E-03 2.73E-03 5.38E-05 5.99E-03 -3.29E-03 -8.22E-04 1.25E-04 9.53E-02 -3.11E-01 1.41E-03 1.92E-02 
70 1.94E-04 -2.57E-04 1.19E-06 -3.23E-04 -3.96E-04 -1.27E-04 2.41E-04 -3.00E-04 6.38E-04 -9.10E-04 3.13E-05 
71 4.88E-04 4.57E-04 2.96E-04 1.17E-03 1.07E-04 5.08E-04 2.26E-05 -3.86E-03 2.29E-02 1.14E-04 -3.78E-03 
72 1.33E-04 -1.29E-05 -3.58E-05 -1.83E-04 6.63E-05 1.38E-04 -4.36E-05 3.09E-04 4.72E-05 1.03E-05 5.92E-05 
73 3.67E-06 -5.15E-05 -3.33E-04 -1.94E-04 2.87E-04 3.61E-04 3.09E-05 3.89E-04 1.43E-03 -2.91E-05 8.11E-05 
74 1.54E-05 -7.14E-05 -1.44E-04 -3.49E-04 4.33E-04 3.83E-04 3.99E-04 2.14E-04 1.22E-03 -9.95E-05 2.05E-04 
  
 
3
8
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Parameters 45 46 47 48 49 50 51 52 53 54 55 
75 -3.81E-05 2.27E-04 6.81E-04 -2.95E-04 7.58E-04 5.63E-04 2.57E-04 1.42E-04 -1.26E-03 8.94E-05 -2.25E-05 
76 -8.50E-04 -9.28E-04 -5.06E-04 7.58E-05 1.12E-03 6.28E-04 6.72E-05 2.66E-03 2.25E-02 9.91E-04 -1.72E-03 
77 -2.14E-04 1.67E-04 -7.23E-05 -1.64E-05 1.71E-05 9.11E-06 5.47E-05 -2.39E-06 3.23E-04 1.54E-05 8.26E-06 
78 5.68E-05 -2.25E-05 1.63E-05 5.61E-07 -3.56E-05 -2.79E-05 -1.35E-05 -3.33E-05 -7.98E-05 2.51E-06 -4.85E-06 
79 -2.14E-04 8.36E-05 3.48E-04 -2.93E-04 -6.93E-05 -1.53E-04 -3.62E-05 -1.31E-04 6.86E-04 -2.37E-05 4.78E-05 
80 3.40E-04 -2.66E-04 1.07E-04 7.13E-05 1.31E-05 -3.38E-05 -7.79E-05 -2.11E-05 -5.91E-04 -1.31E-05 1.58E-06 
 
Parameters 56 57 58 59 60 61 62 63 64 65 66 
56 2.59E-03           
57 2.18E-03 6.26E-03          
58 2.11E-03 5.05E-03 2.38E-02         
59 -3.56E-05 -1.39E-05 1.64E-04 1.66E-02        
60 8.08E-05 -4.27E-05 -9.83E-05 1.58E-04 3.55E-02       
61 5.63E-05 -5.63E-05 -2.05E-04 6.01E-08 1.10E-02 6.08E-02      
62 4.41E-06 9.00E-05 -2.34E-04 2.81E-04 3.24E-04 -7.98E-04 6.15E-02     
63 -7.65E-05 -2.18E-04 -2.36E-04 7.53E-04 -2.80E-04 5.84E-04 1.28E-02 4.04E-02    
64 -1.19E-04 -1.12E-04 -5.03E-04 -5.04E-04 8.38E-04 7.16E-04 7.36E-03 8.98E-03 1.18E-01   
65 1.39E-04 1.73E-04 3.18E-04 7.60E-04 1.42E-03 1.81E-03 5.80E-03 4.79E-03 1.24E-03 4.65E-02  
66 1.92E-04 1.90E-04 1.72E-04 4.34E-04 -8.47E-04 -4.76E-04 4.96E-03 4.09E-03 -7.61E-05 2.77E-02 4.35E-02 
67 -3.16E-06 2.61E-05 2.58E-04 2.26E-04 -3.35E-04 -3.44E-04 4.33E-03 3.88E-03 1.12E-03 7.66E-03 4.64E-03 
68 1.34E-03 2.25E-03 -1.63E-03 3.28E-03 -5.51E-03 1.39E-03 1.46E-02 2.08E-03 1.75E-02 9.10E-03 -9.65E-04 
69 -1.45E-03 -2.15E-03 2.77E-03 -3.81E-03 2.12E-03 -1.03E-02 -1.80E-02 -2.12E-03 -2.21E-02 7.33E-04 2.22E-04 
  
 
 
3
8
2 
Parameters 56 57 58 59 60 61 62 63 64 65 66 
70 2.24E-05 1.03E-05 -9.84E-05 8.16E-05 -1.76E-04 -1.04E-03 1.25E-03 6.90E-04 2.15E-03 1.59E-03 9.14E-04 
71 -5.64E-05 -1.11E-04 5.84E-04 -4.37E-04 4.11E-04 1.30E-04 -1.97E-03 -1.03E-03 -1.60E-03 -2.67E-04 -2.04E-03 
72 -2.64E-03 -2.21E-03 -2.15E-03 4.29E-06 -9.75E-05 5.93E-04 6.08E-04 4.72E-04 8.99E-04 4.88E-05 2.00E-04 
73 -2.14E-03 -6.36E-03 -5.03E-03 3.20E-05 2.58E-04 9.18E-04 -7.99E-04 1.48E-04 7.64E-04 -9.23E-04 -7.56E-04 
74 -2.08E-03 -5.04E-03 -2.40E-02 -8.05E-05 -4.05E-04 3.01E-04 5.42E-04 4.04E-04 2.59E-03 -6.65E-04 1.43E-04 
75 3.54E-05 -8.31E-06 -1.16E-04 -1.68E-02 -2.70E-04 -5.53E-04 -2.56E-04 -8.58E-04 -2.47E-04 -1.43E-03 -5.33E-04 
76 -3.42E-04 8.05E-05 2.44E-04 -6.40E-04 -1.05E-03 1.09E-02 -1.23E-02 -1.02E-02 -1.90E-02 -3.10E-02 -1.13E-02 
77 8.59E-06 -1.46E-05 -4.93E-05 -3.94E-06 3.44E-04 2.71E-04 -4.94E-04 -1.91E-05 -1.72E-04 -1.98E-04 -6.87E-05 
78 -5.76E-06 -7.06E-06 -9.83E-06 -2.43E-05 -7.41E-05 -5.74E-05 1.50E-04 7.93E-06 -2.58E-06 1.04E-04 5.66E-05 
79 6.25E-05 1.14E-04 -3.48E-04 8.04E-06 1.94E-04 8.37E-05 1.09E-03 -6.06E-05 1.53E-03 5.54E-04 2.88E-04 
80 -9.27E-06 -1.46E-05 1.75E-05 2.07E-05 -3.57E-04 -4.42E-04 1.08E-03 5.41E-05 4.97E-04 3.95E-04 1.47E-04 
 
Parameters 67 68 69 70 71 72 73 74 75 76 77 
67 1.39E-02           
68 2.19E-03 4.42E+00          
69 3.10E-03 
-
4.71E+00 6.33E+00         
70 
-9.56E-
04 -3.38E-03 -7.51E-04 3.80E-03        
71 8.96E-05 -4.65E-01 3.26E-01 
-9.59E-
05 1.02E-01       
72 -2.79E- -4.26E-03 7.08E-03 2.73E-04 -9.98E- 1.07E-02      
  
 
3
8
3 
Parameters 67 68 69 70 71 72 73 74 75 76 77 
04 06 
73 
-6.04E-
04 6.33E-03 -8.57E-03 8.23E-04 
-5.54E-
04 4.00E-03 2.08E-02     
74 
-9.57E-
04 1.31E-02 -1.68E-02 1.62E-03 
-1.27E-
03 6.76E-03 2.91E-03 7.65E-02    
75 
-1.08E-
04 -7.30E-03 5.21E-03 
-4.74E-
04 1.45E-03 4.56E-05 9.64E-05 2.26E-04 2.03E-02   
76 
-1.96E-
03 2.20E-01 
-
1.45E+00 
-2.88E-
02 1.24E-01 
-8.70E-
03 
-7.85E-
03 
-1.50E-
02 6.48E-03 1.65E+00  
77 
-9.96E-
05 5.17E-05 -8.82E-04 
-3.97E-
06 3.13E-05 
-6.99E-
05 
-3.18E-
05 3.84E-05 6.62E-05 3.71E-04 2.05E-03 
78 3.17E-05 1.32E-04 1.68E-04 6.39E-06 
-2.58E-
06 3.25E-05 4.48E-05 9.59E-05 
-5.47E-
06 -3.17E-04 -8.41E-05 
79 6.48E-05 1.15E-02 -1.38E-02 2.91E-04 
-1.19E-
03 9.69E-05 
-6.68E-
05 1.33E-04 
-3.29E-
04 -3.62E-03 -8.98E-05 
80 1.68E-04 1.91E-03 -8.46E-04 9.44E-06 
-2.26E-
04 9.45E-05 5.42E-05 
-1.36E-
04 
-1.92E-
04 -5.72E-04 -1.41E-03 
 
Parameters 78 79 80 
78 5.14E-03   
79 5.03E-05 2.94E-03  
80 4.22E-04 3.44E-04 4.32E-03 
  
 
 
3
8
4 
 
 
  
  
 
3
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Table 48: Parameter covariance matrix, female (pooled) estimates 
Parameters 1 2 3 4 5 6 7 8 9 10 11 
1 2.86E-03                     
2 -1.37E-04 3.68E-03          
3 -4.96E-03 -6.76E-05 1.35E-02         
4 -5.97E-05 -2.18E-03 6.92E-05 3.84E-03        
5 2.23E-03 -6.50E-05 -5.37E-03 -6.21E-04 3.73E-02       
6 1.34E-04 3.85E-05 -3.70E-04 -6.03E-05 2.43E-04 1.92E-03      
7 4.68E-04 -4.97E-05 -1.16E-03 -3.45E-05 2.85E-04 8.62E-04 3.11E-03     
8 -1.97E-04 -5.05E-05 6.65E-04 3.57E-05 -1.43E-04 1.36E-07 -4.33E-05 1.68E-02    
9 -1.37E-04 -5.68E-05 3.19E-04 -1.71E-05 2.71E-04 2.27E-05 1.85E-05 8.63E-03 1.87E-02   
10 -3.94E-04 -4.49E-05 9.50E-04 1.09E-04 -5.80E-04 3.18E-05 1.39E-05 5.13E-03 6.76E-03 4.47E-02  
11 -2.07E-04 -1.64E-04 4.96E-04 1.59E-04 -1.82E-03 1.66E-04 2.31E-04 6.06E-04 3.02E-04 -5.51E-05 2.53E-02 
12 -2.45E-04 -5.00E-05 6.51E-04 7.50E-05 -1.85E-03 6.65E-05 5.34E-05 4.53E-04 2.30E-04 -9.07E-05 1.78E-02 
13 1.00E-04 1.68E-05 -2.50E-04 -3.60E-05 1.63E-04 3.63E-05 5.10E-05 1.35E-03 1.08E-03 3.93E-04 1.59E-03 
14 4.11E-04 -8.20E-05 -1.12E-03 2.57E-05 -2.19E-04 3.81E-05 1.53E-04 -2.93E-05 1.05E-04 -6.33E-04 6.78E-04 
15 7.03E-04 1.42E-04 -1.74E-03 -7.09E-05 -4.98E-03 -3.73E-04 -3.73E-04 -1.11E-03 -1.81E-03 -1.29E-03 2.93E-03 
16 -3.00E-06 -2.30E-05 5.06E-05 1.21E-05 -8.60E-05 5.24E-06 -1.04E-05 1.97E-04 1.28E-04 3.65E-04 2.24E-04 
17 1.30E-04 -2.44E-05 -3.82E-04 5.20E-06 -7.21E-05 4.73E-07 3.37E-05 -2.46E-05 -8.71E-05 -3.17E-04 1.83E-04 
18 -7.08E-05 -2.62E-05 2.50E-04 2.21E-05 -1.10E-04 -1.05E-05 -1.45E-05 1.67E-04 4.22E-05 2.06E-04 5.41E-05 
19 -2.52E-06 -3.10E-05 -1.66E-04 2.13E-05 1.14E-04 7.39E-06 3.91E-05 1.64E-04 1.59E-04 2.10E-04 9.18E-05 
20 5.28E-05 -8.87E-05 -4.75E-04 3.97E-05 3.40E-04 1.78E-05 3.38E-05 2.93E-04 2.69E-04 -3.73E-05 5.39E-05 
21 2.30E-04 1.00E-04 -6.17E-04 -1.11E-04 1.92E-04 7.96E-07 1.52E-04 -3.09E-04 -3.92E-04 -3.12E-04 -4.87E-04 
  
 
 
3
8
6 
Parameters 1 2 3 4 5 6 7 8 9 10 11 
22 -2.71E-04 -1.67E-04 7.08E-04 -1.10E-04 -6.31E-04 -2.32E-04 -1.01E-04 1.60E-05 -4.55E-05 -9.76E-07 -6.33E-06 
23 -1.19E-03 -1.19E-04 2.84E-03 1.39E-04 -9.93E-05 -2.56E-04 -5.22E-04 -1.73E-02 -9.41E-03 -5.22E-03 -7.67E-04 
24 -6.35E-04 -1.99E-05 1.51E-03 5.63E-05 -5.11E-04 -2.27E-04 -3.19E-04 -8.45E-03 -1.89E-02 -6.71E-03 -5.42E-04 
25 -1.86E-04 7.41E-05 7.95E-04 -3.03E-06 -4.96E-03 9.73E-05 -7.50E-05 -5.14E-03 -6.88E-03 -4.64E-02 8.40E-05 
26 -6.10E-04 8.69E-05 1.77E-03 -2.69E-05 8.88E-03 -7.34E-05 -4.74E-04 -5.02E-04 -2.37E-04 2.08E-04 -2.59E-02 
27 -3.04E-04 9.63E-05 4.35E-04 -2.30E-04 8.16E-03 -1.38E-04 -4.21E-04 -4.54E-04 -2.32E-04 1.19E-04 -1.75E-02 
28 -3.55E-04 3.26E-05 8.40E-04 1.68E-04 2.10E-03 -1.22E-04 -9.75E-05 -1.40E-03 -1.17E-03 -3.69E-04 -1.93E-03 
29 2.05E-05 4.59E-06 -4.63E-05 -2.62E-05 3.22E-05 -1.56E-05 5.27E-07 -7.41E-06 -2.68E-06 -2.05E-06 -3.50E-06 
30 -3.39E-05 4.07E-06 8.04E-05 3.42E-05 1.58E-05 1.84E-05 -4.83E-06 2.78E-05 2.78E-05 2.87E-05 -3.05E-05 
31 7.77E-05 -5.15E-05 -1.40E-04 -7.62E-05 1.72E-03 -7.45E-05 -2.61E-04 -1.57E-04 -6.77E-05 -3.17E-04 -2.81E-04 
32 -1.99E-04 -1.27E-04 4.92E-04 2.31E-04 -3.15E-05 1.50E-04 1.58E-04 7.36E-05 1.43E-04 3.58E-04 1.54E-05 
33 -5.28E-04 1.22E-05 1.04E-03 -8.68E-05 -1.77E-03 -7.52E-05 1.71E-04 -1.00E-04 -8.37E-06 -9.91E-05 -5.31E-05 
34 -3.46E-04 6.89E-05 8.33E-04 2.04E-05 -3.51E-03 7.53E-05 1.52E-04 -6.67E-05 -1.17E-04 -3.42E-05 1.51E-05 
35 -6.02E-04 3.26E-04 1.34E-03 8.75E-05 -3.54E-03 -2.96E-05 9.82E-05 -1.83E-04 -2.48E-04 7.89E-05 -4.48E-06 
36 -7.22E-05 -4.21E-05 2.28E-04 1.60E-04 -1.49E-04 -8.50E-06 -3.13E-04 3.01E-04 3.15E-04 2.95E-04 4.94E-04 
37 1.12E-03 -3.65E-04 -5.32E-03 -2.57E-04 -3.22E-02 3.05E-04 3.43E-03 -1.74E-03 -1.72E-03 -1.64E-03 1.09E-03 
38 2.94E-04 1.67E-03 -7.41E-04 -1.09E-03 2.60E-04 4.68E-05 3.47E-05 -8.11E-05 -7.93E-05 -1.11E-04 -1.67E-05 
39 -4.30E-07 1.07E-04 -1.02E-05 -6.12E-05 -7.76E-06 2.72E-06 3.54E-06 1.35E-06 2.22E-06 3.33E-06 -5.32E-06 
40 -2.12E-04 -1.33E-03 6.85E-04 8.64E-04 -1.34E-04 -3.26E-05 -9.98E-06 6.08E-05 6.11E-05 8.31E-05 1.46E-05 
41 -9.63E-06 -1.72E-04 1.89E-05 2.66E-04 -2.01E-05 -1.57E-05 -1.08E-05 -2.70E-06 -4.72E-06 1.87E-06 1.73E-06 
42 4.15E-05 2.83E-04 -3.62E-05 -2.20E-04 1.96E-03 2.44E-05 3.80E-06 8.62E-06 -1.40E-05 -3.14E-05 -4.56E-05 
43 7.40E-06 -4.61E-06 -1.14E-05 -3.65E-06 1.73E-05 1.12E-04 5.27E-05 2.09E-07 5.62E-07 7.35E-07 7.02E-06 
44 1.71E-05 6.76E-05 -2.85E-05 -4.61E-05 1.17E-05 5.35E-05 1.62E-04 -6.08E-06 -6.15E-06 -3.00E-06 1.56E-05 
  
 
3
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Parameters 1 2 3 4 5 6 7 8 9 10 11 
45 2.46E-06 6.98E-05 -2.00E-05 -4.48E-05 1.32E-05 3.04E-06 -1.14E-06 4.87E-04 2.38E-04 1.18E-04 1.85E-05 
46 3.06E-06 1.99E-05 -1.07E-05 -1.72E-05 -7.67E-06 -2.39E-07 -3.74E-06 2.44E-04 5.22E-04 1.61E-04 9.25E-06 
47 2.55E-06 2.60E-05 -1.64E-05 -9.73E-06 -1.84E-06 2.69E-06 4.39E-06 1.11E-04 1.53E-04 8.96E-04 -3.37E-06 
48 -6.20E-06 -9.64E-05 1.98E-05 6.08E-05 -4.41E-05 5.74E-06 1.57E-05 1.99E-05 1.33E-05 1.46E-06 7.93E-04 
49 -8.19E-06 -1.02E-04 2.54E-05 6.69E-05 -6.08E-05 -2.97E-07 8.38E-06 1.42E-05 1.10E-05 1.51E-06 5.26E-04 
50 4.27E-06 2.19E-05 -9.73E-06 -1.24E-05 7.16E-06 6.08E-07 9.37E-07 3.69E-05 2.51E-05 4.10E-06 4.50E-05 
51 1.73E-05 4.03E-05 -4.50E-05 -2.34E-05 -1.62E-05 1.59E-06 2.83E-06 -3.60E-06 1.80E-06 -1.01E-05 2.79E-06 
52 -8.25E-06 9.84E-05 6.33E-06 -6.51E-05 -3.28E-04 -1.81E-05 -2.73E-05 -1.54E-05 -4.06E-05 -5.72E-05 9.82E-05 
53 -1.45E-06 -8.08E-07 3.66E-06 1.25E-06 -5.27E-07 3.91E-07 -1.11E-06 7.73E-06 3.98E-06 9.01E-06 7.85E-06 
54 3.16E-06 1.11E-05 -7.65E-06 -7.34E-06 -1.31E-05 -4.51E-07 3.33E-07 -3.52E-06 -3.23E-06 -7.23E-06 4.23E-06 
55 -5.85E-06 -5.59E-06 1.24E-05 4.48E-06 -2.66E-06 -2.55E-07 -9.11E-07 2.89E-07 2.93E-08 2.69E-06 1.17E-06 
56 -8.67E-06 -1.18E-05 1.77E-05 7.92E-06 -3.01E-06 9.39E-07 -6.57E-07 4.44E-06 3.37E-06 5.62E-06 2.94E-06 
57 -8.27E-06 -6.61E-06 1.73E-05 6.16E-06 -9.59E-06 1.23E-06 5.60E-07 4.03E-06 1.75E-06 -5.77E-06 1.92E-06 
58 7.92E-07 1.07E-05 -2.66E-06 -3.74E-06 3.86E-06 5.22E-07 1.02E-06 -8.61E-06 -8.45E-06 -1.00E-05 -5.35E-06 
59 -7.59E-06 -2.86E-05 1.67E-05 3.91E-07 -1.11E-05 -1.99E-05 -1.09E-05 -5.70E-06 -6.56E-06 1.17E-06 -3.58E-06 
60 -6.30E-05 -3.25E-04 1.43E-04 2.02E-04 5.45E-05 -2.14E-05 -3.31E-05 -5.11E-04 -2.52E-04 -1.12E-04 -2.77E-05 
61 -4.97E-05 -7.23E-05 9.69E-05 4.51E-05 -8.01E-06 -1.85E-05 -2.15E-05 -2.22E-04 -5.14E-04 -1.53E-04 -1.41E-05 
62 -6.04E-06 -1.04E-04 1.97E-05 6.19E-05 -2.34E-04 8.02E-06 2.01E-06 -1.09E-04 -1.54E-04 -9.08E-04 3.67E-06 
63 -1.83E-05 -8.17E-05 4.17E-05 5.41E-05 5.01E-04 7.87E-06 -1.30E-05 5.43E-07 -6.67E-06 4.68E-06 -8.14E-04 
64 -2.63E-05 -6.66E-05 4.17E-05 3.22E-05 4.12E-04 9.66E-06 -1.15E-05 5.42E-06 -3.70E-06 8.58E-06 -5.18E-04 
65 -1.63E-05 -3.47E-05 2.96E-05 2.95E-05 1.12E-04 -1.43E-06 -6.33E-06 -2.36E-05 -2.15E-05 -3.65E-07 -5.85E-05 
66 4.99E-07 -6.85E-07 1.73E-08 -2.60E-06 7.87E-06 -1.40E-06 -1.42E-06 1.02E-06 8.73E-07 3.86E-08 -1.19E-07 
67 -1.53E-06 -1.47E-06 2.94E-06 3.22E-06 -8.70E-06 1.15E-06 1.16E-06 -2.15E-06 -1.94E-06 9.01E-07 -1.02E-06 
  
 
 
3
8
8 
Parameters 1 2 3 4 5 6 7 8 9 10 11 
68 -3.38E-07 -2.16E-05 8.41E-06 1.56E-06 1.18E-04 -6.05E-06 -1.83E-05 -1.12E-05 -7.56E-06 -1.85E-05 -1.03E-05 
69 1.31E-05 3.26E-05 -5.43E-05 3.44E-05 4.76E-05 2.82E-05 2.92E-05 2.17E-05 2.71E-05 8.57E-06 1.90E-05 
70 -1.18E-05 -9.21E-05 9.66E-06 5.67E-05 -7.78E-05 -1.03E-05 1.27E-05 -4.33E-06 -4.90E-06 4.42E-07 -1.21E-06 
71 -1.50E-06 -9.74E-05 -5.67E-06 7.46E-05 -1.76E-04 -3.58E-06 1.72E-05 -2.09E-06 -8.84E-06 -1.98E-06 2.61E-06 
72 -7.71E-06 -1.77E-05 -2.10E-05 1.64E-05 -1.09E-04 -1.40E-07 6.64E-06 -7.69E-06 -1.20E-05 -1.94E-05 2.29E-06 
73 1.01E-06 -1.39E-05 1.31E-06 1.40E-05 -6.89E-06 -3.39E-06 -1.45E-05 3.59E-06 3.40E-06 6.54E-06 8.30E-06 
74 1.12E-04 3.51E-04 -4.47E-04 -2.31E-05 -1.89E-03 6.64E-05 2.23E-04 1.69E-04 2.06E-04 8.95E-05 6.21E-05 
75 -4.92E-06 8.00E-04 -9.19E-05 -4.74E-04 3.43E-05 1.64E-05 -8.75E-06 -3.35E-05 -5.07E-05 -4.31E-05 2.66E-06 
76 -2.04E-03 -3.49E-05 5.50E-03 2.05E-04 -2.69E-03 -1.50E-04 -5.66E-04 2.25E-04 1.10E-04 3.28E-04 2.39E-04 
77 -1.42E-05 -1.37E-04 4.81E-05 8.82E-05 -5.72E-06 -9.63E-06 -5.48E-06 1.44E-06 1.01E-06 1.42E-06 -3.23E-06 
78 -5.38E-05 -1.89E-03 3.00E-04 1.23E-03 -7.01E-06 -3.91E-05 1.91E-05 6.02E-05 7.61E-05 9.59E-05 -5.77E-06 
 
Parameters 12 13 14 15 16 17 18 19 20 21 22 
12 2.03E-02           
13 1.08E-03 6.14E-03          
14 2.97E-04 9.91E-05 3.63E-02         
15 2.34E-03 5.90E-04 -7.40E-02 2.33E-01        
16 2.75E-05 -1.62E-04 1.48E-05 -6.45E-04 6.01E-04       
17 1.50E-04 2.01E-05 2.17E-03 -1.46E-02 -2.51E-05 2.46E-03      
18 -5.51E-05 -2.96E-06 -1.30E-04 1.91E-04 7.14E-07 -2.38E-05 2.11E-03     
19 -4.94E-05 -2.31E-05 -1.81E-04 -6.32E-05 3.51E-06 5.11E-06 1.73E-03 4.86E-03    
20 -4.72E-05 -6.92E-05 -4.30E-04 2.53E-04 9.71E-05 -4.16E-05 1.69E-03 3.90E-03 1.59E-02   
  
 
3
8
9 
Parameters 12 13 14 15 16 17 18 19 20 21 22 
21 -4.22E-04 -2.03E-05 8.37E-05 4.53E-04 -5.63E-06 -1.85E-05 -6.15E-05 -5.22E-05 -1.06E-04 1.16E-02  
22 3.75E-05 -1.41E-04 -5.83E-05 -8.00E-05 7.01E-06 -1.16E-05 7.05E-06 -2.82E-05 -5.39E-05 2.18E-05 1.72E-03 
23 -5.65E-04 -1.48E-03 -3.55E-04 5.81E-04 -1.83E-04 -8.33E-05 -9.83E-05 -2.41E-04 -4.94E-04 2.11E-04 4.10E-04 
24 -4.33E-04 -1.12E-03 -3.05E-04 1.43E-03 -1.22E-04 1.54E-05 -1.05E-05 -1.95E-04 -4.06E-04 2.66E-04 4.85E-04 
25 1.73E-04 -5.55E-04 6.49E-04 1.78E-03 -3.81E-04 3.08E-04 -1.81E-04 -2.90E-04 -9.14E-05 1.98E-04 8.27E-04 
26 -1.85E-02 -1.72E-03 -1.07E-03 -4.49E-03 -2.21E-04 -3.09E-04 -6.57E-06 -1.07E-04 -1.20E-04 3.59E-04 1.56E-04 
27 -2.01E-02 -1.18E-03 -6.03E-04 -3.51E-03 -4.41E-05 -2.31E-04 5.93E-05 -1.40E-05 -3.18E-05 3.04E-04 4.90E-05 
28 -1.37E-03 -6.29E-03 -1.72E-04 -1.10E-03 1.63E-04 -7.75E-05 1.22E-05 -8.81E-06 2.03E-05 -2.93E-05 3.72E-04 
29 -9.42E-06 1.66E-05 -4.20E-04 9.58E-04 -9.28E-07 -2.79E-05 -1.77E-06 4.17E-06 9.43E-06 2.54E-05 -4.12E-06 
30 -8.10E-06 -3.05E-05 7.96E-04 -2.66E-03 8.12E-06 1.69E-04 1.69E-06 -1.73E-06 -7.44E-06 -3.08E-05 1.03E-05 
31 -5.72E-05 2.01E-04 -4.84E-05 4.81E-04 -6.32E-04 2.40E-05 -2.61E-06 -7.60E-06 -1.03E-04 -1.20E-05 -7.54E-05 
32 2.61E-04 -3.79E-04 -3.43E-03 1.88E-02 7.41E-05 -3.09E-03 8.13E-05 4.58E-05 1.64E-04 -1.34E-04 -5.28E-06 
33 2.81E-05 -3.24E-05 1.84E-05 -1.24E-04 -4.46E-06 -3.36E-05 -2.12E-03 -1.76E-03 -1.77E-03 -5.30E-05 3.79E-05 
34 1.17E-04 5.34E-05 2.18E-04 3.48E-04 1.77E-05 -2.17E-05 -1.68E-03 -4.88E-03 -3.80E-03 2.37E-05 2.55E-06 
35 9.95E-05 7.37E-05 4.42E-04 -4.27E-04 -1.26E-04 3.53E-05 -1.66E-03 -3.92E-03 -1.65E-02 4.00E-05 1.47E-04 
36 4.37E-04 4.30E-05 -4.94E-05 -3.29E-04 1.02E-06 2.75E-05 6.56E-05 5.75E-05 1.13E-04 -1.16E-02 -5.82E-05 
37 -2.48E-05 6.75E-04 2.69E-03 1.27E-02 2.08E-04 -1.11E-03 -1.80E-04 1.11E-04 2.09E-04 4.62E-04 -8.43E-04 
38 5.10E-06 3.15E-05 1.71E-05 1.65E-04 -1.41E-05 8.19E-06 -1.28E-05 -5.57E-06 -2.34E-05 1.01E-04 -1.17E-04 
39 -6.17E-07 -1.53E-06 1.21E-07 -4.78E-07 -5.70E-07 -1.57E-07 -9.01E-07 -1.82E-06 -4.50E-07 1.84E-06 1.19E-06 
40 -6.14E-06 -2.18E-05 -1.50E-05 -1.23E-04 1.10E-05 -5.70E-06 1.11E-05 4.40E-06 1.75E-05 -7.81E-05 9.12E-05 
41 -1.06E-06 1.33E-06 1.08E-07 2.86E-07 7.75E-07 -1.21E-06 1.76E-06 2.21E-06 -4.91E-07 -1.57E-06 -2.02E-05 
42 -4.68E-05 8.90E-06 -2.24E-05 -3.34E-04 -1.43E-06 -9.90E-06 2.17E-06 4.51E-07 -3.00E-06 1.70E-05 -2.31E-05 
43 4.19E-06 -2.59E-07 -4.75E-07 -1.70E-05 -1.10E-07 4.26E-07 -9.45E-07 1.45E-06 2.30E-06 2.40E-06 -1.85E-05 
  
 
 
3
9
0 
Parameters 12 13 14 15 16 17 18 19 20 21 22 
44 1.07E-05 1.40E-06 4.10E-06 -2.17E-05 -1.62E-06 1.77E-06 -1.28E-06 6.63E-07 1.83E-06 7.66E-06 -1.35E-05 
45 1.28E-05 3.58E-05 -1.84E-06 2.28E-06 7.14E-06 -2.95E-06 -2.08E-07 2.86E-06 4.76E-07 -3.79E-06 -6.17E-06 
46 7.36E-06 2.49E-05 7.59E-06 -4.10E-05 3.30E-06 -1.20E-06 -1.71E-07 2.21E-06 1.98E-06 -7.75E-06 -5.52E-06 
47 -3.94E-06 2.28E-06 -4.87E-06 -5.75E-05 7.59E-06 -4.43E-06 9.64E-07 3.57E-06 -7.90E-06 -5.03E-06 -1.74E-06 
48 5.28E-04 4.48E-05 6.92E-06 8.49E-05 7.22E-06 4.57E-06 7.66E-07 3.18E-06 3.26E-06 -1.39E-05 1.01E-06 
49 6.38E-04 2.80E-05 7.16E-06 6.78E-05 1.38E-08 2.62E-06 -2.59E-07 -2.49E-07 2.62E-06 -8.94E-06 5.77E-06 
50 3.04E-05 1.63E-04 4.97E-06 1.30E-05 -5.29E-06 1.56E-06 2.85E-07 1.32E-06 9.58E-07 -5.53E-06 -6.13E-06 
51 5.97E-06 5.81E-06 8.06E-04 -1.67E-03 -7.85E-07 5.18E-05 -4.96E-06 -5.49E-06 -8.15E-06 2.54E-06 -3.08E-06 
52 7.48E-05 1.25E-05 -1.69E-03 5.45E-03 -1.49E-05 -3.45E-04 2.83E-06 -5.98E-06 -1.13E-05 3.19E-05 -6.26E-06 
53 7.44E-08 -5.32E-06 -1.53E-06 -1.35E-05 1.76E-05 -1.24E-06 1.25E-07 2.87E-07 -1.07E-07 -2.93E-06 8.16E-07 
54 2.79E-06 1.90E-06 5.14E-05 -3.40E-04 -1.09E-06 5.79E-05 -4.48E-07 -7.56E-07 -1.44E-06 4.33E-07 -1.12E-06 
55 -8.06E-07 -6.08E-09 -5.07E-06 1.28E-06 7.62E-08 -6.12E-07 5.28E-05 4.43E-05 4.29E-05 -3.28E-06 -3.76E-07 
56 -1.06E-06 1.13E-06 -6.68E-06 -9.21E-06 5.03E-07 -1.18E-06 4.48E-05 1.26E-04 1.01E-04 -5.92E-06 -6.77E-07 
57 -3.96E-10 1.08E-06 -6.06E-06 -2.27E-05 -4.49E-07 -1.04E-06 4.32E-05 1.01E-04 4.03E-04 -4.81E-06 1.66E-06 
58 -3.93E-06 -6.55E-06 -5.34E-06 3.93E-05 -9.92E-07 -2.29E-06 -7.51E-07 -1.34E-06 -1.76E-06 3.51E-04 -2.42E-06 
59 -2.21E-06 -6.30E-06 -5.31E-08 -2.00E-06 8.64E-07 -9.84E-07 -1.18E-06 -2.11E-06 -2.20E-06 -5.32E-06 1.00E-04 
60 -2.42E-05 -4.35E-05 -1.10E-05 -5.10E-05 -3.90E-06 3.34E-06 2.57E-06 -2.31E-06 4.80E-06 -1.74E-05 2.13E-05 
61 -1.04E-05 -2.19E-05 -1.14E-05 3.77E-06 -4.09E-06 -2.00E-07 1.97E-06 -2.69E-06 -1.60E-06 -7.86E-07 2.79E-05 
62 4.17E-06 -6.91E-06 1.08E-05 1.01E-04 -7.96E-06 7.14E-06 -9.67E-07 -3.03E-06 -1.51E-06 6.53E-08 3.75E-05 
63 -5.52E-04 -4.75E-05 -1.54E-05 -1.90E-04 -5.76E-06 -6.09E-06 1.28E-06 5.18E-07 6.13E-08 1.81E-06 1.01E-05 
64 -6.41E-04 -2.94E-05 -1.43E-05 -1.70E-04 1.10E-06 -4.94E-06 1.71E-06 -6.97E-07 3.62E-07 -6.56E-06 1.39E-06 
65 -4.35E-05 -1.66E-04 -1.88E-06 -6.04E-05 4.48E-06 -2.98E-06 1.71E-06 -1.02E-06 -6.99E-07 1.59E-06 2.94E-05 
66 -9.18E-07 8.90E-07 -1.01E-05 2.17E-05 -5.40E-08 -6.75E-07 -5.32E-07 -2.64E-07 -5.21E-07 3.31E-07 3.87E-07 
  
 
3
9
1 
Parameters 12 13 14 15 16 17 18 19 20 21 22 
67 7.69E-07 -1.87E-06 1.87E-05 -6.09E-05 7.70E-08 4.04E-06 6.02E-07 5.58E-07 8.06E-07 -5.60E-07 4.25E-07 
68 -1.83E-06 6.01E-06 -1.45E-06 -1.94E-06 -1.67E-05 3.95E-07 -9.12E-07 -7.78E-07 -3.26E-06 3.39E-06 -7.40E-06 
69 2.80E-05 -7.88E-06 -6.66E-05 4.08E-04 4.46E-06 -7.29E-05 6.69E-06 3.50E-06 1.00E-05 -6.20E-06 -1.74E-05 
70 1.95E-07 -2.24E-06 2.08E-06 7.11E-06 9.50E-07 -2.03E-07 -5.51E-05 -4.52E-05 -4.32E-05 -3.53E-06 1.84E-06 
71 2.35E-06 -4.47E-06 7.03E-06 4.58E-05 5.90E-07 2.60E-06 -4.40E-05 -1.28E-04 -9.46E-05 -3.70E-07 -4.69E-07 
72 7.31E-06 -7.14E-06 1.00E-05 1.04E-05 -2.96E-07 3.27E-06 -4.35E-05 -1.01E-04 -4.27E-04 -8.59E-07 -5.35E-06 
73 6.97E-06 3.87E-06 5.15E-06 -3.48E-05 1.73E-06 2.59E-06 1.27E-06 1.74E-06 2.35E-06 -3.54E-04 3.54E-06 
74 -2.80E-05 8.15E-05 9.60E-05 4.27E-04 3.51E-06 -2.37E-05 1.82E-06 -1.57E-05 2.73E-05 -1.57E-05 -4.37E-05 
75 1.19E-06 1.45E-05 -3.56E-05 1.08E-04 2.58E-06 -1.03E-05 1.85E-06 -1.31E-05 -4.65E-05 4.36E-05 -4.05E-05 
76 2.97E-04 -9.16E-05 -4.53E-04 -7.66E-04 2.78E-05 -1.66E-04 9.35E-05 -9.71E-05 -2.25E-04 -2.67E-04 3.33E-04 
77 -6.08E-06 6.38E-07 -2.58E-06 -8.72E-06 9.41E-07 -1.36E-06 8.54E-07 7.00E-07 3.08E-08 -3.60E-06 1.90E-06 
78 -4.81E-05 -2.50E-05 1.39E-05 -1.00E-04 1.76E-05 1.97E-06 1.19E-06 2.12E-06 2.38E-05 -8.56E-05 1.00E-04 
 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
23 3.44E-02           
24 1.04E-02 2.45E-02          
25 7.17E-03 8.64E-03 6.21E-02         
26 3.02E-03 2.32E-03 7.07E-04 3.26E-02        
27 2.61E-03 2.02E-03 1.98E-04 2.07E-02 2.89E-02       
28 1.96E-03 1.84E-03 9.82E-04 4.03E-03 2.69E-03 9.38E-03      
29 1.42E-05 1.99E-06 9.21E-06 6.21E-06 -1.50E-05 -3.83E-05 2.04E-04     
30 -3.23E-05 -1.89E-05 -4.20E-05 5.67E-05 2.63E-05 5.52E-05 -2.19E-04 3.07E-04    
  
 
 
3
9
2 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
31 5.90E-04 4.78E-04 1.08E-03 8.39E-04 3.64E-04 -5.25E-04 -9.33E-06 -7.82E-06 1.91E-03   
32 -2.07E-04 -6.13E-04 -3.30E-04 1.21E-04 -6.57E-04 5.67E-04 -2.10E-03 1.34E-03 -1.69E-04 5.11E-02  
33 6.34E-04 2.73E-04 3.01E-04 3.27E-04 2.97E-04 9.94E-06 -2.76E-05 3.66E-05 4.60E-05 4.58E-05 6.57E-03 
34 5.85E-05 1.43E-04 3.32E-04 -8.94E-05 -2.61E-05 -1.33E-04 -4.15E-08 -7.75E-06 3.69E-04 -1.59E-04 2.92E-03 
35 1.22E-03 5.21E-04 7.33E-04 4.48E-04 2.29E-04 1.29E-04 3.43E-05 -4.16E-05 7.29E-04 -6.58E-04 4.35E-03 
36 -3.07E-04 -3.43E-04 -3.71E-04 -7.00E-04 -3.33E-04 5.57E-05 -5.01E-05 3.79E-05 -1.54E-04 8.67E-04 6.57E-05 
37 -6.01E-03 -5.35E-03 -6.67E-03 -1.53E-02 -5.93E-03 -2.13E-05 8.99E-04 -7.28E-03 -1.29E-02 6.19E-02 -3.09E-03 
38 -1.44E-04 -7.19E-05 6.32E-05 -1.12E-04 -5.76E-05 -2.96E-05 9.39E-06 -7.70E-06 -1.75E-06 -1.24E-04 -5.69E-05 
39 -8.89E-06 -8.06E-06 3.59E-06 -1.78E-06 -5.84E-06 1.49E-06 -2.70E-07 1.04E-07 -7.82E-07 2.73E-06 -5.50E-06 
40 8.22E-05 3.52E-05 -5.03E-05 7.89E-05 1.35E-05 7.85E-06 -6.11E-06 5.43E-06 1.22E-05 6.93E-05 1.60E-05 
41 9.73E-06 8.97E-06 -1.54E-05 1.16E-05 6.88E-06 6.63E-06 -3.00E-06 3.16E-06 -1.04E-05 4.52E-05 1.16E-05 
42 8.13E-05 3.19E-05 -2.04E-04 5.04E-04 4.24E-04 1.27E-04 8.54E-06 -7.05E-06 1.13E-04 1.60E-06 -8.16E-05 
43 -1.10E-05 -1.56E-05 1.14E-05 8.98E-06 8.08E-06 -1.33E-06 -1.34E-06 1.19E-06 -3.99E-06 2.40E-05 -7.65E-06 
44 -2.58E-05 -1.43E-05 5.49E-06 -1.81E-05 -1.38E-05 -4.66E-06 -9.31E-07 9.06E-07 -1.76E-05 1.78E-05 1.03E-05 
45 -5.23E-04 -2.32E-04 -1.22E-04 -1.75E-05 -1.12E-05 -3.07E-05 1.17E-06 -1.51E-06 -8.08E-06 3.21E-06 -5.97E-06 
46 -2.63E-04 -5.26E-04 -1.66E-04 -1.54E-05 -1.22E-05 -2.45E-05 8.90E-07 -1.59E-06 -5.85E-06 1.63E-05 -8.89E-06 
47 -1.20E-04 -1.61E-04 -9.16E-04 -4.20E-06 -1.30E-06 -3.67E-06 -2.93E-07 1.41E-06 -1.41E-05 4.27E-06 -2.78E-06 
48 -2.21E-05 -1.39E-05 -2.25E-06 -8.08E-04 -5.17E-04 -5.76E-05 -1.11E-06 4.14E-07 -6.58E-06 1.95E-05 2.86E-06 
49 -1.52E-05 -1.12E-05 2.03E-06 -5.44E-04 -6.33E-04 -4.22E-05 -1.93E-06 1.87E-06 1.11E-06 3.68E-05 2.80E-06 
50 -4.16E-05 -2.29E-05 -8.31E-06 -4.66E-05 -2.73E-05 -1.65E-04 1.65E-07 -7.12E-07 6.13E-06 -4.69E-06 -2.97E-06 
51 -1.29E-05 -1.08E-05 1.48E-05 -1.90E-05 -1.45E-05 -8.53E-06 -9.44E-06 1.83E-05 -1.04E-06 -8.07E-05 -2.03E-06 
52 9.34E-06 3.98E-05 9.10E-05 -1.75E-04 -1.46E-04 -3.59E-05 2.03E-05 -5.98E-05 -9.87E-07 4.40E-04 2.38E-05 
53 -6.03E-06 -3.92E-06 -9.89E-06 -7.42E-06 -1.28E-06 5.44E-06 -2.44E-08 9.96E-08 -1.77E-05 3.11E-06 6.94E-08 
  
 
3
9
3 
Parameters 23 24 25 26 27 28 29 30 31 32 33 
54 8.34E-07 1.26E-06 8.48E-06 -8.92E-06 -4.40E-06 -3.26E-06 -4.71E-07 3.89E-06 5.19E-08 -7.65E-05 5.77E-08 
55 3.42E-06 1.75E-06 -1.58E-06 1.79E-06 -2.93E-07 1.42E-06 -2.93E-07 3.71E-07 -3.37E-07 1.77E-06 -5.40E-05 
56 1.28E-06 -4.96E-07 -5.34E-06 2.37E-06 -1.51E-07 1.18E-07 -2.10E-07 5.53E-07 -8.32E-07 3.90E-07 -4.36E-05 
57 1.90E-06 6.98E-07 8.28E-08 2.67E-06 -2.60E-06 2.22E-06 -5.90E-07 1.10E-06 -1.36E-06 2.16E-06 -4.20E-05 
58 6.38E-06 6.46E-06 8.60E-06 3.71E-06 1.38E-07 6.37E-06 3.97E-07 -6.07E-07 1.46E-06 -2.84E-06 1.14E-06 
59 9.73E-06 2.52E-05 3.30E-05 8.55E-06 9.95E-08 2.74E-05 3.97E-07 8.95E-08 -6.92E-06 -1.38E-05 -8.20E-07 
60 1.66E-03 3.14E-04 2.03E-04 1.65E-04 1.44E-04 6.61E-05 1.64E-06 -1.88E-06 3.47E-05 -3.19E-05 1.92E-05 
61 3.13E-04 8.22E-04 2.49E-04 1.16E-04 9.64E-05 4.99E-05 -3.35E-06 3.78E-06 3.16E-05 -9.56E-06 5.23E-06 
62 1.96E-04 2.41E-04 1.54E-03 4.08E-05 8.82E-06 2.81E-05 -5.34E-07 -1.16E-06 5.71E-05 -4.17E-06 2.38E-06 
63 1.31E-04 1.00E-04 3.76E-05 1.20E-03 6.76E-04 1.58E-04 3.49E-06 -1.91E-06 5.29E-05 -2.26E-05 9.07E-06 
64 1.28E-04 9.31E-05 5.32E-06 6.80E-04 1.16E-03 8.48E-05 4.25E-07 -8.02E-07 2.62E-05 -5.17E-05 2.17E-05 
65 6.35E-05 4.88E-05 3.25E-05 1.64E-04 8.47E-05 3.29E-04 1.03E-06 -1.29E-06 -2.54E-05 1.75E-05 4.49E-07 
66 2.80E-06 -2.65E-06 -1.18E-06 3.12E-06 3.10E-07 5.19E-07 1.20E-05 -1.28E-05 -8.96E-07 -1.23E-04 8.59E-07 
67 -1.42E-06 3.59E-06 4.92E-07 -6.77E-07 -4.15E-07 -4.10E-07 -1.28E-05 1.73E-05 -3.17E-07 8.47E-05 -5.71E-08 
68 3.78E-05 3.38E-05 5.78E-05 5.70E-05 3.21E-05 -2.64E-05 -8.77E-07 -4.16E-07 9.89E-05 5.60E-06 6.13E-06 
69 -7.85E-05 -3.44E-05 -1.77E-05 -3.41E-05 -6.11E-05 1.77E-05 -1.23E-04 8.50E-05 3.95E-06 2.74E-03 -2.44E-05 
70 1.12E-05 -1.55E-06 -9.90E-07 1.15E-05 1.97E-05 -3.67E-06 2.40E-08 3.34E-07 4.42E-06 -4.11E-06 3.01E-04 
71 -4.01E-05 9.50E-06 -1.35E-05 -8.90E-06 -5.48E-06 -1.10E-05 6.02E-07 -1.79E-06 3.37E-05 4.16E-06 1.01E-04 
72 2.59E-05 7.52E-06 8.20E-06 1.25E-05 2.52E-05 1.29E-05 4.04E-06 -4.22E-06 3.38E-05 -4.81E-05 1.77E-04 
73 -1.02E-06 -9.33E-06 -1.66E-05 -1.50E-05 4.54E-06 3.85E-06 -2.44E-07 -5.65E-07 -1.19E-05 2.03E-05 -1.27E-05 
74 -5.99E-04 -5.24E-04 -5.25E-04 -9.86E-04 -4.35E-04 9.37E-05 6.44E-05 -4.19E-04 -7.90E-04 3.47E-03 -2.36E-04 
75 -1.76E-05 1.24E-05 4.69E-05 -2.43E-05 -8.15E-06 -1.92E-06 4.89E-06 -3.05E-06 -1.06E-05 -6.13E-05 -1.34E-05 
76 1.45E-03 8.03E-04 4.12E-04 7.62E-04 3.07E-04 4.12E-04 -2.47E-05 4.05E-05 -1.00E-04 2.48E-04 5.83E-04 
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Parameters 23 24 25 26 27 28 29 30 31 32 33 
77 1.26E-05 8.66E-06 -1.37E-05 1.31E-05 1.54E-05 -2.15E-06 -4.23E-07 9.88E-07 -8.96E-07 1.06E-07 1.33E-05 
78 1.96E-05 -1.07E-05 -1.34E-04 5.78E-05 5.07E-05 -1.06E-05 -8.32E-06 3.93E-06 -1.49E-06 1.44E-04 2.18E-05 
 
Parameters 34 35 36 37 38 39 40 41 42 43 44 
34 1.23E-02           
35 3.33E-03 4.00E-02          
36 3.95E-05 -1.80E-04 1.35E-02         
37 -4.43E-03 -7.13E-03 2.35E-03 8.37E-01        
38 -3.03E-05 7.99E-05 -5.90E-05 -1.06E-05 4.58E-03       
39 3.85E-06 4.44E-06 -1.81E-06 3.76E-05 -1.30E-04 1.58E-03      
40 -5.58E-06 -1.17E-04 4.70E-05 -2.13E-04 -3.40E-03 -1.82E-04 4.79E-03     
41 6.33E-06 1.84E-07 1.07E-05 6.27E-05 1.38E-04 -2.04E-03 1.03E-04 6.10E-03    
42 -1.74E-04 -8.50E-05 -1.40E-05 -2.03E-03 6.67E-04 4.05E-04 5.44E-04 -1.78E-03 3.44E-02   
43 -2.16E-06 -1.95E-06 -5.09E-06 4.21E-05 4.06E-05 1.40E-05 -7.53E-07 -6.19E-05 8.78E-05 1.95E-03  
44 1.23E-05 8.69E-06 -1.93E-05 1.98E-04 1.32E-04 5.00E-05 7.85E-05 -1.27E-04 -8.85E-05 8.82E-04 2.69E-03 
45 -8.20E-06 4.76E-06 3.25E-06 4.59E-05 5.43E-07 -4.48E-05 4.20E-05 1.39E-05 4.44E-05 8.20E-06 -6.97E-06 
46 -1.66E-05 -8.56E-06 5.29E-06 1.56E-04 -2.48E-05 -7.97E-05 4.44E-05 7.64E-05 1.82E-04 -3.24E-05 -5.10E-06 
47 -1.54E-05 -3.80E-06 3.65E-06 3.24E-05 -1.26E-04 8.86E-05 8.90E-05 -1.08E-04 3.52E-05 3.08E-05 4.84E-05 
48 7.81E-07 -3.64E-06 1.05E-05 -1.54E-05 -1.34E-04 -1.50E-04 1.33E-04 2.56E-04 -1.20E-03 1.20E-04 2.05E-04 
49 4.44E-06 -4.08E-06 6.51E-06 -6.75E-05 -1.41E-04 -3.03E-05 1.15E-04 7.03E-06 -1.24E-03 2.39E-05 8.04E-05 
50 -4.07E-06 -2.94E-06 4.20E-06 3.96E-05 1.10E-04 -1.45E-05 -7.92E-05 6.87E-06 1.52E-04 1.09E-05 -6.32E-06 
51 2.89E-06 9.41E-06 -1.02E-06 7.08E-05 1.14E-04 5.36E-06 -1.51E-04 -5.09E-05 -4.95E-04 8.38E-06 3.29E-05 
  
 
3
9
5 
Parameters 34 35 36 37 38 39 40 41 42 43 44 
52 4.84E-05 3.32E-05 -2.88E-05 4.38E-04 2.38E-04 -2.32E-04 -2.22E-04 5.68E-04 -6.01E-03 -3.21E-04 -4.38E-04 
53 -1.08E-06 -2.17E-08 3.01E-06 6.14E-06 6.24E-06 -3.01E-06 -1.99E-05 -2.05E-05 -6.40E-05 1.53E-06 3.56E-06 
54 2.19E-06 3.49E-06 2.11E-07 -2.68E-05 5.31E-05 -3.61E-05 -3.78E-05 6.96E-05 -2.58E-04 -9.64E-06 -1.14E-05 
55 -4.35E-05 -4.21E-05 2.59E-06 -5.80E-06 -2.43E-05 -1.95E-05 2.86E-05 5.45E-05 -8.59E-06 -1.03E-06 3.02E-06 
56 -1.27E-04 -9.94E-05 4.95E-06 -2.45E-05 -3.29E-05 -5.46E-05 4.27E-05 1.09E-04 -8.73E-06 7.56E-06 1.90E-05 
57 -9.88E-05 -4.00E-04 1.66E-06 -1.00E-05 -6.98E-05 8.63E-05 9.07E-07 -3.90E-04 1.63E-04 2.99E-05 2.54E-05 
58 8.01E-07 4.02E-06 -3.53E-04 -1.96E-05 6.19E-05 -2.43E-06 -7.37E-05 4.28E-05 3.30E-05 -2.02E-05 1.23E-05 
59 -5.31E-06 -5.94E-06 5.33E-06 -3.37E-05 -5.00E-05 -2.26E-04 4.12E-05 2.75E-04 -4.58E-04 -2.42E-04 -8.42E-05 
60 -3.08E-05 -4.46E-06 1.32E-05 -4.13E-04 -5.20E-04 -4.04E-04 -5.75E-05 1.04E-03 1.61E-03 -9.20E-05 -1.82E-04 
61 2.02E-05 5.02E-06 -8.51E-06 -4.41E-04 -2.30E-04 -8.93E-05 -1.49E-04 2.26E-04 7.73E-04 -1.43E-04 -1.30E-04 
62 1.82E-06 5.33E-06 -1.24E-05 -4.39E-04 2.43E-06 -2.13E-04 6.79E-05 4.23E-04 -4.30E-03 1.37E-04 -1.90E-05 
63 -6.31E-06 6.40E-06 -9.05E-06 -8.65E-04 -1.85E-04 -4.82E-05 9.86E-05 2.14E-04 9.74E-03 6.77E-05 -1.82E-04 
64 -2.53E-06 2.41E-05 1.34E-05 -3.66E-04 -1.57E-04 7.69E-05 -3.16E-04 -3.10E-04 8.69E-03 -4.44E-05 -2.78E-04 
65 -7.13E-06 1.19E-05 6.41E-06 1.33E-04 -1.86E-04 6.32E-05 -8.39E-06 2.37E-05 2.97E-03 -6.33E-05 3.16E-05 
66 1.20E-06 4.05E-06 -9.30E-08 6.61E-05 1.19E-05 -1.55E-05 7.06E-06 2.67E-05 -1.03E-05 -1.15E-05 2.32E-06 
67 -1.87E-06 -4.30E-06 -8.08E-07 -4.21E-04 -2.03E-05 2.48E-05 -2.30E-06 -4.72E-05 8.92E-05 1.57E-05 -1.00E-05 
68 3.49E-05 3.42E-05 -1.30E-05 -7.90E-04 3.95E-05 -1.31E-04 1.62E-04 2.07E-04 1.76E-03 -8.54E-05 -3.68E-04 
69 -1.25E-05 -5.28E-05 2.54E-05 3.46E-03 -1.03E-04 1.43E-04 -1.25E-04 -2.01E-04 6.78E-04 1.20E-04 2.22E-04 
70 1.02E-04 1.72E-04 -8.34E-06 -1.70E-04 -2.34E-04 -2.45E-05 -2.47E-04 -2.05E-06 -1.19E-03 -2.21E-05 2.57E-04 
71 5.78E-04 3.50E-05 -5.50E-07 -2.96E-04 -1.67E-04 8.69E-05 -2.49E-04 -1.59E-04 -2.81E-03 8.86E-05 2.61E-04 
72 4.62E-05 1.98E-03 -6.15E-06 -4.15E-04 -1.21E-04 6.21E-05 -7.27E-04 3.14E-04 -2.44E-03 4.68E-05 1.37E-04 
73 -4.65E-07 -1.13E-05 4.56E-04 1.80E-04 -3.61E-05 1.07E-04 1.83E-05 -2.22E-04 -3.01E-04 7.65E-06 -1.89E-04 
74 -3.39E-04 -4.29E-04 1.82E-04 4.77E-02 -2.95E-04 1.54E-03 -2.42E-03 -2.55E-03 -3.76E-02 6.23E-05 4.39E-03 
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Parameters 34 35 36 37 38 39 40 41 42 43 44 
75 8.50E-06 1.11E-04 -3.03E-05 -2.09E-04 1.06E-03 -1.38E-05 -8.01E-04 -1.82E-05 1.62E-04 -4.02E-06 2.99E-05 
76 4.96E-04 9.25E-04 9.47E-05 -2.11E-03 -3.16E-04 -7.89E-06 2.39E-04 2.42E-05 -3.78E-05 -7.62E-06 -1.69E-05 
77 1.45E-06 -3.73E-06 3.28E-06 -6.81E-05 -1.95E-05 -1.06E-03 3.62E-04 2.48E-03 -6.98E-04 -1.43E-05 -8.74E-05 
78 1.11E-05 -1.37E-04 5.55E-05 3.39E-04 -2.14E-03 -1.72E-05 1.71E-03 8.57E-05 -3.44E-04 -7.51E-07 -7.92E-05 
 
Parameters 45 46 47 48 49 50 51 52 53 54 55 
45 1.34E-02           
46 6.64E-03 1.46E-02          
47 2.99E-03 4.51E-03 3.67E-02         
48 4.34E-04 2.37E-04 -1.07E-04 1.96E-02        
49 2.91E-04 1.73E-04 -1.15E-04 1.38E-02 1.63E-02       
50 1.05E-03 7.93E-04 6.01E-05 1.27E-03 9.10E-04 4.69E-03      
51 -4.45E-05 -1.21E-04 -7.88E-05 1.45E-04 1.03E-04 4.38E-05 2.32E-02     
52 -2.16E-04 -3.44E-04 -1.57E-03 2.75E-03 1.98E-03 5.36E-04 -4.86E-02 1.56E-01    
53 2.07E-04 1.10E-04 2.70E-04 1.73E-04 9.60E-06 -1.22E-04 8.58E-05 -6.14E-04 5.00E-04   
54 -5.80E-05 -9.75E-05 -1.46E-04 1.30E-04 9.26E-05 2.64E-05 1.46E-03 -9.84E-03 -2.21E-05 1.66E-03  
55 2.10E-05 -3.13E-06 4.77E-05 -1.76E-05 -6.79E-05 2.16E-05 -1.34E-04 1.50E-04 -2.89E-06 -1.25E-05 1.47E-03 
56 2.52E-05 1.21E-05 8.81E-05 -2.46E-05 -5.46E-05 -2.09E-06 -1.91E-04 -4.05E-05 5.95E-06 -1.15E-05 1.21E-03 
57 2.07E-04 7.41E-05 -4.88E-05 -1.05E-04 -1.16E-04 -1.26E-04 -2.17E-04 -2.03E-04 5.55E-05 -5.52E-05 1.15E-03 
58 -5.29E-05 -2.99E-04 9.05E-05 -2.30E-04 -2.38E-04 -1.58E-04 -4.44E-06 5.48E-04 -2.95E-05 1.26E-05 -1.02E-05 
59 8.76E-06 2.22E-05 -2.75E-05 3.68E-05 5.02E-05 -9.35E-05 -2.28E-05 1.32E-04 3.97E-06 1.16E-05 -4.14E-07 
60 -1.39E-02 -7.19E-03 -3.23E-03 -5.60E-04 -4.77E-04 -1.09E-03 -2.16E-05 1.33E-04 -2.31E-04 6.72E-05 -1.61E-05 
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Parameters 45 46 47 48 49 50 51 52 53 54 55 
61 -6.51E-03 -1.47E-02 -4.57E-03 -3.91E-04 -3.53E-04 -7.51E-04 4.22E-05 3.39E-04 -1.13E-04 9.17E-05 1.44E-05 
62 -3.02E-03 -4.60E-03 -3.79E-02 1.61E-04 1.78E-04 -1.27E-04 1.12E-04 2.39E-03 -2.84E-04 1.91E-04 -4.80E-05 
63 -4.42E-04 -2.38E-04 8.43E-05 -2.01E-02 -1.43E-02 -1.28E-03 -3.15E-04 -4.09E-03 -1.89E-04 -1.88E-04 2.48E-05 
64 -3.52E-04 -2.18E-04 8.15E-05 -1.37E-02 -1.62E-02 -9.20E-04 -3.11E-04 -3.04E-03 -3.67E-05 -1.37E-04 4.98E-05 
65 -1.10E-03 -8.72E-04 -1.10E-04 -1.50E-03 -1.12E-03 -4.77E-03 -5.61E-05 -1.13E-03 1.20E-04 -6.11E-05 -2.76E-05 
66 1.68E-06 3.75E-06 -1.25E-05 -5.22E-06 -1.24E-05 1.78E-06 -2.81E-04 6.19E-04 -4.29E-07 -1.63E-05 1.44E-06 
67 5.81E-06 2.60E-06 3.60E-05 -2.30E-05 6.42E-07 -1.45E-05 5.39E-04 -1.78E-03 6.78E-06 1.12E-04 -1.74E-06 
68 -1.74E-04 -3.55E-05 -2.29E-04 -2.11E-04 -4.30E-05 1.69E-04 -1.46E-04 4.89E-04 -5.49E-04 1.73E-05 7.22E-06 
69 1.00E-04 1.36E-04 1.94E-04 1.77E-04 3.76E-04 -1.34E-04 -2.22E-03 1.29E-02 4.65E-05 -2.13E-03 1.81E-05 
70 -1.37E-05 2.02E-05 -7.40E-05 -7.47E-06 1.94E-05 -2.93E-05 1.54E-04 6.68E-05 -3.35E-06 1.16E-05 -1.50E-03 
71 -2.82E-05 -4.75E-05 -1.20E-04 7.49E-05 1.00E-04 5.32E-06 2.55E-04 5.27E-04 -6.75E-06 2.79E-05 -1.19E-03 
72 -1.93E-04 -3.83E-05 8.21E-05 1.19E-04 1.19E-04 1.68E-04 2.24E-04 4.33E-04 -7.53E-05 8.43E-05 -1.14E-03 
73 5.73E-05 2.53E-04 -7.89E-05 2.37E-04 2.56E-04 1.58E-04 2.58E-05 -5.00E-04 2.84E-05 -1.44E-05 1.20E-05 
74 -9.45E-04 -1.09E-03 -1.07E-03 7.81E-04 -1.01E-06 3.48E-04 1.50E-03 1.12E-02 4.56E-04 -9.03E-04 -7.10E-05 
75 5.54E-05 -1.15E-05 1.56E-05 -6.57E-05 -8.18E-05 2.20E-05 3.86E-05 1.22E-05 1.16E-06 1.38E-05 -1.93E-06 
76 -9.42E-06 -4.60E-06 -8.50E-06 1.07E-05 1.20E-05 -4.51E-06 -2.01E-05 1.00E-05 2.18E-06 -3.23E-06 5.30E-06 
77 1.91E-05 8.50E-05 -6.31E-05 1.00E-04 -2.83E-05 1.42E-06 -5.16E-05 2.85E-04 -1.51E-05 3.02E-05 2.96E-05 
78 -8.52E-05 -2.92E-05 -2.89E-05 1.07E-04 1.18E-04 -2.69E-05 -5.01E-05 -1.47E-04 1.26E-06 -1.55E-05 5.58E-06 
 
Parameters 56 57 58 59 60 61 62 63 64 65 66 
56 3.63E-03           
57 2.82E-03 1.45E-02          
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Parameters 56 57 58 59 60 61 62 63 64 65 66 
58 8.63E-06 5.69E-05 9.08E-03         
59 8.07E-06 -6.56E-05 4.61E-05 1.72E-03        
60 4.19E-06 -2.93E-04 1.37E-04 2.58E-04 3.11E-02       
61 1.47E-05 -1.15E-04 2.80E-04 3.00E-04 7.61E-03 2.05E-02      
62 -1.26E-04 -2.84E-05 -9.53E-05 6.46E-04 4.62E-03 5.95E-03 5.25E-02     
63 5.06E-05 8.66E-05 2.24E-04 -5.16E-06 2.48E-03 1.92E-03 3.79E-04 2.68E-02    
64 3.56E-05 8.47E-05 2.06E-04 -5.66E-05 2.28E-03 1.82E-03 -6.05E-05 1.67E-02 2.58E-02   
65 -3.89E-06 1.17E-04 1.65E-04 2.09E-04 1.33E-03 1.38E-03 3.65E-04 3.48E-03 2.48E-03 7.81E-03  
66 6.93E-06 2.72E-06 1.26E-05 3.54E-06 3.19E-05 3.47E-06 2.81E-05 2.79E-05 -1.59E-05 -4.80E-06 2.01E-04 
67 -5.77E-06 5.11E-06 -1.97E-05 -2.32E-06 -5.78E-05 -1.54E-05 -7.46E-05 2.37E-05 1.83E-05 2.50E-05 -2.18E-04 
68 -4.37E-06 -7.87E-05 3.83E-05 -2.07E-05 8.80E-04 4.68E-04 1.13E-03 8.87E-04 3.92E-04 -5.30E-04 -1.78E-05 
69 -1.23E-06 1.14E-04 -6.94E-05 -7.80E-05 -5.02E-04 -5.96E-04 -4.00E-05 -2.44E-05 -6.58E-04 2.66E-04 -2.03E-03 
70 -1.24E-03 -1.18E-03 1.67E-05 -1.98E-05 1.77E-04 5.39E-05 9.37E-05 4.64E-05 1.30E-04 -9.19E-05 -1.74E-05 
71 -3.70E-03 -2.74E-03 -1.06E-06 -1.07E-04 -3.60E-04 -1.16E-04 2.75E-04 -3.76E-04 -2.83E-04 -1.75E-04 1.83E-05 
72 -2.82E-03 -1.41E-02 5.75E-05 -7.94E-05 6.23E-04 -6.07E-05 6.93E-04 -1.89E-04 4.09E-05 -2.99E-04 3.43E-05 
73 -2.12E-05 -3.65E-05 -9.15E-03 -6.56E-05 -2.47E-04 -3.13E-04 -1.16E-04 -5.41E-04 -2.52E-04 -1.15E-04 -2.43E-05 
74 2.28E-05 1.09E-05 1.87E-06 -9.94E-04 -6.88E-03 -4.56E-03 -6.63E-03 -1.56E-02 -5.85E-03 3.66E-04 1.34E-03 
75 -1.67E-05 -2.09E-05 1.61E-05 -1.01E-05 -1.84E-04 -3.93E-05 -5.03E-05 -3.55E-05 -5.20E-06 -4.04E-05 1.28E-06 
76 8.20E-06 8.36E-06 2.91E-07 8.88E-06 7.59E-05 4.76E-05 3.21E-06 1.65E-05 3.12E-05 1.58E-05 -3.83E-07 
77 5.91E-05 -2.19E-04 1.90E-05 2.94E-04 5.92E-04 1.35E-04 2.32E-04 1.66E-04 -1.38E-05 -6.47E-05 2.21E-05 
78 8.36E-06 1.57E-05 -1.62E-05 2.75E-05 3.88E-04 7.49E-05 1.11E-04 9.77E-05 8.45E-05 3.78E-05 -3.47E-07 
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Parameters 67 68 69 70 71 72 73 74 75 76 77 
67 3.05E-04           
68 -7.09E-06 2.04E-03          
69 1.32E-03 2.13E-06 4.80E-02         
70 3.27E-05 1.29E-04 -1.62E-04 5.75E-03        
71 -3.21E-05 4.53E-04 -1.28E-04 2.09E-03 1.15E-02       
72 -4.98E-05 7.52E-04 -4.68E-04 3.52E-03 1.45E-03 4.39E-02      
73 1.86E-05 -2.38E-04 5.48E-04 1.27E-05 7.77E-05 -4.56E-06 1.10E-02     
74 -7.71E-03 -1.47E-02 6.05E-02 -4.33E-03 -4.00E-03 -6.77E-03 2.83E-03 8.57E-01    
75 -2.74E-06 1.68E-06 -2.33E-05 -5.95E-05 -4.08E-05 -8.67E-06 -1.23E-05 4.42E-05 1.22E-03   
76 1.17E-06 -1.65E-06 -9.50E-06 1.63E-05 1.02E-05 1.27E-05 -1.24E-06 -8.98E-05 -3.65E-05 2.66E-03  
77 -3.49E-05 1.83E-04 -1.94E-04 4.19E-05 -1.09E-04 7.76E-05 -1.59E-04 -2.11E-03 -3.17E-05 2.56E-05 1.63E-03 
78 4.17E-06 2.26E-05 -4.59E-05 1.21E-04 1.40E-04 1.86E-05 2.96E-05 -4.42E-04 -8.54E-04 1.38E-04 1.20E-04 
 
Parameters 78 
78 2.47E-03 
 
 
  
  
 
 
4
0
0 
11.5. Appendix E: Appendix to Chapter 7 
 
Table 49: Distribution of age among smokers across drinking and gender categories, GHS 2006 data 
 
Smoker, At-risk drinker Smoker, Not at-risk drinker 
Age group (1) Males (2) Females (3) Males (4) Females 
18-24 13.43% 12.95% 8.29% 9.58% 
25-34 22.50% 26.11% 22.00% 18.96% 
35-44 24.32% 23.78% 22.12% 21.86% 
45-54 18.51% 17.83% 18.27% 19.26% 
55-64 14.34% 14.01% 16.83% 16.77% 
65-74 5.99% 4.03% 9.62% 9.58% 
75-100 0.91% 1.27% 2.88% 3.99% 
Total 100.00% 100.00% 100.00% 100.00% 
 
The propensity to drink to at-risk levels falls with age, as shown by the higher proportion of respondents aged 55 and over in columns 
(3) and (4) compared with columns (1) and (2) of Table 49. 
.
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Table 50: Published RR functions linking average daily consumption (x, grams of alcohol) to disease risk 
Condition Risk function Source 
Malignant neoplasm of lip, oral cavity and pharynx   (  )                      
 Tramacere et al 2010 
[429]  
Malignant neoplasm of oesophagus   (  )            Corrao et al 2004 [430] 
Malignant neoplasm of colon and rectum   (  )                                
Malignant neoplasm of liver and intrahepatic bile 
ducts   (  )                      
 
Malignant neoplasm of larynx   (  )                       Islami et al 2010 [431] 
Malignant neoplasm of breast Female               Key et al 2006 [432] 
Epilepsy and status epilepticus   (  )                      
 Samokhvalov et al 2010 
[433] 
Hypertensive diseases   (  )                                Corrao et al 2004 [430] 
Cardiac arrhythmias               Kodama et al 2011 [434] 
Haemorrhagic stroke   (  )          Corrao et al 2004 [430] 
Ischaemic stroke   (  )                                         
Oesophageal varices   (  )                            
Gastro-oesophagel laceration  Male              Purshouse et al 2009 [253] 
 Female               
Unspecified liver disease   (  )                           Corrao et al 2004 [430] 
Acute and chronic pancreatitis   (  )            
Psoriasis Male                          
   Gutjahr et al 2001 [435] 
 Female                              
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Condition Risk function Source 
Spontaneous abortion Female                            
Diabetes mellitus (type II) Male                               
 Female                             
Ischaemic heart disease Male   (  )         √           Corrao et al 2004 
[430] 
 Female   (  )         √           
Cholelithiasis Male                             Gutjahr et al 2001 [435] 
 Female                              
 
  
  
 
4
0
3 
 
Table 51: Number of patient-specific hospital admissions, by ICD-10 code, year beginning April 2005, from NWPHO report * 
  Number of patient specific hospital admissions 
Condition ICD-10 Males Females 
  18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
Road traffic accidents V(many) 3,536 3,098 2,906 1,736 1,217 589 638 1,324 1,348 972 730 648 505 733 
Pedestrian traffic accidents V(many) 65.8 84 76 52 39 28 58 37.1 36 34 34 55 34 78 
Water transport accidents V90-V94 21.7 47 56 28 33 11 7 6.3 11 14 12 11 12 11 
Air and space transport accidents V95-V97 3.5 18 32 18 10 7 0 0.7 6 3 2 2 1 0 
Falls W00-W19 6,126 7,586 7,582 6,694 8,016 10,993 38,526 2,981 5,071 5,520 6,600 11,303 19,646 110,695 
Work/machine injuries W24-W31 3,249 4,289 3,708 2,247 1,549 640 280 790 1,020 939 577 337 183 160 
Firearm injuries W32-W34 197.4 114 78 47 27 12 5 18.9 10 15 4 5 0 1 
Drowning W65-W74 8.4 5 10 10 11 9 11 5.6 4 8 4 6 4 12 
Inhalation of gastric contents W78-W79 24.5 40 59 60 85 148 323 13.3 34 47 48 74 91 391 
Fire injuries X00-X09 210 240 202 140 104 92 113 56.7 83 88 64 60 60 166 
Accidental excessive cold X31 4.9 2 8 8 13 13 56 0 2 4 2 3 13 106 
Intentional self-harm/Event of 
undetermined intent 
X60-X84, Y10-
Y34 3,354 4,690 4,214 2,169 1,101 532 637 6,532 5,690 5,726 3,170 1,467 759 897 
Malignant neoplasm of lip, oral 
cavity and pharynx C00-C14 22 54 208 742 1119 896 703 15 55 137 321 498 496 598 
Malignant neoplasm of 
oesophagus C15 4 20 149 651 1832 2366 2656 2 5 62 218 603 921 1925 
Malignant neoplasm of colon C18 20 81 279 779 2456 4206 5230 12 71 272 753 1905 3164 5430 
Malignant neoplasm of rectum C20 4 29 151 646 1836 2712 2531 6 40 142 386 888 1295 1895 
Malignant neoplasm of liver and 
intrahepatic bile ducts C22 10 18 51 118 298 461 549 7 13 31 85 183 296 490 
Malignant neoplasm of larynx C32 0 5 45 226 681 665 637 0 2 17 61 123 125 162 
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  Number of patient specific hospital admissions 
Condition ICD-10 Males Females 
  18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
Malignant neoplasm of breast C50 0 0 0 0 0 0 0 22 827 4987 8979 10229 7093 5277 
Epilepsy and status epilepticus G40-G41 1376 2350 3054 2974 3235 3344 4062 1763 3225 3489 3144 3220 3026 4887 
Hypertensive diseases I10-I15 244 492 811 1263 2312 3814 9886 166 404 554 860 1705 3290 14387 
Cardiac arrhythmias I47-I48 211 640 1619 3384 9159 17756 32982 247 619 981 1779 4811 12162 42213 
Haemorrhagic stroke 
I60-I62, I69.0-
I69.2 81 233 508 868 1161 1467 2197 67 184 542 871 1047 1306 2952 
Ischaemic stroke 
I63-I66, I69.3-
I69.4 36 164 610 1697 4444 7673 12386 43 200 506 1070 2385 5406 17418 
Oesophageal varices I85 34 70 176 369 455 393 275 24 49 95 176 287 329 267 
Gastro-oesophageal laceration-
haemorrhage syndrome K22.6 216 311 261 133 177 239 353 179 172 127 91 118 153 328 
Unspecified liver cirrhosis K73,K74 36 106 454 583 656 503 490 39 97 243 422 734 932 867 
Acute and chronic pancreatitis K85,K86.1 117 425 846 970 1114 1062 1168 250 583 780 846 1074 1093 1605 
Psoriasis L40 excl L40.5 99 298 514 514 517 327 247 221 443 439 396 436 294 319 
Spontaneous abortion O03 0 0 0 0 0 0 0 6647 17174 10977 327 4 1 93 
Diabetes mellitus E11 54 276 988 2126 3675 5067 5207 63 323 964 1725 2580 3660 5255 
Ischaemic heart disease I20-I25 78 727 4754 13264 25464 29833 32581 42 265 1742 5336 10801 16068 29885 
Cholelithiasis K80 151 904 2266 3270 4827 6540 8243 2027 6775 9257 9118 10805 9689 13509 
Alcohol-induced pseudo-Cushing's 
syndrome E24.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Mental and behavioural disorders 
due to use of alcohol F10 2568 4893 7885 7440 5944 3343 1768 1162 1841 3111 2980 1958 1010 835 
Degeneration of nervous system 
due to alcohol G31.2 0 1 30 71 64 42 24 0 1 15 29 26 11 10 
Alcoholic polyneuropathy G62.1 0 6 9 25 33 20 11 0 4 4 15 8 5 6 
Alcoholic myopathy G72.1 0 0 2 8 10 5 4 0 0 1 1 1 1 1 
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  Number of patient specific hospital admissions 
Condition ICD-10 Males Females 
  18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
Alcoholic cardiomyopathy I42.6 0 7 46 119 159 103 37 0 0 6 9 11 3 9 
Alcoholic gastritis K29.2 46 91 128 97 55 30 14 21 19 39 28 17 9 3 
Alcoholic liver disease K70 13 233 1229 2316 2590 1467 522 7 167 675 1139 1091 657 267 
Chronic pancreatitis (alcohol-
induced) K86.0 27 155 331 261 146 52 18 8 32 80 72 30 17 3 
Ethanol poisoning T51.0 72 112 108 55 22 6 3 113 129 153 82 25 7 3 
Methanol poisoning T51.1 1 3 2 4 1 0 1 2 1 4 3 0 0 2 
Toxic effect of alcohol, unspecified T51.9 38 53 79 36 13 3 2 56 63 76 40 20 5 1 
Accidental poisoning by and 
exposure to alcohol X45 55 55 53 34 13 9 5 54 48 54 29 13 2 7 
* For eight conditions, these figures differ from those in the NWPHO report.  Hostpital statistics for these conditions, mental and behavioural disorders due to use of 
alcohol, ethanol poisoning, epilepsy and status epilepticus, hypertensive diseases, cardiac arrhythmias, unspecified liver cirrhosis, Acute and chronic pancreatitis, 
diabetes mellitus, were adjusted to correct for apparent inconsistencies with HSCIC data, as described in the main text. 
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Table 52: Number of deaths, by ICD-10 code, year beginning January 2005, from NWPHO report 
  Number of deaths 
Condition ICD-10 Males Females 
  18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
Road traffic accidents V(many) 384 336 301 143 113 70 102 79 58 55 40 43 48 83 
Pedestrian traffic accidents V(many) 38 26 30 34 33 31 89 12 5 12 16 16 19 61 
Water transport accidents V90-V94 2 2 3 2 6 1 1 0 0 0 0 0 0 0 
Air and space transport accidents V95-V97 1 1 5 7 5 2 0 0 0 1 2 1 0 0 
Falls W00-W19 16 38 91 108 175 241 754 4 10 29 53 82 123 1130 
Work/machine injuries W24-W31 1 2 7 5 5 0 2 2 0 0 0 1 1 0 
Firearm injuries W32-W34 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
Drowning W65-W74 19 16 19 21 18 12 10 0 3 1 10 8 6 6 
Inhalation of gastric contents W78-W79 3 6 17 15 27 25 50 0 4 5 15 7 13 81 
Fire injuries X00-X09 3 15 22 7 24 18 30 2 8 9 13 4 16 45 
Accidental excessive cold X31 2 1 4 4 5 6 12 1 0 0 1 5 3 31 
Intentional self-harm/Event of 
undetermined intent 
X60-X84, Y10-
Y34 327 726 926 685 457 248 258 105 213 278 263 193 107 140 
Malignant neoplasm of lip, oral 
cavity and pharynx C00-C14 2 3 37 157 283 252 254 2 1 11 42 100 114 247 
Malignant neoplasm of 
oesophagus C15 2 6 57 262 875 1116 1667 0 1 15 85 246 411 1318 
Malignant neoplasm of colon C18 4 12 39 197 563 1216 2227 2 15 58 130 470 894 2618 
Malignant neoplasm of rectum C20 1 5 9 41 108 198 245 1 1 13 66 138 287 884 
Malignant neoplasm of liver and 
intrahepatic bile ducts C22 4 10 24 106 241 424 553 4 5 17 45 109 227 515 
Malignant neoplasm of larynx C32 0 1 5 41 109 142 183 0 0 2 15 14 30 66 
Malignant neoplasm of breast C50 0 0 0 5 11 23 39 2 70 552 1149 1969 1960 4595 
Epilepsy and status epilepticus G40-G41 41 74 113 97 65 65 98 22 55 46 48 53 39 138 
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  Number of deaths 
Condition ICD-10 Males Females 
  18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
Hypertensive diseases I10-I15 0 11 41 85 177 290 846 1 6 10 38 91 224 1642 
Cardiac arrhythmias I47-I48 0 2 0 6 20 91 705 0 0 0 4 13 96 1766 
Haemorrhagic stroke 
I60-I62, I69.0-
I69.2 10 45 157 312 491 666 1306 10 33 144 319 473 733 2294 
Ischaemic stroke 
I63-I66, I69.3-
I69.4 1 9 48 139 542 1789 8444 3 16 23 88 286 1406 16973 
Oesophageal varices I85 0 2 1 2 8 5 3 0 0 1 1 2 2 7 
Gastro-oesophageal laceration-
haemorrhage syndrome K22.6 0 0 2 1 2 2 11 0 0 1 1 0 4 11 
Unspecified liver cirrhosis K73,K74 2 7 86 165 232 211 196 0 7 41 70 121 188 287 
Acute and chronic pancreatitis K85,K86.1 2 9 26 52 71 89 191 2 5 10 21 30 90 350 
Psoriasis L40 excl L40.5 0 0 1 1 2 2 1 0 0 0 0 1 0 3 
Spontaneous abortion O03 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
Diabetes mellitus E11 0 0 6 12 35 121 371 0 1 0 5 18 86 530 
Ischaemic heart disease I20-I25 8 77 704 2242 5626 10618 26342 1 17 146 477 1525 4643 29367 
Cholelithiasis K80 0 0 1 5 14 36 119 0 1 0 5 16 39 262 
Alcohol-induced pseudo-Cushing's 
syndrome E24.4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Mental and behavioural disorders 
due to use of alcohol F10 5 33 71 126 105 39 19 0 10 26 47 37 10 9 
Degeneration of nervous system 
due to alcohol G31.2 0 0 0 1 0 2 1 0 0 0 1 0 1 0 
Alcoholic polyneuropathy G62.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Alcoholic myopathy G72.1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
Alcoholic cardiomyopathy I42.6 0 2 9 15 20 5 8 0 0 3 5 2 4 2 
Alcoholic gastritis K29.2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
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  Number of deaths 
Condition ICD-10 Males Females 
  18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
Alcoholic liver disease K70 2 61 382 827 802 388 139 5 41 208 427 362 167 61 
Chronic pancreatitis (alcohol-
induced) K86.0 1 4 7 18 11 2 0 0 0 1 2 2 3 1 
Ethanol poisoning T51.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Methanol poisoning T51.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Toxic effect of alcohol, unspecified T51.9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Accidental poisoning by and 
exposure to alcohol X45 5 12 36 27 14 5 0 1 8 18 14 8 2 0 
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Table 53: English population 2005, by age and gender, ONS data [438] 
Males Females 
18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
2352400 3362900 3866200 3177900 2879300 1983600 1477700 2260100 3374900 3906300 3232600 2971800 2206100 2383700 
 
Table 54: Mean weekly and peak daily alcohol use among at-risk drinkers and others in England, GHS 2006 sample 
 Mean weekly alcohol units Peak daily alcohol units 
 At-risk drinkers Not At-risk drinkers At-risk drinkers Not At-risk drinkers 
Age  Men Women Men Women Men Women Men Women 
18-24 45.4 30.8 6.9 4.0 13.8 9.4 3.9 2.7 
25-34 44.5 30.6 7.0 3.6 13.5 8.8 4.0 2.4 
35-44 42.3 29.1 7.2 3.6 10.6 8.0 4.1 2.2 
45-54 46.0 31.2 7.2 3.6 10.1 6.9 3.6 2.1 
55-64 47.4 28.8 6.4 2.9 9.1 5.7 2.7 1.6 
65-74 42.0 23.7 5.9 2.2 6.9 4.3 2.3 1.1 
75+ 36.7 23.6 5.0 1.6 4.9 3.0 1.4 0.7 
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Table 55: Mean alcohol consumption by drinking category, gender and age, GHS 2006 
  
Males Females 
  
18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
At-risk 
drinkers 
Weekly units 45.39 44.50 42.34 45.99 47.42 42.01 36.74 30.84 30.61 29.13 31.16 28.85 23.73 23.60 
Daily units 6.48 6.36 6.05 6.57 6.77 6.00 5.25 4.41 4.37 4.16 4.45 4.12 3.39 3.37 
g/day 51.88 50.86 48.39 52.56 54.20 48.01 41.99 35.25 34.98 33.29 35.61 32.97 27.12 26.98 
Others 
Weekly units 6.94 6.95 7.18 7.20 6.43 5.85 5.03 3.98 3.59 3.60 3.59 2.91 2.23 1.65 
Daily units 0.99 0.99 1.03 1.03 0.92 0.84 0.72 0.57 0.51 0.51 0.51 0.42 0.32 0.24 
g/day 7.93 7.95 8.20 8.23 7.35 6.69 5.75 4.54 4.11 4.11 4.10 3.33 2.55 1.88 
 
Table 56: Peak alcohol consumption by drinking category, gender and age, GHS 2006 
  
Males Females 
  
18-24 25-34 35-44 45-54 55-64 65-74 75+ 18-24 25-34 35-44 45-54 55-64 65-74 75+ 
At-risk 
drinkers 
Daily units 13.84 13.46 10.62 10.08 9.14 6.94 4.92 9.37 8.83 8.03 6.90 5.68 4.25 2.99 
g/day 110.70 107.69 84.94 80.65 73.10 55.53 39.32 74.95 70.68 64.23 55.20 45.47 34.03 23.92 
Others 
Daily units 3.95 4.00 4.07 3.62 2.72 2.26 1.39 2.69 2.39 2.20 2.11 1.57 1.08 0.68 
g/day 31.58 31.97 32.56 28.98 21.75 18.10 11.10 21.49 19.10 17.61 16.84 12.56 8.61 5.45 
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Table 57: Deaths within 90 days of admission HES-ONS linked data [540] 
Primary diagnosis: 3 character code Description 
Finished 
admission 
episodes 
Total 
deaths 
within 90 
days  
Alcohol-induced pseudo-Cushing's syndrome E24.4 869 8 
Mental and behavioural disorders due to use of 
alcohol F10 47,402 721 
Degeneration of nervous system due to alcohol G31.2 2,331 328 
Alcoholic polyneuropathy G62.1 7,930 70 
Alcoholic myopathy G72.1 731 33 
Alcoholic cardiomyopathy I42.6 5,637 295 
Alcoholic gastritis K29.2 93,286 1,176 
Alcoholic liver disease K70 14,886 3,298 
Chronic pancreatitis (alcohol-induced) K86.0 10,884 396 
Ethanol poisoning T51.0 1,350 15 
Methanol poisoning T51.1 1,350 15 
Toxic effect of alcohol, unspecified T51.9 1,350 15 
Accidental poisoning by and exposure to alcohol X45 
  Malignant neoplasm of lip, oral cavity and pharynx C00-C14 19,672 1,872 
Malignant neoplasm of oesophagus C15 30,977 6,775 
Malignant neoplasm of colon C18 81,277 7,697 
Malignant neoplasm of rectum C20 38,572 3,080 
Malignant neoplasm of liver and intrahepatic bile 
ducts C22 8,132 2,267 
Malignant neoplasm of larynx C32 4,849 486 
Malignant neoplasm of breast C50 173,815 6,635 
Epilepsy and status epilepticus G40-G41 45,414 1,355 
Hypertensive diseases I10-I15 39,739 2,108 
Cardiac arrhythmias I47-I48 110,860 3,994 
Haemorrhagic stroke 
I60-I62, 
I69.0-I69.2 24,386 7,288 
Ischaemic stroke 
I63-I66, 
I69.3-I69.4 72,413 14,142 
Oesophageal varices I85 7,063 435 
Gastro-oesophageal laceration-haemorrhage 
syndrome K22.6 63,310 1,287 
Unspecified liver cirrhosis K73,K74 4,785 610 
Acute and chronic pancreatitis K85,K86.1 29,851 1,417 
Psoriasis 
L40 not 
L40.5 12,975 49 
Spontaneous abortion O03 44,532 6 
Diabetes mellitus E11 29,525 1,638 
Ischaemic heart disease I20-I25 287,506 15,136 
Cholelithiasis K80 101,040 1,199 
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Table 58: Distribution of age among smokers across drinking and gender categories, GHS 2006 data 
 At-risk Drinkers Not At-risk Drinkers 
Age Category Males Females Males Females 
18-24 years 13.4% 13.0% 8.3% 9.6% 
25-34 years 22.5% 26.1% 22.0% 19.0% 
35-44 years 24.3% 23.8% 22.1% 21.9% 
45-54 years 18.5% 17.8% 18.3% 19.3% 
55-64 years 14.3% 14.0% 16.8% 16.8% 
65-74 years 6.0% 4.0% 9.6% 9.6% 
75-100 years 0.9% 1.3% 2.9% 4.0% 
Total 100.0% 100.0% 100.0% 100.0% 
 
This Table displays the distribution of GHS 2006 adult smoker respondents, sub-divided by gender and drinking status, across age 
categories.  Smokers who are at-risk drinkers are on average younger than the remainder of the smoking sample.  Over 95% of female 
at-risk drinking smokers are aged 18-65; this figure is just over 94% for male counterparts.  By contrast, 12.5% of male smokers who 
don’t drink above guideline levels are over 65 years old; this figure is over 13.5% for corresponding females. 
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Table 59: Alcohol-related costs [401, 450] and mean utility values [253, 453] 
ICD-10 
code 
Cost of a 
hospital 
admission 
Mean utility value, by age category 
18-24 25-34 35-44 45-54 55-64 65-74 75+ 
E24.4 £6,453.26 0.61  0.59  0.56  0.53   0.51   0.48   0.45  
F10 £6,605.56  0.57   0.55   0.52  0.50   0.48  0.45  0.42  
G31.2 £18,776.16  0.61   0.59   0.56   0.53   0.51   0.48   0.45  
G62.1 £11,701.47 0.61   0.59   0.56   0.53   0.51   0.48   0.45  
G72.1 £14,441.75  0.65   0.63   0.60   0.57   0.54   0.52  0.48  
I42.6 £9,551.50  0.65   0.63   0.60   0.57  0.54   0.52   0.48  
K29.2 £13,850.34  0.54   0.52   0.50   0.48   0.45   0.43   0.40  
K70 £5,142.60  0.56   0.54   0.52   0.49   0.47   0.45   0.42  
K86.0 £21,481.97 0.51   0.49   0.47   0.45   0.42   0.40   0.38  
T51.0 £5,143.71 0.43   0.42   0.40   0.38  0.36   0.34   0.32  
T51.1 £4,973.63  0.43   0.42   0.40  0.38   0.36   0.34   0.32  
T51.9 £29,880.66  0.73   0.71   0.67   0.64   0.61   0.58   0.54  
X45 £2,004.35  0.64   0.62   0.59   0.56   0.53   0.51   0.47  
C00-C14 £9,288.03  0.72   0.69   0.66   0.63   0.60   0.57   0.53  
C15 £6,845.68  0.78   0.76   0.72   0.69   0.65   0.62   0.58  
C18 £10,316.33  0.84   0.81   0.78   0.74   0.70   0.66   0.63  
C20 £8,942.30  0.86   0.83   0.79   0.75   0.72   0.68   0.64  
C22 £7,014.66  0.69   0.67   0.64   0.61   0.58   0.55   0.51  
C32 £6,600.00  0.91   0.88   0.84   0.80   0.76   0.72   0.67  
C50 £4,995.86  0.84   0.81   0.77   0.74   0.70   0.66   0.62  
G40-G41 £8,715.52  0.70   0.68   0.65   0.62   0.59   0.56   0.52  
I10-I15 £5,575.04  0.62   0.60   0.57   0.55   0.52   0.49   0.46  
I47-I48 £7,951.80  0.77   0.74   0.71   0.68   0.64   0.61   0.57  
I(many – 
hem strok) £6,378.78  0.80   0.77   0.73   0.70   0.66   0.63   0.59  
I(many – 
isch 
stroke) £8,339.77  0.75   0.72   0.69   0.66   0.63   0.59   0.56  
I85 £8,064.08  0.64   0.62   0.59   0.56   0.54   0.51   0.48  
K22.6 £2,465.69  0.71   0.68   0.65   0.62   0.59   0.56   0.53  
K73,K74 £5,108.14  0.95   0.91   0.87   0.83   0.79   0.75   0.70  
K85,K86.1 £5,509.45  0.70   0.67   0.64   0.61   0.58   0.55   0.52  
L40 not 
L40.5 £5,496.11  0.68   0.66   0.63   0.60   0.57   0.54   0.50  
O03 £4,045.38  0.84   0.81   0.78   0.74   0.70   0.67   0.63  
V(many - 
road) £15,988.08  0.69   0.67   0.64   0.61   0.58   0.55   0.51  
V(many - 
ped) £25,885.31  0.73   0.71   0.68   0.64   0.61   0.58   0.54  
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ICD-10 
code 
Cost of a 
hospital 
admission 
Mean utility value, by age category 
18-24 25-34 35-44 45-54 55-64 65-74 75+ 
V90-V94 £6,252.05  0.93   0.90   0.86   0.82   0.78   0.74   0.69  
V95-V97 £8,840.02  0.68   0.66   0.63   0.60   0.57   0.54   0.51  
W00-W19 £4,730.17  0.66   0.64   0.61   0.58   0.55   0.52   0.49  
W24-W31 £5,851.85  0.68   0.66   0.63   0.60   0.57   0.54   0.51  
W32-W34 £5,004.75  0.68   0.66   0.63   0.60   0.57   0.54   0.51  
W65-W74 £3,355.03  0.71   0.69   0.66   0.62   0.59   0.56   0.53  
W78-W79 £3,905.31  0.89   0.86   0.82   0.78   0.74   0.70   0.66  
X00-X09 £3,666.30  0.66   0.64   0.61   0.58   0.55   0.52   0.49  
X31 £4,926.94  0.66   0.64   0.61   0.58   0.55   0.52   0.49  
X60-
X84,Y10-
Y34 £4,693.48  0.97   0.94   0.89   0.85   0.81   0.77   0.72  
X85-Y09 £5,073.68  0.66   0.64   0.61   0.58   0.55   0.52   0.49  
E11 £5,866.30  0.66   0.64   0.61   0.58   0.55   0.52   0.49  
I20-I25 £5,082.57  0.46   0.45   0.43   0.41   0.39   0.37   0.34  
K80 £5,291.56  0.71   0.68   0.65   0.62   0.59   0.56   0.52  
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11.6. Appendix F: Appendix to Chapter 8 
Table 60: Confounded transition probabilities to smoking next year 
 Men Women 
Behaviour last year "NAR,NS" "AR,S" "AR,NS" "NAR,S" "NAR,NS" "AR,S" "AR,NS" "NAR,S" 
19-25 years old 0.076 0.842 0.165 0.816 0.044 0.826 0.090 0.829 
26-35 years old 0.049 0.888 0.067 0.829 0.038 0.861 0.070 0.858 
36-45 years old 0.031 0.893 0.049 0.875 0.028 0.890 0.043 0.867 
46-55 years old 0.023 0.876 0.046 0.893 0.021 0.865 0.038 0.878 
56-65 years old 0.014 0.926 0.026 0.868 0.015 0.880 0.028 0.840 
66-75 years old 0.010 0.826 0.018 0.883 0.010 0.840 0.007 0.846 
76-101 years old 0.007 0.714 0.015 0.832 0.004 0.889 0.017 0.909 
 
Table 61: Confounded transition probabilities to at-risk drinking next year 
 Men Women 
Behaviour last year "NAR,NS" "AR,S" "AR,NS" "NAR,S" "NAR,NS" "AR,S" "AR,NS" "NAR,S" 
19-25 years old 0.095 0.590 0.552 0.195 0.068 0.566 0.533 0.187 
26-35 years old 0.056 0.659 0.651 0.133 0.041 0.657 0.596 0.090 
36-45 years old 0.054 0.816 0.749 0.113 0.036 0.780 0.676 0.077 
46-55 years old 0.064 0.793 0.774 0.085 0.041 0.821 0.680 0.056 
56-65 years old 0.053 0.828 0.797 0.085 0.030 0.779 0.732 0.054 
66-75 years old 0.051 0.856 0.795 0.078 0.020 0.731 0.705 0.049 
76-101 years old 0.034 0.861 0.799 0.010 0.015 0.667 0.508 0.033 
 
